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ABSTRACT 
Class II M IC molecules at the surface of antigen -presenting cells present peptides to 
CD4` T lymphocytes. CLIP represents a nested set of peptides derived from the primary 
interaction site of the class II MHC molecular chaperone, invariant chain (Ii), which binds 
to many allelic variants, unlike fragments of protein antigen. 
Antigen- derived peptides are tethered within the binding groove of the class II MHC 
heterodimer by an elaborate hydrogen -bond network involving main -chain amide protons 
and carbonyl oxygen atoms, together with interactions of several constituent amino acid 
side chains within individual MHC pockets (Stern et al., 1994). It is the extensive allelic 
polymorphism within these latter subsites that results in each a(3 dimer exhibiting the 
capacity to bind a distinct repertoire of peptides (Hurley & Steiner, 1995). This study has 
revealed that CLIP sustains an interaction with different allelic variants of the I -A isotype, 
I -A I -Ad and I -Ak, not by forming strong side -chain interactions (Chapter 3) but, rather, 
through a network of main -chain hydrogen bonds (Chapter 4). The phylogenetically - 
conserved central continuous region, CLIP91 -99, is intolerant of backbone 
stereochemical disruptions by serial D- alanine- substitutions. Experiments with truncated 
and frame -shift analogues of CLIP showed that for effective binding to I -A molecules, the 
sequence element CLIP90 -100 must be incorporated into a peptide of thirteen or more 
residues including at least three residues N- terminal to this motif. 
A measure of positive side -chain interaction with T -A molecules occurred via Thr 95, Leu 
98 and Met 102, which were predicted to contact the class II MHC heterodimer outside of 
the immediate environment of the polymorphic pockets of the peptide- binding groove 
(Chapter 3). Similarly, the binding of CLIP to a representative mouse class II MHC 
variant of the I -E isotype involved the formation of an elaborate hydrogen bonding 
scheme via the main -chain atoms of the peptide, while anchoring contacts were apparent 
between the same CLIP side chains and the I -Ed aß dimer at regions of the molecule 
distinct from the pockets of the groove (Chapter 5). 
The relationship between the structure and binding of CLIP analogues suggests that there 
is a general backbone motif of a periodic nature within this sequence that minimises 
deleterious contacts and allows promiscuous association with class II MHC molecules. 
However, several conserved inhibitory contacts modulate this affinity such that CLIP may 
dissociate enabling efficient presentation of antigen- derived peptides. 
vii 
The binding of CLIP to I -Ag7 from non -obese diabetic (NOD) mice has also been shown 
to be dependent upon a number of critical anchor contacts made through the C- terminal 
residues of the peptide sequence in addition to the main -chain hydrogen bond network 
observed in other CLIP -I -A complexes (Chapter 6). Moreover, the (3Asp57Ser mutation 
in I -At confers a strong preference for peptides that exhibit an acidic residue at the P9 
position, while the (3Pro56His mutation appears to reduce the extent of ligand exchange 
that takes place at the cell surface. The possible ways in which these properties of I -Ag' 
may contribute to the development in autoimmunity in NOD mice are discussed. 
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CHAPTER 1. 
General introduction 
General introduction 1 
1.1. The immune system and the major histocompatibility 
complex (MHC) 
In higher vertebrates, many proteins implicated in immunological processes are encoded 
within a single genetic region known as the major histocompatibility complex (MHC). In 
humans, the MHC spans nearly 4000 kb in the short arm of chromosome 6 and its gene 
products are referred to as HLA (human leucocyte antigens; Figure 1.la). The mouse 
MHC genetic region is known as the H -2 complex and has been mapped to chromosome 
17 (Figure Llb). 
A critical requirement of the immune system is the ability to differentiate self from foreign 
(non -self) matter and eliminate the latter. The significance of MHC- encoded molecules in 
the adaptive immune response was first recognised from their ability to provoke vigorous 
rejection of intra- species tissue grafts (Gorer, 1936, 1937; Snell, 1948). Of particular 
interest in this reaction are the class I and class H MHC molecules. These membrane - 
bound glycoproteín receptors bind fragments of protein antigen and display them at the 
cell surface. An immune response is initiated when the peptide ligand is recognised and 
engaged by the highly specific receptors of T cells (TCR) in the context of the MHC 
molecule. The dual requirement for a T cell to be able to recognise not only the peptide 
antigen but also the host MHC molecule in the trimolecular complex is called MHC 
restriction (Zinkernagel & Doherty, 1974). 
1.2. A division of labour: class I and class II MHC molecules 
Together, class I and class II MHC molecules enable the vertebrate immune system to 
maintain complete surveillance of the cellular environment for any evidence of foreign 
metabolic activity. The most significant distinction between these two populations of 
MHC molecules is a functional one based upon their site of ligand loading. 
Class I MHC molecules are expressed by almost all nucleated cells and, typically, bind 
peptides in the endoplasmic reticulum (ER) that are derived from protein antigen residing 
in the cytosol. These proteins may include those generated by intracellular pathogens, 
such as viruses or parasites. The proteolytic machinery of the proteasome complex 
degrades these antigens into short peptide fragments which are carried into the lumen of 
the ER by TAP (transporter associated with antigen processing), an ATP -binding 
heterodimer comprising the MHC- encoded gene products, TAP -1 and TAP -2. Within 
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Figure 1.1 The class II region of the major histocompatibility complex. 
The genetic region known as the major histocompatibility complex (MHC) consists of three classes of 
genes. Class I and II MHC gene products are involved in presentation of peptide antigens to T cells. The 
class III region encodes a mixture of proteins, only some involved in immunological processes. The 
human class II MHC region (a) spans 1000 kb region on the short arm of chromosome 6. The genes 
encoding the classical class II MHC molecules are clustered in three major polymorphic subregions, 
HLA -DR, -DP, and -DQ. Not all known loci localised within this region are shown. The mouse class II 
MHC region (b) has been mapped to the short arm of chromosome 17. Subunits of classical mouse class 
II MHC molecules are encoded by H2 -A and -E loci- The DRA and Ea genes are invariant (Lee et al., 
1982; Das et al., 1983; Ayane et al., 1986). The gene products of other loci found within the class II 
MHC region are indicated in the legend. Horizontal arrows indicate direction of transcription. 
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this site, the peptides bind to the newly -synthesised class I MHC molecules and the now - 
stable complexes travel via the constitutive secretory pathway to the cell surface for 
presentation to CD8' T lymphocytes (Figure 1.2). For a comprehensive review of the 
class I MEC- mediated pathway of antigen presentation, see Pamer & Cresswell (1998). 
By contrast, class H MHC molecules present peptides sampled from the subset of 
proteins that gain access to the endocytic compartments, for example, by endocytosis at 
the cell surface (Figure 1.2). Thus, the peptide repertoire of class II MHC molecules may 
include fragments derived from proteins of extracellular pathogens, such as bacteria. 
These molecules present their peptide cargo to CD4' T lymphocytes and are expressed 
only by specialised antigen -presenting cells (APC). These APC include B lymphocytes, 
macrophages (e.g. Kupffer cells in the liver), dendritic ceIIs (e.g. Langerhans cells of the 
skin), the thymic epithelium and activated T cells in most species except the mouse. Other 
cell types may also be induced to express class II MHC molecules through the actions of 
external stimuli, such as cytokines (e.g. Wright et al., 1986; Pujol- Borrell et al., 1987; 
Glimcher & Kara, 1992; Bourdoulous et al., 1993; Albanesi et al., 1998). Alterations in 
the tissue distribution of class H MHC molecules has been linked to the development of a 
number of diseases, including Crohn's disease (Koretz et al., 1987; Momburg et al., 
1988) and Grave's disease (Catálfamo et al., 1999). 
1.3. The structural organisation of MHC molecules 
Research over the last decade has advanced our understanding of antigen presentation 
considerably, in particular, how peptide ligands interact with MHC molecules. In 
molecular terms, a major breakthrough was the elucidation of the X -ray crystallographic 
structure of the human class I MHC molecule, FILA -A2 (Bjorkman et al., 1987b). 
1.3.1 Class I MHC molecules 
The product of the class I MHC- encoded gene is a 44-45 kDa transmembrane 
glycoprotein that possesses a short carboxy -terminal cytoplasmic domain ( -30 amino 
acids), a single transmembrane domain (-25 amino acids) and three N}12-terminal 
extracellular domains (al, a2, a3) each of 90-92 amino acids (reviewed by Brodsky & 
Guaglíardí, 1991). A peptide- receptive class I MHC molecule is created when this heavy 
chain forms a non -covalent association with the second subunit, the 12 kDa, non -MHC- 
encoded, soluble light chain, 132 microglobulin (132m). 
class I MHC class II MHC 
Figure 1.2 Schematic outline of the class I and class 11 MHC antigen processing and presentation pathways. 
The two pathways of MHC -mediated antigen presentation enable the vertebrate immune system to maintain surveillance of both the exrracellular and intracellular 
environments by presenting fragments of foreign proteins, as well as many self- proteins, to the circulating T-cell population. The class I MHC subunits, the heavy chain 
and [12m associate together in the endoplasmic reticulum (ER) chaperoned by calnexin (details not shown) then bind peptides delivered into the ER by the TAP complex. 
The binding of peptide stabilises the class I MHC molecule and it moves via the secretory pathway to the cell surface. In the class II MHC pathway of antigen 
presentation, the a and l subunits associate in the ER followed by the interaction of a third polypeptide, the invariant chain (Ii). Nonameric a lIi complexes traverse the 
Golgi compartment into the endocytic route. In the MIIC (MHC class II compartments), the invariant chain is degraded progressively and dissociates from each all duner 
leaving CLIP (class II MHC -associated invariant chain peptides; shown in red). HLA -DM facilitates the dissociation of CLIP for the loading of peptides derived from 
exogenous protein antigens that have been endocytosed at the cell surface. 
n 
A 
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The three -dimensional analysis of HLA -A2 revealed that the class I MHC molecule 
exhibits two distinct extracellular structural motifs (Figure 1.3; Bjorkman et al., 1987b). 
At the membrane -proximal end, the a3 domain of the heavy chain and the 132m form an 
immunoglobulin -type structure. Most significantly, at the membrane- distal end, the a, 
and cc, domains of the heavy chain form a deep cleft comprising a platform of a single 
eight- stranded, anti- paraIIel 13- pleated sheet, topped by two anti -parallel ct- helices. This 
represents the site at which the peptide antigen binds (Bjorkman et al., 19876). 
The class I MHC peptide- binding groove is effectively closed at each end by the a -helix 
of the a, domain. The dimensions of this space permit a peptide of 8 -11 amino acids to 
bind in an extended conformation (Madden et al., 1991). Peptides at the larger end of this 
length range may exhibit a kink in the centre in order for their terminal residues to be 
accommodated. The extended conformation of the peptide results in the side chains of the 
constituent amino acids extending from the groove in a roughly alternating pattern. It is 
this composite surface of peptide bound within the MHC groove that is recognised by the 
TCR in the trimolecular complex (Bjorkman et al., 1987a). 
1.3.2 Class IT MHC molecules 
Owing to the overall similarities in both sequence and the Iocation of conserved and 
polymorphic residues between class I and class II MHC molecules, a model of the class U 
MHC protein was proposed in 1988 . based upon the molecular details of the class I MHC 
structure (Brown et al., 1988). A number of class II MHC molecules of both human 
(Brown et al., 1993; Jardetzky et al., 1994; Stern et al., 1994; Ghosh et al., 1995; Dessen 
et al., 1997) and mouse (Fremont et al., 1996, 1998b; Scott et al., 1998) origins have 
now been analysed by X -ray crystallography and have confirmed the main features of this 
model. 
Like class I MHC molecules, those of the class II MHC consist of a non- covalently- 
linked heterodimer. In this case, both glycoprotein chains are encoded within the MHC 
genetic region and span the membrane bilayer (Figure 1.3; reviewed by Brodsky & 
Guagliardi, 1991). The class II MHC a- subunit has a relative molecular mass (M,) of 
33 -35 kDa and carries two N- linked oligosaccharides. The Mr of the 13- subunit is 25 -30 
kDa and this polypeptide is modified by a single N- linked carbohydrate moiety. Similar 
to the class I MI-IC heavy chain, each class II MHC subunit exhibits two extracellular N- 
terminal domains of 90 -100 amino acids, a single transmembrane domain of 20 -25 
amino acids and a short carboxyl - terminal cytoplasmic domain of 10 -15 amino acids. 
Lumen 
Membrane 
Cytoplasm 
52ID 
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HLA- DMIH -2M Invariant chain (Ii) 
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Figure 1.3 Domain organisation of the molecular components of MHC -mediated antigen presentation. 
MHC antigen presentation is mediated by two different glycoprotein heterodimers. Class I MHC molecules consist of a large 44-45 kDa transmembrane polypeptide with 
three extracellular domains (al, a2 & a3), non -covalently associated with the smaller 12 kDa 32- microglobulin (132m). Class II MHC molecules are composed of two 
integral membrane polypeptide chains, the a -chain (33 -35 kDa) and (3 -chain (25 -30 kDa), each folding to yield two lumenal domains. Antigen- derived peptides bind to both 
classes of MHC molecule within a cleft formed at the protein surface by the membrane -distal domains. Like the class II MHC molecule, HLA -DM (H -2M in the mouse) 
consists of an aß heterodimer but its groove is unable to accomodate a peptide due to close packing of the al and ßl domains and additional disulphide bonds. The invariant 
chain (li) is a type H integral membrane protein, inserted into the membrane in an inverted polarity relative to other transmembrane proteins. The primary interaction site 
between Ii and class II MHC molecules is the exon 3- derived CLIP region (shown in red). See text for references. 
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The membrane -distal domains of each subunit (a, and ß,) associate to form a structure 
that constitutes the peptide- binding region of the molecule. 
The structure of the class II MEC peptide -binding groove resembles that of class I MEC 
molecules except for two significant features. Firstly, the two polypeptide components of 
the heterodimer, the a- and 3- chains, contribute equally to its formation, with four of the 
eight 13- strands and one helical region being derived from each subunit (Brown et al., 
1993). Secondly, two turns near the amino terminus of the class I MHC a, helical region 
are replaced in the class II MHC structure by a stretch of extended chain. In addition, the 
specific amino acid side chains that occlude the ends of the class I MHC peptide- binding 
site are not present in the class II MEC heterodimer. These latter structural features leave 
the class II MHC peptide -binding groove open at both ends, thereby allowing the NH,- 
and COOH- termini of a bound peptide to protrude. Accordingly, ligands eluted from 
class II MHC molecules are typically longer than class I M IC peptides, measuring 12 -19 
amino residues in length (Rudensky et al., 1991; Chicz et al., 1992, 1993; Hunt et al., 
1992). Within the class H MHC peptide -binding groove, these ligands are bound in a 
straight, extended conformation with a pronounced left- handed twist, such that successive 
side chains project from the backbone approximately every -130° (Stern et al., 1994). 
This arrangement is similar to a type II polyproline helix, which has an angle of projection 
of -120° per residue. 
1.3.3 Interactions at the peptide -MHC molecule interface 
Two types of intermolecular interactions provide positive binding energy to secure a 
peptide ligand within the MEC peptide -binding groove. The first of these is the 
formation of hydrogen bonds between main -chain atoms of the peptide backbone and 
highly- conserved residues of the MHC heterodimer. Within class I MEC molecules, 
such residues are clustered at each end of the cleft, situated to contact the first and last 
residues of the peptide (Madden et al., 1991). Within the open -ended groove of class II 
NEC molecules, conserved residues with hydrogen- bonding potential are distributed 
more evenly and these bonds form at intervals along the peptide backbone (Brown et al., 
1993; Figure 1.4a). 
The formation of main -chain hydrogen bonds between the MHC peptide- binding groove 
and the ligand represents a source of positive binding energy that is entirely independent 
of the peptide sequence. This is not the case with the second type of interaction between 
peptide ligand and MHC receptor. The primary sequences of both class I and class II 
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Figure 1.4 The class II MHC peptide- binding groove 
Antigen- derived peptides are tethered within the cleft of class II MHC molecules by interactions 
involving the side chains of the individual residues and/or the main -chain atoms of the polyamide 
backbone. (a) The peptide -binding groove typically encompasses a nine -residue stretch of the bound 
peptide (P 1 -P9). An elaborate network of hydrogen bonds forms between peptide main -chain carbonyl 
oxygen atoms and amide protons and highly -conserved residues of the MHC heterodimer. Shown is 
the hydrogen- bonding scheme between the ovalbumin peptide, Ova323 -339, and the mouse class II 
MHC molecule, I -Ad (adapted from Scott et al., 1998). Five notable pockets exist within the class II 
MHC peptide- binding groove. These sites accommodate every second or third amino acid side chain of 
the bound ligand. Pocket interactions are typically made via the peptide side chains at relative 
positions, P1, P4, P6, P7 and P9. The intervening peptide residues, P2, P3, P5 and P8 are oriented 
sideways across the groove or project outwards from this site to establish TCR contact points. The 
amino acid composition of each pocket varies considerably between individual MHC allotypes which 
results in different preferential peptide -sequence binding motifs. Amino acid positions of particular 
interest are shown in (h) on the a- carbon backbone trace of the human class II MHC molecule, HLA- 
DR1 (adapted from Hurley & Steiner, 1995). The arrows highlight the residues at positions 356 and 
f357 which are of significance in the I -Ag7 class II MHC molecule of non -obese diabetic (NOD) mice 
(discussed in Chapter 6). Throughout this thesis, I -A class II MHC residues are numbered according to 
the secondary structure -based scheme proposed by Fremont et al. (1998b) in order to be consistent with 
previous alignments of I -E and HLA -DR (Kabat, 1991). The nomenclature used to define the individual 
regions of secondary structure within the groove is also given in Fremont et al. (1998b). 
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MHC gene products exhibit extreme allelic diversity within defined subregions or 
' hypervariable segments' of each polypeptide chain. Upon folding into the mature MHC 
molecule, these polymorphic residues are concentrated into different subsites or 'pockets' 
within the binding groove. These localised environments provide important binding sites 
for the downward -oriented amino acid side chains of the bound peptide (Figure 1.4b). 
Of particular interest in this study are the interactions that take place between peptides and 
class II MIIC molecules. Typically, X -ray crystallographic structures of class II MHC 
a(3 dimers have revealed five notable pockets within the peptide -binding groove (Stern et 
al., 1994; Ghosh et al., 1995; Fremont et al., 1996, 1998b; Dessen et al., 1997; Scott et 
al., 1998). These sites accommodate every second or third amino acid side chain within a 
nine -residue stretch of the bound peptide, designated residues Pl -P9, i.e. pocket 
interactions are typically made via the peptide side chains at relative positions, Pl, P4, 
P6, P7 and P9 (Figure 1.4a). However, the amino acid accommodated within the Pl 
pocket is not the first peptide residue to interact with the class II MIIC molecule. 
Hydrogen bonds are present between the class IT MHC molecule and the residues of the 
peptide backbone at relative positions, P -1 and P -2, where P -1 is the amino acid 
immediately preceding the Pl residue. Similarly, the PIO and Pl 1 residues form van der 
Waals interactions with residues of the MHC binding cleft. Accordingly, all 13 residues 
between P -2 and P11 typically exhibit interpretable electron density within the peptide - 
binding groove of crystallised peptide -class H MHC complexes, indicative of having 
ordered structure (Stern et al., 1994; Ghosh et al., 1995; Dessen et al., 1997; Fremont et 
al., 1998b; Scott et al., 1998). 
The distinct amino acid composition of each pocket within the binding groove of a given 
MHC molecule results in these sites displaying preferences for peptide residues of 
particular size and physicochemical characteristics. The binding of such residues 
provides positive binding energy to the complex, for example, though the fulfilment of 
electrostatic or hydrophobic requirements. The most important of these preferences are 
referred to as 'anchor' positions within the peptide sequence. For the purposes of this 
study, an anchor residue shall be defined as one that provides positive binding energy to 
stabilise the resultant complex to the extent that it will not form in its absence. Thus, 
MHC molecules that differ in their primary sequence will exhibit different anchor 
preferences and, similarly, distinct peptide- binding sequence motifs. This represents the 
means by which different MHC allelic variants may bind diverse sets of peptides (Hurley 
& Steiner, 1995; Rammensee et al., 1995). 
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The residues within a peptide sequence do not act independently of each other but rather 
may be influenced by interactions at neighbouring positions. For example, favourable 
contacts between several peptide side chains within just a subset of the available pockets 
may overcome inhibitory interactions at adjacent sites. In this way, each MHC molecule 
may accommodate a huge array of different peptides by various combinations of 
optimally- and suboptimally -occupied pockets. It has been estimated that between 650- 
2000 structurally- divergent peptide sequences may bind to the single mouse class II MHC 
variant, I -A' (Hunt et al., 1992). 
The diversity of peptides presented by both a single and a set of distinct MEC allotypes is 
of considerable functional significance. The entire pool of MHC alleles within a 
population is extensive - more than 50 at some loci. However, each individual may 
express only between 3 -6 of these variants depending on whether they are inherited in a 
homozygous or heterozygous state. Together, these MHC molecules must exhibit great 
versatility in the range of peptides they may bind in order to ensure adequate presentation 
of the proteolysed remains of each and every foreign invader. The efficiency of this 
process is reflected in the variation observed between individuals with respect to 
susceptibility to different diseases. For some pathological conditions, the HLA alleles 
expressed may be the primary risk factor (Thorsby, 1995). 
1.3.4 The nomenclature of class I and class II MHC molecules 
An examination of the different molecules encoded within the MHC requires first an 
understanding of both the terminology used to describe them and the nomenclature 
applied to classify them. In both humans and mice, three distinct forms or 'isotypes' of 
the class I MHC molecule are expressed, HLA -A, HLA -B, HLA -C and H -2K, H -2D, H- 
2L, respectively. Humans also express three class II MHC isotypes, FILA -DR, HLA -DP 
and HLA -DQ, but only two are present in mice, H -2A and H -2E. These are homologous 
to HLA -DQ and HLA -DR, respectively. The mouse gene equivalent to that encoding the 
HLA -DP [3- chain, Pb (formerly Aß3), is an untranscribed pseudogene (Widera & Flavell, 
1985) and no corresponding mouse DP a -chain gene has been found (Figure 1.1). 
Within the genetic locus of each class II MHC isotype, there exist a number of subregions 
that encode different forms of the a- and 13 -chain polypeptides of the protein heterodimer, 
e.g. HLA -DQAJ. The gene products of these sub -loci may be classified further between 
different individuals into allelic variants or 'allotypes'. Such tissue typing of FILA gene 
products was conducted originally by serological means through the assessment of 
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different antibody reactivities. More recently, the development of molecular biology 
techniques, such as restriction fragment length polymorphism (RFLP) analysis and the 
polymerase chain reaction (PCR), has allowed HLA polymorphism to be characterised 
more precisely at the level of the DNA sequence (reviewed by Corzo et al., 1995 and 
Wade, 1996). For example, the serologically- defined HLA -DQ8 all dimer may be 
represented more accurately using the nomenclature which defines its allelic composition, 
HLA -DQA 1 *0302/HLA -DQB 1 *0302. 
The set of alleles within the MHC of a particular individual is called the haplotype. Such 
terminology is particularly important in the description of the MHC molecules expressed 
by different inbred strains of mice. Each strain has been assigned an arbitrary haplotype 
code written in superscript. For example, the collection of MHC alleles expressed by 
mice of the BALB /c strain has been designated the d haplotype or H -2d (Coligan et al., 
1994). Accordingly, the individual alleles expressed by these animals are named H -2Kd, 
H -2Dd, H -2Aad, H -2Ebd and so on. The gene products are named similarly, for example, 
H -2Kd, H -2Dd, H -2Ad and H -2Ed. The mouse class II MHC molecules are also known 
more simply as I -Ed and I -Ad, using the nomenclature derived from the original 
description of these molecules as the immune response -associated (Ia) antigens encoded 
by the immune response (Ir) genes within the I region of the mouse MHC (Benacerraf, 
1981; Klein et al., 1981). 
Lastly, it should be noted that the a -chain sequences of HLA -DR and H -2E class H MHC 
molecules exhibit minimal polymorphism between individuals (e.g. Korman et al., 1982; 
Larhammar et al., 1982; Lee et al., 1982; Das et al., 1983; Mengle -Gaw & McDevitt, 
1985; Ayane et al., 1986). The alleles encoding these polypeptides may be written simply 
as HLA -DRA and H -2Ea, respectively. 
1.3.5 Conformational features of peptide -bound class II MHC molecules 
Aside from the obvious functional necessity, both class I and class II MHC molecules 
must bind peptide ligand for structural maturation. The association of peptide provides 
critical stabilising interactions that bring about conformational rearrangements in the 
molecular architecture to yield molecules stable enough to withstand the rigours of antigen 
presentation at the cell surface. Without it, these molecules are folded poorly, exhibit 
aberrant glycosylation and are likely to accumulate intracellularly in aggregates in the ER 
and be targeted for degradation (Townsend et al., 1989; Ljunggren et al., 1990; Germain 
& Rinker, 1993). 
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The conformational states of both class I and II MHC molecules may be distinguished by 
their reactivity with different antibodies (Reske & Weitzel, 1985; Mellins et al., 1990; 
Elliott et al., 1991; Germain & Hendrix, 1991). Additionally, class II MHC molecules 
may be analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS - 
PAGE) to provide a convenient, if artificial, means of assessing conformational features. 
Upon SDS -PAGE, without prior heat denaturation and in the absence of reducing agents, 
class II MHC molecules show 3 distinct forms (Sadegh -Nasseri & Germain, 1991). The 
so- caIIed `compact' or C dimers migrate with an approximate molecular weight of 63 kDa 
in human (52 -56 kDa in mouse) and are formed by most (Germain & Hendrix, 1991) but 
not all peptide -bound class II MHC aß dimers (e.g. McIlins et al., 1990; Chicz et al., 
1992; Riberdy et al., 1992). The 'floppy' or F dimers migrate in a diffuse band at 63-67 
kDa and represent an intermediate, partially- dissociated form that occurs under mild 
denaturation conditions. Finally, in the complete absence of any stabilising influence of 
bound peptide, the class II MHC molecule is easily denatured in the presence of SDS 
detergent and migrates as disassembled a- and (3- monomers. 
1.4. The interaction of class II MHC molecules with the 
invariant chain, Ii 
For the efficient functioning of the class II MHC pathway of antigen presentation, it is 
essential that these a(3 dimers do not acquire antigen- derived peptides within the ER. Yet 
at the same time, the unstable, empty molecules must remain in a peptide- receptive state, 
avoid aggregation and be transported into the endocytic route. All of these events are 
mediated through the interaction with a third, non - polymorphic polypeptide, the invariant 
chain (Ii). 
1.4.1 The structure of the invariant chain protein 
Ii was first identified by two -dimensional PAGE of immunoprecipitates of mouse I -A and 
I -E class II MHC molecules (Jones et al., 1978a). The protein exhibits an unusual amino 
acid composition, being particularly rich in methionine residues and also contains large 
numbers of the basic residues, lysine and arginine, to give it a pI value between 8.0 -8.5 
(McMillan et al., 1981). An examination of the deduced amino acid sequence of the 
human (Homo sapiens; Strubin et al., 1984, 1986a; Kudo et al., 1985) mouse (Mus 
musculus; Koch et al., 1987), rat (Rattus norvegicus; McKnight et al., 1989) and cow Ii 
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protein (Bos taunts; Niimi et al., 1996) reveals minimal polymorphism between the 
different species (Figure 1.5). For example, human and mouse Ii exhibit 76% sequence 
identity at the protein level. 
li is a type II, integral membrane protein, meaning that it lacks a cleavable signal sequence 
and is therefore oriented in the membrane in an inverted polarity compared with most 
transmembrane proteins, including the cc- and (3- chains of the class II MHC heterodimer, 
i.e. with its carboxy -terminus on the lumenal side and its amino -terminus exposed to the 
cytoplasm (Singer et al., 1984; Strubin et al., 1984; Lipp & Dobberstein, 1986; Figure 
1.3). The Ii gene is not linked to the MHC (Day & Jones, 1983) but, rather, is encoded 
chromosome 18 in mice (Richards et al., 1985; Yamamoto et al., 1985) and on the long 
arm of chromosome 5, band q32, in humans (Claesson -Welsh et al., 1984; Genuardi & 
Saunders, 1988). However, the expression of this gene is regulated by the same 
mechanisms that control the expression of the class II MHC subunits, for example, 
through the binding of the class II MIIC transactivator protein (C1ITA) to the promoter 
region (Chang & Flavell, 1995). 
The li protein exhibits a short amino- terminal cytoplasmic tail, a single transmembrane 
domain (approximately 26 amino acids) and a large, lumenal carboxyl- terminal domain 
(Claesson et al., 1983; Figure 1.3). Human Ii exits in 4 isoforms of relative molecular 
mass, 31 -33 kDa, 33 -35 kDa, 41-43 kDa and 43-45 kDa (Strubin et al., 1986a; 
O'Sullivan et al., 1987; Figure 1.6). The range in Mr observed for each form reflects 
minor variations in their rate of migration upon SDS -PAGE. Within this thesis, these 
forms shall be referred to hereafter as p31, p33, p41 and p43, respectively. The p31 and 
p41 Ii proteins are derived by the alternate splicing of an additional exon, 6b, which 
extends the extracellular carboxyl -terminal domain by 64 amino acids to add a cysteíne- 
rich, thyroglobulin type 1 -like domain (Strubin et al., 1986a; O'Sullivan et al., 1987). 
The p33 and p43 forms arise as a result of a second in -phase AUG codon for the initiation 
of translation and thus represent N- terminally- extended forms of p31 and p41, 
respectively (Strubin et al., 1986b; O'Sullivan et al., 1987). The mouse, rat and bovine Ii 
genes do not appear to exhibit the alternative initiation codon upstream and as a result 
these species do not synthesise the p33 or p43 Ií variants (Koch et al., 1987; McKnight et 
al., 1989; Niimi et al., 1996). In human B cells, the most abundant form is p31, for 
which there is a 10 -fold excess of mRNA over that encoding p41 (Strubin et al., I986a). 
Throughout this thesis, Ii and all li- derived peptides, both mouse and human, are 
numbered according to the Ii sequence alignment shown in Figure 1.5. The mature Ii 
protein displays extensive co- translational and post -translational modifications, including 
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Figure 1.5 Sequence alignment of the invariant chain protein. 
The amino acid sequence of the mouse invariant chain protein, deduced from cDNA clones (Mus 
musculus; Koch et al., 1987), is aligned with rat (Rattus norvegicus: McKnight et al., 1989), cow (Bos 
taurus; Niimi et al., 1996) and human & (Homo sapiens; Strubin et al., 1984, 1986a; Kudo et al., 1985). 
Sequences are given in single letter amino acid code and numbered with reference to human li. The mouse 
Ii protein exhibits deletions at positions 27 and 138 plus an insertion at 186 relative to human p43. 
Putative N -linked glycosylation sites are marked in green. The stretch of amino acids of the 
transmembrane region are coloured blue. The 16 amino acids of the N- terminal extension of human p43 
are in italics. Putative sorting signals for endosomal compartments are indicated by magenta shading. The 
exon 3- derived CLIP segment is coloured red. The additional 64 amino acid element encoded by the 6b 
exon is highly homologous to a thyroglobulin repeat (TgR). This was not seen in the sequenced bovine & 
clone and is represented by dashes. The cysteine residue to which pahnitic acid is bound (Cys 28) is 
marked with an asterisk. The serine residue to which chondroitin sulphate is conjugated (Ser 202 in p31 
Ii) is marked with a dot. 
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phosphorylation (Spiro & Quaranta, 1989; Anderson & Roche, 1998; Kuwana et al., 
1998; Anderson et al., 1999b), both N- and 0-linked glycosylation and sialylation 
(Machamer & Cresswell, 1982, 1984; Schröder et al., 1999) and the addition of a 
palmitic acid chain via a thioester linkage to Cys 28 (Koch & Hammerling, 1985, 1986; 
Simonis & Cullen, 1986). A small proportion of Ii (2 -5 %) is also modified to a 
proteoglycan by the addition of a chondroitin sulphate moiety to Ser 202 (Sant et al., 
1985; Giacoletto et al., 1986; Miller et al., 1988). Although Ii does not represent a typical 
structural component of class II MHC antigens at the cell surface (Sung & Jones, 1981), 
these molecules may be the exception. This modified form of Ii is believed to act like an 
accessory molecule, enhancing the stimulation of T cell responses through interaction 
with CD44 (Naujokas et al., 1993). Cell- surface Ii has been designated CD74. 
1.4.2 The roles of Ii 
Shortly after biosynthesis in the ER, the a- and (3- subunits of the class H MHC molecules 
associate to form non -covalently- linked heterodimers (Figure 1.2). Newly- synthesised Ii 
polypeptides also oligomerise, forming homotrimeric complexes via interchain disulphide 
bridges in their cytoplasmic tails between residues, 163 -183 (Figure 1.6; Biljmakers et 
al., 1994a; Bertolino et al., 1995). Each of these Ii trimers represents a scaffold onto 
which three c43 class II MHC dimers may assemble (Roche et al., 1991; Marks et al., 
1995a) in a process facilitated by the association of the ER- resident protein, calnexin 
(Anderson & Cresswell, 1994; Schreiber et al., 1994; Arunachalam & Cresswell, 1995; 
Romagnoli & Germain, 1995; Williams & Watts, 1995). Each individual (a(3li)3 
nonamer may contain non -identical class II MHC heterodimers as a result of the multiple 
isotypes and allotypes expressed within class II MEC- positive cells. Once assembled, 
these multimeric, high molecular weight complexes are transported into the Golgi 
complex at which location they undergo glycosylation and terminal sialylation. 
The association of Ii with the class II MHC molecules in the ER has a number of 
important functions. In support of this, li- deficient (Ii °) mice exhibit significantly 
reduced presentation of antigens by class II MHC molecules, defective B cell 
development and impaired positive selection of CD4+ T cells (e.g. Bikoff et al., 1993; 
Viville et al., 1993; Naujokas et al., 1995; Shachar & Flavell, 1996; Wong & Rudensky, 
1996). Firstly, the initial assembly of the a(3 heterodimers onto the Ii trimer scaffold is 
critical for stabilising the class II MHC molecules in a correctly- folded state for their 
egress from the ER (Roche et al., 1991). In the absence of Ii, a(3 heterodimers 
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Figure 1.6 The structural organisation of the invariant chain protein. 
Human invariant chain exists in four isoforms resulting from an alternative translation intiation codon and the alternate splicing of the 6b exon. The 16- residue N- 
terminal extension is indicated by cross -hatching. The alternatively -spliced 64 -amino acid element encoded within exon 6b is shaded. Numbering on the p31 Ii 
marks the exon boundaries. Also indicated are the cytoplasmic domain (yellow), transmembrane domain (blue), CLIP region (red) and trimerisation signal 
(green). The site of palmitic acid addition (Cys 28) is marked with an asterisk. The chondroitin sulphate addition at Ser 202 (p31 numbering) is marked with a 
diamond. Putative glycosylation sites are indicated by lollipops. See text for references. rn 
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accumulate intracellularly and are poorly terminally -glycosylated (Schaiff et al., 1991, 
1992; Anderson & Miller, 1992; Elliott et al., 1994a). This observation also illustrates 
the second role for Ii, that of assisting the class H MHC molecules to leave the ER and 
travel through the Golgi complex to the trans -Golgi network (TGN). Here, the a131i 
complexes are sorted and diverted from the default secretory pathway into the endocytic 
route by virtue of two leucine -based localisation signals mapped to the N- terminal 
cytoplasmic tail of Ii (Bakke & Dobberstein, 1990; Lotteau et al., 1990). One of these 
motifs has been identified to involve the residues, Leu 7 and I1e 8 (Pieters et al., 1993; 
Figure 1.5). The other is located between Pro 15 -Leu 17 (Bremner et al., 1994; Odorizzi 
et al., 1994). Each is reported to require an acidic amino acid 4-5 residues N- terminal to 
the leucine motif (Pond et al., 1995). These or other signals may also act to retain the 
class II MHC molecules within this location until their Ii chaperone is degraded with 
concomitant loading of antigen- derived peptide (Loss & Sant, 1993; Gorvel et al., 1995). 
The extent to which af3Ii complexes reach the endosomes via internalisation from the cell 
surface versus direct trafficking from the TGN is still unresolved but may depend upon 
the cell type (e.g. Roche et al., 1993; Simonsen et aL, 1993; Benaroch et al., 1995; Swier 
& Miller, 1995a; Salamero et al., 1996; Wang et al., 1997; Rang et al., 1998; Liu et al., 
1998; Saudrais et al., 1998; Ong et al., 1999). A similar course may also be taken by 
some class II MHC molecules in Ii° cells, possibly by way of a signal within a highly - 
conserved region of the class II MHC 13- chain, residues 80 -83 (Chervonsky et al., 1994; 
Tan et al., 1997a). 
The third function of Ii is to prevent class II MHC aß dimers from forming premature 
associations with antigen -derived peptides both within the ER and while in transit to the 
endosomes (Roche & Cresswell, 1990b, 1991; Teyton et al., 1990; Demotz, 1993; 
Newcomb & Cresswell, 1993; Long et aL, 1994). Similarly, this interaction thwarts the 
binding of intact, endogenous polypeptides in the ER (Busch et al., 1995, 1996). This 
feature of the Ii protein involves the exon 3- encoded region, residues 82 -107 (Figure 1.6; 
Romagnoli & Germain, 1994). The deletion of these residues abrogates the binding of Ii 
to class II MIIC molecules, confirming this as the principle site of contact between these 
proteins (Freisewinkel et al., 1993; Biljmakers et al., 1994a). 
In the absence of a(3 heterodimers in human cells, Ii trimers are retained in the ER by a 
double arginine retention signal in the N- terminal extension shared by the p33 and p43 
forms (Figure 1.6; Marks et al., 1990; Arunachalam et al., 1994; Schutze et al., 1994). 
The p31 and p41 forms of Ii lack this signal but may also be retained through the 
formation of mixed trimers, containing at least one li subunit with the ER retention signal 
(Lamb & Cresswell, 1992). 
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1.5. Formation of antigenic peptide -class II MHC complexes 
Unlike class I MHC molecules, which reach the cell surface within minutes after their 
arrival in the TGN, there is a 1 -3 hour delay between the appearance of class II MHC 
molecules in the TGN and their deposition at the cell surface (Neefjes et al., 1990). 
During this time, the aßli complexes are targeted to compartments in the endocytic 
pathway where li is degraded and antigen- derived ligand is bound. 
1.5.1 The proteolytic degradation of Ii 
Before class II MHC molecules may bind antigen- derived peptides for presentation to 
CD4` T cells at the ceII surface, the a(3 heterodimcrs must first be released from their 
interaction with Ii (Roche et al., 1992). This is achieved through the step -wise removal 
of fragments of the Ii protein generated by proteolytic cleavage (Mario et al., 1994). 
I8 
The proteolysis of Ii occurs via three major degradation intermediates, all of which remain 
complexed with the class II MHC aß dimers: the 21 -22 kDa leupeptin- induced 
polypeptides ('LIP; Blum & Cresswell, 1988), the small leupeptin- induced peptides 
('SLIP') of 10 -14 kDa (Nguyen et al., 1989; Mario et al., 1994) and, lastly, the nested 
set of class II MHC- associated invariant chain peptides or 'CLIP' (Rudensky et al., 1991; 
Chicz et al., 1992, 1993; Hunt et al., 1992; Riberdy et al., 1992; Sette et al., 1992a). 
The LIP fragments correspond to the N- terminal two -thirds of the Ii protein including the 
cytoplasmic and transmembrane regions, the signals responsible for sorting and retention 
and the exon 3- derived region necessary for interaction with the all dimer (Figure 1.6). 
Cleavage of the intact li to produce LIP is proposed to occur between residues Leu 174 - 
Phe 175, a bond conserved in human, mouse, rat and cow Ti (Figure 1.5; Kageyama et 
al., 1996). The SLIP fragments are produced when LIP is cleaved approximately 
between Ii residues 105 and 106 (Chapman, 1998). This releases the individual agli 
trimers from their nonameric complex. The cleavage of SLIP then yields c43 class II 
MHC dimers complexed with CLIP (Xu et al., 1994; Amigorena et al., 1995; Morkowski 
et al., 1995; Kageyama et al., 1996). These last Ii fragments are derived almost 
exclusively from the exon 3- encoded li moiety (residues 82 -107) shown to be critical for 
the li -class II interaction and which blocks the premature binding of antigen- derived 
peptides (Freisewinkel et al., 1993; Romagnoli & Germain, 1994). 
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The bulk of Ii proteolysis occurs within the later parts of the endocytic pathway, 
involving acidic proteases (Blum & Cresswell, 1988; Roche & Cresswell, 1991). The 
identification of the key proteases involved in the production of LIP, SLIP and CLIP has 
been complicated by the high degree of functional redundancy that exits amongst such 
enzymes within these cellular compartments. Studies in B-Iymphoblastoid cell lines (B- 
LCL) using protease inhibitors have demonstrated that Ií proteolysis in these APC may be 
initiated by an aspartyl proteinase (Marie et al., 1994). Enzymes of this nature, such as 
the cathepsins D and E, are found in high concentration in lysosomal compartments and 
are optimally active at acidic pH. The cysteine proteinase, cathepsin B, has also been 
implicated in the generation of the LIP and SLIP fragments (Reyes et al., 1991; Roche & 
Cresswell, 1991; Mizuochi et al., 1994; Xu et al., 1994). This enzyme exhibits both 
endo- and dipeptidyl-peptidase activity and is active at both acidic and neutral pH. 
However, APC from knockout mice that are genetically- deficient in either cathepsin B or 
D expression show no obvious defection class II MHC antigen presentation (Villadangos 
et al., 1997; Deussing et al., 1998). 
By contrast, an essential role in the degradation of Ii has been shown for the cysteine 
protease, cathepsin S. This enzyme is believed to catalyse the final cleavage of the SLIP 
fragment to produce the CLIP -class II MHC complexes (Riese et al., 1996). Two 
potential cleavage sites are the bonds, Arg 78 -Met 79, or Lys 80 -Leu 8I, both conserved 
in mouse, rat, human and cow Ii and consistent with the known substrate preferences of 
cathepsin S (Figure 1.5; Riese et al., 1996). The disruption of cathepsin S activity in 
APC prevents the complete proteolysis of both human and mouse Ii, resulting in the 
accumulation of afl dimers complexed with 10 -13 kDa SLIP -like fragments and the 
inhibition of class II MHC- mediated antigen presentation (Riese et al., 1996, 1998; 
Villadangos et al., 1997; Nakagawa et al., 1999). Mice lacking expression of this 
enzyme exhibit defective humoral immune responses (Shi et al., 1999). Cathepsin S is 
expressed predominantly in the major APC types and is a potent endopeptidase active 
over a broad pH range (Shi et al., 1992, 1994; Bromme et al., 1993). The inhibition of 
this enzyme by the endogenous cysteine protease inhibitor, cystatin C, has been 
suggested to be a means by which antigen presentation by class II MEC molecules is 
controlled during the maturation of dendritic cells (Pierre & Mellman, 1998; Driessen et 
al., 1999). 
Sequence features of the Ii protein may influence its own proteolysis and that of other 
proteins. The amino -terminal region of Ii shares 50% sequence homology with members 
of the cystatin superfamily and may inhibit the activity of cathepsins L and H (Katunuma 
et al., 1994). In addition, the alternatively- spliced segment of the p41 isoform of Ii is a 
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member of the thyroglobulin type -1 domain class of cysteine protease inhibitors (Lenarcic 
& Bevec, 1998). This Ii fragment shows potent inhibition of cathepsin L (Ogrinc et al., 
1993; Bevec et al., 1996; Fineschi et al., 1996) by binding within the active site cleft in a 
novel wedge- shaped fold that is stabilised by three internal disulphide bonds between 
cysteine residues, 197 -216, 227 -234 and 236 -255 (Figure 1.5; Guncar et al., 1999). 
This may account for the ability of the p41 Ii isoform to enhance the presentation of a 
particular subset of antigens (Peterson & Miller, 1992), for example, by preventing the 
proteolytic destruction of some epitopes. Similarly, p41 itself has a longer half -life in the 
endosomal compartments than p31 (Arunachalam et al., 1994) and a 12 kDa SLIP -like 
fragment exhibits a prolonged association with the class II MHC molecules (Fineschi et 
al., 1995, 1996). However, these two Ii isoforms display largely equivalent effects upon 
other aspects of class II MHC- mediated presentation of antigens, including subunit 
assembly, endosomal localisation, peptide acquisition, cell -surface expression and CD4` 
T cell development (Shachar et al., 1995; Takaesu et al., 1995, 1997; Serwe et al., 1997; 
Wright et al., 1998). Inhibition of cathepsin S by the p41 fragment is unlikely as a result 
of a number of possible unfavourable electrostatic interactions (Guncar et al., 1999). 
1.5.2 The mediation of peptide loading by HLA- DM/H -2M 
A key step in the presentation of antigen by class H MHC molecules is the release of the 
aß dimers from their association with CLIP. Only once these final proteolytic fragments 
of Ii have been displaced may the individual molecules bind antigen- derived peptides 
(Freisewinkel et al., 1993; Romagnoli & Germain, 1994). This process is facilitated by 
another MHC- encoded heterodimer, HLA -DM (H -2M in the mouse). 
HLA -DM is a non -classical MHC molecule encoded by the genes DMA and DMB which 
display only limited allelic polymorphism (Figure 1.la; Carrington et al., 1993; 
Sanderson et al., 1994b). The homologous genes in the mouse are designated Ma and 
Mb and are similarly non -polymorphic (Figure 1.1b; Hermel et al., 1995). The a- and 11- 
chains exhibit 25 -30% sequence identity to those of the classical class II MHC 
heterodimers and the molecules share similar domain arrangements, including the 
formation of a membrane -distal peptide- binding groove (Figure 1.3; Cho et al., 1991; 
Kelly et al., 1991). However, in HLA -DM and H -2M this site is not capable of 
accommodating a peptide ligand. The a- helices of the at and (31 domains are packed 
closely together .so as to occlude all but a single pocket (Fremont et al., 1998a; Mosyak et 
al., 1998). The molecules are also thought to be more rigid due to the formation of two 
General introduction 21 
disulphide bonds additional to those found in the classical peptide -receptive class II MHC' 
molecules (Figure 1.3). 
A role for HLA -DM in the class II MHC- mediated pathway of antigen presentation was 
first proposed from the finding that a deficiency in the expression of this molecule was 
responsible for the aberrant functioning of a set of mutant APC, generated by ethyl 
methane sulphonate (EMS) treatment of an EBV- transformed human B lymphoblastoid 
cell line, 8.1.6 (Kelly et al., 1991; Mellins et al., 1991; Denzin et al., 1994; Fling etal., 
1994; Morris et al., 1994). These mutants had been characterised by their loss of the 
conformation- sensitive epitope recognised by the anti - FILA -DR3 monoclonal antibody, 
16.23 (Pious et al., 1985) and were unable to present determinants derived from native 
protein antigen, although capable of presenting exogenously -added peptide (Mellins et al., 
1990). The cells had intact structural genes of both Ii and class II MHC molecules and 
expressed normal Ievels of each. However, the HLA -DR molecules were unstable in 
SDS detergent and cell -surface aß dimers were loaded predominantly with the Ii 
peptides, CLIP (Riberdy et al., 1992; Sette et al., 1992a; Monji et al., 1994). A similar 
phenotype has been observed subsequently for APC from H -2M knockout mice (Fung- 
Leung et al., 1996; Martin et al., 1996; Miyazaki et al., 1996). 
FILA -DM is now recognised to be able to facilitate the binding of antigen -derived peptides 
to class H MHC aß dimers by inducing the dissociation of pre- existing ligands from 
these molecules (The following details are also applicable to mouse H -2M). Susceptible 
peptides include but are not limited to CLIP (Denzin & Cresswell, 1995; Sherman et al., 
1995; Sloan et al., 1995; van Ham et al., 1996) and possibly also the larger Ii fragments, 
LIP and SLIP (Denzin & Cresswell, 1995; Denzin et al., 1996; Schafer et al., 1996). 
The sensitivity of a given peptide -class II MHC complex to the actions of HLA -DM is 
determined by its overall kinetic stability, such that this molecule enhances the 
dissociation rate of all peptides but to an extent directly proportional to their intrinsic rate 
of dissociation (Kropshofer et al., 1996; Weber et al., 1996). HLA -DM also stabilises 
the empty class II MHC heterodimer so generated against functional inactivation and 
aggregation until a more stable interaction has formed with another peptide (Denzin et al., 
1996; Kropshofer et al., 1997; Kovats et al., 1998). In this way, HLA -DM is able to 
influence the array of peptides presented at the cell surface to T lymphocytes by skewing 
the population towards those that form long -lived complexes with class II MHC 
molecules (Sloan et al., 1995; Katz et al., 1996; Lightstone et al., 1997). 
The expression of HLA -DM closely parallels that of conventional class H MHC 
molecules. I-ILA -DM gene products are expressed constitutively in APC under the 
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influence of the class II MHC transactivator (CIITA; Chang & Flavell, 1995) and may be 
induced in other tissues by IFN -'y (Kelly et al., 1991). However, the molar ratio of HLA- 
DM to class II MHC molecules in vivo is less than 1:5 (Schafer et al., 1996). Consistent 
with this, HLA -DM is active in substoichiometric quantities in vitro and a single molecule 
is able to convert 3 -12 CLIP- lILA -DR complexes per minute (Vogt et al., 1996). 
The mediation of peptide loading of class II MHC molecules by HLA -DM takes place 
optimally between pH 4.5 -5.5 (Denzin & Cresswell, 1995; Sherman et al., 1995; Sloan 
et al., 1995). This is compatible with the intracellular accumulation of these molecules 
within the mildly acidic, class II MHC- enriched vesicles of the endocytic route (Denzin et 
al., 1994; Karlsson et al., 1994; Sanderson et al., 1994a; Green et al., 1995; Robbins et 
al., 1996). Both HLA -DM and H -2M are targeted to these compartments by virtue of a 
tyrosine -based motif in the cytoplasmic tail of 13-chain (Lindstedt et aI, 1995; Marks et 
al., 1995b), similar to that of the lysosomal- associated membrane protein, LAMP -1, 
which co- resides intracellularly with these molecules (Williams & Fukuda, 1990; Copier 
et al., 1996). HLA -DM is found infrequently at the cell surface, consistent with this 
consensus sequence signalling rapid internalisation from the plasma membrane in clathrin- 
coated pits (Ktistakis et al., 1990). In this absence of this motif, Ii may direct FILA- 
DM/H-2M into the appropriate endocytic compartments (Lindstedt et al., 1995; Copier et 
al., 1998). 
The molecular mechanism by which HLA -DM is believed to facilitate peptide exchange 
from class II MHC c43 dimers involves the transient association of these molecules. Such 
an interaction has been observed by co- immunoprecipitation (Denzin et al., 1996; 
Sanderson et al., 1996). The inhibition of FILA -DM activity by either the addition of an 
N- linked glycan to position 94 on the a, domain of the HLA -DR3 heterodimer 
(Sanderson et al., 1996; Guerra et al., 1998) or the binding of the CerCLIP.1 antibody to 
the N- terminus of CLIP complexed with FILA -DR3 (Denzin & CressweII, 1995) 
implicates a region on a lateral face of the class II MHC molecule as a potential site of 
contact. The interaction between HLA -DM and HLA -DR may take place through exposed 
hydrophobic domains, each shielding the other from the aqueous environment. Under 
acidic conditions approximating those of the endocytic compartments, both HLA -DM and 
FILA -DR molecules undergo conformational changes that lead to the exposure of such 
non -polar regions (Runnels et al., 1996; Ullrich et al., 1997; Busch et al., 1998). In this 
environment, the HLA -DM molecule may stabilise a more open conformation of the class 
II MHC peptide- binding groove that favours the rapid dissociation and association of 
peptides. HLA -DM is proposed to dissociate when the available interactive surface is 
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reduced as a result of a conformational change in the class II MHC a(3 dimer upon its 
forming a stable association with a peptide (Ullrich et al., 1997). 
1.5.3 HLA -DO, a regulator of HLA -DM activity 
23 
Another molecular component of the class II MHC- mediated antigen presentation pathway 
is HLA -DO (H -20 in the mouse), the product of the genes, DNA and DOB (Oa and Ob 
(formerly Aß2) in the mouse; Figure 1.1; Larhammar et al., 1985; Tonnelle et al., 1985; 
Trowsdale & Kelly, 1985; Servenius et al., 1987; Karlsson & Peterson, 1992). Like 
HLA -DM, this molecule is a non -classical class II MHC heterodimer that displays 
minimal allelic polymorphism. HLA -DO resides intracellularly in stable complexes with 
HLA -DM within the endocytic compartments (Liljedahl et al., 1996; Denzin et al., 1997). 
This association is required for the efficient exit of HLA -DO from the ER, despite the 
presence of two endosomal localisation signals within its ß -chain (Samaan et al., 1999). 
A population of H -20 has also been described complexed with Ii ( Karlsson et al., 1991; 
Douek & Altmann, 1997). 
Although much still remains to be learned of HLA -DO, this molecule would appear to 
regulate the stringency with which HLA -DM facilitates peptide exchange (Denzin et al., 
1997; van Ham et al., 1997; Kropshofer et al., 1998; Liljedahl et al., 1998). Complexes 
of HLA -DO and HLA -DM have been isolated in association with HLA -DR molecules 
(Kropshofer et al., 1998). HLA -DO is able to enhance the ability of HLA -DM to stabilise 
empty class II MHC aß dimers (Kropshofer et al., 1998) and may influence the pH range 
over which HLA -DM is active ( Liljedahl et al., 1998). Studies of H -20- deficient mice 
suggest that this molecule may also serve to promote the presentation of particular 
antigens, for example, those internalised into B cells by their membrane immunoglobulin 
receptors versus those captured by fluid -phase endocytosis (see below, § 1.5.4; Liljedahl 
et al., 1998). 
The possibility that HLA -DO may regulate the activities of HLA -DM is particularly 
interesting in light of its unusual tissue distribution. Mouse H -20 is expressed in B cells 
and in a subset of thymic medullary epithelial cells, independently of the presence of 
classical class II MHC molecules. This molecule has not been detected in dendritic cells 
and macrophages (Wake & FIavell, 1985; Karlsson et al., 1991). Human I-ILA -DO has a 
similar pattern of expression but is also present in some dendritic cell populations (Douek 
& Altmann, 1997). The expression of HLA -DO is not induced by the CIITA like many 
other MHC gene products (TonneIIe et al., 1985; Denzin et al., 1997) and the Ob gene is 
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not sensitive to upregulation by IFN -y (Wake & FlaveIl, 1985). HLA -DOB is inducible 
by IFN -y but the mRNA is unstable (Ponzoni et al., 1993). Together, these findings 
suggest that HLA- DO/H -20 may have a critical role in regulating the specific peptide 
repertoire presented by these particular APC. 
1.5.4 The processing of protein antigens for presentation by class II 
MHC molecules 
Prior to presentation by class II MHC molecules at the cell surface, protein antigens must 
enter the endocytic route and undergo processing. The internalisation of proteins may 
occur by a number of different means (reviewed by Lanzavecchia, 1990 and Watts, 
1997). Random samples of extracellular proteins may be engulfed by fluid -phase 
pinocytosis. Macrophages and dendritic cells capture particulate antigen contained within 
immune complexes by phagocytosis. B cells use the membrane immunoglobulins (mlg) 
of the multimeric B cell receptor (BCR) to mediate the highly -efficient uptake of specific 
antigens. 
Upon internalisation, the antigen typically travels down a progressively decreasing pH 
gradient through the early and fate endosomes before reaching the lysosomes (pH 4.5- 
5.0), the major site of intracellular proteolysis (Harding & Geuze, 1993). Antigens 
bound to the BCR may exhibit accelerated targeting into class II MHC- enriched 
compartments (Mitchell et al., 1995). The extent of processing required for a given 
antigen to be presented by a class II MHC molecule will depend upon the spatial 
environment of T cell determinants within the molecule. For example, an epitope within a 
tight globular protein may require proteolytic cleavage to be released from its steric 
constraints, whereas others may require simply the unfolding of the polypeptide. Antigen 
processing has been defined as any change in the protein which affords it the 
conformational flexibility to be able to interact with both the MHC peptide -binding site 
and, subsequently, the TCR (Allen, 1987). The size of a protein fragment does not 
dictate the need for processing and intact proteins may bind to class II MHC molecules via 
exposed determinants (Streicher et al., 1984; Lindner & Unanue, 1996; Arunachalam et 
al., 1998). 
The presence of an MHC- binding determinant within a protein is not sufficient to 
guarantee its presentation at the cell surface. In addition to ease of access, the specificity 
of the proteolytic enzymes encountered will have a major influence upon the 
immunodominance of different epitopes. Both exo- and endo -proteolytic activities 
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present within the acidic compartments of the endocytic route, including the aspartyl 
proteases (e.g. cathepsins D and E) and the cysteine proteases (e.g. cathepsins B, L and 
S; reviewed by Watts, 1997; Chapman, 1998 and McGrath, 1999). Additional enzymes 
within this system are still being discovered (Manoury et al., 1998). 
1.5.5 The effect of pH on the interaction of peptides with class II MHC 
molecules 
The rate of association of a peptide with a class II MHC molecule is unusually slow for a 
ligand- receptor interaction (Buus et al., 1986). Binding is proposed to proceed via a 
short-lived kinetic intermediate before undergoing a slow structural transition (Sadegh- 
Nasseri & McConnell, 1989). Once formed, the terminal peptide -aß complexes are 
extremely stable with half -lives ranging from several hours to days (Buus et al., 1986; 
Roche & Cresswell, 1990a). This is of considerable functional significance in allowing 
each peptide -bound class II MHC molecule to be surveyed adequately at the cell surface 
by the T cell population. 
In addition to the actions of HLA -DM ( §1.5.2), the formation of stable peptide -MHC 
complexes in vivo is facilitated by high proton concentration. The effect of pH on this 
reaction was first proposed to explain discrepancies observed between the efficient 
presentation of antigen in vivo (Harding et al., 1989; Davidson et al., 1991) and the slow 
rate of complex formation at neutral pH in vitro (Buus et al., 1986; Jensen, 1990). 
Agents that raised the pH in the endocytic compartments, such as ammonium chloride and 
chloroquine, inhibited efficient antigen processing (Ziegler & Unanue, 1982) and the 
formation of functional antigen -class II MEC complexes was accelerated markedly in 
vitro at pH values approximating those of the intracellular endosomal vesicles (Jensen, 
1990, 1992; Sadegh -Nasseri & Germain, 1991; Tampé & McConnell, 1991; Wettstein et 
al., 1991). 
An optimal rate of complex formation is achieved typically between pH 4.5 -6.0 (Jensen, 
1990; Harding et al., 1991; Mouritsen et al., 1992; Sette et al., 1992b). The optimum pH 
depends on both the particular peptide and class E MHC molecule under consideration 
(Wettstein et al., 1991; Sette et al., 1992b). As a result, individual class II MHC c43 
dimers have been proposed to load their peptide cargo in different locations within the 
endocytic pathway, as best suits their pH binding optima (Jensen, 1991; Sette et al., 
1992b). The exposure of different allotypes to distinct pools of peptides may be a means 
by which to broaden the peptide repertoire presented at the cell surface. 
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High proton concentration appears to accelerate not only the association of peptides with 
class II MHC molecules, but also the rate at which complexes dissociate (Sadegh -Nasseri 
& Germain, 1991; Tampé & McConnell, 1991; Reay et al., 1992; Sette et al., 1992b). 
This may still have the net result of enhancing the peptide- binding capacity by increasing 
the pool of active, unoccupied receptor sites available (Jensen, 1991; Sette et al., 1992b). 
The low -pH enhancement of both the association and dissociation rates of a peptide-a13 
complex may arise by such conditions increasing the conformational flexibility of the 
molecule to render the peptide -binding groove more accessible. Conformational changes 
have been detected in class II MHC proteins at acidic pH (Lee et al., 1992; Boniface et 
al., 1996; Runnels et al., 1996; Reich et al., 1997; Ullrich et al., 1997). 
1.5.6 The intracellular site of peptide -class II MHC complex formation, 
the MIIC 
Numerous studies have implicated the acidic compartments of the endocytic pathway as 
the site at which class II MHC molecules and peptides interact (Ziegler & Unanue, 1982; 
Harding et al., 1990; Jensen, 1990, 1991; Neefjes et al., 1990; Wettstein et al., 1991; 
Sette et al., 1992b). However, the exact location within this intracellular network at 
which peptide -aß complexes form has been difficult to pinpoint. Using the techniques 
of density -gradient electrophoresis (Tulp et al., 1994), immunoelectron microscopy 
(Harding & Geuze, 1993) and percoll- density gradient centrifugation (Qiu et al., 1994; 
West et al., 1994), the majority of class II MHC molecules have been identified to 
accumulate in a group of intracellular compartments, designated collectively the MIIC for 
'MHC class II compartments'. The conflicting morphology and marker profiles of the 
MIIC reported by different studies supports the notion that these are not specialised 
endocytic structures but, rather, a heterogeneous set of acidic vesicles exhibiting features 
of both late endosomes and early lysosomes (reviewed by Geuze, 1998 and Neefjes, 
1999). MIIC have been identified in all types of professional APC (Harding & Geuze, 
1993; Kleijmeer et al., 1995; Nijman et al., 1995; Peters et al., 1995). 
Newly- synthesised c4lIi nonamers may enter the endocytic route from the TGN at the 
level of the transferrin receptor -positive (TfR') early endosomes (Romagnoli et al., 1993; 
Castellino & Germain, 1995; Pond & Watts, 1999). However, the early endosomes are 
unlikely to be the sites of class II MHC peptide Ioading due to both their minimal 
proteolytic activity and lack of HLA -DM (Peters et al., 1995; Fernandez -Borja et al., 
1996). Instead, agli complexes progress to Iater endocytic vesicles in a process 
facilitated by the actin cytoskeleton (Barois et al., 1998). The first significant proteolytic 
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sites to be accessed by these complexes are the early MIIC. Some a(3Ii may also enter 
these compartments directly from the TGN (Lotteau et al., 1990; Neefjes et al., 1990; 
Peters et al., 1991, 1995). The early MIIC are TfR' like the early endosomes but also 
exhibit evidence of Ii degradation through the progressive disappearance of both lumenal 
and cytoplasmic epitopes of anti -Ii antibodies (Tulp et al., 1994; Kleijmeer et al., 1997). 
These compartments fit the description of the 'class II MHC- containing vesicles' (CIIV) 
identified by free -flow electrophoresis in the mouse B cell line, A20 (Amigorena et al., 
1994). Further Ii degradation takes place within the intermediate MIIC which are a 
collection of TfR- compartments characterised by the presence of abundant internal 
vesicles and the late endosomal marker, the mannose -6- phosphate receptor (MPR; 
Kleijmeer et al., 1994, 1996; Peters et al., 1995; Xu et al., 1995; Morkowski et al., 1997; 
Stang et al., 1998). Finally, the intermediate MIIC mature into the late MIIC. These are 
dense, multilaminar vesicles, positive for the lysosomal markers, cathepsin D, CD63, 
LAMP -1 and (3- hexosaminidase, but negative for MPR, TfR and invariant chain 
(Kleijmeer et al., 1994, 1996; Peters et al., 1995). All subclasses of the MIIC are 
enriched for class li MHC and FILA -DM (Sanderson et al., 1994a; Fernandez -Borja et 
al., 1996; Kleijmeer et al., 1997; Morkowski et al., 1997; Tan et al., 1997b) and maybe 
accessed by antigen internalised through membrane Ig, consistent with these being the 
major intracellular sites of class II MHC maturation (West et al., 1994). Peptide -loaded 
class II MI-IC molecules are detected in all MIIC but to the greatest extent in the late MIIC 
(Castellino & Germain, 1995; Kleijmeer et al., 1997; Morkowski et al., 1997; Stang et 
al., 1998). 
1.5.7 Deposition of peptide -uß complexes on the cell surface 
Once antigen -derived peptides have been loaded into the groove of class H MHC 
molecules in the MIIC, the complexes must migrate to the cell surface to present their 
cargo to the T cell repertoire. The TfR` early MIIC and CIIV may recycle their contents 
back to the plasma membrane directly by means of the conventional receptor -recycling 
pathway. However, for the TfR- intermediate and late MIIC, alternative mechanisms 
must exist. 
One possibility is that assembled peptide -class II MHC complexes from the later 1VIIIC 
might exhibit retrograde transport through the endocytic route and exploit the recycling 
machinery of the early endosomes. However, peptide -loaded class II MHC molecules are 
still able to reach the surface of B cells after these compartments have been ablated, 
suggesting that this is not the predominant mechanism (Pond & Watts, 1997). 
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Alternatively, the NIIIC may fuse directly with the plasma membrane. Protein markers of 
the MIIC, such as LAMP -1 and CD63, have been found in indentations on the surface of 
B cells, co- localised with class II MHC molecules (Raposo et al., 1996). These 
molecules would be expected to be internalised soon after reaching this site by virtue of 
the targeting signals in their cytoplasmic tails (Williams & Fukuda, 1990; Metzelaar et al., 
1991). The limiting membranes of class II MEC- positive vesicles have also been 
visualised fusing with the plasma membrane (Wubbolts et al., 1996). However, a kinetic 
analysis of this process suggests that it too is unlikely to be the major mechanism by 
which mature peptide -aß complexes are delivered to the cell surface (Raposo et al., 
1996). Another possibility is the existence of specialised transport vesicles. These would 
require some form of yet -uncharacterised sorting event in the M IC. Candidate class II 
MHC- enriched vesicles derived from phagolysosomes have been identified in 
macrophages (Harding & Geuze, 1992). 
1.6. Deviations from the classical pathway of class II MHC 
antigen presentation 
1.6.1 Class II MHC- mediated presentation of endogenous peptides 
Although the peptide repertoire sampled by class II MI-IC aß dimers in the MHC is 
derived predominantly from internalised extracellular proteins ( §1.5.4), an examination of 
the pool of naturally- processed peptides presented by these molecules reveals that some 
ligands originate from proteins that reside within the cell (Nelson et al., 1992; Chicz et 
al., 1993, 1994; Newcomb & Cresswell, 1993; Rötzschke & Falk, 1994; Harris et al., 
1996; Godkin et al., 1997). These may include viral antigens which have been 
synthesised during an infection (Sekaly et al., 1988; Jacobson et al., 1989; Jaraquemada 
et al., 1990; Nuchtern et al., 1990; Malnati et al., 1992, 1993; Khanna et al., 1997; 
Oxenius et al., 1997). In many cases, intracellular proteins are available to bind to class 
II MHC molecules simply by being natural inhabitants of the endocytic pathway. 
However, others are localised elsewhere within the cell with no obvious means of 
accessing the MIIC (e.g. Brooks et al., 1991; Brooks & McCluskey, 1993; Loss et al., 
1993). This has been termed the endogenous pathway of class II MHC antigen 
presentation (reviewed by Lechler et al., 1996). 
It is possible that determinants within some cytosolic proteins might gain access to class II 
MHC molecules in the endocytic route when the proteins are degraded in the lysosomes at 
the end of their useful lifespan, for example, transported via autophagie vacuoles (Dunn, 
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1990; Seglen & Bohley, 1992; Liou et aL, 1997) or by binding to specific receptors 
(Chiang et al., 1989; Cuervo & Dice, 1996). Others may enter these sites when entire 
dead cells are engulfed by phagocytosis. 
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An alternative mechanism is that class II MHC aß dimers may bind antigen in the ER 
prior to the interaction of Ii. This may involve either small protein fragments or partially - 
folded proteins which are subsequently trimmed (Weiss & Bogen, 1991; Biljmakers et 
al., 1994b; Busch et al., 1995, 1996; Lechler et al., 1996). Under normal conditions, 
this process is likely to involve only a minority of class II MHC molecules due to the 
molar excess of li present in the ER, its faster on -rate than that of antigen- derived peptides 
and the neutral pH within this site (Biljmakers et al., 1994h; Bodmer et al., 1994; Busch 
et aL, 1995). However, this phenomenon may be of some significance if the ratio of li to 
class II MHC molecules is altered, for example, during an inflammatory response or in 
the context of high antigen load during a viral infection. A population of class II MHC 
molecules form complexes with peptides and polypeptides in the ER of li° cells (Busch et 
al., 1995, 1996; Lechler et al., 1996). 
Class I MHC molecules may also deviate from their classical pathway of antigen 
presentation and display peptides of extracellular origins (e.g. Carbone & Bevan, 1990; 
Rock et al., 1990; Kovacsovics- Bankowskí et at., 1993; Pfeifer et al., 1993). In this 
respect, it is interesting to note that some empty class I MHC heterodimers are able to 
associate with Ii (Cerundolo et al., 1992; Sugita & Brenner, 1995; Vigna et al., 1996) and 
this interaction has been found to direct these molecules into the endocytic route (Sugita & 
Brenner, 1995). 
1.6.2 Role of class II MHC receptor recycling in antigen presentation 
Similar to other cell -surface receptors, peptide -bound class H MHC molecules on the 
plasma membrane may be internalised periodically into the early endosomes ( Pernis, 
1985; Schmid et al., 1988; Machy et al., 1990; Reid & Watts, 1990; Salamero et al., 
1990; Swier & Miller, 1995b). This process appears to be controlled by signal motifs 
located in each cytoplasmic tail of the a(3 dimer (Pinet et al., 1995; Zhong et al., 1997; 
Forquet et al., 1999). Within the early endosomes, the recycling class II MHC molecules 
encounter new antigens and may undergo peptide exchange (Adorini et al., 1989; Harding 
et al., 1990; Reid & Watts, 1990; Pedrazzini et al., 1991; Griffin et al., 1997; Pinet & 
Long, 1998). This represents a mechanism of ligand acquisition distinct from that 
involving the newly -synthesised a(3 dimers in the MIIC (§1.5.6; Davidson et al., 1991). 
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Only a minority of recycling class II MEC molecules are candidates for reuse. Most 
complexes formed between antigen- derived peptides and class II MHC molecules are very 
stable with half -lives approximating those of the aß dimers themselves (e.g. 
Lanzavecchia, 1987; Jensen, 1989, 1992; Lee & Watts, 1990; Lanzavecchia et al., 1992; 
Bot et al., 1996; Monji & Pious, 1997). Such molecules are unlikely to present more 
than one peptide antigen during their life -time. However, other peptide -class II MHC 
combinations have a higher rate of turnover (e.g. Ceppellini et al., 1989; Harding et al., 
1989; Adorini & Nagy, 1990a; Tampé & McConnell, 1991; Marsh et al., 1992; Muller et 
al., 1993; Poirier & Chain, 1993; Nelson et al., 1994). A population of class II MEC 
molecules associated with low affinity peptides, or even empty, has been detected on the 
surface of B cells in vivo (Germain & Hendrix, 1991). Peptide exchange by these 
molecules during recycling may enable more stable determinants to be presented to T 
cells. The displacement of one ligand in favour of a strong T cell responder has been 
observed in vitro (Reay et al., 1992). 
A number of class II MHC- restricted antigenic determinants have now been described that 
are able to be presented at the cell surface independently of protein synthesis and in the 
absence of Ii and HLA -DM, consistent with their binding to pre- existing molecules within 
the early endosomes (Nadimí et al., 1991; Pinet et al., 1994, 1995; Lindner & Unanue, 
1996; Griffin et al., 1997). TypicaIIy, only antigens that do not require extensive 
processing are suitable for presentation by the recycling receptors (Davidson et al., 1991). 
The early endosomes exhibit a much reduced catabolic capacity compared with the MIIC 
( §1.5.6; Schmid et al., 1988), such that only superficial epitopes within a protein are able 
to be Iiberated within this environment. Several determinants have been reported to 
associate with recycling class II MEC molecules as intact, partially unfolded polypeptides 
(e.g. Lindner & Unanue, 1996; Vergelli et al., 1997). The targeting of distinct antigens 
towards the pool of recycling all dimers might be influenced by the individual Ig subunits 
of the BCR (Bonnerot et al., 1995). Preprocessed peptides may also bind to the class II 
MHC molecules directly at the cell surface without need of internalisation into the early 
endosomes (Shimonkevitz etal., 1983; Ceppellini et al., 1989; Busch et al., 1990; Monji 
& Pious, 1997). 
1.6.3 The superantigens 
In addition to conventional peptide antigens, class II MHC molecules are also able to 
present another type of ligand to T lymphocytes, the superantigens (SAgs). These are a 
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novel class of proteins of microbial origins, so- called because of their potent ability to 
stimulate high numbers of T cells (an estimated 10-20% of the T cell repertoire compared 
with a conventional antigen response of <1 in 1000 T cells; reviewed by Li et al., 1999 
and Lavoie et al., 1999). Superantigens have been implicated in the development of 
numerous diseases. The Staphylococcus aureus enterotoxins (SEs) are associated with 
food poisoning (e.g. SEA and SEB; Kotzin et al., 1993) and the S. aureus TSST -1 
superantigen causes toxic shock syndrome (Bohach et al., 1990). The mouse mammary 
tumour virus (MMTV) superantigens play a critical role in viral transmission (reviewed by 
Acha -Orbea et al., 1999) and SAgs have also been implicated in the development or 
progression of rabies (Astoul et al., 1996), autoimmunity (Paliard et al., 1991; Brocke et 
al., 1993, 1998; Luppi & Trucco, 1996; Renno & Acha- Orbea, 1996; Conrad et al., 
1997; Schiffenbauer et al., 1998) and a number of skin conditions (Leung et al., 1993, 
1995; Cavarelli et al., 1997; Vath et al., 1997). 
The presentation of SAgs by class II MHC molecules is distinct from that of conventional 
peptide antigens. Processing of the protein by the APC is not required. X -ray 
crystallographic analyses of a number of different SAg- HLA -DR complexes have 
revealed that these proteins bind intact, predominantly outside the conventional peptide - 
binding site (Jardetzky et al., 1994; Kim et al., 1994; Dessen et al., 1997). For example, 
SEB interacts exclusively with the a, domain of the HLA -DRI heterodimer, to one side 
of the groove (Jardetzky et al., 1994). TSST -1 associates with both the a, and 131 
domains of the class II MHC molecule but also contacts residues of the associated peptide 
(Kim et al., 1994). The sequence of this peptide may modulate the degree of T cell 
stimulation by TSST -1 (von Bonin et al., 1995; Wen et al., 1996, 1997). 
The interaction between SAgs and T lymphocytes is also unique. The specificity of a T 
cell for a SAg is determined almost exclusively by the identity of the variable (3 -chain 
(Vß) domain of the TCR (e.g. Kappler et al., 1988; MacDonald et al., 1988; Pullen et al., 
1988; White et al., 1989; see below, §1.7.1). SAgs take advantage of the organisation 
inherent in conventional antigen presentation to nigger a subset of peripheral T cells 
directly through this region (Fields et al., 1996; Li et al., 1998). Such excessive 
stimulation then leads to a massive release of inflammatory cytokines and the eventual 
anergy or deletion of the activated T cells (Kawabe & Ochi, 1990, 1991; Rellahan et al., 
1990). 
General introduction 32 
1.7. Class II MHC- mediated presentation of antigen to CD4` T 
cells 
1.7.1 Class II MHC molecules and T cell activation 
T lymphocytes interact with MHC molecules on the surface of APC via the T cell receptor 
(TCR). This is a disulphide- linked, transmembrane heterodimer composed of a and ß 
polypeptides (alternatively, a minority of TCR are composed of y and S chains; Davis & 
Bjorkman, 1988). The a and R subunits are members of the fg superfamily and, like 
antibodies, are generated clonally by somatic rearrangement of germline variable (V), 
diversity (D) and joining (J) gene segments. Sequence hypervariability is prominent in 
the complementarity- determining regions (CDR) that form the binding interface of the 
TCR with the peptide -MHC complex (For reviews on the structural basis of the 
recognition of peptide -MHC complexes by T cells, including an examination of recent X- 
ray crystallographic data, see Garcia & Teyton, 1998; Mazza et al., 1998 and Garcia et 
al., 1999). 
Each TCR participates in a non -covalent interaction with a non -polymorphic, multi - 
subunit signalling complex, CD3, composed of y, S and e chains and a disulphide- linked 
homodimer (Weiss, 1993). The engagement of a peptide -bound MEC molecule by 
the TCR in the presence of appropriate costimulatory signals and the co- receptor 
glycoprotein, CD4 or CD8, activates tyrosine kinases leading to the phosphorylation of 
tyrosine residues within immunoreceptor tyrosine -based activation motifs (ITAMs) in the 
cytoplasmic tails of the CD3 components. This initiates a cascade of signalling events 
within the T lymphocytes via many different signal transduction pathways (reviewed by 
Clements et al., 1999; Germain & Stefanova, 1999 and Medema & Borst, 1999). 
A T cell becomes activated and mounts an effector response only when a defined number 
of TCR have been triggered (Viola & Lanzavecchia, 1996; Lanzavecchia, 1997; 
Lanzavecchia et al., 1999). This threshold may be lowered by the presence of co- 
stimulatory molecules. The efficiency with which TCR are triggered is influenced by the 
overall avidity of the MHC -TCR interaction. The avidity is defined as the product of the 
number of TCR on the cell surface, the number of peptide -MHC complexes upon the 
APC, the intrinsic affinity of the TCR for this complex and the affinity of the peptide for 
the MHC molecule (Kim et al., 1996; Alam et al., 1999; Legge et al., 1999). A typical B 
cell displays on its cell surface 105 -106 class II MHC molecules of any given allotype 
(Trucco et al., 1980; Ceppellini et al., 1989; Busch et al., 1990; Roucard et al., 1996). 
The minimum number of specific peptide -class II MHC complexes required for T cell 
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recognition and proliferation is estimated to be 10-100 per cell (Watts & McConnell, 
1986; Demotz et al., 1990; Harding & Unanue, 1990; Srinivasan et al., 1991). The 
sensitivity of this process may lie in the serial engagement of TCR ( Valitutti et al., 1995; 
Valitutti & Lanzavecchia, 1997). The MHC -TCR interaction typically displays a fast rate 
of dissociation (Corr et al., 1994; Matsui et al., 1994; Sykulev et al., 1994; Lyons et al., 
1996). This allows the same peptide -MHC combination to trigger multiple TCR and thus 
amplify and sustain the activation response, ultimately inducing cell -cycle progression, 
cytokine production and cellular proliferation. 
T cell responses to low- affinity antigens might also be facilitated by the formation of class 
II MHC superdimers. These complexes contain two parallel MHC molecules oriented in 
the same direction and have been observed by X -ray crystallography (Brown et al., 1993; 
Fremont et al., 1996), cell -surface fluorescence imaging (Cherry et al., 1998) and the 
immunoprecipitation of class II MHC molecules from B cells (Schafer & Pierce, 1994; 
Roucard et al., 1996; Schafer et al., 1998). It has been suggested that these 'dimers of 
dimers' may cross -link the TCR and signal B cells to up- regulate co- stimulatory 
molecules (Brown et al., 1993). The involvement of MHC dimerisation in T cell 
stimulation is not precluded by the serial engagement model of TCR ligation ( Valitutti et 
al., 1995) and the disruption of contact residues between the class II MHC superdimers 
has been shown to impact upon the activation of some T cell clones (Goodman et al., 
1995; Nydam et al., 1998). However, some evidence for the existence of class II MHC 
superdimers has been dismissed as crystallisation -packing phenomena and antibody - 
related artefacts (Hitzel et al., 1999). 
1.7.2 MHC molecules and the development of the T cell repertoire 
Immunocompetent T cells develop from bone marrow- derived stem cells within the 
thymus (reviewed by Zuniga- Pflücker & Lenardo, 1996; Rodewald & Fehling, 1998 and 
Spits et al., 1998). These lymphoid progenitors become committed to the T cell lineage 
through the actions of cytokines and develop into pro -thymocytes. Proliferation and 
further differentiation produces the pre -T cells which are now double positive for the co- 
receptors, CD4 and CD8, and express newly -rearranged a(3 TCR and the subunits of the 
CD3 complex. However, these immature CD4'CD8' cells are programmed to die. The 
rescue of thymocytes from this fate and their final steps of differentiation into mature T 
cells are dependent upon signals received from interactions between the TCR and MHC 
molecules. 
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The presentation of antigen by MHC molecules on the surface of APC is critical to the 
selection of a functional TCR repertoire from the initial pool of randomly -rearranged a(3 
dimers. Each clonally -restricted TCR produced by somatic rearrangement of the V, J and 
D region genes must be assessed for its capacity to interact with MHC molecules of the 
parental haplotype (i.e. MHC restriction). At the same time, the TCR must not exhibit too 
high an affinity for the self -peptides that are associated with the MHC molecules. This 
process is of crucial importance in preventing the release of mature, self -reactive T 
lymphocytes into the periphery, which could lead to the development of autoimmunity. 
In common with the activation of T cells in the periphery (§l .7.1), a popular model of T 
cell selection proposes a defining role for the overall avidity of an MHC molecule for a 
TCR in determining the fate of an immature T cell, i.e. the interrelationship between the 
number of TCR on the thymocyte, the number of peptide -MHC complexes on the 
selecting APC, the affinity of the TCR for this complex and the affinity of the peptide for 
the MHC molecule (Ashton -Rickardt et al., 1994; Ashton -Rickardt & Tonegawa, 1994). 
Cells that express TCR that are unable to interact productively with the self -MHC, i.e. an 
MHC -TCR interaction of very low avidity, are destined to die from neglect. Those 
whose TCR bind to peptide -MHC complexes with an overall avidity above this threshold 
are rescued from programmed cell death by positive selection. However, if the MHC- 
TCR avidity is too high, negative selection occurs upon this population and the thymocyte 
is targeted for clonal deletion by apoptosis or functional inactivation (anergy). In this 
way, T cells are selected to be 'tolerant' of self -antigens (For reviews on T cell selection, 
see Anderson et al., 1999 and Sebzda et al., 1999) 
Double- positive CD4 +CD8+ thymocytes are located predominantly within the thymic 
cortex (Shortman et al., 1990). Epithelial cells within this site (cTEC) mediate the 
positive selection of T cells (Anderson et al., 1994; Ernst et al., 1996). The interaction 
between the TCR and M-TC molecules at this stage also defines the lineage commitment 
of each immature T cell. Thymocytes differentiate into either CD8+ or CD4+ single - 
positive cells dependent upon the specificity of their TCR aß dimer for class I or class II 
MHC molecules on the cTEC (Teh et al., 1988; Kaye et al., 1989). Negative selection of 
potentially self -reactive T cells takes place subsequently at the cortico- medullary junction 
upon bone marrow- derived dendritic cells and macrophages (Lo & Sprent, 1986). It is 
estimated that as few as 3 -5% of thymocytes may make the transition from the immature 
double -positive to mature single -positive phenotype ready for release into the periphery 
(Shortman et al., 1990). 
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It is of interest to note that the maturation of class II MHC molecules differs between the 
two cell populations involved in the thymic selection of CD4` T cells. While cathepsin S 
catalyses the Iate stages of Ii degradation in bone marrow -derived APC 01.5.1), 
cathepsin L performs this role in the cTEC (Cresswell, 1998; Nakagawa et al., 1998). 
Class II MHC molecules expressed by cTEC have also been reported to exhibit a longer 
association with fragments of Ii than those within medullary TEC or peripheral APC (Farr 
et al., 1996; Kasai et al., 1996; Oukka et al., 1997). The recent description of a novel 
serine protease that is restricted in expression to the c'I'LC provides further evidence of a 
unique proteolytic environment within these cells (Bowlus et al., 1999). The need for 
antigen presentation by class II MHC molecules to be equivalent between the APC 
mediating negative selection in the thymic medulla and those circulating in the periphery is 
understandable. However, it is less clear why the positively -selecting cTEC should 
differ. 
1.8. A pivotal role for CLIP in the class II MHC pathway of 
antigen presentation 
A remarkable feature of Ii is its ability to maintain chaperone functions for nascent class II 
MHC molecules even throughout its proteolysis in the endocytic compartments. Essential 
to this property is the interaction of Ii with the 03 dimers via the CLIP region irrespective 
of allotype, unlike the specificity exhibited for antigen- derived peptides. The generation 
of the CLIP aI complex is a critical point in the class II MHC pathway of antigen 
presentation. Upon this structure hinges the eventual outcome of every newly - 
synthesised class II MHC molecule. For example, if CLIP is released from the aß dimer 
prematurely, an inappropriate peptide may bind or, equally undesirable, the empty 
molecules may aggregate and thereby he targeted for degradation. On the other hand, if 
the timely release of CLIP in the MTIC is disrupted, class II MHC molecules will not duly 
he able to bind suitable peptide ligands. In both instances, the consequence of this 
deviation from the desired outcome is the same - deficiency in a critical part of the cell - 
mediated immune response. 
1.9. Project objectives 
With the fundamental aim of elucidating the molecular mechanisms underlying the 
promiscuous associations of CLIP with different class II MHC allotypes, the research 
presented herein explores the binding of this sequence to the mouse a13 dimers, I -Ad, I- 
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Au, I -Ak and I -Ed, At the commencement of this project, the interaction of CLIP with 
class H MHC had yet to be examined by X -ray crystallography. Nevertheless, there 
already existed a significant amount of evidence to support the notion that this sequence 
may occupy the peptide- binding groove, suggesting that CLIP must possess unique 
features that allow it to overcome the structural variability of each distinct binding groove. 
It was the immediate goal of this research to determine the basis of this peculiar property 
of CLIP by examining the binding of side -chain or configurationally -substituted 
analogues of mouse CLIP86 -104 and, additionally, sets of length -altered CLIP and 
frameshifted 15 -mers. 
Having defined the general motif by which CLIP interacts with the groove of a variety of 
class H MHC molecules, it became apparent that this sequence might be employed as a 
mechanistic probe to compare the binding properties of different allotypes. Of greatest 
interest would be an investigation to advance our understanding of the relationship 
between disease susceptibility and certain MHC allelic variants. The non -obese diabetic 
(NOD) mouse is an animal model of the chronic human autoimmune disorder insulin 
dependent diabetes mellitus (IDDM) and expresses an atypical class II MHC molecule, I- 
Ag7. This molecule is one of several examples of MHC allotypes known to influence the 
risk to an individual of developing autoimmunity. The I -Ag' molecule contains two 
unique mutations within the peptide -binding site and therefore may be expected to display 
altered CLIP binding properties. The differences revealed have been rationalised in terms 
of the role of I -Ag' in diabetes aetiology. 
CHAPTER 2. 
Materials and Methods 
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The general experimental protocols and reagents used routinely throughout this research 
are described in this chapter. All research reported in this thesis was carried out under 
PC2 laboratory conditions as stipulated by the Genetic Manipulation Advisory Committee 
(GMAC) of Australia. Use and disposal of radioactive substances was performed in 
accordance with the Australian National University (ANU) radiation safety guidelines. 
2.1. Reagents, buffers and media formulations 
The specific chemical reagents used in the laboratory procedures described in this thesis 
are given in Appendix A, together with the supplier's name. Unless specified otherwise, 
all reagents and chemicals used are of analytical grade. Buffer solutions and cell culture 
media are detailed in Appendix B. 
2.2. Cell culture 
2.2.1 Cell lines 
All antigen -presenting cell lines used in this research are listed in Table 2.1, together with 
details of the class II M-IC molecules expressed and source. Table 2.2 provides 
information on the class II MHC- restricted T cell hybridomas used in the antigen 
presentation assays. The mouse helper T cell line, HT -2 (Watson, 1979) used in the 
interleukin -2 (IL -2) bioassay 02.7.1) was provided by Prof. H. O. McDevitt, Stanford 
University, CA, USA. 
2.2.2 Cell growth conditions 
Mammalian cell lines were maintained in RPMI 1640 culture medium (Commonwealth 
Serum Laboratories, VIC, Australia; Appendix BI) supplemented with 2 g/L sodium 
bicarbonate, 5 -10% (v /v) heat- inactivated foetal bovine serum (FBS; Trace Biosciences, 
NSW, Australia), 0.05 mM (3- mercaptoethanol, 2 mM L- glutamine, 10 mMHEPES and 
antibiotics (100 U /mL penicillin, 100 .tg/mL streptomycin). All media were sterilised by 
passage through 0.2 um cellulose acetate membrane bottle -top filters (Costar Scientific, 
MA, USA) before use. In this thesis, the terms `culture medium' or `RPMI' refer to the 
complete 10% (v /v) FBS/RPMI formulation described here, unless stated otherwise. Cell 
lines transfected with cDNA encoding class II MHC genes also co- express the neo 
Table 2.1 Antigen -presenting cells 
APC Class II MHC Source Reference 
A20 AadAßd, EadEßd McDevitt° Kim et al. (1979) 
CH27 AakA(3k, Ea'`E(3k McDevitt° Houghton et al. (1986) 
M12.A3' EadEßd Cooke` Glimcher et al. (1985) 
M12.C3° class H MHC negative McDevitt° Glimcher et al. (1985) 
1 -5.41' Aa °A(3° this lab Gautam et al. (1992) 
M12.D1' AadAI3d McDevitt`' unpublished 
M12.NOD` EadEßd, AadA(3c7 Cooker Quartey -Papafio et al. (1995) 
M12.ASP' EadEßd AadA3g7Aws7 Cooked Quartey -Papafio et al. (1995) 
M12.PRO` EadEßd, AadAßg7Pross Cooker Quartey- Papafio et al. (1995) 
°Derived by y- radiation mutagenesis of the H -2d B cell lymphoma, M12.4.1. The MI2.C3 cells express intact Ea "Eß" polypeptides 
but they are glycosylated abnormally and fail to reach the cell surface. In both M12.C3 and M12.A3 cells, the Aßd gene is defective 
but the Aad gene is transcribed normally and endogenous Aad may form functional hybrids with transfected Aß gene products. 
'Derived from M12.C3 by transfection of cDNA encoding Ace and A(3" (1 -5.4) or Act' and A(3d (M12.D). 
`Derived from M12.A3 by transfection of genomic DNA encoding AV' (M12.NOD) or AV encoding an aspartic acid at position 57 
(M12.ASP) or a proline at position 56 (M12,PRO). 
dSupplied by Prof. H. O. McDevitt, Stanford University, CA, USA. 
`Generously provided by Dr A. Cooke, University of Cambridge, Cambridge, UK. 
Table 2.2 T cell hybridomas 
T cell hybridoma H -2 restriction Peptide specificity Source Reference 
3D0 -54.8 I-Aa Ova323-339 Marrack" Shimonkevitz et al. (1983) 
3A9 I-Ak HEL46-61 Allen" Allen & Unanue (1984) 
1934.4 I-A° MBP Acl-11 this lab Wraith et al. (1989) 
13.26 I-E° SWM132-147 Jones` Morel et al. (1987) 
12 -26X I-E° 7,.rep 12-26 Jones` unpublished 
1H11.3 HEL105-120 Adorini° Adorini et al. (1988a) 
2G7.1 I-Ek HEL1-18 Adorini`t Adorini etat. (1991) 
4C1.6 I-Ek HEL108-116 Adorini`' Leighton et al. (1991) 
2B4 I-Ek mCytc88-103 Davis' Samelson et al. (1983) 
'Gift from Prof. P. Marrack, National Jewish Hospital and Research Centre, CO, USA. 
bGift from Prof. P. M. Allen, Washington University School of Medicine, MO, USA. 
`Gift from Prof. P. P. Jones, Stanford University, CA, USA. 
"Supplied in collaboration with Dr L. Adorini, Roche Milano Ricerche, Milan, Italy. 
`Gift from Prof. M. M. Davis, Stanford University, CA, USA. 
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antibiotic resistance gene and these cultures were positively selected for one week at 
monthly intervals in culture medium supplemented with the antibiotic, G -418 sulphate 
(Geneticin; Gibco BRL, NY, USA; Southern & Berg, 1982): 200 µg/mL for 1 -5.4 and 
M12.D; 1 mg /mL for M12.NOD, M12.PRO and M12.ASP. Growth medium for the IL- 
2- dependent cell line, HT -2, was supplemented with 50 U /mL recombinant mouse IL -2, 
provided kindly by Ms E. R. O'Neill, JCSMR. All cell lines were treated for one week at 
4-5 monthly intervals with Mycoplasma Removal Agent (ICN Biomedicals, Tokyo, 
Japan) at 0.5 p.g /mL. 
Cell cultures were maintained in polystyrene, gamma -irradiated tissue culture flasks 
(Nunc, Roskilda, Denmark) at 37 °C in a 5% CO, atmosphere within an automated 
incubator (model 3194; Forma Scientific, OH, USA) with humidity provided by a 
solution of 0.025% (w /v) benzalkonium chloride/ 1% (w /v) SDS in sterile ddH2O. 
Incubators were disinfected regularly with 75% (v /v) ethanol (EtOH) or a solution of the 
virucidal disinfectant, Virkon (Antec International, Suffolk, UK) prepared according to 
the manufacturer's specifications. 
Centrifugation of cells for the purpose of counting or washing was performed in IS mL 
polypropylene, gamma -irradiated, conical Falcon tubes (Becton Dickinson, NJ, USA) at 
300 x g for 3-4 minutes in a Clements 2000S benchtop centrifuge (1200 rpm; NSW, 
Australia). Viable cell numbers were determined by the exclusion of the vital dye, trypan 
blue (0.4% w /v; Sigma Chemical Co., MO, USA), as observed on a haemocytometer 
under a light microscope. 
2.2.3 Cryogenic storage of cell culture collections 
Samples of all cell lines used in this research were stored cryogenically to maintain tissue 
culture collections. Healthy, rapidly -dividing cells were pelleted by centrifugation at 4 °C 
(300 x g, 3-4 min) and washed once in fresh RPMI. Cell pellets were resuspended at 
106 cells per mL in chilled culture medium containing 10% (v /v) dimethyl sulphoxide 
(DMSO) as a cryoprotectant. Aliquots of 1 mL were dispensed into polypropylene 
CryoTubes (Nunc, Roskilda, Denmark) and frozen slowly on dry ice before transferring 
to liquid nitrogen for long -term preservation. 
To reconstitute frozen cell lines, vials were thawed quickly in a 37 °C waterbath and 9 mL 
of culture medium (prewarmed to 37 °C) was added immediately to dilute the DMSO 
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cryoprotectant. Cells were washed twice in fresh RPIVI to remove any traces of DMSO 
and resuspended in a sterile culture vessel for cell proliferation. 
2.3. Synthetic peptides 
2.3.1 Peptide synthesis 
The synthetic peptides used in this research are listed in Table 2.3. Specific substituted 
and/or truncated analogues of CLIP are detailed in the relevant chapters. All peptide 
syntheses were performed at the ANU Biomolecular Resource Facility (ACT, Australia) 
by Mr K. N. McAndrew and Dr P. J. Milburn. 
The sets of substituted CLIP a- carboxamide analogues were assembled using the solid - 
phase simultaneous multiple- peptide synthesis (SMPS) methodology described by 
Houghten (1985) which employs standard tert- butoxycarbonyl (t -Boc) chemistry and 1% 
cross-linked p-methylbenzhydrylamìne polystyrene resin. Following a- deprotection, 
side -chain deprotection and cleavage from the resin were achieved by solvolysis in liquid 
hydrogen fluoride using 10% anisole as a carbonium ion scavenger (Houghten et al., 
1986). The peptide and resin were then washed twice with diethyl ether to remove 
organic compounds and the peptide was dissolved in 10% acetic acid and lyophilised. 
Antigen- derived peptides and large batches of CLIP were synthesised using standard 9- 
fluorenylmethoxycarhonyl (Fmoc) /N- methylpyrolidone chemistry on 1% cross -linked p- 
hydroxymethylphenoxymethylpolystyrene resin with an Applied Biosystems peptide 
synthesiser (model 430A; Perkin Elmer, CA, USA). Cleavage and deprotection were 
achieved in 95% TFA in the presence of the appropriate scavengers. Crude peptides 
synthesised by either Fmoc or t -Boc chemistry were purified to premium grade ( >99% 
purity) by dissolving in a minimal volume of 3 M guanidine thiocyanate, 0.1 M potassium 
phosphate, pH 4.0 and eluting from reversed -phase C18 HPLC columns using 
acetonitrile gradients in 0.1% aqueous trifluoroacetic acid (TFA). Product integrity was 
confirmed by mass spectroscopy and lyophilised peptide stocks were stored in 
chemically- resistant, air -tight plastic vials at -20 °C. To reduce moisture absorption, 
vessels were equilibrated to room temperature before opening. 
Where required, biotinyl moieties were conjugated to peptides while still on the resin. N- 
terminal biotinylation was performed after a- deprotection in a solution of 20 mM 
sulfosuccinimidyl 6- (bíotinamido) hexanoate (Pierce, IL, USA; 1.0 mL per 20 µmoles of 
Table 2.3 Synthetic peptides 
Source protein Peptide Amino acid sequence MW H -2 restrictions 
Bacteriophage X cI repressor ñsepl2-26 LEDARRLKAIYEKKK 1862 I-Ad, I-Ed'k 
Heat shock protein, mouse (HSP60) p12(166-185) EEIAQVATISANGDKDIGNI 2059 I-Ag7 
Hen egg lysozyme HEL1-18 KVFGRCELAAAMKRHGLD 2003 I-Ek 
HEL 10-23 AAMKRHGLDNYRGY 1652 I-A57 
HEL46-61 NTDGSTDYGILQINSR 1754 I-Aa,k 
HEL105-120 MNAWVAWRNRCKGTDV 1907 I-E,d.k I-Ak 
Invariant chain, mouse CLIP81-109" LPKSAKPVSQMRMATPLLMRPMSMDNMLL 3291 all mouse allotypes 
Moth cytochrome c mCytc88-103 ANERADLIAYLKQATK 1805 I-Ek 
Mouse serum albumin MSA560-574 KPKATAEQLKTVMDD 1675 I-Ag7 
Myelin basic protein, rat MBP Ac1-1 16 ACASQKRPSQRHG 1293 I-A" 
Myelin oligodendrocyte glycoprotein, rat rMOG8-22 PGYPIRALVGDEQED 1659 I-A7 
Ovalbumin, chicken egg Ova322-339` KISQAVHAAHAEINEAGR 1902 Ad.k,u.g7 
Sperm whale myoglobin SWM132-147 NKALELFRKDIAAKYK 1909 I-Ed 
"Mouse CLIP is numbered according to the human p31 Ii sequence (Chapter 1, Figure 1.5) throughout this work for ease of comparison between these systems. 
bAc denotes amino -terminal acetylation 
`Unless to be biotinylated, ovalbumin peptide was synthesised with an additional C- terminal tyrosine residue (Ova323 -339Y) to increase solubility in aqueous solutions. 
dI -Ad.k- binding peptides taken from Sette et al. (1989a) and Adorini et al. (1988b); I -E°J'- binding peptides from Schild et al. (1995); I -A "- binding peptides from Zamvil et 
al., 1986 (MBP Act -11) and Gautam et al., 1992 (Ova323 -339); I -Ag7- binding peptides from Bockova et al., 1997 (p12(166- 185)), Hurtenbach et al., 1993 (HEL1O -23), 
Reich et al., 1994 (MSA560 -574), Amor et al., 1996 (rMOG8 -22) and Smilek et al., 1990 (Ova323 -339). 
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peptide) and 100 mM N- hydroxybenzotriazole in 1:1 (v /v) N,N- 
dimethylformamide/dichloromethane. The reaction mixture was shaken vigorously at 
room temperature for 1 hour. The biotinylated peptides were deprotected, cleaved and 
purified following normal procedure. 
2.3.2 Preparation of peptide stock solutions 
43 
Lyophilised peptides were reconstituted to a stock concentration of 5 mM in sterile 
phosphate- buffered saline (PBS; Appendix B1) containing 0.01% (w /v) sodium azide. 
To help preserve the chemical integrity of peptides in solution, stocks were stored at - 
20°C in single -use aliquots. Peptides that are poorly soluble in aqueous solutions may 
exhibit cytopathic effects on lymphocytes at high concentrations in vitro (Amor et al., 
1996). To aid dissolution of such peptides, a small volume of sterile 20% (v /v) 
DMSO/PBS was added. For antigen presentation assays and cell -surface peptide binding 
assays, peptides were diluted subsequently into RPMI culture medium, thereby avoiding 
possible cytotoxic effects by ensuring a final concentration of DMSO of less than 0.1 %. 
For assays using purified class 11 MHC, known water -insoluble peptides were dissolved 
at 10 mM in 100% DMSO and diluted subsequently to 1 -5 mM with aqueous 0.01% 
(w /v) NaN3/PBS solution. 
2.3.3 Measurement of circular dichroism 
To examine the secondary structure of D- amino acid -substituted CLIP86 -104, circular 
dichroic (CD) spectra were measured. Peptides were dissolved in 50% (v /v) 
trifluoroethanol/ 10 mM sodium phosphate, pH 7.4 at a concentration of 50 p.M and 
placed into a quartz cell with a 1 mm pathlength. Circular dichroism was recorded at 
25 °C using a Jovin Yvon CD6 spectrometer (Instruments SA, NJ, USA) with time 
averaging over 2 seconds per 0.2 nm increment. All CD measurements were performed 
by Dr P. J. Milburn of the ANU Biomolecular Resource Facility, ACT, Australia. 
2.4. Antibodies 
2.4.1 Antibody sources 
All monoclonal antibodies used in this research are listed in Table 2.4, together with their 
Table 2.4 Monoclonal antibodies. 
Antibody Specificity Subclass Hybridoma Source Reference 
14 4 4S I-Ea° k,P,r,a IgG2a ATCC HB 32 McDevittd Ozato et al. (1980) 
MK-D6 I_ARaP,9 IgG2a ATCC HB 3 McDevittd Kappler et al. (1981) 
10-3.6.2 I_ A ¡f,k.rs,u,g7 IgG2a ATCC TIB 92 McDevitt' Oi et al. (1978) 
10-2.16 I A (ìFr'f,kr,s,u,g7 IgCJ26 ATCC TIB 93 ATCC` Oi et al. (1978) 
M5/114.15.2 I_Aßb.a.9 I-Eak IgG2b (rat) ATCC TIB 120 McDevittd Bhattacharya et al. (1981) 
OX6° I_Af,k,r,s.u,g7 IgG, MRC-0X6 Cookef McMaster & Williams (1979) 
P4H5 Ii lumenal domain IgGI P4H5 Jones" Mehringer et al. (1991) 
In-1 Ii cytoplasmic domain` IgG2 In-1 Jonesg Koch et al. (1982) 
°OX6 recognises a common determinant present on H -2A molecules of several mouse strains including NOD (I -A "7) and the NOD mutants I -Ag' 7 
and I- A "7Pro5" (Quartey -Papafio et al., 1995) but not I -A' (Liu et al., 1993). It was raised against rat I- A- equivalent, RT1.B class II MHC molecules. 
'Hamster mAb raised against the mouse Ii peptide 100 -117 (RPMSMDNMLLGPVKNVTK) 
`Recognises a determinant in the N- terminal cytoplasmic tail of Ii. 
'Supplied by Prof. H. O. McDevitt, Stanford University, CA, USA. 
Purchased from the American Type Culture Collection, MD, USA. 
(Purified 0X6 -FITC was kindly provided by Dr A. Cooke, University of Cambridge, Cambridge, UK. 
"Gift from Prof. P. P. Jones, Stanford University, CA, USA. 
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specificity, IgG subclass and source. 
The following polyclonal antibodies were purchased from Pierce (IL, USA): 
- Goat anti -mouse IgG (H +L), unconjugated 
- Goat anti -rat IgG (H +L), unconjugated 
- Goat anti -rat IgG (H +L), horseradish peroxidase- conjugated 
2.4.2 Protein A purification of monoclonal antibodies 
Monoclonal antibodies were purified by the low salt, Protein A- Sepharose affinity - 
chromatography method described by Harlow & Lane (1988). Ascitic fluid or the culture 
supernatant of mAb- producing hybridomas were used as sources of crude antibody, 
estimated to contain between 1 -10 mg/mL and 20 -50 µg /mL of antibody, respectively 
(Harlow & Lane, 1988). Briefly, 1 -2 mL columns of pre -swollen Protein A- Sepharose 
6 MB (Pharmacia Biotech, Uppsala, Sweden) were poured and equilibrated in 50 mL 100 
mM Tris, pH 8.0. A 1 mL column of swollen Protein A- Sepharose may adsorb between 
10-20 mg of pure IgG (Harlow & Lane, 1988) and is therefore sufficient for 1 -2 mL 
ascitic fluid or 200 -400 mL of culture supernatant. The pH of the antibody solution was 
adjusted to 8.0 with a 1 /10 volume of 1.0 M Tris, pH 8.0 and the solution was passed 
several times through the protein A- Sepharose column. The beads were washed 
sequentially with 10 column volumes each of 100 mM Tris, pH 8.0 and 10 mM Tris, pH 
8.0 (Appendix B2.1). Antibody was eluted with 100 mM glycine, pH 3.0 and 15 
samples of 500 pL each were collected into 50 µL 1 M Tris, pH 8.0 in microfuge tubes. 
Fractions containing the immunoglobulins were identified from UV absorbance readings 
at 280 nm and the concentration of the purified mAb was calculated (A280 of 1 = 0.75 
mg/mL IgG; Harlow & Lane, 1988). All antibody -containing fractions were pooled and 
dialysed (cellulose acetate tubing, MW cutoff >_ 12000; Sigma Chemical Co., MO, USA) 
against PBS for 2 days at 4 °C. Purified antibody was stored at 4 °C in PBS with NaN3 
added to 0.02% (w /v). 
2.4.3 Biotinylation of monoclonal antibodies 
Monoclonal antibodies were conjugated to an N- hydroxysuccinimido ester of biotin using 
the method of Goding (1983). Briefly, 1 -2 mg/mL purified monoclonal antibody was 
dialysed at 4 °C against 500 mL biotin labelling buffer, pH 8.4 (Appendix B2.2) with 
three changes over 2 days. The protein concentration was determined by the UV 
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absorbance at 280 nm (A280). A fresh IO mg /mL anhydrous solution of N- 
hydroxysuccinimidobiotin (NHS- biotin; Pierce, IL, USA) was prepared in DMSO and 10 
µL was added for each milligram of antibody. The conjugation mixture was incubated for 
1 -2 h at room temperature then unreacted biotinylation reagent was removed by dialysis at 
4 °C against 500 mL 0.1% (w /v) NaN3/PBS with three changes over 2 days. Biotinylated 
mAb were stored at 4 °C. 
2.4.4 Fluoresceination of monoclonal antibodies 
Monoclonal antibodies were conjugated to the fluorochrome, fluorescein isothiocyanate 
(FITC) using the method described by Coligan et al. (1994). Briefly, purified 
monoclonal antibody was dialysed against 500 mL FITC labelling buffer (Appendix 
B2.3) at 4 °C with three changes over 2 days to remove free NH4' ions and raise the pH to 
9.2. The concentration of the dialysed antibody was determined from the UV absorbance 
at 280 nm. A 5 mg/mL stock of anhydrous FITC (Pierce, IL, USA) in DMSO was 
prepared immediately before use and 20 !IL was added dropwise for each milligram of 
antibody. The tube containing the conjugation mixture was wrapped in aluminium foil 
and agitated by inversion for 2 hours at room temperature. Unreacted FITC was removed 
by dialysis in 500 mL FITC dialysis buffer (Appendix B2.3) at 4'C in darkness with 
three changes over 2 days. Fluoresceinated mAb were stored in darkness at 4 °C. 
2.5. Sodium dodecyl sulphate -polyacrylamide gel 
electrophoresis (SDS -PAGE) and protein detection 
Proteins were separated for analytical purposes using SDS -PAGE. All gel 
electrophoresis was performed using an XCeII II Mini -Cell apparatus (Novel 
Experimental Technology (NOVEX), CA, USA). 
2.5.1 Tris -glycine SDS -PAGE 
SDS -PAGE was performed routinely using the Tris -glycine gel system (Laemmli, 1970). 
All Tris -glycine gels were prepared according to the formulations given by Harlow & 
Lane (1988). Protein samples were diluted with Tris -glycine sample buffer containing 
2% (w /v) SDS (Appendix B3.1) and loaded onto a 5% stacking geI (pH 6.8) overlaying a 
resolving gel (pH 8.8) of 10 %, 12% or 15% (w /v) acrylamide (Appendix B3.1). 
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Denatured samples were prepared in sample buffer supplemented with 2 -5% (v /v) of the 
reducing agent, 2 -ME, and boiled for 5 min before loading, In accordance with a 
discontinuous buffer system, gels were run in a Tris - glycine running buffer, pH 8.3 
(Appendix B3.1) and all buffers contained 0.1% (w /v) SDS. Electrophoresis was 
performed at a constant voltage of 80 V through the stacking gel and then increased to 150 
V for protein resolution. Molecular weight ranges were visualised during electrophoresis 
using rainbow -coloured high -range protein MW markers (Amersham, Buckinghamshire, 
UK) prepared for loading as for the denatured samples. 
2.5.2 Tris -tricine SDS -PAGE 
For the resolution of low molecular weight proteins and large peptides, samples were 
separated on pre -cast NOVEX Tris- tricine gradient gels (10 -20% (w /v) acrylamide) using 
a discontinuous buffer system, as developed by Schägger & von Jagow (1987). Samples 
were prepared for loading by dilution in Tris- tricine sample buffer containing 2% (w /v) 
SDS (Appendix B3.1). For denatured samples, the sample buffer was supplemented 
with 2 -5% (v /v) 2 -ME and samples were boiled for 5 minutes before loading. Gel 
running buffers consisted of 0.2 M Tris, pH 8.9 in the outer tank (anode; Appendix 
B3.1) and a Tris- tricine buffer, pH 8.3 containing 0.1% SDS in the inner tank (cathode; 
Appendix B3.1). Gels were run at 125 V constant voltage for 90 min. As with Tris- 
glycine gels ( §2.5.1), the inclusion of a rainbow MW marker on each gel permitted 
visualisation of electrophoresis. 
2.5.3 Silver staining of SDS -polyacrylamide protein gels 
Proteins were stained with silver salts using the method described in detail by Sambrook 
et al. (1989). Protein samples were separated on 12% SDS- polyacrylamide gels by the 
standard protocol ( §2.5.1). To estimate the molecular weight of electrophoresed proteins, 
a 2 volume of uncoloured, mid -range protein molecular weight markers (Promega, 
WI, USA) was run alongside the protein samples on each gel prepared for silver staining. 
Upon completion of SDS -PAGE, gels were removed from their plates and rinsed briefly 
in ddH2O. To obtain optimal silver staining results, handling of gels was minimised and 
all silver staining procedures were performed using scrupulously clean glassware. All 
solutions were prepared using ddH2O to minimise contaminants that may interfere with 
the sensitivity of silver staining. Electrophoresed proteins were fixed in gel- fixing 
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solution (Appendix B3.2) for 3 -12 h at room temperature. An extended fixing time was 
found to be optimal to ensure complete diffusion of SDS and 2 -ME from the gel matrix 
which interfered with silver staining. When the acid had leeched fully into the gel 
(bromophenot blue in the sample buffer turns yellow), gels were rocked gently in 30% 
(v /v) EtOH for 30 minutes twice, then rehydrated with three 10 min washes in ddH2O. 
Proteins were stained using a 0.1% (w /v) solution of silver nitrate (freshly diluted in 
ddH2O from a 20% (w /v) stock; Appendix B3.2) for 30 min. Both sides of the gel were 
washed for 20 seconds under a gentle stream of ddHZO, then the stain was developed by 
incubating the gel in a freshly -prepared solution of sodium carbonate/ formaldehyde 
(Appendix B3.2) until bands were visible. The reaction was quenched in a I% (v /v) 
acetic acid solution for 5 min and the gel was washed twice in ddH2O for 10 -20 min. 
Gels were dried at 80 °C for 2 h onto damp blotting paper using a vacuum gel drier (model 
583; Bio -Rad, CA, USA). 
2.5.4 Western blotting 
For immunodetection and analysis, proteins were immobilised on Trans -Blot 
nitrocellulose membranes (Bio -Rad, CA, USA) by electrophoretic transfer from SDS- 
polyacrylamide gels. Electroblotting was performed in an XCe11 II Mini -Cell Blot module 
(NO VEX, CA, USA) at 30 V constant for 1.5 -2 h using the NOVEX- recommended 
Western transfer buffer (Appendix B3.3). The efficiency of transfer was monitored by 
the movement of pre- stained rainbow protein standards (Amersham, Buckinghamshire, 
UK). 
After transfer, nitrocellulose membranes were washed briefly with PBS and then dried at 
room temperature for at least 30 minutes. To prevent non -specific adsorption of 
immunoreagents, membranes were incubated in Western blocking buffer containing 0.1% 
(v /v) Tween -20 and 5% (w /v) low fat milk powder (Appendix B3.3) either at room 
temperature for 1.5 h or at 4 °C overnight. Biotinylated primary antibody was diluted as 
appropriate in Western blocking buffer and hound to target proteins on the membrane by 
incubation either overnight at 4 °C or for 1.5 h at room temperature. Unbound primary 
antibody was removed by rinsing membranes twice briefly in Western wash buffer 
containing 0.1% (v /v) Tween -20 (PBS -T; Appendix B3.3) followed by 3 longer washes 
(1 x 15 min, 2 x 5 min). Membranes were probed with a horseradish peroxidase- 
streptavidin conjugate (S -HRP; Pierce, IL, USA) for 1 h at room temperature followed 
by three washes in Western blocking buffer (15 min each) and two washes in Western 
Materials and Methods 49 
wash buffer (5 min each). Protein immunodetection was achieved by enhanced 
chemiluminescence (ECL) using a Western blot ECL kit (Amersham, Buckinghamshire, 
UK). Chemiluminescent blots were recorded on X -OMAT autoradiography film (Kodak, 
NY, USA) and the molecular weight of proteins estimated by reference to ECL 
biotinylated protein molecular weight standards (Amersham, Buckinghamshire, UK). 
2.6. Purification of class II MHC proteins 
Mouse class II MHC molecules were purified from detergent lysates of B cell lymphomas 
by immunoaffinity chromatography using a method adapted from Gorga et al. (1987). 
2.6.1 Preparation of antibody affinity columns 
The Sepharose column matrix was prepared for coupling according to the manufacturer's 
recommendations. Briefly, I g of CNBr- activated Sepharose 4B powder (Pharmacia 
Biotech, Uppsala, Sweden) was swollen in 20 mL 1 mM HC1 for 2 h then washed in a 
sintered glass funnel with a further 300 mL 1 mM HC1 to remove freeze -drying additives. 
The Sepharose beads were rinsed in 30 mL coupling buffer, pH 8.3 (Appendix B4.1) and 
the pH checked to be 8 -9. Purified class II MHC -specific mAb (10 mg per column) was 
dialysed against 1 L coupling buffer overnight at 4 °C and the A280 of the dialysed mAb 
was recorded. A thick slurry of resin was added to the mAh and rocked either for 2 h at 
room temperature or overnight at 4 °C. The resin was pelleted at 50 x g for 1 min using a 
Clements 2000S benchtop centrifuge (500 rpm; NSW, Australia) and the A280 of the 
supernatant measured again to confirm antibody conjugation to the Sepharose matrix. To 
block any remaining active groups, the beads were resuspended in 5 mL 0.2 M glycine, 
pH 8.0 for either 3 h at room temperature or overnight at 4 °C. Antibody -coupled beads 
were then washed sequentially in 50 mL coupling buffer, 50 mL 0.1 M acetate buffer 
(Appendix B4.1) and 50 mL 0.5% (v /v) IGEPAL/PB S, centrifuging between washes at 
50 x g for 2 min. Columns were stored at 4 °C in 0.05% (w /v) NaN3/ 0.5% (v /v) 
IGEPAL /PBS. 
2.6. 2, Affinity purification of class II MHC molecules 
Class II MHC- expressing cells were grown in bulk in sterile roller bottles in 5% FBS/ 
RPMI to a minimum of 109 cells total. The cells were pelleted at 540 x g for 30 min at 
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4 °C in 1 L polypropylene bottles using a Beckman J -6M/E centrifuge (rotor JS -4.2, 1500 
rpm; CA, USA) and resuspended in a small volume of ice -cold PBS. Cell suspensions 
were transferred to 50 mL polypropylene Falcon tubes (Becton Dickinson, NJ, USA) and 
washed twice more with PBS, pelIeting cells between washes at 300 x g for 5 min at 4 °C 
(Jouan CR412 centrifuge, 1200 rpm; St Nazaire, France). To lyse membranes, cells 
were incubated for 10 min on ice at 108 cells /mL in PBS lysis buffer containing 0.5% 
(v /v) of the non -ionic detergent, IGEPAL CA -630 (Sigma Chemical Co., MO, USA) and 
a cocktail of protease inhibitors (Appendix B4.2). The lysate was centrifuged at 1600 x g 
at 4 °C for 30 min (Jouan CR412, 3000 rpm; St Nazaire, France) to remove large cellular 
debris and nuclear material and the resulting supernatant was cleared of cytoskeletal 
elements by ultracentrifugation in polyallomer Quick -Seal tubes (Beckman, CA, USA) at 
50 000 x g for I h in a Beckman L8 -70 ultracentrifuge (rotor 70.1Tí, 23 500 rpm; CA, 
USA) precooled to 4 °C. 
For immunoaffinity purification, the detergent lysate was passed through a 0.2 pm 
cellulose acetate Minisart syringe filter (Sartorius, Göttingen, Germany) then the mixture 
applied three times to a prepared mAb column. The column was washed with 200 mL 
0.5% (v /v) IGEPAL/ PBS before the proteins were eluted with class II MHC elution 
buffer, pH 11.5 (Appendix B4.2). Approximately fifteen 1.5 mL fractions of eluate were 
collected into microfuge tubes, each containing 120 µL citrate -phosphate buffer, pH 5.0 
(Appendix B4.2) for immediate neutralisation. Following each class II MEC preparation, 
columns were washed with a further S mL elution buffer then 100 mL 0.5% (v /v) 
IGEPAL/PBS and stored as before. 
Samples containing the class II MHC proteins were identified by silver staining on a 12% 
SDS- polyacrylamide gel and confirmed by Western blotting. Such fractions were pooled 
and dialysed (cellulose acetate tubing, MW cutoff ? 12000; Sigma Chemical Co., MO, 
USA) for 2 days at 4 °C against 0.5% (v /v) IGEPAL/ PBS containing 0.025% (w /v) 
NaN3 (Appendix B4.2). Purified class II MHC molecules were then spin- concentrated at 
5000 x g in a Sorvall RC -5B centrifuge (rotor SS -34, 6500 rpm; Du Pont, CT, USA) at 
room temperature using Centricon -10 ultrafiltration microconcentrators (Amicon, MA, 
USA) and stored at 4 °C. 
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2.7. Peptide binding assays 
2.7.1 Antigen presentation assay 
The formation of specific peptide -class II WIC complexes was assessed by quantifying 
T cell activation using an IL -2 bioassay, as described by Coligan et al. (1994). 
Serial dilutions of peptide antigen in 50 ¡IL RPM' (concentration range typically 100 -1.5 
µM) were prepared in triplicate wells of a polystyrene 96 -well flat -bottom microtitre plate 
(Nunc, Roskilde, Denmark). T cell hybridoma and APC cultures were washed twice in 
normal medium and resuspended at 5 x 105 cells /mL. To each well was added 50 ¡IL of 
each cell suspension (2.5 x 104 cells per well) plus 50 ¡CL normal medium to give a total 
volume of 200 .tL per well. To measure background, 100 µL of media was added to 100 
µL APC/ T cell hybridoma suspension with no antigen. Plates were incubated at 37 °C 
for 18 -24 h, then 150 1L/well culture supernatant was harvested into a fresh 96 -well 
microtitre plate and frozen for 30 min at -70 °C to lyse any suspended cells. 
To measure T cell responses, the culture supernatant was assayed for IL -2 activity using a 
secondary culture of the IL -2- dependent T cell line, HT -2 (Watson, 1979). HT -2 cells 
were prepared first by washing 4x in fresh normal medium to remove residual IL -2, then 
resuspended at 105 cells /mL and 50 µL /well added to an equal volume of thawed culture 
supernatant. A positive control of 50 µL HT -2 cells growing in 50 AL normal medium 
supplemented with 50 U /mL recombinant mouse IL -2 was established. HT -2 cells were 
cultured in the supernatant overnight and the degree of proliferation determined by a 4 
hour pulse at 37 °C with 0.5 ,ICi/well [3H]thymidine (Amersham, NSW, Australia; 
Appendix B5.1). Cells were harvested onto glass fibre filters using a Micro Cell 
Harvester (Skatron Instruments AS, Lier, Norway) and the filter radioactivity counted on 
a Betaplate liquid scintillation counter (model 1205; Wallac Oy, Turku, Finland). 
[3H]thymidine incorporation data was recorded as counts per minute (cpm). 
For competition assays, APC and T cell hybridomas were incubated in triplicate wells 
with a 50 ¡AL serial dilution of the competitor peptide (concentration range typically 200-3 
µM) and a single dose of antigenic peptide chosen from a preliminary titration assay. The 
maximal level of T cell activation was shown in triplicate wells containing antigen but no 
competitor. Each competitor was tested in at least two independent experiments. 
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2.7.2 Cell- surface peptide binding assay 
The ability of specific peptides to bind to cell - surface class II MHC molecules was 
examined by flow cytometry. Using a modification of the method developed by Busch et 
al. (1990), cells were incubated with synthetic peptides conjugated to biotin and then 
stained with an avidin -FITC conjugate (Pierce, IL, USA). Analysis of stained cells by 
flow cytometry yields a fluorescent signal related to the number of biotinylated peptide - 
MHC complexes formed. 
2. 7.2.1 Flow cytometry system 
Flow cytometry experiments were performed on a Becton Dickinson FACScan flow 
cytometer (CA, USA) using Hewlett Packard Lysis II software for data acquisition. 
Post -acquisition analysis was performed using the WinMDI software package written and 
kindly provided by J. Trotter of the Scripps Research Institute, CA, USA. 
For each cell sample, the forward light scatter (FSC detector), side light scatter (SSC 
detector) and FITC fluorescence (FL1 detector, 530 ± 30 nm bandpass filter) of 10 000 
events were collected. Only viable cells were measured, as determined by electronic 
gating on FL3 (670 nm longpass filter) of cells staining positive for the DNA -binding 
fluorochrome, propidium iodide (PI; Sigma Chemical Co., MO, USA). Cellular debris 
were eliminated from consideration by gating on the FSC versus SSC dot plot during 
post -acquisition analysis. In all experiments, data were collected at 256 channel 
resolution and cell -surface fluorescence signals were expressed as the median 
fluorescence intensity (MFI) to represent accurately the central tendency of the cell 
population. 
2. 7.2.2 Preparation of cell samples for flow cytometric analysis 
All reagents used in the flow cytometry experiments were diluted into a PBS -based FACS 
medium (Appendix B5.2) containing 1% (w /v) bovine serum albumin (BSA, Fraction V; 
Armour Pharmaceuticals, Eastbourne, UK) or 1% (v /v) heat -inactivated FBS. 
To analyse the binding of a biotinylated peptide to a particular MEC allotype, a dilution 
series of the peptide (concentration range, 250-81.1M) was prepared in a polystyrene 96- 
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well round -bottom microtitre plate (Coming, NY, USA). APC were washed once in 
fresh RPMI, resuspended at 2 x 106 cells /mL and a 50 pL volume was dispensed into 
each sample well, i.e. 100 000 live cells per sample at the time of establishing the 
experiment. All subsequent incubations and washes were performed within the microtitre 
plate unless otherwise stated. Centrifugations were conducted at 4 °C for 3-4 min at 300 
x g in a Jouan CR412 centrifuge (1200 rpm; St Nazaire, France). 
Cells were incubated for 18 -20 h at 37 °C in a CO2 incubator to allow for peptide binding. 
Excess unbound peptide was removed by washing cells twice in 200 µL ice -cold FACS 
medium at 4 °C and all subsequent steps were performed on ice to keep cellular metabolic 
activities at a minimum. To detect biotinyl groups bound on the plasma membrane, cells 
were stained with 100 AL avidín -FITC for 30 minutes. Total cell -surface class II MHC 
expression was quantified for each experiment by staining a control cell sample with an 
appropriate ErIC- conjugated mAb. After incubation with fluorochrome- conjugated 
species, samples were washed three times (twice with 200 µL ice -cold FACS medium, 
once with 100 µL PI (typically 10 tg /mL; Appendix B5.2)), resuspended in 150 µL ice - 
cold FACS medium and transferred into individual 1 mL round -bottom, polystyrene tubes 
(50 x 6 mm; Bacto, NSW, Australia) for flow cytometry sample analysis. 
For competitive cell -surface peptide binding assays, APC were coincubated for 18 -20 
hours with a dilution series of unbiotinylated competitor (250 -16 µM) and a single dose 
of hiotinylated peptide selected from an initial titration assay. Samples were prepared and 
analysed as described above. Each competitor was tested in at least two independent 
experiments and the mean dose yielding 50% inhibition (ICSO) was calculated by non- 
linear regression using the data analysis software package, GraphPad Prism (Version 2.0; 
GraphPad Software, Inc., CA, USA). Briefly, competitive binding curves were At to the 
data using the built -in sigmoidal dose -response (variable slope) equation. The top plateau 
of the curve was set as the maximum signal of the biotinylated peptide binding alone, 
obtained experimentally from a duplicate sample containing no competitor. The bottom 
plateau was set as zero following subtraction of the signal arising from non -specific 
associations, as measured in the absence of the biotinylated peptide. 
Prior to their use in peptide- binding flow cytometry experiments, a suitable working 
concentration of all dye- conjugated mAb (biotinylated or fluoresceinated) was determined 
by titrating them against a suitable cell line. Each new batch of avidin -FITC was titrated 
against the A20 cell line pre- incubated with a working concentration of the biotinylated 
mAb, MK -D6. 
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2.7.3 Purified class II MHC binding assay 
54 
The binding of biotinylated peptides to immunoaffinity- purified class II MHC molecules 
was measured using an adaptation of the method of Jensen (1991). 
2.7.3. I Microtitre plate preparation 
Polystyrene 96 -well IMMULON microtitre plates (Dynex Technologies, VA, USA) were 
prepared with an initial coating of 100 p.L /well of 50 tg/mL goat anti-mouse IgG (H +L) 
(Pierce, IL, USA; Appendix B5.3) in PBS overnight at 4 °C. Plates were washed 
thoroughly with 0.1% (v /v) Tween- 20/PBS (PBS -T) three times and 100 [IL/well of anti - 
class II MHC antibody was added at 50 }tg /mL in borate buffer, pH 8.0 (Appendix 
B5.3). Plates were incubated overnight at 4 °C then washed in PBS -T as before. To 
block non -specific binding sites, plates were incubated with 100 IlL/well milk buffer 
(Appendix B5.3) overnight at 4 °C, then washed as before and stored at 4 °C with 100 
.sL/well of 0.01% (w /v) azide/PBS -T. 
2. 7.3.2 Formation of peptide -class II MHC complexes 
In a polystyrene, 96 -well, round -bottom microtitre plate (Corning, NY, USA), 25 pL of 
immunoaffinity- purified class II MHC was added to an equal volume of a biotinylated 
peptide dilution series (concentration range typically 100-1 11M) in a citrate- phosphate 
binding buffer, pH 5.0 (Appendix B5.3). To determine levels of non- specific binding, 
negative controls were established consisting of MHC alone, peptide alone and binding 
buffer with neither MHC nor peptide. The plates were sealed with parafilm to prevent 
evaporation and the reaction mixture was incubated at 37 °C for 24 -48 hours. 
2.7.3.3 Class II MHC capture and ELISA plate development 
To prepare antibody -coated ELISA plates for MHC capture, the plates were washed three 
times in PBS -T and 100 µL MBN solution was added to each well (Appendix B5.3). 
The peptide -MHC binding mixture was neutralised for capture with 50 4L/well of Tris 
neutralising buffer (Appendix B5.3), then the MBN was discarded from the ELISA plate 
and 100 µL of the neutralised solution was added Plates were incubated for 3 h at RT to 
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allow for MHC capture, then washed three times in PBS -T and 100 pL/well of 1 /1000 
streptavidin -HRP (Pierce, IL, USA) in PBS -T was added. Plates were incubated for 1 h 
at RT, washed four times in PBS -T and 100 µL /well of ABTS/ H202 substrate mixture 
(Appendix B5.3) was added. The presence of bound biotinylated peptide -class II MHC 
complexes was determined by the development of a green colour after incubating the plate 
in darkness at room temperature for at Ieast 30 minutes. ELISA plates were read at 405 
rim with a reference wavelength of 495 nm on a THERMOmax microplate reader 
(Molecular Devices, CA, USA) and measurements were recorded using the SOFTmax 
software package provided by the manufacturer. Data are presented as absorbance 
readings at 405 nm in optical density (OD) units. 
For competition studies, each new preparation of purified class II MHC was first titrated 
in a binding assay against a biotinylated peptide dilution series to determine the best 
concentration combination. In each competition experiment, 12.54, purified MHC was 
incubated with 25 µL of a dose range of non -labelled competitor peptide (dilutions 100- 
12.5 11M) and 12.54L of a single dose of biotinylated peptide was selected from the 
preliminary titration assay. All competitor peptides were tested in at least two independent 
assays. ICSO values were calculated as described previously ( §2.7.2). 
CHAPTER 3. 
The contribution of individual CLIP side chains to the 
interaction with mouse I -A class II MHC molecules 
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3.1. Introduction 
The particular array of peptide antigens that may be presented by a given class II MEC 
molecule to CD4` T lymphocytes is dictated by the amino acid composition of the peptide - 
binding groove. Specifically, the residues of the a, and 13, domains which fold to form 
the pockets within this site may vary by up to 20% between any two individual allotypes 
which results in considerably different preferential sequence binding motifs (for an 
examination of this, see Hurley & Steiner, 1995). However, during the normal course of 
the maturation of class II MHC molecules, the digestion of Ii within the endocytic 
compartments leaves aII aß dimers associated transiently with a nested set of peptides 
derived from the same single region of the Ii protein, residues 81 -107, the so- called CLIP 
(class II MHC- associated invariant chain peptides; Rudensky et al., 1991; Chicz et al., 
1992, 1993; Hunt et al., 1992; Riberdy et al., 1992; Sette et al., 1992a). It was the aim 
of this research to address how the CLIP sequence is able to associate with so many 
different class II MHC allotypes, seemingly regardless of their individual ligand binding 
preferences. 
At the commencement of this investigation, very little information on the structural details 
of the CLIP -class II MHC interaction was in existence. Most critically, the site on the 
MI-IC heterodimer at which CLIP interacts had not been identified unequivocally, for 
example, by X -ray crystallographic analysis. This was of some importance since a 
scenario in which CLIP associates external to the polymorphic class If MHC binding 
cleft, where the sequences of the a- and [3- chains are more highly conserved (Kaufman & 
Strominger, 1982; Benoist et al., 1983a; Choi et al., 1983; Kaufman et al., 1984; 
Schenning et al., 1984), would account readily for the degenerate nature of CLIP binding 
to these molecules. However, such a model was incompatible with certain empirical data 
available at this time. For example, the initial description of CLIP had been made 
following its identification amongst antigen- derived ligands that had been eluted from the 
peptide- binding groove of different class H MEC allotypes (Rudensky et al., 1991; Chicz 
et al., 1992, 1993; Hunt et al., 1992; Riberdy et al., 1992; Sette et al., 1992a). 
Moreover, competition binding assays had shown that CLIP and antigenic peptides were 
mutually exclusive in their associations with the a(3 dimers (Chicz et al., 1992; Hunt et 
al., 1992; Riberdy et al., 1992; Sette et al., 1992a). This provided compelling evidence 
for one common binding site upon the class H MHC molecule for these two ligands. In 
further support of this idea, it was observed that, despite the overall promiscuity with 
which CLIP associates with these molecules, the affinity of the interaction was not 
uniform between different MHC allotypes (Avva & Cresswell, 1994; Bangia & Watts, 
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1995; Liang et al., 1995; Sette et al., 1995). This feature had some resemblance to the 
binding of antigen- derived peptides to different class II MHC variants and implicated once 
more the peptide -binding groove as the site of CLIP interaction, since this is the primary 
location of allelic variation within the MHC heterodimer. 
Nevertheless, not all features of the CLIP -class II MHC interaction could be reconciled 
with a binding site in common with antigenic peptides. For example, in addition to their 
unusually promiscuous binding behaviour, CLIP ligands complexed with class II MHC 
molecules were peculiar in their incapacity to confer resistance to subunit dissociation of 
the aß dimer in the presence of the detergent, SDS, a feature highly characteristic of 
conventional peptide ligands (e.g. Germain & Hendrix, 1991; Sadegh -Nasseri & 
Germain, 1991; Riberdy et al., 1992; Sette et al., 1992a). Moreover, with regards to the 
allotype- dependent affinities of the CLIP -class II MHC interaction, superantigens were 
also reported to bind to some class II MHC variants better than others (Herrmann et al., 
1989; Herman et al., 1990; Scholl et al., 1990a, 1990b), despite it being known that they 
interacted primarily at conserved sites outside of the polymorphic peptide- binding cleft 
(Jardetzky et al., 1994; Kim et al., 1994). These features allowed the possibility that 
CLIP might bind to class IT MEC molecules in a mode different from that of antigen - 
derived peptides. In this respect, it could be envisaged that the ability of CLIP to compete 
with such ligands might arise via an allosteric mechanism, whereby CLIP bound to a less 
polymorphic site on the aß dimer some distance from the conventional peptide- binding 
groove and from here influenced the binding of antigenic peptides, for example, by a shift 
in the molecular conformation. Without further knowledge of the binding interaction at 
this time, this possibility could not be excluded. 
A definitive means by which to elucidate the molecular basis of the promiscuity with 
which CLIP is able to interact with class II MHC molecules would be to dissect the 
specific intermolecular forces involved in binding. With this aim, Gautam and coworkers 
began a series of experiments in 1994 to explore the interaction of CLIP with several 
variants of the I -A isotype of mouse class II MHC molecules. In particular, these 
researchers set out to determine which specific CLIP residues were crucial for 
association. Using single L- alanine- substituted CLIP analogues as competitors in antigen 
presentation assays, Gautam and colleagues showed that the binding of CLIP to the 
molecules, I -A °, I -Ak and I -Ad, was generally tolerant of such side chain substitutions. 
Indeed, the majority of the L- alanine- substituted CLIP hound essentially like the wild - 
type CLIP86 -104 peptide, with relatively few side chains within this sequence 
responsible for modulating the binding affinity. Now published (Gautam et al., 1995), 
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these preliminary findings provided the impetus for the subsequent investigations 
presented herein. 
The initial task of this study was to build upon the results of Gautam et al. (1995) and use 
alternative methods of analysis to provide intersecting evidence on the role of particular 
CLIP residues in the interaction with mouse I -A class II MHC molecules. In this chapter, 
a model of degenerate CLIP binding is proposed and examined, and the virtues and 
limitations of each experimental approach are discussed. 
3.2. Materials and Methods 
The experimental procedures performed in this chapter are described fully in Chapter 2. 
Briefly, the mouse B cells lines, A20 (H -2 "), CH27 (H -2k), M12.D (I -A°) and 1 -5.4 (T- 
A" ), detailed previously in Chapter 2, Table 2.1, were used as APC for cell -surface 
peptide binding assays. Mouse I -A° molecules were purified from detergent- solubilised 
membrane preparations from the BALB/c-derived B cell lymphoma, A20, by 
immunoaffinity chromatography on an MK -D6 mAb column ( §2.6). I thank Mrs Y. M. 
Gautam (Laboratory technician) for purifying these proteins. 
L- alanine- substituted CLIP86 -104 analogues are Iisted in Table 3.1. Figure legends state 
peptide concentrations used in the binding assays. Competitor peptides were tested over 
the concentration range 16-250 µM for cell -surface binding assays (Chapter 2, §2.7.2) 
and 25 -200 µM for immunoassays with purified I -A° ( §2.7.3). Experiments to 
determine the relative binding affinity of peptides to purified I -A° as a function of pH 
(Figures 3.4 & 3.5) were kindly performed by Mrs Y. M. Gautam. 
3.3. Results 
3.3.1 The binding of L- alanine- substituted CLIP analogues to cell- surface 
I -A class II MHC molecules 
To examine the role of particular amino acid residues within the CLIP sequence for 
binding to I -A class II MHC molecules, Gautam et al. (1995) used L- alanine- substituted 
analogues of the CLIP86 -104 peptide (Table 3.1) as competitors in antigen presentation 
assays with I- A- restricted T cell hybridomas. The capacity of each CLIP analogue to 
disrupt the productive association between peptide determinant and MHC heterodimer, 
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K86A L-Ala 
P87A - L-Ala 
V88A L-Ala 
S89A - L-Ala 
Q90A - - L-Ala 
M91A L-Ria 
R92A L-Ala 
M93A L-Ala 
wtCLIP86-104 K P V S Q M R M L-Ala T P L L M R P M S M 
T95A L-Ala 
P96A L-Ala 
L97A L-Ala 
L98A L-Ala 
M99A L-Ala 
R100A L-Ala - 
P101A L-Ala - 
M102A L-Aia - - 
S103A L-Ala 
M104A L-Ala 
Amino acid sequences of wild -type CLIP86 -104 and its single L- alanine- substituted analogues are 
shown. Native amino acid residues are represented with a dash. 
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and thereby inhibit the MEC- restricted T cell response, maybe interpreted as reflecting 
the ability of the individual monosubstituted peptides to bind to the given MHC allotype. 
An alternative approach by which the efficiency of the binding interaction between a 
peptide and a class II MHC molecule may be assessed involves measuring the number of 
complexes formed between them on the surface of antigen presenting cells. These 
complexes may be detected readily by, first, incubating the cells with a biotin- conjugated 
form of the peptide, then staining with avidin which has been derivatised with the 
fluorochrome, fluorescein isothiocyanate (RFC). Measuring the resultant fluorescence 
by flow cytometry yields a signal which bears a direct relationship to the concentration of 
the biotinylated peptide -MEC complexes on the cell surface (Busch et al., 1990). 
Similar to the antigen presentation assay, the cell- surface peptide binding assay permits a 
wide array of peptide analogues to be tested for binding by using them as competitors, in 
this case against the biotinylated wild -type ligand. The ability of the 19 -mer, CLIP86 - 
104, and its two extended variants, CLIP81 -104 (24 -mer) and CLIP81 -109 (29 -mer), to 
compete against biotínylated CLIP86 -104 for binding to the cell- surface class II MHC 
molecules expressed by the mouse B cell lymphomas, A20 and CH27, is shown in 
Figure 3.1. It is of interest to note that, for both cell lines, all three length variants 
showed the same degree of competition against the biotinylated peptide, i.e. the additional 
residues present on the longer CLIP ligands did not appear to contribute any further net 
positive binding energy to the interaction. 
Using the cell - surface peptide binding assay, the contribution of individual side chains 
within the CLIP sequence to the binding affinity for I -A molecules was examined further, 
this time employing the L- alanine- substituted CLIP analogues as competitors against the 
biotinylated wild -type peptide, CLIP86 -104. Shown in Figure 3.2 are the results of one 
such assay, representative of the experimental findings. Mean ICso values, calculated 
from two independent experiments, i.e. the concentration of competitor peptide required 
to inhibit 50% of the biotinylated CLIP86 -104 signal, are given atop each bar to provide a 
quantitative representation of the overall trends observed. Using the same I -A- expressing 
mouse APC lines as the original antigen presentation experiments of Gautam et al. 
(1995), the results obtained with this flow cytometry -based method (Figure 3.2) correlate 
well with the earlier experiments. The majority of the L- alanine- substituted CLIP 
analogues (solid fill pattern) competed essentially the same as the unlabelled wild -type 
CLIP sequence, CLIP86 -104 (cross -hatched fill pattern), for binding to the cell -surface 
class II MHC molecules expressed by the three cell lines, 1 -5.4 (I -Ad), CH27 (H -2k) and 
A20 (H -2d). The substitutions of the wild -type CLIP residues that deviated notably from 
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Figure 3.1 Competition by CLIP ligands with biotinylated CLIP86 -104 
for binding to cell- surface class II MHC molecules at pH 7.0. 
The 19 -mer wild -type peptide, CLIP86 -104, and its two extended variants, CLIP81 -104 (24 residues) 
and CLIP81 -109 (29 residues), were examined for their ability to inhibit the cell -surface binding of 
biotinylated CLIP86 -104 (50 µM) to (a) CH27 and (b) A20 cells. Data presented represent the mean 
percentage inhibition ± SD from two independent experiments. Cells were incubated with biotinylated 
peptide and competitor for 18 hours at 37 °C before flow cytomteric analysis, as described ìnChapter 2, 
§2.7.2. 
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Figure 3.2 Competition by L- alanine -substituted CLIP86 -104 for cell - 
surface binding to I- A- expressing cell lines. 
Multiple doses of CLIP86 -104 analogues with single L- alanine substitutions were tested for competition 
against biotinylated CLIP/16-104 (1 -5.4, 75 µM; CH27 & A20, 50 µM) for binding to the I -A MHC 
molecules of the cell lines (a) 1 -5.4 (I -A °), (b) CH27 (H -2k) and (c) A20 (H -2d). A single competitor 
dose which yielded -50% inhibition of the biotinylated CLIP signal by wild -type CLIP86 -104 (cross- 
hatched fill pattern) is shown for brevity (125 µM). All assays were perfomed twice with equivalent 
results, as described in Chapter 2, §2.7.2. Solid bars represent competition by the substituted CLIP 
analogues and empty bars represent the maximal biotinylated CLIP signal in the absence of competitor. 
Binding levels are expressed as median fluorescence intensity, from which background counts measured 
in the absence of biotinylated peptide have been subtracted (1 -5.4, 2.94; CH27, 3.40; A20, 3.69). IC50 
values for are given for competitors above each bar. 
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this pattern were R92A, M93A, T95A, P96A, M99A and M102A for I -Ai, M91A, 
M93A, T95A, P96A and M102A for I -Ak and T95A and M102A for I -Ad. 
It is interesting to note in the results of the cell -surface binding assay (Figure 12) that the 
signal generated in the positive control sample of biotinylated CLIP86 -104 alone (empty 
fill pattern) differed substantially between the three cell lines. Specifically, the A20 cells 
appeared consistently to bind CLIP better than the CH27 or 1-5.4 lines. In the 
experiment shown, for example, biotinylated CLIP86 -104 binding to the I -Ad molecules 
of the A20 cell line yielded a median fluorescence intensity of 79.85 units, compared with 
24.49 units and 12.46 units for CH27 and 1 -5.4, respectively. This was despite the same 
concentration of biotin- conjugated peptide supplied to both the A20 and CH27 cells (50 
µM) and even more to 1 -5.4 (751.1M). These observations may be explained by the 
finding that CLIP has a higher affinity for I -Ad than I -Ak (Bangia & Watts, 1995; Liang et 
al., 1995; Sette et al., 1995). Alternatively, the A20 cells may express greater numbers of 
class II MHC molecules at their plasma membrane. In this respect, it should be noted that 
both the B cell lymphoma cell lines, A20 and CH27, used in this study constitutively 
express class H MHC molecules of the I -E isotype also, which possibly may have bound 
the biotinylated CLIP or its substituted analogues. 
In the previous antigen presentation assays (Gautam et al., 1995), the T cell hybridomas 
used were I -A- restricted, thereby avoiding the possibility that the presence of I -E 
molecules may influence the examination of CLIP binding during these experiments. In 
order to assess whether the fluorescence signal measured in the experiments with the A20 
and CH27 cell lines presented herein reflected the association of CLIP with the I -A 
molecules on the surface of these cells only, the binding of the L- alanine- substituted CLIP 
analogues was examined to class II MHC molecules of the transfectant B cell line, M12.D 
(Chapter 2, Table 2.1). These cells are derived from the class II MEC- negative cell line, 
M12.C3 (Glimcher et al., 1985), which has been transfected with Aotd /A(3d cDNA to 
express only I -Ad molecules at the plasma membrane. In a cell -surface peptide binding 
assay (Figure 3.3), biotinylated CLIP bound equally well to the I -Ad molecules of the 
M12.D cell line (a median fluorescence intensity of 33.11 units) as to the A20 cells shown 
previously in Figure 3.2, taking into account the different levels of expression of the cell - 
surface class II MHC molecules between these two cell lines on the day of the experiment 
(for the data shown, a median fluorescence intensity reading of 120 units for M12.D and 
209 units for A20, as determined by staining with the fluoresceinated, anti -I -Ad mAb, 
MK- D6- FITC). Moreover, the L- alanine- substituted CLIP bound to the I -Ad molecules 
on the surface of the M12.D cells with an identical pattern of results to those obtained 
with A20. Again, mean IC50 values of two independent experiments are shown atop each 
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Figure 3.3 Competition by L- alanine -substituted CLIP86 -104 for cell - 
surface binding to M12.D cells at pH 7.0. 
Multiple doses of CLIP86 -104 analogues with single L- alanine substitutions were tested for competition 
against biotinylated CLIP86 -104 (50 µM) for binding to I -Ad class II MHC molecules on the surface of 
M12.D cells. Shown is a single competitor concentration (125 4M) which yielded -50% inhibition of 
biotinylated CLIP binding by wild -type CLIP86 -I04 (cross- hatched fill pattern). The assay was 
performed twice with equivalent results. Cells were incubated with biotinylated peptide and competitor 
for 18 hours at 37 °C before flow cytometric analysis, as described in Chapter 2, §2.7.2. Solid bars 
represent competition by the substituted CLIP analogues and the maximum biotinylated CLIP signal with 
no competitor present is depicted by the empty bar. Binding levels are expressed as median fluorescence 
intensity (MFI). The background signal from non- specific binding was measured in the absence of 
biotinylated peptide and has been subtracted from data shown (M12.D, 2.77 MFI units). IC50 values for 
are given for competitors above each bar. 
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bar in Figure 3.3. From these findings it may be assumed that any contribution of CLIP 
binding to cell -surface I -E molecules on the cell line, A20 and, by extension, CH27, does 
not obscure nor alter the pattern observed of the L- alanine- substituted CLIP analogues 
binding to I -A. The inability of CLIP to bind to the I -E class H MHC molecules under the 
conditions of the cell -surface peptide binding assay, an interesting observation in itself, is 
the subject of Chapter 5 of this thesis. 
3.3.2 The binding of L- alanine -substituted CLIP analogues to purified 
I -Ad at pH 5.0 
The generation of CLIP -class H MHC complexes and loading of these molecules with 
peptides in general, both occur in vivo within the acidic environment of the endocytic 
compartments (Chapter 1, §1.5). However, antigen presentation assays and cell- surface 
binding assays examine peptide -MHC interactions in a cellular context, which excludes 
the possibility of probing this interaction in anything other than the neutral pH conditions 
needed to sustain cell survival unless the cells are fixed, for example, using 
paraformaldehyde (Jensen, 1990). In this study, an alternative approach was chosen by 
which to investigate peptide binding to class H MHC molecules at a physiologically - 
relevant acidic pH, namely, an ELISA -type assay with affinity- purified class II MHC 
proteins. This method increases the probability that the binding interactions observed 
involve only the a(3 dimers of interest, in this case, ensuring no influence upon the results 
of CLIP binding to I -E molecules. 
As with the cell -surface binding assay, the immunoassay with purified MHC uses a 
biotinylated ligand to generate a signal, against which different peptide analogues may be 
tested as competitors. Figure 3.4 shows the ability of biotinylated CLIP86 -104 to bind to 
mouse I -Ad, purified by affinity chromatography from the BALB /c- derived B cell 
lymphoma, A20. The binding of this peptide at pH 5.0 was enhanced with respect to 
binding at neutral pH. A similar but even more striking pH- dependent effect was seen 
with I -Ad binding its biotinylated antigen- derived Iigand, Ova322 -339 (Figure 3.5a). It is 
likely that a more acidic environment also serves to increase the specificity of peptide 
binding. This is illustrated in Figure 3.5b, where the I -Ek- restricted peptide, mCytc88- 
103, from the moth cytochrome c protein (Schild et al., 1995) did not bind to the I -Ad 
molecules at pH 5.0 but did show some association at pH 7.0. 
Using the immunoassay, the ability of the L- alanine- substituted CLIP analogues to 
compete with biotinylated CLIP86 -104 for binding to mouse I -Ad was examined at pH 
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Biotinylated marine CLIP86 -104 was incubated with affinity -purified I -Ad proteins at 37 °C for 48 hours 
at pH 7.0 (open circles) or pH 5.0 (closed circles), as described in Chapter 2, §2.7.3. I -Ad molcules were 
purified from the BALB /c- derived B cell lymphoma, A20, by affinity chromatography 02.6). Results 
shown are representative of two independent assays. Binding levels are expressed in optical density (OD) 
units, read at 405 nm with a reference wavelength of 495 nm. The signal from non- specific associations 
was determined from the binding of biotinylated peptide in the absence of MHC molecules and has been 
subtracted from data shown (pH 7.0, 0.061 OD units; pH 5.0, 0.059 OD units). 
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Figure 3.5 The binding of antigen -derived peptides to purified I -Ad. 
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Biotinylated peptides (a) Ova322 -339 and (b) mCytc88 -103 were incubated with I -Ad at 37 °C for 48 
hours at pH 7.0 (open circles) or pH 5.0 (closed circles), as described in Chapter 2, §2.7.3. I -Ad 
molecules were purified from the BALB /c- derived B cell lymphoma, A20, by affinity chromatography 
( §2.6). For each peptide is shown one of two independent experiments with equivalent results. Binding 
levels are expressed in optical density (OD) units, read at 405 nm with a reference wavelength of 495 nm. 
The signal from non -specific associations was determined from the binding of biotinylated peptide in the 
absence of MHC and has been subtracted from data shown (pH 7.0, 0.061 OD units; pH 5.0, 0.059 OD 
units). 
CLIP side -chain interactions with I -A 68 
5.0 (Figure 3.6). Under these conditions, the effects of residue replacement in the CLIP 
sequence upon binding to the I -Ad molecules were significantly more pronounced than 
observed previously using the cell -surface binding assay (Figures 3.2 and 3.3) and the 
antigen presentation assay (Gautam et al., 1995) at pH 7.0. Specifically, a number of 
interactions between the amino acid side chains of CLIP and the I -Ad molecule that were 
not present under the neutral pH conditions of the previous assay methods were now 
observed. As before, mean ICSO values of two independent experiments atop each bar 
provide a quantitative representation of the trends observed. Of particular note, the 
substitution by L- alanine of the wild -type Leu 98 residue in the CLIP sequence eliminated 
the ability of this peptide to bind in the immunoassay at pH 5.0. Moreover, inhibitory 
contributions by the native CLIP side chains, Pro 96 and Met 99, were revealed under the 
weakly acidic conditions of this assay. 
3.4. Discussion 
3. 4.1 A comparison of binding assay methods 
Unlike antigen- derived peptide ligands, whose ability to bind to a given class II MEC 
glycoprotein is dictated by the particular amino acid composition of the peptide -binding 
groove, the Ii- derived peptides, CLIP, exhibit the capacity to associate irrespective of 
these specific binding motifs (Rudensky et al., 1991; Chicz et al., 1992, 1993; Hunt et 
al., 1992; Riberdy et al., 1992; Sette et al., 1992a). To explore the molecular mechanism 
underlying this binding degeneracy, this study has employed a set of CLIP86 -104 
analogues exhibiting single L- alanine substitutions (Table 3.1). Within a peptide 
sequence, such amino acid replacements by the prototype residue, L- alanine, permit each 
wild -type residue to be examined in turn as to the contribution of its side chain to the 
binding interaction. These analogues have been used to dissect the promiscuous 
interaction of CLIP with variants of mouse class II MHC molecules of the I -A isotype. 
The binding of CLIP to the molecules, I -A°, I -A`` and I -Ad, has been studied previously 
using the L- alanine- monosubstituted analogues as competitors in antigen presentation 
assays with I -A- restricted T cell hybridomas (Gautam et al., 1995). The investigation 
initiated in that study has been extended here, with an examination of the binding of these 
side -chain substituted analogues to the same three I -A allotypes by two further 
experimental approaches, firstly, the analysis of the binding of these peptides to cell- 
surface I -A molecules and, secondly, the assessment of their interaction with affinity - 
purified I -Ad. 
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Figure 3.6 Competition by L- alanine -substituted CLIP86 -104 for binding 
to purified I -Ad at pH 5.0. 
Multiple doses of CLIP86 -104 analogues with single L- alanine substitutions were tested for competition 
against biotinylated CLIP86 -104 (30 µM) for binding to I -Ad molecules affinity- purified from the 
BALB /c- derived B cell lymphoma, A20 (Chapter 2, §2.6). A single competitor dose which yielded 
-50% inhibition of the biotinylated CLIP signal by wild -type CLIP86 -104 (cross- hatched fill pattern) is 
shown (200 pM). Binding levels are expressed in optical density (OD) units, read at 405 nm with a 
reference wavelength of 495 mn. Solid bars represent competition by the substituted CLIP analogues. 
The maximum biotinylated CLIP signal with no competitor present is depicted by the empty bar. Assays 
were performed twice with consistent results. Binding levels are expressed in optical density (OD) units, 
read at 405 nm with a reference wavelength of 495 nm. Non -specific signal was determined from the 
binding of biotinylated peptide in the absence of MHC molecules and has been subtracted from the data 
shown (I -Ad, 0.085 OD units). IC50 values for are given for competitors above each bar. An asterisk 
represents an ICSO value >1000 AM. 
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Antigen presentation assays determine the relative number of productive associations 
formed between peptide antigen determinants and class II MHC molecules, measured in 
terms of the capacity of an appropriately- restricted T cell to recognise them. In this way, 
such experiments provide important data regarding the functional character of the 
complexes formed. These assays are particularly sensitive, requiring only very low 
concentrations of peptide and are highly specific due to the nature of MHC- restricted T 
ceII recognition. Increasing their utility, these assays also permit peptide analogues to be 
used as competitors to determine the importance of different structural features of the 
ligand for binding. However, when competition studies are performed in this manner 
with different class II MHC variants, comparisons of inhibitory potential may be 
complicated by the need to use different antigenic peptides between allotypes and, 
similarly, different T cell hybridomas. Additionally, although this method provides a 
useful way to determine the binding propensity of a particular peptide for class II MHC 
molecules in a whole cell model, the precise interactions between just peptide and binding 
groove may be obscured by downstream effects involving the T cell receptor. For 
example, the substitution of a glutamic acid residue for valine at position [329 in the floor 
of the peptide- binding site of I -Ek has been shown to decrease the functional presentation 
of the HIV -1 gpl60 determinant, T1(428 -443) to a specific T cell hybridoma, however 
the binding of the peptide itself to the class II MEC heterodimer is unaffected (Boehncke 
et al., 1993). By contrast, an amino acid substitution within this particular peptide 
sequence led to enhanced T cell stimulation as a result of an increase in the extent of 
binding between the peptide -MHC pair. 
The flow cytometry-based cell -surface binding assay involves incubating cells with 
biotinylated, synthetic peptide, then staining with avidin conjugated to the fluorochrome, 
FITC. The fluorescence signal generated is related directly to the relative ability of the 
biotinylated peptide to bind to the class II MI-IC molecules at the plasma membrane of 
either mouse (Mozes et al., 1989) or human cells (Rothbard et al., 1989). As with the 
antigen presentation assay, this method allows the structural requirements of peptides for 
binding to be defined easily by using a series of substituted analogues as competitors, in 
this case, against the biotinylated signal peptide. However, because the assay operates 
regardless of peptide antigenicity or TCR recognition, this method has the advantage of 
permitting a single peptide sequence (such as the promiscuous CLIP) to be used to probe 
the binding interactions of different class II MEC variants. The flow cytometry assay is a 
comparatively rapid, reliable and simple means for screening large numbers of peptides 
and, regardless of day -to -day fluctuations in class II MHC expression amongst cells in 
culture, the method displays an extraordinary degree of reproducibility. Also, a high 
degree of specificity is exhibited regarding the binding of the fluoresceinated avidin to 
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biotinylated peptide -class II MEC complexes and with minimal background fluorescence 
due to the high- affinity nature of the avidin- biotin interaction (Kd- 10 -15 M; Green, 
1975). Unfortunately, however, this assay method tends to consume large amounts of 
peptide and may be less sensitive than the T cell assay in detecting the influence of some 
amino acid substitutions on the peptide -MEC interaction. 
Both the antigen presentation and flow cytometry binding assay protocols involve 
providing an exogenous supply of a synthetic peptide of interest to whole cells, in order 
to gain a measure of the ability of the peptide to associate with a certain class II MEC 
molecule. Monji & Pious (1997) have reported that such exogenously- provided peptides 
are presented as efficiently by aldehyde -fixed B lymphoblastoid APC as by unfixed cells. 
Furthermore, these investigators did not find that exogenous peptides bound detectably to 
nascent intracellular class II MEC molecules nor were the peptides provided in such a 
manner found to accumulate intracellularly to any great extent. Together, these results 
indicate that intracellular processes do not contribute extensively to presentation of 
exogenously- suppled peptides. Rather, the binding of such peptides appears to occur 
primarily, or even exclusively, to a subset of pre- existing class II MI-IC molecules at the 
plasma membrane. Given the sensibly irreversible nature of cognate peptide-class II 
MEC binding (e.g. Buus et al., 1986; Lanzavecchia et al., 1992; Bot et al., 1996), 
suitable candidate c,13 dimers would be only those associated weakly with peptide or 
heterodimers already devoid of ligand as a result of prior dissociation. Depending on cell 
type examined, such forms of class II MEC molecule have been estimated to represent 
between 1 -15% of the 105 -106 total cell surface molecules of any given allotype (Trucco 
et al., 1980; Watts & McConnell, 1986; Buus et al., 1988; Ceppellini et al., 1989; Roche 
& CressweIl, 1990b). Accordingly, Busch et al. (1990) have calculated from a flow 
cytometry binding assay using the B lymphoblastoid cell line, MAJA, that the biotinylated 
T cell determinant, HA307 -319, binds to approximately only 1% of the total number of 
HLA -DR1 a(3 dimers estimated to be present on the surface of these cells. Although 
seemingly low, this number of molecules occupied with biotinylated peptide is still clearly 
within the limits of detection for this method. Likewise, in the context of the antigen 
presentation assay, the approximate 103 -104 class II MEC molecules per cell that this 
percentage represents exceeds the 10 -100 specific peptide -bound complexes estimated to 
be necessary for T helper cell stimulation and proliferation (Watts & McConnell, 1986; 
Demotz etal., 1990; Harding & Unanue, 1990; Srinivasan et al., 1991). 
In contrast to the binding of exogenously- provided peptides, the bulk of processed 
antigen fragments in situ bind to class II MHC molecules intracellularly, specifically 
within the acidic compartments of the endocytic route (Rudensky et al., 1994; Castellino 
t 
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& Germain, 1995; Morkowski et al., 1997). Under such conditions of high proton 
concentration, peptide binding has been shown to exhibit accelerated rates of association 
(Jensen, 1990, 1991; Harding et al., 1991; Wettstein et al., 1991; Mouritsen et al., 1992; 
Sette et al., 1992b). It is therefore useful to have an experimental means by which to 
examine the interaction of peptide with aß dimers under conditions that mimic the 
physiological situation. In this study, this has been achieved using affinity- purified class 
H MHC glycoproteins in an enzyme -linked immunoassay. This very direct means of 
examining peptide MHC binding involves capturing the class II MHC complexes with 
appropriate solid -phase monoclonal antibodies following an incubation period with 
biotinylated peptide. Bound biotin -conjugated ligand is quantified by incubation with 
streptavidin -HRP followed by a chromogenic substrate, such as ABTS (Jensen, 1991). 
This method provides an advantage over the flow cytometry and antigen presentation 
assays in that the binding reactions may be performed under conditions of controlled 
acidity, including at the low pH conditions found at the site of peptide loading in vivo 
within the endocytic compartments. Furthermore, a considerable degree of selectivity is 
ensured at the outset by the use of immunopurified class II MEC molecules. This 
increases significantly the probability that the ligand interactions observed involve only 
the aß dimers of interest. The binding assay itself displays a high degree of specificity 
by exploiting the extremely stable, high affinity avídin biotin interaction for detecting the 
peptide -bound complexes, similar to the cell -surface binding assay. This method also 
exhibits a high degree of sensitivity due to its avoidance of other interfering cellular 
processes, such as proteolysis. Moreover, only small quantities of reagents are 
consumed, the assay may be performed with multiple samples simultaneously and the 
system is compatible with the use of dimethyl sulphoxide (DMSO) to dissolve peptides 
that are insoluble in aqueous solutions. Critical to the success of this technique is the 
selection of an appropriate anti -class H MHC monoclonal antibody to capture the peptide - 
bound complexes -a conformation- specific antibody should be avoided as it may bias 
which molecules are captured. However, the experimental protocols for this assay are 
more involved than those of the antigen presentation or the flow cytometry cell -surface 
binding assay due to the requisite MHC purification step. Moreover, some binding 
interactions may be disrupted in the presence of particular detergents, including those 
used frequently to solubilise the class II MHC proteins during purification, e.g. Nonidet 
P -40 (NP -40; Fraser, 1989; Avva & CresswelI, 1994; Kropshofer et al., 1995b). 
Nevertheless, this assay method provides a useful means for a further examination of 
particularly interesting peptide MHC binding interactions, for example, those highlighted 
previously by a preliminary screening with the flow cytometry-based assay method. 
Unfortunately, time did not permit the purification of sufficient quantities of mouse I -Ak 
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and I -A" proteins during this study in order to examine their interaction with CLIP by this 
ELISA -type method. 
No one experimental method will provide a complete account of the details of an intricate 
and dynamic biochemical association, such as that taking place between a peptide ligand 
and a class II MHC glycoprotein. The three approaches described above, despite their 
individual limitations, each provide important information on different aspects of the 
interaction: the antigen presentation assays on the functional nature or immunogenicity of 
the complex, the cell -surface binding assays on the specific structural features required for 
class II MHC binding in the context of the whole cell and the immunoassay on the effects 
of different environmental conditions such as ionic strength, detergent and proton 
concentration on the peptide -class H MEC complex formation. When examined together, 
the individual data sets complement each other to provide a comprehensive analysis of 
how peptide ligands interact with different class II MHC molecules. 
3.4.2 CLIP uses minimal anchor interactions for binding to I -A class II 
MHC molecules 
The results presented herein, obtained the whole cell, flow cytometry -based assay and the 
immunoassay performed with purified class H MHC proteins, are largely consistent with 
those of the corresponding antigen presentation experiments employing I- A- restricted T 
cell clones performed previously by Gautam et al. (1995). 
The results from the cell -surface peptide binding assays indicate that the majority of single 
side -chain substitutions within the CLIP sequence have little effect on the binding to I -A 
molecules (Figures 3.2 & 3.3). Indeed, in most instances, the L- alanine- substituted 
CLIP analogues competed for binding to the I -A aß dimers essentially like wild -type 
CLIP86 -104. Deviations from this trend were seen, however, with the substitution by L- 
alanine of the residues Arg 92, Met 93, Thr 95, Pro 96, Met 99 and Met 102 for I -A 
Met 91, Met 93, Thr 95, Pro 96 and Met 102 for I -Ak and Thr 95 and Met 102 for I -A°. 
Interestingly, not all of these particular effects were apparent to the same extent in the 
original antigen presentation assays of Gautam et al. (1995), for example, that of 
substituting the CLIP residue, Met 102. Similarly, some interactions highlighted in the 
earlier experiments of Gautam et al. (1995) were not as clearly defined in the cell -surface 
binding experiments presented herein. This is most evident in the case of the M99A 
analogue which was observed to bind extremely well to I -Ad and I -A5 in the antigen 
presentation assays. These differences likely reflect the distinct nature of the competition 
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established in each of these experimental methods, i.e. the direct competition between the 
L- alanine- substituted CLIP and the biotinylated wild -type form in the cell -surface binding 
assay, compared with that in the antigen presentation assay between the substituted 
analogues and a high affinity antigen- derived peptide. 
Using an immunoassay technique with purified I -Ad molecules at pH 5.0, the role of 
certain CLIP residues in this binding interaction was even more pronounced, as illustrated 
by the large differences in the ICSO values apparent between individual side -chain 
substitutions (Figure 3.6). For example, the substitution by L- alanine of the residues, 
Pro 96 and Met 99, produced analogues which bound with very high affinity to the I -Ad 
molecules under these conditions. By contrast, the L98A CLIP analogue did not bind at 
all to these molecules at pH 5.0. In this respect, the Leu 98 residue of the CLIP sequence 
may be deemed an anchor residue for I -Ad at pH 5.0, i.e. a residue which provides 
positive binding energy to stabilise the resultant complex to the extent that the interaction 
is not sustained in its absence. 
Anchor residues are a common feature of conventional class H MHC antigen- derived 
ligands and are largely allele- specific, for example, acting through the fulfilment of 
particular electrostatic requirements or hydrophobic preferences dictated by the 
polymorphism of the peptide- binding groove (e.g. Allen et al., 1987; Sette et all, 1987; 
Adorini et al., 1988a; Kwok et al., 1996a; Nelson et al., 1996b). However, from an 
examination of the cell -surface binding assay data recorded at pH 7.0 (Figures 3.2 & 
3.3), although certain side chains do seem to contribute some measure of positive binding 
energy to the interaction of CLIP with I -A ", I -Ad and I -Ak (e.g. Met 102), it is apparent 
that no other anchor residues exist within the CLIP sequence to uphold its binding to 
these molecules. Similarly, in the antigen presentation experiments of Gautam et al. 
(1995), the only amino acid in the CLIP86 -104 ligand that may possibly constitute an 
anchor residue under the conditions of this assay method is the methionine at position 91 
for binding to I -Ak. Even in the immunoassays presented herein (Figure 3.6), where the 
higher proton concentration was found to enhance the stringency with which the 
modifications in the primary CLIP sequence affected the association with I -Ad, no other 
amino acid besides Leu 98 may be defined as an anchor. Rather, the binding of CLIP to 
I -A molecules using these three different experimental methodologies is notable for the 
number of strong inhibitory interactions, for example, through the side chains of the 
residues, Met 93 (I -A" and I -Ak, Figure 3.3, Gautam et al., 1995), Pro 96 (I -A ", Figure 
3.3; I -Ak, Figure 3.3, Gautam et al., 1995; I -Ad, Figure 3.6) and Met 99 (I -A ", Figure 
3.3; I -Ak, Gautam et al., 1995; I -Ad, Figure 3.6, Gautam et al., 1995). This behaviour 
has been investigated for the wild -type CLIP methionine residues at positions 93 and 99 
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for binding to I -A molecules and determined to be a consequence of steric hindrance 
arising from the bulk of their long aliphatic side chains (Gautam et al., 1995). 
3.4.3 A model for the degenerate binding of CLIP to class II MHC 
molecules 
The experiments reported herein identify yet another characteristic shared between CLIP 
and antigen- derived peptides: the ability of certain peptide side -chain substitutions to 
modulate the binding affinity of the interaction with class II MHC molecules. At the time, 
this finding added to the accumulating experimental evidence supporting the MHC 
peptide -binding groove as the common binding site of these two types of ligand. This 
was eventually confirmed in November 1995 with the publication of the crystal structure 
of a single CLIP ligand bound to the human class II MHC molecule, HLA -DR3 
(DRA/DRB 1 *0301; Ghosh et al., 1995). In this analysis, CLIP was identified within 
this site with its downward- oriented side chains positioned in the pockets of the cleft in a 
manner almost identical to that observed in the previous study of the antigenic influenza 
virus haemagglutinin peptide, HA306 -318, complexed with HLA -DR1 
(DRA/DRB I *0101; Stern et al., 1994). 
The results of the L- alanine substitution experiments presented above and previously 
(Gautam et al., 1995) have a number of implications for the binding of CLIP within the 
class II MHC peptide -binding groove. For example, the absence of optimal anchor 
residues within this peptide sequence, with a tendency instead for certain side chains to be 
involved in strained interactions at the binding interface, means that this ligand would be 
unlikely to form highly stable complexes with the aß dimers. This provides a likely 
explanation for the inability of CLIP to form complexes with I -A molecules that are able 
to withstand denaturation in the presence of SDS detergent (Gautam et al., 1995; Stebbins 
et al., 1996; Weenink et al., 1997), namely, that insufficient binding energy is present to 
drive the conformational rearrangement into the highly -stable compact dimer 
characteristically seen when class II MHC molecules are loaded with conventional cognate 
antigen- derived peptides. The probability that CLIP -I -A complexes are not highly stable 
is also of considerable functional significance. With each newly- synthesised class II 
MHC molecule that enters the antigen presentation pathway being unable to bind peptide 
antigen until it is free of CLIP (Roche & Cresswell, 1990b, 1991), a strong interaction 
between this ligand and the a(3 dimer would be undesirable. Consistent with this, the 
mutation in intact Ii of Met 93 or Met 99 to L- alanine has been shown to inhibit antigen 
presentation by some mouse class II MHC allotypes (Gautam et al., 1997). 
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Most significantly, the absence of notable allele- specific anchor side chains within the 
CLIP sequence in the interaction with mouse I -A molecules suggests a mechanism for the 
degenerate binding of this peptide to the many different class II MHC variants. Through 
the fulfilment of such contacts, an antigen- derived peptide typically becomes restricted in 
the subset of MHC allotypes to which it may bind. By contrast, the residues of the CLIP 
sequence may occupy the pockets of any I -A binding groove, albeit suboptimally. It 
would appear that this ligand concertedly minimises both highly -favourable and extremely 
negative side -chain interactions to offer a good compromise for binding to many different 
aß dimers. 
In agreement with this model of the degenerate binding of mouse CLIP, Malcherek et al. 
(1995) and Geluk et al. (1995) have examined the binding of human CLIP to several 
variants of the HLA -DR class II MHC isotype and find it also to lack major allele- specific 
contacts. Consequently, Malcherek et al. (1995) proposed that the CLIP ligand achieves 
promiscuous interactions with HLA -DR molecules by exhibiting a 'supermotif, a 
sequence which is compatible with the binding motifs of many different class II MEC 
allotypes. Interestingly, however, this supermotif for FILA -DR does feature the use of 
anchor residues, in the form of the three conserved CLIP methionine residues at positions 
91, 93 and 99. Specifically, these investigators determined that the substitution of Met 91 
by L- alanine decreased markedly or eliminated the binding to all the molecules examined 
(HLA -DR1, DR2, DR3 (formerly HLA -DR17) and HLA -DR7). Likewise, the CLIP Met 
93 residue was shown to provide a favourable component to the interaction with HLA- 
DR1 and DR3, and Met 99 appears to play a similar anchoring role to HLA -DR2, DR3 
and DR7 molecules (The results of these two studies disagree over whether this residue is 
also provides positive binding energy to the interaction with HLA -DRI). These finding 
are not necessarily in conflict with the mode of degenerate binding proposed above for the 
association of CLIP with I -A molecules however, since these methionine anchors are 
clearly promiscuous, accepted by most FILA -DR molecules by representing a compromise 
of the particular side -chain anchors actually preferred at each of these positions (see 
below, §3.4.5). In this sense, these residues are stili suboptimal for binding to these 
molecules and, consistent with this, the majority of the resultant CLIP- HLA -DR 
complexes remain unable to traverse the activation energy barrier of the conformational 
change to form the compact dimer to thereby achieve stability in the presence of SDS 
detergent (Riberdy et al., 1992; Sette et al., 1992a; Hitzel & Koch, 1996). 
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3.4.4 The interaction of CLIP side chains with I -A class II MHC 
molecules 
The publication of the crystal structure of CLIP complexed with the human class II MHC 
molecule, HLA -DR3, provided important spatial details on the localisation of every 
residue of the CLIP sequence within the peptide- binding groove (Ghosh et al., 1995). X- 
ray crystallographic data are now also available for the three -dimensional structure of I -Ak 
associated with the antigenic hen egg lysozyme peptide, HEL50 -62 (Fremont et al., 
1998b), and of I -Ad molecules complexed either with a peptide derived from hen egg 
ovalbumin (Ova323 -339) or from influenza virus haemagglutinin (HA126 -138; Scott et 
al., 1998). The comparative structure of the I -An heterodimer may be extrapolated from 
that of I -Ak since these molecules differ by only six residues in the a -chain and ten in the 
3- chain, all of which are located within the domains that contribute to the peptide- binding 
groove (Davis et al., 1989). Homology modelling has also been used to examine the 
interaction between these different I -A class II MHC molecules and their cognate antigen - 
derived peptide ligands, for example, I -Ak with the hen egg lysozyme peptide, HEL52 -61 
(Weber et al., 1998), I -Ad with the mouse IgG2ab heavy chain allopeptide determinant, 
y2aó435 -451 (Bartnes et al., 1997), I -Au with the N112-terminal peptide of myelin basic 
protein (MBP), Ac1-11 (Lee et al., 1998) or simply just the I -Aa and I -Ak molecules 
alone (Tate et al., 1995; Nelson et al., 1996a, 1996b; Nydam et al., 1998). This 
technique has been applied previously in an attempt to visualise the interaction of CLIP 
with these molecules as well (Lee & McConnell, 1995; Liang et al., 1996). Together, 
this information may be used to examine features of the model of degenerate CLIP 
binding proposed above and to gain insight into the molecular basis of the effects 
observed in the I -A binding studies presented herein when certain of the amino acid side 
chains of this ligand were substituted with L- alanine. 
Extrapolation of the structural details between different class II MHC variants is aided by 
the high overall degree of conservation observed in the primary amino acid sequence 
outside the polymorphic pockets of the peptide -binding groove (Kaufman & Strominger, 
1982; Benoist et al., 1983a; Choi et al., 1983; Kaufman et al., 1984; Schenning et al., 
1984). Consistent with this, the X -ray crystallographic structures of I -Ak (Fremont et al., 
1998b) and I -Ad (Scott et al., 1998) closely resemble those of other class II MHC 
molecules described previously (HLA -DR3, Ghosh et al., 1995; HLA -DR1, Brown et 
al., 1993; Stern et al., 1994; HLA -DR4, Dessen et al., 1.997; I -Ek, Fremont et al., 1996). 
The I -A peptide -binding groove encompasses a nine- residue stretch of the bound peptide 
(Pl -P9) and exhibits five pockets in which the side chains of the ligand are 
accommodated at relative positions, P1, P4, P6, P7 and P9. The intervening peptide 
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residues, P2, P3, P5 and P8 are oriented sideways across the groove or project outwards 
from this site to establish TCR contact points (Chapter I, Figure 1.4). 
Not seen in the previous human HLA -DR and mouse I -Ek structures though, the two I -A 
heterodimers show an unusual (3 -bulge at the base of the P4 pocket in the (3 -sheet 
platform which lines the floor of the peptide -binding groove. This feature arises from an 
insertion in the I- A/HLA -DQ a -chain sequence of a glycine residue in the ct domain at 
position 9a relative to the canonical structures of I- E/IILA -DR and is likely to change a 
number of interactions, not only between the a- and (3- chains, but also with the bound 
peptide. Specifically, it causes the central region of this ligand (between residues P3 -P6) 
to be drawn deeper into the groove, with the C- terminus (residues P9 -P11) extending 
more upwards. Another I- A- conserved amino acid insertion relative to I- E/HLA -DR 
molecules occurs in the 31 domain at position 84a, lying at the end of the H2b helix 
(residues f379 -1384a) which flanks the P1 binding pocket (Chapter I, Figure 1.4). A 
deletion is also present in the molecules, I- Ak'f's, 57 at residues (365 and (366. In the X -ray 
crystallographic structures of I -Ad (Scott et al., 1998), I -Ek (Fremont et al., 1996), HLA- 
DR1 (Brown et al., 1993; Stern et al., 1994), HLA -DR3 (Ghosh et al., 1995) and HLA- 
DR4 (Dessen et al., 1997), these particular residues lie at the junction between the HI 
(1352-1364) and H2a helices ((365 -(377), contributing to a high crest above the peptide - 
binding groove which represents a likely interaction site for TCR and monoclonal 
antibodies. In this respect, the significant reduction of this topological feature in the 
crystal structure of I -Ak is of some interest given the distinct patterns of mAb reactivities 
observed between the two groups of molecules, I- Ak'f's'°'g' and I -A'' (Chapter 2, Table 
2.4; discussed further in Chapter 6, §6.4.5). Throughout this thesis, I -A class II MHC 
residues are numbered according to the secondary structure -based scheme proposed by 
Fremont et al. (1998b) in order to be consistent with previous alignments of I -E and 
lILA -DR (Kabat, 1991). Further conformational features of class II MHC -bound 
peptides are discussed in Chapter 4. 
Crystallographic analysis of the CLIP -HLA -DR3 complex revealed the CLIP ligand to be 
aligned with its Met 91 residue positioned in the first major pocket at relative position, Pl 
(Ghosh et al., 1995). An identical binding register was predicted to be the most 
energetically- favourable for the binding of this ligand to I -Ad, I -Au and I -A5 (Lee & 
McConnell, 1995). Using this alignment, Table 3.2 shows a summary of the interactions 
made by CLIP side chains with the pockets of the three I -A variants, based upon the 
experimental results presented herein (Figures 3.2, 3.3 & 3.6). Structural data from X- 
ray crystallographic analyses and homology modelling arc also shown, as is information 
on points of polymorphism between these molecules (Davis et al., 1989) and existing 
6. 
Table 3.2 The interaction of CLIP side chains with the pockets of the I -A peptide- binding groove. 
Shown are the amino acid residues whose atoms contribute to the major polymorphic pockets of the peptide- binding grooves of the class II MHC molecules, I -A5, I -Ad and 
I -A ", as determined by X -ray crystallographic analysis and/or homology modelling of these structures (Lee & McConnell, 1995; Tate et al., 1995; Liang et al., 1996; 
Nelson et al., 1996; Bartnes et al., 1997; Fremont et al., 1998b; Lee et al., 1998; Nydam et al., 1998; Scott et al., 1998; Weber et al., 1998). Within each pocket, these 
residues form either hydrogen bonds or van der Waals interactions with the atoms of the amino acid side chains of a bound peptide. Throughout this thesis, class II MHC 
residues are numbered according to the secondary structure -based sequence alignment of the a, and f3, domains of the molecules, I -A5, I -F5 and HLA -DR, reported by 
Fremont et al. (1998b). The primary amino acid sequences of the a, and [3, domains of the different I -A molecules are taken from Davis et al. (1989). Polymorphic residues 
between the I -A molecules are italicised. Those underlined provide a specific physicochemical property to the pocket to govern its overall peptide side -chain preference. For 
each I -A allotype, the peptide residues commonly found at each of these positions have been taken from alignments of naturally- processed ligands (Nelson et al., 1996; 
Bartnes et al., 1997; Fremont et al., 1998b; Lee et al., 1998; Scott et al., 1998). The individual side chains of the native CLIP sequence that bind at these positions are 
shown in italics beneath the respective pocket number. 
'The nature of the interaction of the native CLIP side chains is summarised from the cell -surface binding assays (pH 7.0; Figures 3.2 & 3.3) and immunoassays (pH 5.0; 
Figure 3.6) presented in this chapter. 
°(3Asp 57 is mutated to a serine residue in the I -A'7 class II MHC molecule from the non -obese diabetic (NOD) mouse. The presence of a non -Asp residue at this position 
has been linked to the development of autoimmune diabetes in both these animals and in humans. The effects of this substitution on the peptide- binding properties of the 
I -Ae7 molecule are examined in Chapter 6 of this thesis. 
represents an anchor side chain within the CLIP sequence, such that binding to the I -A molecule is not sustained if this residue is substituted with L- alanine. 
represents the provision of positive binding energy by this CT,IP side chain at the binding interface. / represents the provision of negative binding energy by this CLIP side chain at the binding interface. 
represents no notable contribution of binding energy by the CLIP side chain to the interaction with I -A or, in the case of the wild -type CLIP residue at the P4 
position, Ala 94, where this side chain was not examined by substitution analysis. 
AlIotype 
I-Ak 
Pl 
Met 91 
P4 
Ala 94 
P6 
Pro 96 
P7 
Leu 97 
P9 
Met 99 
aPhe 24, aLeu 31, aPhe 32, 
carp 43, aArg 52 aArg 53, 
aPhe 54, (3Asn 82, ßThr 85 
Pocket character: medium, amphiphilic 
Residues observed: e.g. Asp, Glu, Thr, Cys 
°CLIP interaction: 
I-Ad aHis 24, aLeu 31, aPhe 32, 
aTrp 43, alle 52, aLeu 53, 
aPhe 54, ßAsn 82, ßPro 85 
Pocket character: large, unrestricted 
Residues observed: e.g. Tyr, Thr, Glu, Ser 
°CLIP interaction: 
aPhe 24, aLeu 31, aPhe 32, 
aTrp 43, aArg 52, aSer 53, 
ßTyr 81, ßThr 85 
Pocket character: large 
Residues observed: e.g. Val 
°CLIP interaction: 
aTyr 9, aGly 9a, aAsn 62, 
ßPhe 11, ßPro 13, ßLeu 26, 
ß11e 28, ßGlu 74 ßVal 78 
large, hydrophobic 
e.g. Ile, Val, Leu, Asn 
aTyr 9, aGly 9a, aAsn 62, 
ßPhe 11, ßGly 13, ßThr 28, 
13Glu 74, ßAla 78 
medium, hydrophobic 
e.g. Val, Ile, Leu, Ala 
aTyr 9, aAsn 62, ßPro 13, 
ßTyr 26, ßThr 28, ßGlu 74 
shallow, solvent- exposed 
e.g. Ser 
aThr 11, aAsn 62, aThr 65, 
aGly 66, aAsn 69, ßlis 9, 
ßPhe 11, ßTyr 30 
medium, polar 
e.g. Glu, Gln 
aAsn 62, aAla 65, aGlu 66, 
ßVal 9, ßPhe 11, 3Tyr 30 
shallow, amphiphilic 
e.g. Ala, Val, Ser 
fi 
alle 10, aAsn 62, aThr 65, 
aGly 66, ßVal 9, ßPhe 11, 
ßTyr 30 
deep, hydrophobic 
e.g. Phe, Tyr 
N 
aThr 65, aAsn 69, ß11e 28, 
ßTyr 30, ßTyr 47, ßTrp 61, 
[3Gln 64, ßTyr 67, ßArg 70 
shallow, hydrophobic 
no basic residues 
aAsn 69, ßThr 28, Tyr 30, 
ßTrp 61, ß11e 67, ßThr 71 
aHis 68, aAsn 69, alle 72, 
aLeu 73, aArg 76, ßTyr 37, 
ßAsp 576, ßTrp 61 
medium, amphiphilic 
e.g. Ser, Thr, Ala, Gly 
aHis 68, aAsn 69, alle 72, 
aArg 76, ßVal 38, ßAsp 57°, 
3Tyr 60, ßTrp 61 
shallow, hydrophobic medium 
e.g. Ala, Leu, Gly, Val e.g. Ala, Ser, Val 
aAsn 69, ßThr 28, ßTyr 30, 
ßTyr 47, ßTyr 61, ßTyr 67, 
ßArg 70 ßGlu 74 
shallow, solvent -exposed medium 
e.g. Arg e.g. Ser 
N 
aVal 72, aArg 76, ßLeu 38, 
ßAsp 576, ßTyr 61 
J 
CLIP side -chain interactions with I -A 80 
knowledge of their individual amino acid side -chain preferences, taken from the alignment 
of known I -A- binding peptides and naturally- processed ligands (Nelson et al., 1996b; 
Bartnes et al., 1997; Fremont et al., 1998b; Lee et al., 1998; Reizis et al., 1998; Scott et 
al., 1998). In this way, the likely molecular basis for the effects observed may be 
assessed. 
An alignment of known I -Ak- binding peptides, for example, shows an overwhelming 
preference at the Pl position for an aspartic acid residue (Nelson et al., 1996b; Fremont et 
al., 1998b). Indeed, the replacement of this anchor residue by an alanine in the HEL46- 
61 peptide has been shown to cause a 130 -fold reduction in its ability to compete for 
binding to the I -Ak molecule and a concomitant reduction in the SDS stability of the 
complex from 96% to 6% (Nelson et al., 1996b). This decrease in binding capacity may 
be recovered to some extent by restoring at least the carboxy- portion of the Asp side 
chain in the form of an asparagine residue. In explanation of these effects, the X -ray 
crystallographic analysis of the HEL -I -Ak complex has revealed that an aspartic acid side 
chain in the Pl pocket exhibits a near -perfect fit and forms a stabilising salt bridge with 
the guanidinium group of the otArg 52 residue. Meanwhile, the aliphatic portion of the 
Asp (or Asn) side chain makes a number of hydrophobic interactions with both the aPhe 
24 and aPhe 54 residues within this site. The ability of the CLIP Met 91 residue to 
provide positive binding energy to the interaction with I -Ak (Figure 3.2; Gautam et al., 
1995) would thus appear to arise from its likely capacity to fulfil these latter interactions. 
By contrast, no such favourable contacts appear to be made between this side chain and 
the larger Pl pocket of the I -An molecule (Figure 3.2) nor with the I -A3 molecule unless at 
pH 5.0 (Figures 3.2, 3.3 & 3.6). 
The role of the native CLIP residue that corresponds to the I -A P4 pocket was not 
examined by substitution analysis in this study, being already L- alanine (Ala 94). 
However, it is interesting to note that some effects of substituting the adjacent Met 93 
residue were observed. The P3 binding site does not typically constitute a major pocket 
because it is largely just a hydrophobic surface from which the corresponding peptide side 
chain is oriented sideways or away from the peptide- binding groove (Fremont et al., 
1998b; Lee et al., 1998; Scott et al., 1998). It has been suggested, however, that the 
local plasticity of the class II MHC molecule may allow for a peptide side -chain to form 
an interaction at this site as an alternative to that at the P4 pocket (Rammensee et al., 1995; 
Weber et al., 1998). This is likely to be of particular significance in the event of an 
unsuitable anchor residue at P4. In the experiments presented herein, an inhibitory effect 
of the Met 93 side chain was observed upon the binding of CLIP to I -A° and I -Ak (Figure 
3.2). Such an effect was also apparent in the antigen presentation experiments of Gautam 
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et al. (1995) and, by examining the binding of further Met 93 substituted CLIP ligands, 
these authors were able to show this to be a consequence of steric conflict at the P3 site. 
Consistent with this, small, non -polar residues are typically found at this position in 
naturally -processed ligands of the I -A class II MHC molecules (e.g. for the HEL -I -Ak 
crystal structure, Gly 54; for I -Ad, Ala 326 from Ova323 -339, Gly 130 from HÁ126- 
138; for I -A °, Ala 1 from MBPAcI -11; Fremont et al., 1998b; Lee et al., 1998; Scott et 
al., 1998). 
At the P6 pocket, all three I -A allotypes examined in this study showed that the native 
CLIP residue at this position, Pro 96, contributed negative binding energy to the 
interaction (Figures 3.2, 3.3 & 3.6). Although the exact nature and size of this pocket 
differs between these molecules, all appear to be unsuitable for accommodating the rigid, 
cyclic amino acid side chain. Subsequently, Liang et al. (1996) have created CLIP 
analogues which exhibit even greater affinity for the I -A5 and I -A° molecules by targeting 
amino acid substitutions at the P6 position to their individual binding preferences, Glu 
and Tyr, respectively. 
At the P7 pocket of the I -A" molecule, Gautam et al. (1995) found previously an 
inhibitory interaction with the Leu 97 residue of the CLIP ligand. Although not apparent 
in the cell -surface binding assays presented herein (Figure 3.2), this finding has been 
predicted to arise from an I -A °- specific polymorphism at position 061 (Trp --* Tyr) which 
may create a shift inwards of the extremities of this site to favour a smaller side chain (Lee 
& McConnell, 1995). In most class II MHC molecules, however, the P7 pocket is noted 
to be shallow and frequently unrestricted in its amino acid preference. The side chain of 
the bound peptide at this position is typically oriented sideways towards the a- helical 
walls of the peptide- binding groove rather than downwards towards the 3 -sheet floor as 
in most side chain -pocket interactions (Fremont et al., 1998b; Scott et al., 1998). This 
would account for the passive accommodation of the Leu 97 CLIP side chain within the I- 
Ak and I -Ad molecules (Figures 3.2 & 3.3). 
Lastly, the inhibitory nature of the native CLIP residue, Met 99, at the P9 pocket for 
binding to I -A molecules is also the result of steric strain at this position (Figures 3.2 & 
3.6). Data from the X -ray crystallographic structures and homology models of these 
molecules would indicate that the respective pockets are simply not large enough to 
accommodate this bulky side chain (Lee & McConnell, 1995; Fremont et al., 1998b; Lee 
et al., 1998; Scott et al., 1998). In agreement with this, Gautam et al. (1995) have shown 
that a progressive decrease in the length of the amino acid side chain at the CLIP position 
99 creates a corresponding increase in the capacity of these ligands to bind. The P9 
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pocket of I -A" has been predicted to be smaller than that of the I -Ak and I -Ad molecules as 
the result of an I -A"- specific polymorphism at position 038 (Leu in I -A "; Val in I -Ad and 
I Ak; Lee & McConnell, 1995). X -ray crystallographic analysis of this site in the HEL --I- 
Ak complex has also revealed an elaborate hydrogen bonding network to be in place 
between the peptide Ser 60 side chain and the residues of the MHC groove, including 
1Asp 57 whose carboxylate group also forms a salt bridge with the cLArg 76 residue at 
the base of this pocket (Fremont et al., 1998b). The presence of the large Met 99 side 
chain within the P9 pocket may destabilise this network and/or weaken the important salt 
bridge interaction. 
The remaining wild -type CLIP residues within the nine -residue peptide -binding motif, 
Arg 92 (P2), Thr 95 (P5) and Leu 98 (P8) are all predicted to be oriented away from the 
class H MHC peptide- binding groove (Ghosh et al., 1995; Lee & McConnell, 1995). It 
is therefore unexpected that they should be able to provide some measure of positive 
binding energy to the interaction with the different I -A molecules. Nevertheless, the Arg 
92 residue is favourable to the interaction of CLIP with I -A" and a similar effect is noted 
through Leu 98 with I -Ad. The side chain of Thr 95 appears to provide positive binding 
energy to all three CLIP -I -A complexes (Figure 3.2, 3.3 & 3.6). Similarly, the Met 102 
residue of the CLIP ligand appears to interact favourably with each of these molecules yet 
from crystallography is predicted to lie outside of the groove (Ghosh et al., 1995; Lee & 
McConnell, 1995). In this respect, it is possible that the atoms of each of these different 
CLIP side chains may still make contact with the I -A molecules beyond the immediate 
bounds of the polymorphic pockets. For example, in the X -ray crystallographic analysis 
of the CLIP- HLA -DR3 complex, the aliphatic portion of the methylene group of the Arg 
92 residue is noted to interact with the surface of the oc13 dimer. This is particularly 
interesting with regards to the model proposed above to account for the promiscuous 
binding of CLIP to I -A class H MHC molecules ( §3.4.3), since it would suggest that 
although the CLIP ligand lacks anchor residues to bind within the major pockets of the 
binding groove, favourable contacts may be formed elsewhere on the class II MHC 
molecules where the amino acid sequence is more highly conserved. Alternatively, the 
decrease in binding of the CLIP ligand observed when these residues are substituted with 
L- alanine may arise simply from effects being transmitted elsewhere within the peptide, 
for example, at adjacent pocket -binding residues. Clearly, it is not always possible to 
determine the molecular processes underlying an experimental observation from either an 
homology model or X -ray crystallographic structure. 
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3.4.5 The different roles of the conserved methionine residues of CLIP 
for binding to I -A versus HLA -DR class II MHC molecules 
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The conserved methionine residues within the CLIP sequence at positions 91, 93 and 99, 
are largely inhibitory in the binding interaction with I -A class II MHC molecules (Figure 
3.2 & 3.6). By contrast, these residues provide anchoring contributions when associated 
with different HLA -DR variants (Geluk et al., 1995; Malcherek et al., 1995). This latter 
phenomenon is likely to be facilitated by the reduced extent of polymorphism in the HLA - 
DR peptide- binding groove as a result of these molecules sharing a common, non - 
polymorphic a -chain (e.g. Korman et al., 1982; Larhammar et al., 1982; Lee et al., 1982; 
Das et al., 1983; Rothbard & Gefter, 1991). At the P1 pocket in which the CLIP residue 
Met 91 binds, for example, almost all HLA -DR variants share a common preference for a 
large, hydrophobic anchor ( Rammensee et al., 1995; Chelvanayagam, 1997). At this 
site, the exact nature of side chain preferred is defined by the dimorphic f386 residue 
(Busch et al., 1991; Demotz et al., 1993; Newton -Nash & Eckels, 1993; Verreck et al., 
1993). Typically, if glycine is present at the 086 position, the HLA -DR heterodimer will 
bind an aromatic side chain in the Pl pocket preferentially, as seen with HLA -DR 1 (Stem 
et al., 1994; Rammensee et al., 1995) and HLA -DR4 (DRA/DRB *0401; Dessen et al., 
1997). In the case of 0Val 86, an aliphatic side chain is favoured, as with HLA -DR3 
(Ghosh et al., 1995; Rammensee et al., 1995). The ability of the Met 91 CLIP to act as a 
promiscuous anchor thus Iíes in the capacity of its bulky -but -flexible, hydrophobic side 
chain to fulfil both of these preferences satisfactorily (Geluk et al., 1995; Malcherek et al., 
1995). Indeed, the interactions at this site are so favourable between this ligand and 
HLA -DR1 that, unlike other CLIP -bound class II MHC, CLIP -HLA -DR1 complexes are 
readily able to resist subunit dissociation in the presence of SDS detergent (Chicz et al., 
1992). However, if the amino acid at position 086 or the adjacent (385 residue in the 
HLA -DR1 molecule is substituted, a dramatic decrease in the overall binding affinity of 
CLIP is observed and the stability of the a0 dimer in SDS is lost (Wu & Gorski, 1996). 
In a manner similar to the Met 91 residue, the Met 93 side chain of the human CLIP 
ligand is also able to form favourable interactions with both HLA -DR1 and DR3 because 
these molecules are alike in having a shallow, non -polar P3 binding site. In fact, it is 
likely that the interaction of the Met 93 CLIP side chain at this site in HLA -DR1 is not 
altogether different from that seen with the methylene group of the Lys 310 residue in the 
X -ray crystallographic analysis of this molecule complexed with the HA306 -318 peptide 
(Stem et al., 1994). likewise, HLA -DR1 and DR3 share a common preference for a 
hydrophobic anchor to bind in the P9 pocket (Rammensee et al., 1995), thereby 
accounting for the promiscuous anchor interaction of the Met 99 CLIP residue at this 
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position (Geluk et al., 1995; Malcherek et al., 1995). Consistent with this argument, 
crystallographic analysis has indeed revealed that the CLIP anchor side chains. Met 91, 
Met 93 and Met 99, are each accommodated in the pockets of the HLA -DR3 molecule that 
exhibit the greatest proportion of their surface area formed by conserved or 
conservatively -substituted amino acids (Ghosh et al., 1995). 
An examination of CLIP binding to the mouse HLA -DR homologue, I -E, which similarly 
displays a non -polymorphic a -chain is presented in Chapters of this thesis. In the 
present chapter, it is instead more relevant to compare the CLIP I -A interaction with the 
binding of this ligand to variants of the I -A human homologue, HLA -DQ. The findings 
with such molecules are strongly consistent with those presented herein with the I -A class 
II MHC. Specifically, an examination of CLIP binding to HLA -DQ2, DQ7 and DQ9 
molecules has revealed that side -chain anchor contacts do not tend to be a feature of this 
interaction, despite being a property of the binding of antigen- derived peptides (Vartdal et 
al., 1996; Raddrizzani et al., 1997). Of further interest, the binding of CLIP to the HLA- 
DQ variants was found to be of low affinity and subsequent modelling studies with FILA- 
DQ7 have highlighted a number of significant differences within the peptide -binding 
grooves of HLA -DQ molecules relative to FILA -DR which are likely to be unfavourable 
for certain CLIP side -chain interactions. In some HLA -DQ molecules, for example, the 
1386 polymorphism within the Pl pocket dictates a specific preference for a polar residue 
(Reed et al., 1997). In this instance, it maybe envisaged that the Met 91 residue of the 
CLIP sequence would be particularly unfavourable for interacting at this site. 
The differing roles of the conserved methionine residues within the CLIP sequence 
between the I -A and HLA -DR molecules highlights an important point regarding the 
interpretation of X -ray crystallographic data. Although highly informative, by their very 
nature such structures cannot furnish all the answers - it is not possible for all the 
biochemical properties of a dynamic interaction between two molecules to be understood 
solely from the details of a single static structure. This also holds true for hypothetical 
three -dimensional structures derived by computer modelling. Experimental data remain 
essential in order to verify theoretical conclusions. This latter point is perhaps best 
illustrated by considering the homology models constructed by Lee & McConnelI (1995). 
Prior to publication of the X -ray crystallographic analysis of the CLIP HILA -DR3 
complex (Ghosh et al., 1995), Lee & McConnell (1995) performed a computer simulation 
of the binding of CLIP within the cleft of HLA -DR3 and the three mouse allotypes, I -A°, 
I -Ak and I -Au, based on the co- ordinates of the HA peptide HLA -DR1 crystal structure 
(Stern et al., 1994). However, upon obtaining an alignment of the Met 91 and Met 99 
CLIP side chains accommodated within the PI and P9 pockets, respectively, these 
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investigators concluded that these residues were anchors for all the different class II MHC 
variants. Moreover, despite claiming to have assessed the accuracy of their models from 
the L- alanine substitution binding data of Gautam et al. (1995), Lee & McConnell (1995) 
reported that no deleterious contacts were present between this peptide and the different 
MHC molecules that they examined. While this is indeed an accurate assessment of the 
situation with HLA -DR molecules (Geluk et al., 1995; Malchcrek et al., 1995), the data 
provided herein and previously (Gautam et al., 1995) have shown that this is clearly not 
the case for CLIP binding to mouse I -A class II MHC molecules. 
Nevertheless, sometimes even empirical data may be interpreted incorrectly. This time 
using an experimental approach, the same group of Lee and coworkers examined the 
effects of replacing the wild -type CLIP residues Met 91 and Met 99 with the amino acid, 
L- leucine (Liang et al., 1996). Such substitutions were found to cause large reductions in 
the stability of the CLIP -I -A complexes relative to those formed with the wild -type 
ligand. In this respect, the data presented herein agree with the findings of Liang et al. 
(1996), that the insertion of the less- flexible, branched, hydrophobic leucine side chains 
into the P9 pocket within the I -A peptide- binding groove causes even greater steric strain 
at the binding interface than the native Met 99 CLIP residue. Indeed, Gautam et al. 
(1995) have examined previously the relative effects of the bulk of the Met 93 and Met 99 
CLIP residues and shown that a progressive decrease in the number of methylene groups 
at these side -chain positions led to a significant improvement in the ability of this ligand to 
bind to the I -A I -A5 and I -A° molecules. However, Lee and coworkers still appear to 
have misinterpreted their data by taking such findings as confirmation that the wild -type 
methionine residues were anchors within the CLIP sequence for binding to I -A class II 
MHC molecules. A similar claim has been made more recently by Naujokas et al. (1998) 
upon observing a decrease in the affinity of the CLIP ligand for I -A° when Met 91 was 
substituted with L- Ieucine. This is simply not supported by the previous experiments of 
Gautam et al. (1995) nor the results presented herein. 
3.4.6 The effects of polymorphism within the class II MHC peptide - 
binding groove on the binding of CLIP 
The experimental results summarised in Table 3.2 indicate that, although CLIP 
demonstrates promiscuous binding to many different class HMHC allotypes, the affinity 
for this ligand is by no means unaffected by the polymorphism of the I -A peptide- binding 
groove. This is illustrated similarly in the results of the cell -surface peptide binding 
assays by the different affinities of biotinylated CLIP86 -104 for the three I -A variants (I 
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Ad » I -Ak > I -An; Figure 3.2). These findings are consistent with both the affinity 
measurements reported by Sette et al. (1995) and the different rates of CLIP dissociation 
from these molecules determined by Bangia & Watts (1995) and Liang et al. (1995), e.g. 
for CLIP86 -102, K, = 4.3 µM for I -Ad, >16 µM for I -Ak at pH 7.0. 
Given that the affinity of a peptide for binding to a particular class II MHC molecule 
typically reflects the overall balance of attractive and repulsive forces present between the 
side chains of the peptide and the residues lining the groove (Chapter 1, § 1.3.3), an 
explanation for the differing affinities of the I -Ad, I -Ak and I -Au molecules for CLIP may 
be obtained by an examination of their respective binding motifs. Indeed, comparison of 
the X -ray crystallographic analysis of I -Ak (Fremont et al., 1998b) and I -Ad (Scott et al., 
1998) reveals a significant difference between these molecules in the relative importance 
of their having the polymorphic pockets of the groove occupied by peptide side chains. 
For example, all of the five side chains of the HEL50 -62 ligand that interact at these sites 
in the crystal structure of I -Ak were buried almost entirely, thereby contributing a large 
measure of positive binding energy to the complex (Fremont et al., 1998b). By contrast, 
the X -ray crystallographic analysis of the I -Ad peptide -binding groove revealed the 
pockets in this molecule to be relatively shallow overall and frequently only partially filled 
by the side chains of the hound peptides, HA126 -138 or Ova323 -339 (Scott et al., 
1998). 
It would thus appear that, unlike I -Ak molecules, ligands may bind well to I -Ad without 
having need of major anchor residues. Of particular note, the large Pl pocket in I -Ad 
appears able to accommodate peptide side chains of quite different physicochemical 
characteristics without necessarily having any effect upon the overall binding affinity 
(Bartnes et al., 1997). This is in agreement with previous findings that this ailotype 
exhibits a binding motif of only six consecutive amino acids (Sette et al., 1987, 19896; 
residues P4-P9, as determined by Scott et al., 1998) instead of the usual nine -residue 
motif displayed by other class H MHC variants. Moreover, T cell recognition of such 
complexes does not appear to be strictly dependent upon the presence of a good anchor at 
the Pl position either (Bartnes et al., 1997). Rather, the only key pocket interaction that 
does appear to be required for a peptide to bind to I -Ad involves the side chain at position 
P4. At this position, an alignment of known I -Ad- binding peptides and naturally - 
processed ligands has shown a critical preference for an aliphatic amino acid (Table 3.2; 
Bartnes et al., 1997; Reizis et al., 1998; Scott et al., 1998). In both the crystal structures 
of I -Ad, this requirement is fulfilled by a valine residue (Val 131 in HÁ126 -138, Val 327 
in Ova323 -339; Scott et al., 1998). 
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It is therefore likely that CLIP is able to bind with high affinity to I -Ad class II MHC 
molecules because of their relatively unrestricted peptide -binding motif. By contrast, the 
CLIP sequence is less able to fulfil the more critical anchor requirements of the I -Ak 
molecule and, consequently, binds with diminished capacity. Following this argument, I- 
A° would then be expected to exhibit the most restricted anchor requirements of all, given 
its very low affinity for the CLIP ligand (Figure 3.2). This latter idea is consistent with 
the recent finding that the very low affinity of the MBP Acl -11 peptide for the I -An 
heterodimer arises from this ligand adopting a binding register which leaves part of the 
peptide -binding groove empty (the positions Pl and P2) and none of the polymorphic 
pockets accommodating a suitable, strong anchor side chain (Lee et al., 1998). However, 
when a tyrosine residue was substituted into either the MBP Acl -11 peptide or CLIP at a 
position corresponding with the large P6 pocket, a significant increase in the stability of 
binding was observed, as determined by measurement of the dissociation kinetics. A 
similar effect was obtained by extending the amino- terminus of the MBP Acl -I I peptide 
with six residues of the N112- terminus of the Ova323 -339 peptide. The ability of CLIP to 
bind to I -Ad, I -Ak and I -A° allotypes without fulfilment of specific anchor requirements 
suggests that the interaction must therefore be driven by interactions through the peptide 
backbone. The contribution of the main -chain atoms of the CLIP sequence to the 
interaction with I -A class H MHC molecules is the subject of Chapter 4. 
The effect of allelic variation in the modulation of the binding affinity of CLIP has also 
been reported for human class II MHC molecules (Avva & Cresswell, 1994; Sette et al., 
1995). For example, this ligand has been shown to bind with higher affinity to HLA- 
DR1 than to HLA -DR3 (Sette et al., 1995). In this respect, it is likely that, similar to the 
situation for the I -A molecules, the differences seen in the CLIP binding affinities reflect 
the varying abilities of this sequence to fulfil the HLA -DRI and DR3 binding motifs. For 
example, examination of the structure of the HLA -DR3 molecule and known peptide 
ligands reveals that, in addition to the preference for a large hydrophobic residue at the Pl 
position, there exists another major anchor requirement at the P4 pocket (Ghosh et al., 
1995; Rammensee et al., 1995). Here, a strong preference is displayed for an aspartic 
acid side chain to interact with the HLA- DR3 -specific arginine at position (374 (f3Ala 74 in 
HLA -DR1). In the interaction of CLIP with HLA -DR3 however, this position is 
occupied only by a small alanine residue (Ala 94) which leads to a slight collapse inwards 
in this region of the 13 -chain a -helix which forms one wall of the groove (Ghosh et al., 
1995). In the event of a non -ideal P4 anchor, as in the case of binding CLIP, HLA -DR3 
molecules are then noted to show a secondary preference motif to compensate, in the form 
of a positively- charged residue at the P6 pocket to interact with the negatively -charged 
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(3Asp 28 residue (Rammensee et al., 1995). Again, this is not fulfilled when CLIP binds 
to HLA -DR3. 
It is also IikeIy that the overall superior ability of the CLIP sequence to meet the motif 
preferences of HI.A -DR1 is the reason that this complex is able to attain stability in SDS 
detergent (Chicz et al., 1992). Consistent with this argument, the introduction into the 
CLIP sequence of the HLA- DR3 -specific anchor residue, aspartic acid, at the P4 position 
(Ala94Asp) also leads to the formation of an SDS- stable complex (Malcherek et al., 1995) 
and these peptides are no longer able to be removed from the peptide -binding groove by 
the actions of HLA -DM (van Ham et al., 1996). Conversely, replacement by an alanine 
residue of this P4 Asp anchor in the HLA -DR3- binding peptide, ApoB2877 -2894, 
creates an SDS -unstable complex that is now susceptible to dissociation induced in the 
presence of HLA -DM. It has thus been suggested that the ability of HLA -DM to catalyse 
the removal of CLIP from class II MHC molecules may hinge upon this ligand lacking 
such optimal anchor residues and the resulting the stability they that confer ( Kropshofer et 
al., 1996; van Ham et al., 1996; Weber et al., 1996). It is worth noting, however, that 
the ability of a cognate peptide to confer resistance to the dissociation of the class II MHC 
subunits in the presence of SDS detergent is an arbitrary indicator. The molecular basis 
underlying this feature is not well understood and, frequently, the behaviour of a peptide - 
aß complex upon SDS -PAGE does not correlate with the more relevant functional state 
of these molecules. For example, despite their SDS -stability, CLIP -bound HLA -DR1 
molecules are still sensitive to the peptide- exchange functions of HLA -DM molecules 
(Sloan et al., 1995; Kropshofer et al., 1996). Moreover, the characteristics of a given 
peptide -class II MHC complex in SDS is unrelated to whether it may be recognised by 
CD4' T lymphocytes (Wu et al., 1996). For this reason, one must be very cautious in 
using this property as a measure of how well a peptide binds to a given a(3 dimer. The 
relationship between SDS- stability and peptide binding affinity is discussed further in 
Chapter 6 ( §6.4.4). 
Lastly, but significantly, binding affinity is also affected by proton concentration. Low 
pH values approximating those found in the acidic intracellular compartments of 
metabolically- active APC have been shown to accelerate markedly the formation of 
functional antigen -class II MHC complexes (Jensen, 1990, 1991; Harding et al., 1991; 
Wettstein et al., 1991; Mouritsen et al., 1992; Sette et al., 1992b). In this study, the 
binding of both CLIP (Figure 3.4) and the ovalbumìn peptide Ova322 -339 (Figure 3.5a) 
to I -A° molecules was increased at pH 5.0 relative to binding at pH 7.0. The molecular 
processes underlying the ability of acidic conditions to enhance peptide binding to class II 
MHC molecules are discussed in Chapter 5, §5.4.4. 
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3.5. Conclusions 
In this chapter, the contributions from individual side chains within the CLIP sequence to 
the binding interaction with the mouse class H MEC molecules, I -Ad, I -Ak and I -A° have 
been examined. This has been achieved by using a set of CLIP analogues, each with a 
single L- alanine residue substitution introduced into the sequence, as competitors against 
biotinylated CLIP86 -104 in either cell- surface binding assays at pH 7.0 or, for purified I- 
Ad, in an immunoadsorption assay at pH 5.0. The ability of such side chain -substituted 
peptides to bind to class H MHC I -A allotypes in these experiments was consistent with 
results obtained previously through their capacity to inhibit I- A- restricted T -cell responses 
(Gautam et al., 1995). 
The results presented herein, coupled with those of Gautam et al. (1995), indicate that the 
CLIP sequence binds to class II MHC molecules of the mouse I -A isotype without strong 
anchor residues. In this respect, the binding of CLIP differs from that of conventional 
antigen- derived ligands. Some measure of positive binding energy is provided to the 
association of CLIP with I -A through the side chains, Thr 95 and Met 102, together with 
Arg 92 for I -A° and Met 91 for I -Ak. However, an examination of structural data of the I- 
A molecules (e.g. Lee & McConnell, 1995; Fremont et al., 1998b; Scott et al., 1998) 
indicates that these residues are not accommodated within the polymorphic pockets of the 
peptide- binding groove but, rather, contact the aß dimer outside of this site where the 
sequence is more conserved. This is likely to facilitate the ability of the CLIP ligand to 
bind promiscuously to different class II MHC allelic variants. 
Of the CLIP side chains that do bind within the pockets of the I -A peptide -binding 
groove, several are inhibitory to the interaction, e.g. Pro 96 at the P6 pocket and Met 99 
at P9. These deleterious side -chain contacts, together with the lack of strong anchor 
residues, may be significant is ensuring that the CLIP ligand is able to be displaced 
efficiently in vivo to allow the binding and presentation of antigen -derived peptides. The 
lack of optimal anchor residues within the CLIP sequence suggests that the interaction 
must be maintained predominantly by another means, possibly via the backbone. The 
role of the main chain atoms of the CLIP backbone in the binding of this sequence to I -A 
molecules is investigated in Chapter 4. 
CHAPTER 4. 
The role of main -chain atoms in the binding of CLIP to 
mouse I -A class II MHC molecules 
CLIP backbone interactions with I -A 
4.1. Introduction 
90 
In Chapter 3, the molecular basis of the promiscuous binding of CLIP to different class II 
MHC glycoproteins was explored by examining the contribution of the individual amino 
acid side chains within this peptide sequence. These experiments revealed that the 
substitution of most CLIP side chains had only minor effects upon the overall capacity of 
this ligand to bind to the mouse class II MHC allotypes, I -Ad, I -A° and I -Ak. Moreover, 
the few native side chains that were seen to have a significant influence on the binding 
affinity of this interaction did so chiefly in an inhibitory manner. 
If the amino acid side chains of the CLIP ligand do not form strong favourable contacts 
with the residues of the I -A aß dimers, then it follows that the interaction must instead be 
sustained predominantly by positive binding energy provided through the main -chain 
atoms of the peptide backbone. In this chapter, this possibility has been investigated by 
introducing stereochemical inversions into the CLIP86 -104 sequence in the form of 
single D- alanine substitutions. Such modifications within a peptide typically lead to a 
breakdown of native secondary structure (DeGrado, 1988). It would be predicted, 
therefore, that the incorporation of a D- alanine residue within the CLIP ligand would also 
disrupt the capacity of its backbone to make contacts with the class II MHC heterodimer. 
The contribution of main -chain interactions to the binding affinity of CLIP for the mouse 
allotypes, I -Ad, I -A° and I -Ak, has been assessed using the D- alanine- substituted 
analogues in a series of competitive peptide -binding assays. Further details of the CLIP 
binding motif have been examined using truncated analogues, frameshifted 15 -mers and 
additional L- alanine- substituted variants. The model proposed in Chapter 3 to account for 
the degenerate binding of the CLIP sequence to class H MHC molecules has been 
extended here to incorporate these findings and the possibility is discussed that conserved 
residues within the amino- terminus of this ligand may also modulate its binding to 
different I -A molecules. 
4.2. Materials and Methods 
Full details of the experimental procedures described herein may be found in Chapter 2. 
Briefly, the mouse B cell lines, A20 (H -2d), CH27 (H -2k), M12.D (I -Ad) and 1 -5.4 (I- 
As), were used as APC in both antigen presentation assays and cell -surface peptide 
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binding assays (Table 2.1). The I- A- restricted T cell hybridomas, 3D0 -54.8 (I -Ad- 
restricted, Ova323- 339 -specific), 3A9 (I -Ak- restricted, HEL46 -61- specific) and 1934.4 
(I -Au- restricted, MBPAc1 -11- specific), were used in the antigen presentation assays 
(Table 2.2), together with the IL -2 dependent T cell line, HT -2. For ELISA -based 
peptide binding assays, mouse I -Ad molecules were purified by Mrs Y. M. Gautam 
(Laboratory technician) from the BALB /c- derived B cell lymphoma, A20, by affinity 
chromatography on an MK -D6 mAb column ( §2.6). 
D- alanine- substituted CLIP86 -104 peptides are listed in Table 4.1. Truncated and 
frameshifted 15 -mer CLIP analogues are listed in Tables 4.2 and 4.3, respectively. 
Further substituted and length -altered CLIP analogues are given in Table 4.4. CLIP81- 
104 analogues with single L- alanine substitutions in the amino -terminus are shown in 
Table 4.5. The peptide concentrations used in binding assays are stated in the figure 
legends. Competitor peptides were tested over the range 3 -200 µM in antigen 
presentation assays ( §2.7.1), 32 -250 µM for cell -surface binding assays 02.7.2) and 
from 38 -300 µM for immunoassays with purified I -Ad ( §2.7.3). 
The mouse invariant chain protein sequence used in the secondary structure predictions 
was retrieved from the integrated databases of the National Center for Biotechnology 
Information (NCBI) using the Entrez World Wide Web browser 
( http: / /www.ncbi.nlm.nih.gov/Entrez). Protein secondary structure predictions were 
conducted using two methods: the nearest neighbour secondary structure prediction 
service (NNSSP) of Salamov & Solovyev (1995) available from the University of Houston 
network server (service @theory.bchs.uh.edu; subject line 'man nnssp" for help); and the 
method of Rost & Sander (1993, 1994) from the Pui sec web site (http://www.embl - 
heidelberg.de/ predictprotein /predictprotein.html), accessed through the ExPASy 
proteomics server of the Swiss Institute of Bioinformatics (SIB; 
http: / /www. expasy.ch /tools/"secondary). 
4.3. Results 
4.3.1 D- alanine substitutions within the central CLIP sequence disrupt 
binding to I -A class H MHC molecules 
Prior to their use in competitive binding assays, confirmation was first sought that the 
introduction of single D- alanine residues into the primary sequence of the CLIP86 -104 
ligand (Table 4.1) created the desired disruption of the secondary structure of the peptide. 
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Table 4.1 D- alanine -substituted peptide analogues of CLIP86 -104. 
K86D-Ala D-Ala 
P87D-Ala - D-Ala 
V88D-Ala D-Ala 
S89D-Ala - D-Ala 
Q90D-Ala - - D-Ala 
M91D-Ala D- Ala 
R92D-Ala D-Ala 
M93D-Ala D-Ala 
A94D-Ala K P V S Q M R M D-Ala T P L L M R P M S M 
T95D-Ala D-Ala 
P96D-Ala D-Ala 
L97D-Ala D-Ala 
L98D-Ala D-Al a 
M99D-Ala D-Ala 
R100D-Ala D-Ala - - 
P101D-Ala D-Ala - - - 
MI02D-Ala D-Ala - 
S103D-Ala D-Ala 
M104D-Ala D-Al a 
Amino acid sequences of CLIP86 -[04 analogues exhibiting single D- alanine substitutions are 
shown. Native amino acid residues are represented with a dash. 
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At the commencement of this investigation, the X -ray crystallographic analysis of the 
CLIP- HLA -DR3 complex had yet to be published and, therefore, details of the manner in 
which the CLIP backbone may interact with the class II MHC molecule were unknown 
(Ghosh et al., 1995). However, an estimate of the potential conformation favoured by 
the CLIP ligand could be obtained using secondary structure prediction algorithms. 
Analysis by two such methods revealed that the wild -type CLIP sequence between 
residues 90-101 exhibited strong helix- forming potential (Figure 4.1). Moreover, this 
conformation was preferred irrespective of whether the entire sequence of intact mouse 
p31 invariant chain was analysed (Figure 4.1a) or just the region of this protein encoded 
by exon three, the sequence CLIP81 -107 (Figure 4.1b). 
To determine the disruptive effects of the D- alanine substitutions upon this possible 
conformation of the CLIP sequence, the circular dichroism (CD) of each of the 
configurationally -substituted CLIP analogues was measured under experimental 
conditions that strongly promoted the formation of a- helices. Shown in Figure 4.2a are 
the CD spectra of the monosubstituted CLIP86 -104 variants, K86D -Ala and A94D -Ala, 
representative of the two extremes in conformation found amongst the D- alanine- 
substituted CLIP. Specifically, the CLIP analogues that exhibited D- alanine 
monosubstitutions at the peptide terminus (e.g. K86D -Ala) exhibited similar CD spectra 
to the wild -type peptide, CLIP86 -104, while the introduction of a single D- alanine 
residue within the central region of this sequence caused a pronounced disruption of the 
native peptide conformation (e.g. A94D -Ala). Under the extreme a- helix -promoting 
conditions employed, the difference CD of these two peptides (Figure 4.2b) revealed a 
marked weakening of features characteristic of a- helical conformation in the A94D -Ala 
peptide, i.e. the loss of minima at 208 mn and 222 nm (Johnson, 1990). If the 
introduction of a D- alanine residue is sufficient to destroy the formation of an a -helix 
within this peptide under these conditions then, by extension, such substitutions may also 
be expected to disrupt any other form of periodic conformational structure that the CLIP 
ligand may potentially adopt. 
The role of the CLIP backbone in its binding to I -A class TT MHC molecules was then 
examined using the D- alanine- substituted analogues as competitors in antigen presentation 
assays with the same APC lines and I- A- restricted T cell hybridomas as employed 
previously to investigate the binding of the L- alanine- substituted CLIP analogues 
(Gautam et al., 1995). In contrast to the findings with the side chain- substituted 
analogues, the introduction of a single D- alanine amino acid into the central region of the 
peptide between residues, Met 91 and Met 99, was found to eliminate or reduce 
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Figure 4.1 Secondary structure prediction of mouse invariant chain 
p31 and CLIP81 -107. 
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Conformational tendencies of (a) mouse invariant chain, p31, and (b) the CLIP sequence 81 -107 were 
examined using different secondary structure prediction algorithms. Shown are the results of two such 
methods (PHDsec: Rost & Sander, 1993, 1994; NNSSP: Salamov & Solovyev, 1995) as described in 
Material and Methods 04.2). Secondary structure predictions are indicated by H (helix) and E (strand). A 
dash indicates no statistically- preferred conformation. Mouse p31 Ii is numbered according to the human 
p33 sequence in accordance with the numbering used throughout this thesis (Chapter 1, Figure 1.5). The 
mouse Ii sequence bears two deletions at postions 27 and 138 and an insertion at position 185a relative to 
the human Ii sequence. 
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Figure 4.2 Circular dichroism of D- alanine -substituted CLIP86 -104. 
95 
(a) Circular dichroic (CD) spectra of the configurationally -substituted CLIP86 -104 analogues, K86D -Ala 
and A94D -Ala were recorded under strong 0c- helix -promoting conditions in 50% (v /v) TFE/ 10 mM 
sodium phosphate, pH 7.0 at 25 °C, as described in Chapter 2, §2.3.3. The difference CD between these 
peptides (b) shows abrogation of helix -forming propensity in the A94D -Ala CLIP analogue. 
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Figure 4.3 Competition by D- alanine -substituted CLIP86 -104 for 
antigen presentation to I- A- restricted T cell hybridomas. 
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Multiple doses of CLIP86 -I04 analogues with single D- alanine substitutions were tested in triplicate as 
competitors for presentation by the cell lines (a) 1 -5.4 (I -A°), (b) CH27 (H -2k) and (e) A20 (H -2d) to the 
I- A- restricted T cell hybridomas, 1934.4 (MBP Ac1-l1, 5 pM), 3A9 (HEL46 -61, 1.5 pM) and 3D0 -54.8 
(Ova323 -339Y, 0.05 pM), respectively. A single competitor dose which yielded -50% mean inhibition 
of antigenic T cell stimulation by wild -type CLIP86 -104 (cross- hatched fill pattern) is shown from one 
experiment (1 -5.4, 50 pM; CH27, 100 pM; A20, 12.5 pM). Solid bars represent mean competition by the 
substituted CLIP analogues and empty bars indicate maximal T cell stimulation in the absence of 
competitor peptide. All experiments were repeated three times with consistent results. 
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considerably the ability of the CLIP sequence to compete with antigenic peptide for 
binding to the molecules, I -A", I -Ak and I -Ad (Figure 4.3). For example, few of the D- 
alanine- substituted CLIP analogues, Q90D -Ala to P101D -Ala, showed any capacity 
whatsoever to compete with the MBP Ac 1 -11 peptide for binding to the I -A" molecules of 
the 1 -5.4 cell line (Figure 4.3a). Similarly, CLIP analogues with a D- alanine 
monosubstitution between residues, Arg 92 -Leu 97 inclusive, were unable to compete 
with the antigenic peptide, HEL46 -6I, for presentation by I -Ak molecules of the CH27 
cells, while those with substitutions immediately adjacent to this sequence element 
exhibited a decline in their capacity to bind (Figure 4.3b). Lastly, CLIP analogues did not 
compete with Ova323 -339Y for binding to the I -Ad molecules of the A20 cell line when 
the single D- alanine replacements occurred between the residues, Met 93 -Met 99 
inclusive (Figure 4.3c). Again, a reduction in the binding to these cells was observed 
with a D- alanine amino acid present in the two or three residues flanking this. 
To investigate further the effects of modifying the CLIP backbone stereochemistry, the 
ability of the D- alanine- substituted CLIP analogues to bind to the I -A ", I -Ak and I -Ad 
molecules in a cell -surface peptide binding assay was assessed. This method enables the 
analogues to be examined as competitors against the same peptide for all three allotypes, 
in the form of the promiscuous ligand, wild -type CLIP86 -104. Shown in Figure 4.4 are 
the results of one such assay, illustrative of the experimental findings. Mean ICso values 
have been calculated from two independent experiments and are given atop each 
competitor bar (solid fill pattern) to provide a quantitative representation of the overall 
trends observed. As observed previously using this method (Chapter 3, Figure 3.2), the 
varying levels of signal generated in the positive control sample of the biotinylated 
CLIP86 -1 04 alone (empty fill pattern) between the cell lines reflect accurately the 
different binding affinities for the CLIP ligand of the three I -A allotypes (Bangia & Watts, 
1995; Liang et al., 1995; Sette et al., 1995). Regarding the overall trend, however, all 
three cell lines yielded the same result. A considerable reduction in the ability of CLIP to 
compete for cell -surface binding was observed when the D- alanine residues were 
introduced into the core of the sequence. This finding is consistent with those from the 
antigen presentation assays performed with the same cell Iines (Figure 4.3). 
In Chapter 3 ( §3.3.1), the possibility that the results from cell -surface binding assays 
performed with the cell lines CH27 and A20 may also include a contribution from CLIP 
associating with I -E class II MHC molecules was discussed. This was deemed to be 
unlikely given the similarity in the pattern of results between the binding of the L- alanine- 
substituted CLIP to the cell -surface class H MHC molecules (Chapter 3, Figure 3.2) and 
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Figure 4.4 Competition by D- alanine - substituted CLIP86 -104 for binding 
to cell -surface I -A class II MHC molecules. 
Multiple doses of CLIP86 -104 analogues with single D- alanine substitutions were tested for competition 
against biotinylated CLIP86 -I04 (20 taM) for binding to cell- surface I -A molecules of the cell lines (a) 1- 
5.4 (I -A"), (b) CH27 (I -Ak) and (c) A20 (I -A5). A single competitor dose yielding -50% inhibition of 
biotinylated CLIP binding by wild -type CLIP86 -104 (cross -hatched fill pattern) is shown (1 -5.4, 125 pM; 
CH27, 200 pM; A20, 62.5 pM). Assays were performed three times with consistent results. Solid bars 
represent competition by substituted CLIP and empty bars represent the maximal biotinylated CLIP signal 
with no competitor present. Binding levels are expressed as medían fluorescence intensity (MFI), from 
which background counts have been subtracted (1 -5.4, 3.05; CH27, 3.28; and A20, 3.05). IC50 values for 
each competitor peptide are given on top of each bar. An asterisk represents an IC50 value of >1000 pM. 
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when the same peptides were used as competitors in antigen presentation assays with I -A- 
restricted T cell hybridomas (Gautam et al., 1995). Employing this same logic, it also 
seemed improbable that the results presented in Figure 4.4 were distorted by CI JP 
binding to the I -E molecules on the A20 or CH27 cells, given their similarity to those in 
Figure 4.3 obtained using the antigen presentation assay. In further support of this, the 
binding of the D- alanine analogues to the I -E° cell line, M12.D (I -Ad), showed a pattern 
of results identical to those obtained with the A20 cell line in both the antigen presenting 
assay (Figure 4.5a) and the cell -surface binding assay (Figure 4.5b). Moreover, in an 
immunoassay, affinity- purified I -Ad molecules also yielded the same trend for binding the 
D- alanine substituted CLIP86 -104 analogues (Figure 4.6). As before, mean ICSO values 
from two independent experiments are provided atop each bar. The apparent inability of 
CLIP to bind to I -E class II MHC molecules under the conditions of the cell -surface 
peptide binding assay is discussed in Chapter 5. 
4.3.2 CLIP ligands truncated below 13 residues bind poorly to I -A 
class II MHC molecules 
The results described above illustrate the importance of the backbone conformation in the 
central CLIP sequence element, residues 91 -99, for binding to the class H MHC 
molecules, I -A I -Ak and I -Ad. In order to determine whether this central motif alone 
was sufficient to uphold this interaction, a set of truncated CLIP analogues was 
synthesised in which residues were sequentially deleted pairwise from each end. The 
ability of these peptides to compete against biotinylated wild -type CLIP 86 -104 for 
binding to cell- surface I -A molecules is shown in Table 4.2. Data are presented as mean 
ICS0 values ± standard deviation from two independent experiments. 
Strikingly, when the CLIP sequence was truncated to 13 amino acids or fewer, its ability 
to compete for binding to all three allotypes was reduced (e.g. CLIP89 -101, 90 -100; 
Table 4.2) or even eliminated (e.g. CLIP91 -99). An equivalent result was obtained using 
the truncated CLIP as competitors in antigen presentation assays (Figure 4.7). The 
central CLIP sequence element, residues 91 -99, is therefore insufficient on its own to 
sustain binding to I -A class II MHC molecules. 
The binding of the truncated CLIP was subject to some allele- specific effects, as observed 
previously with the D- alanine- substituted analogues (Figures 4.3 & 4.4). In particular, in 
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Figure 4.5 Competition by D- alanine -substituted CLIP86 -104 for 
binding to M12.D at pH 7.0. 
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Multiple doses of CLIP86 -104 analogues with single D- alanine substitutions were tested as competitiors 
for binding to i -Ad class II MHC molecules expressed by the cell line, M12.D, against (a) Ova323 -339Y 
(0.05 11M) in an antigen presenting assay with the I -Ad- restricted T cell hybridoma, 3D0 -54.8, and (b) 
biotinylated CLIP86 -104 (20 µM) in a cell -surface binding assay. Shown is the dose which yielded 
-50% mean inhibition of antigenic T cell stimulation from triplicate samples (I2.5 pM) or -50% 
inhibition of the binding of biotinylated CLIP (62.5 µM) by wild -type CLIP86 -104 (cross- hatched fill 
pattern), respectively. Both antigen presentation assays and cell -surface peptide binding assays were each 
performed twice with consistent results. Solid bars represent competition by the substituted CLIP 
analogues. For each assay, the maximum signal with no competitor present is depicted by the empty bar. 
Background signals measured in the absence of signal peptides have been subtracted from data shown (a, 
199 cpm; b, MFf, 2.46). 
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Figure 4.6 Competition by D- alanine -substituted CLIP86 -104 for 
binding to purified I -Ad class II MHC molecules at pH 5.0. 
Multiple doses of CT.TP86 -104 analogues with single D- alanine substitutions were tested as competitors 
against biotinylated CLIP86 -104 (25 4M) for binding to I -Ad class II MHC molecules purified from the 
BALB /c- derived B cell lymphoma, A20 (Chapter 2, §2.6). A single competitor dose (150 ttM) which 
yielded -50% inhibition of the biotinylated CLIP signal by wild -type CLIP86 -104 (cross- hatched fill 
pattern) is shown. Solid bars represent competition by the substituted CLIP analogues and the empty bar 
indicates the maximum biotinylated CLIP signal with no competitor present. Binding assays were 
repeated twice with equivalent results. Binding levels are expressed as optical density (OD) read at 405 
nm with a reference wavelength of 495 nm. Non -specific associations were determined from the binding 
of biotinylated peptide in the absence of MHC molecules and have been subtracted from the data shown 
(I-Ad, 0.096 OD units). 
Table 4.2 Competition by truncated CLIP for binding to I -A class II MHC molecules. 
CLIP ICso (µM) 
1 -5.4 (I -Au) CH27 (H-2k) A20 (H-2d) 
86-104 KPVSQMRMATPLLMRPMSM 192.95 ± 22.27 309.30 ± 22.06 123.95 ± 11.95 
87-103 PVSQMRMATPLLMRPMS 52.99 ± 4.07 149.80 ± 32.53 141.45 ± 12.09 
88-102 VS QMRMATP LLMRPM 112.70 ± 7.50 143.55 ± 41.65 202.95 ± 3.18 
89-101 SQMRMATPLLMRP 583.05 ± 139.80 429.35 ± 24.25 649.40 ± 318.20 
90-100 QMRMATPLLMR > 1000 842.90 ± 222.17 > 1000 
91-99 MRMATPLLM > 1000 > 1000 > 1000 
Residues were removed pairwise, sequentially from each end of the CLIP86 -104 sequence. The truncated CLIP were tested at 
multiple doses as competitors against biotinylated CLIP86 -104 (50 µM) for binding to the cell -surface I -A molecules of the 
cell lines, 1 -5.4, C1127 and A20, at pH 7.0. Data are presented as mean IC50 values ± SD (11M) from two independent 
experiments. Background median fluorescence intensity (MFI) values of 3.54, 5.14 and 3.6 relative units were recorded for I- 
A ", I -A5 and I -Ad, respectively. The maximum MFI for each allotype was 13.6, 48.8 and 15.15 relative units, respectively. 
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Figure 4.7 Competition by truncated CLIP ligands for binding to I -A 
class II MHC molecules at pH 7.0. 
Truncated CLIP analogues from which residues were removed pairwise from each end were tested as 
competitors for presentation by the cell lines (a) 1 -5.4 (I -A5), (b) A20 (H -2d) and (c) CH27 (H -2k) to the 
I- A- restricted T cell hybridomas, 1934.4 (MBP Ac1-11, 51.1M), 3D0 -54.8 (Ova323 -339Y, 0.05 ttM) and 
3A9 (HEL46 -61, 1.5 pM), respectively. Data shown represent the mean percentage inhibition ± SD from 
two independent experiments. Within each experiment, peptides were tested in triplicate samples, as 
described in Chapter 2, §2.7 1. 
CLIP backbone interactions with 1 -A 104 
both cell -surface peptide binding assays (Table 4.2) and the antigen presentation assays 
(Figure 4.7), the 17 -mer ligand, CLIP87 -103, consistently competed better than the 19- 
mer, CLIP86 -104, for binding to the I -Au and I -Ak molecules. The 15 -mer, CLIP88- 
102, also competed better than the CLIP86 -104 ligand for binding to the I -Ak molecules. 
A similar effect was seen for this peptide binding to I -A° but in the results of the cell - 
surface binding assay only (Table 4.2). By contrast, the progressive truncation of the 
outermost amino acid pairs from the CLIP86 -104 sequence did not lead to a pronounced 
enhancement of the ability of these peptides to bind to the I -Ad molecules of the A20 cell 
line. Similarly, no such effect was observed when the binding of these peptides to the 
cell -surface class II MHC molecules of the M12.D cell line was examined (data not 
shown) nor to purified I -Ad in an immunoassay at pH 5.0. (These latter results are given 
in Chapter 5, Table 5.1 for comparison with those obtained with purified I -Ed molecules). 
4.3.3 Conserved N- terminal CLIP residues modulate binding to I -A 
The binding data obtained with the truncated CLIP ligands (Table 4.2) revealed that 15 
residues within the native sequence was the minimum length that could still compete 
effectively for binding to all three I -A class allotypes tested. It was therefore of interest to 
determine whether any 15- residue peptide that included the essential CLIP91 -99 sequence 
would be able to bind to these molecules or whether particular residues that flanked this 
region were important also. To address this question, a set of five 15- residue CLIP 
analogues was synthesised, each with a single amino acid frameshift to cover the 
residues, 86 -104, but all still incorporating the essential central CLIP backbone element, 
residues 91 -99. The ability of these peptides to compete against hiotinylated CLIP86 - 
104 for binding to cell -surface I -A molecules is shown in Table 4.3. Again, data are 
presented as mean ICSO values ± standard deviation from two independent experiments. 
Overall, those CLIP ligands that contained all or part of the original N- terminal sequence 
(CLIP86 -100, 87 -101 and CLIP88 -102) were found consistently to compete better for 
binding to the I -A molecules than those that exhibited the corresponding C- terminal CLIP 
residues (CLIP89 -103, 90 -104). As with the truncated peptides (Table 4.2), it was also 
apparent that the loss of the 1 -2 outermost amino -terminal residues again improved the 
binding capacity to I -A° and I -Ak, provided at least two residues were still present 
adjacent to the central 91 -99 core sequence. Once more, this effect did not extend to the 
binding of these ligands to the I -Ad molecules of A20, nor to those of the M12.D cell line 
Table 4.3 Competition by frameshifted CLIP 15 -mers for binding to I -A class II 
MHC molecules. 
CLIP ICso (),(M) 
1 -5.4 (I -N) CH27 (H-2k) A20 (H-2°) 
86-100 KPVSQMRMATPLLMR 183.05 ± 21.14 238.20 ± 25.14 197.45 ± 4.17 
87-101 PVSQMRMATPLLMRP 62.62 ± 7.51 188.20 ± 21.74 157.65 ± 18.46 
88-102 VSQMRMATPLLMRPM 112.70 ± 7.50 143.55 ± 41.65 202.95 ± 3.18 
89-103 SQMRMATPLLMRPMS > 1000 586.70 ± 184.98 437.45 ± 33.59 
90-104 QMRMATPLLMRPMSM > 1000 > 1000 576.40 ± 180.60 
Fifteen -residue CLIP analogues were synthesised, each with a with a single amino acid frameshift. Analogues were tested at 
multiple doses as competitors against biotinylated CLIP86 -104 (50 itM) in a cell -surface binding assay at pH 7.0. Data are 
presented as mean IC50 values ± SD (µM) from two independent experiments. Background levels and maximum signals of 
median fluorescence intensity (MFI) for each allotype are as in Table 4.2. 
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in a cell -surface binding assay (data not shown) or to purified I -Ad in an immunoassay at 
pH 5.0 (Shown in Chapter 5, Table 5.2 for comparison with purified I -Ed). 
The contribution of the particular amino acid residues that flank the central sequence 
element, CLIP91 -99, to the interaction with the molecules, I 4", I -A0 and I -Ad, was 
explored further by assessing the binding abilities of another set of CLIP analogues, this 
time exhibiting a number of different truncations and/or L- alanine substitutions. Shown 
in Table 4.4 are the results of these peptides competing against biotinylated CLIP86 -104 
for binding to cell- surface I -A molecules. Data are presented as mean ICso values ± 
standard deviation from two independent experiments. Some improvement in the binding 
affinity of the CLIP sequence for I -A0 molecules was apparent when the C- terminal 
residue, Met 104, was deleted. However, of most interest, the binding to this allotype 
was again sensitive to modifications of the two outermost amino -terminal residues of the 
CLIP86 -104 sequence, Lys 86 and Pro 87. For example, substitution of either or both 
of these residues with L- alanine enhanced the ability of the resultant CLIP analogue to 
bind (e.g. Ala -CLIP, CLIP87A -104). Similarly, truncation of these residues enhanced 
the binding capacity of CLIP (e.g. 88 -103). This time, however, these effects were not 
as pronounced for the binding of this sequence to class H MHC molecules of the I -Au 
allotype, except in the case of the truncated peptide, CLIP87 -102. Moreover, consistent 
with previous findings (Tables 4.2 & 4.3), no such manipulations of the CLIP sequence 
improved the binding of this ligand to the cell -surface I -Ad molecules of the A20 cell line 
(Table 4.4) nor to purified I -Ad in an immunoassay at pH 5.0 (Chapter 5, Table 5.3). 
The findings described above concerning the ability of the outermost N- terminal residues 
to influence the binding affinity of this peptide sequence for certain I -A allotypes were 
particularly interesting in light of a report published subsequently suggesting that the N- 
terminal residues of the human CLIP sequence may provide a "self -release' mechanism 
by which this ligand could facilitate its own dissociation from HLA -DR molecules 
independently of the actions of HLA -DM (Kropshofer et al., 1995a, 1995b). In order to 
investigate whether such a mechanism was also operative in the interaction of CLIP with 
mouse I -A molecules, peptides exhibiting single L- alanine substitutions in the amino - 
terminal region of the CLIP81 -104 sequence (residues 81 -87) were synthesised (Table 
4.5) and examined once more for binding to the different I- A- expressing cell Iines. 
The titration of biotinylated forms of the N- terminal- substituted mouse CLIP analogues 
with A20 cells in a cell -surface binding assay (Figure 4.8) revealed that substitution of 
several of the individual native N- terminal residues did indeed lead to a change in the 
Table 4.4 Competition by substituted and/or length- altered CLIP for binding to I -A class 
II MHC molecules. 
CLIP ICSO (µM) 
1 -5.4 (I -A°) CH27 (H-2") A20 (H-2') 
86 -104 KPVSQMRMAT P LLMRPMSM 192.95 ± 22.27 309.30 ± 22.06 123.95 ± 11.95 
Ala -CLIP AAVSQMRMATPLLMRPMAA 151.35 ± 37.83 168.05 ± 35.85 161.85 ± 2.05 
86 -103 KPVSQMRMATPLLMRPMS 181.70 ± 3.82 221.75 ± 39.39 178.25 ± 5.30 
86 -103A KPVSQMRMATPLLMRPMA 180.15 ± 6.01 220.80 ± 9.62 172.55 ± 0.78 
87 -104 PVSQMRMATPLLMRPMSM 126.95 ± 5.87 309.45 ± 43.20 128.95 ± 5.87 
87A -104 AVSQMRMATPLLMRPMSM 192.35 ± 13.22 241.35 ± 38.68 138.85 ± 9.55 
87 -102 PVS QMRMAT PLLMRPM 70.92 ± 21.49 337.30 ± 174.37 132.90 ± 18.10 
88 -103 VS QMRMAT P LLMRPMS 165.55 ± 0.64 215.30 ± 46.10 187.00 ± 14.57 
Substituted and/or length- altered CLIP analogues were tested at multiple doses as competitors against biotinylated wild -type 
CLIP86 -104 (50 pM) for binding to the cell -surface I -A class II MHC molecules of the cell lines, 1 -5.4, CH27 and A20. Data are 
presented as mean IC50 values ± SD (pM) from two independent experiments. Background levels and maximum signals of median 
fluorescence intensity (MFI) for each allotype are as in Table 4.2. 
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Table 4.5 N- terminal L- alanine -substituted CLIP81 -104 analogues 
L81A L-Ala 
P82A - L-Ala 
K83A - - L-Ala 
S84A - - - L-Ala 
wild-type L P K S L-Ala K P V S Q M R M A T P L L M R P M S M 
K86A L-Ala 
P87A L-Ala 
Amino acid sequences of CLIP81 -104 analogues bearing single L- alanine substitutions within their N- 
terminus, residues 81 -87. Native amino acid residues are represented with a dash. 
ability of these peptides to bind to the I -Ad molecules expressed by this cell line. 
However, rather than decreasing the ability of CLIP to binding to this M-IC molecule, the 
native residues within this region of the ligand appeared to enhance binding. Specifically, 
when any one of the CLIP residues, Lys 83, Lys 86 or Pro 87, was replaced by L- 
alanine, a marked decline in the binding capacity was observed relative to that of the wild - 
type CLIP81 -104. A similar result was obtained when these same peptides were tested 
for binding to the cell -surface I -Ad molecules of the M12.D cell line (Figure 4.9a) and to 
purified I -Ad in an immunoassay at pH 5.0 (Figure 4.9b). These findings are consistent 
with those obtained with the various truncated, frameshifted and substituted peptides 
binding to A20 cells shown in Tables 4.2 -4.4. For example, modifications of the 
outermost N- terminal residues of the CLIP86 -104 element, such as those seen in the 
peptides, Ala -CLIP and CLIP88 -103, also caused a decrease in the capacity of this 
sequence to hind to this class II MHC allotype (Table 4.4). Furthermore, binding to these 
molecules was not affected noticeably by similar substitutions of single L- alanine amino 
acid residues into the shorter CLIP86 -104 ligand in Chapter 3 (Figures 3.2 & 3.3). 
It was therefore of interest to examine the interaction of the N- terminal L- alanine- 
substituted CL1P81 -104 analogues with the mouse class II MHC allotypes, I -A° and I- 
Ak, which had displayed previously an increase in their affinity for this ligand upon 
modification of its N- terminal residues (Tables 4.2 -4.4). Titration of the biotinylated N- 
terminal- substituted CLIP with the cell lines, 1 -5.4 (I -A ") and CH27 (H -2k) is shown in 
Figure 4.10. Surprisingly, the binding of these peptides to I -A" molecules (Figure 4.10a) 
yielded a similar, although less prominent, pattern of results to that obtained with the I -Ad 
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Figure 4.8 The binding of N- terminal L- alanine -substituted 
CLIP81 -104 analogues to A20 cells at pH 7.0. 
109 
Biotinylated CLIP81 -104 analogues with single L- alanine substitutions in their N- terminus (dashed lines, 
open squares) were compared with biotinylated wild -type CLIP81 -104 (solid line, filled squares) for cell - 
surface binding to the A20 cell line (H -2a). Shown is one of five independent experiments, all yielding 
equivalent results. Binding levels are expressed as median fluorescence intensity (MFI). The background 
signal was determined in the absence of biotinylated peptide and has been subtracted from data shown 
(A20, 3.28). Cells were incubated with biotinylated peptide for 18 hours at 37 °C before flow cytometric 
analysis, as described in Chapter 2, §2.7.2. 
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Figure 4.9 The binding of N- terminal- substituted CLIP81 -104 to M12.D 
cells and purified 1 -Ad class II MHC molecules. 
Biotinylated CLIP81 -104 analogues with single L- alanine substitutions in their N- terminus (dashed lines, 
open squares) were compared with biotinylated, wild -type CLIP81 -104 (solid line, filled squares) for 
binding to (a) the cell -surface I -Ad molecules of the M12.D cell line at pH 7.0 and (b) purified I -Ad 
proteins at pH 5.0. Experiments were each performed three times, as described in Chapter 2, §2.7.2 & 
§2.7.3. Background signal was determined in the absence of biotinylated peptide and has been subtracted 
from the data shown (M12.D, 3.28; I -Ad, 0.052 OD units). 
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Figure 4.10 The binding of PI-terminal-substituted CLIP81 -104 to the cell 
lines, 1 -5.4 and CH27 at pH 7.0. 
Biotinylated CLIP81 -104 analogues with single L- alanine substitutions in their N- terminus (dashed lines, 
open squares) were compared with wild -type biotinylated CLIP81 -I04 (solid line, filled squares) for 
binding to the cell- surface class II MHC molecules expressed by the cell lines, (a) 1 -5.4 (I -Au) and (b) 
CH27 (H -2k). Shown is one of five independent experiments, all with equivalent results. Binding levels 
are expressed as median fluorescence intensity (MFI). Background signal was determined in the absence 
of biotinylated peptide and has been subtracted from data (1 -5.4, 3.40; CH27, 3.05). Cells were incubated 
with biotinylated peptide for 18 hours at 37 °C before flow cytometric analysis (Chapter 2, §2.7.2). 
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allotype (Figures 4.8 & 4.9), i.e. poorer binding of the substituted CLIP variants, K83A, 
K86A and P87A, relative to wild -type CLIP81 -104. Similarly, when the same N- 
terminally- substituted CLIP81 -104 analogues were examined for their ability to bind to I- 
A'` molecules (Figure 4.10b), the substitution of the Lys 86 residue by L- alanine also 
caused a decline the binding capacity relative to the wild -type sequence. However, this 
time, the substitution of Lys 83 and Pro 87 led to an increase in the affinity of this 
sequence for binding to I -Ak. This result was reproduced in five replicate experiments 
and is consistent with the earlier finding that this allotype exhibited the most marked 
improvement in binding CLIP when the Pro 87 residue was truncated from the sequence 
(Tables 4,2 -4.4). 
The three CLIP residues, Lys 83, Lys 86 and Pro 87, shown herein to modulate the 
binding of this ligand to I -A molecules, are conserved in mouse, rat, cow and human Ii 
(Chapter 1, Figure 1.5). Of significant note, these three amino acid residues correspond 
to those identified by Kropshofer et al. (1995b) as being able to influence the dissociation 
rate of human CLIP from HLA -DR molecules. To investigate further the role of these 
CLIP amino -terminal residues, a second series of N- terminal L- alanine- substituted 
peptides was synthesised, this time without conjugation to a biotin moiety so as to be 
suitable for use as competitors in a cell -surface binding assay against the biotinylated 
wild -type peptide, CLIP81 -104. The results of these assays with the cell lines, A20 and 
CH27, are shown in Figure 4.11. Data are presented as mean percentage inhibition from 
two independent experiments. 
For the A20 cells, the K83A and K86A CLIP analogues both showed a reduced capacity 
to compete with biotinylated CLIP81 -104 relative to the wild -type peptide (Figure 4.11a), 
consistent with the results obtained with the biotinylated variants (Figure 4.8). However, 
the Pro 87 substitution this time did not reveal an effect on the binding affinity. The 
results obtained with the CH27 cell line (Figure 4.11b) were also largely in agreement 
with previous results (Figure 4.10b). The K83A and P87A substitutions showed an 
enhanced ability to compete with the biotinylated ligand for binding to the I -Ak allotype, 
although a modulating effect of the K86A substitution was no longer evident. 
Lastly, it was desired to evaluate the ability of the L- alanine- substituted CLIP81 -104 
analogues to compete for binding to purified I -A class II MHC molecules in an 
immunoassay at pH 5.0. The results obtained with aß dimers of the I -A° allotype are 
shown in Figure 4.12, with data presented as mean percentage inhibition calculated from 
two independent experiments. Under these conditions, no obvious differences were 
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Figure 4.11 Competition by N- terminal L- alanine- substituted 
CLIP81 -104 for binding to A20 and CH27 cell lines. 
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CLIP81 -104 analogues with L- alanine substitutions in their N- terminus (dashed lines, open squares) were 
tested for competition against biotinylated wild -type CLIP81 -104 (50 µM; solid line, filled squares) for 
binding to the cell -surface I -A molecules of the cell lines (a) A20 (H -2a) and (b) CH27 (H -2k). Data 
shown represent the mean percentage inhibition ± SD from two independent experiments. Cells were 
incubated with biotinylated peptide and competitor for 18 hours at 37 °C before flow cytometric analysis, 
as described in Chapter 2, §2.7.3. 
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Figure 4.12 Competition by N- terminal L- alanine -substituted CLIP81 -104 
for binding to purified I -Ad at pH 5.0. 
CLIP81 -104 analogues with L- alanine substitutions in their N- terminus (dashed lines, open squares) 
were tested for competition against biotinylated wild -type CLIP81 -104 (30 µM; solid line, filled squares) 
for binding to I -A° class II MHC molecules purified from the BALB /c- derived B cell lymphoma, A20 
(Chapter 2, §2.6). Data shown represent the mean percentage inhibition ± SD from two independent 
experiments. Peptides were incubated at pH 5.0 with immunopurified I -A° for 48 hours at 37 °C before 
capture on a M5 /I14- coated microtitre plate 02.7.3). 
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apparent in the binding capacities of any of the substituted CLIP analogues. 
Unfortunately, however, time constraints did not allow further experimental assessment 
of the possible self -release mechanism of mouse CLIP from any other variants of the I -A 
isotype. Most regrettably, sufficient time was not available to permit the purification of 
adequate quantities of the I -Ak protein from CH27 cells for a similar examination of these 
peptides binding to this allotype under acidic conditions. 
4.4. Discussion 
4.4.1 Central CLIP main -chain atoms provide vital contacts for binding to 
I -A class II MHC molecules 
The attractive forces that uphold an interaction between two amino acid -based 
biopolymers may involve the side chains of the individual residues and/or the atoms of the 
polyamide backbones. In Chapter 3, it was shown that specific side chains of the 
CLIP86 -104 ligand do not provide significant positive binding energy to the association 
with mouse I -A class II MHC molecules. This suggests that this peptide must bind to 
these aß dimers predominantly through interactions mediated by its main chain atoms. 
This possibility has been examined by the experiments described in this chapter using a 
set of CLIP86 -104 analogues exhibiting single D- alanine amino acid substitutions (Table 
4.1). Within these peptides, the inverted orientation of the atoms around the chiral et- 
carbon of the D- alanine residue has been shown to create a conformational disturbance 
(Figure 4.2) which, in turn, may disrupt the ability of the CLIP main chain atoms to form 
contacts with residues of the class II MHC heterodimer. 
Employing the D- alanine- substituted analogues in competitive binding assays with the 
molecules, I -A°, I -Ak and I -Ad, it was found that any configurational substitution within 
the central region of the CLIP sequence, i.e. residues 91 -99, reduces the binding 
potential of this ligand (Figure 4.3 -4.6). This is in striking contrast to the results 
reported in Chapter 3, where many side -chain substitutions within this same segment of 
the CLIP sequence were tolerated (Figures 3.2 & 3.3). Thus, unlike the CLIP side 
chains within this region, the main -chain atoms do indeed provide a vital contribution to 
enable this peptide to interact with these class II MHC molecules. Nevertheless, the 
binding potential of the central sequence element of CLIP alone is not sufficient to sustain 
the interaction (Table 4.2 & Figure 4.7). Rather, it represents the essential basic 
framework of the binding motif of this ligand. Experiments with truncated, frameshifted 
and further substituted CLIP analogues revealed collectively that this CLIP91 -99 
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sequence must be flanked by several additional amino acids in order to bind efficiently to 
the mouse I -A variants (Tables 4.2-4.4 & Figure 4.7). In particular, 2 -3 additional 
residues at the amino- terminus of this sequence element were required for effective 
binding, altogether forming a peptide of at least 13 amino acids in length. The inclusion 
of certain N- terminal residues beyond the main 13 -mer binding determinant also appears 
to modulate the affinity of CLIP for the different I -A molecules (Tables 4.2 -4.4 & 
Figures 4.7 -4.11). 
The 13- residue minimum length requirement for the CLIP sequence to bind to I -A a(3 
dimers is consistent with the number of residues deemed necessary to uphold the 
interaction between human CLIP and the molecules, HLA -DR1, DR2, DR3(17) or DR7 
(Geluk et al., 1995; Malcherek et al., 1995). This size also correlates well with that of 
naturally -processed antigen- derived peptides eluted from the binding groove of different 
mouse and human class II MPIC variants, typically being within 10-28 amino acids in 
length (Rudensky et al., 1991; Hunt et al., 1992; Chicz et al., 1992, 1993; Rammensee et 
al., 1995). At the time, these similarities provided yet more support for the notion that the 
groove was the site of the CLIP interaction. This was soon to be confirmed with the 
publication of the crystal structure of the CLIP -HLA -DR3 complex (Ghosh et al., 1995). 
As described in Chapter 3 ( §3.4.3), X -ray crystallographic analysis revealed that CLIP 
binds within the peptide- binding groove of the HLA -DR3 a(3 dimer in a manner highly 
similar to that seen previously with the antigenic influenza virus haemagglutinin peptide, 
HA306 -318, complexed with HILA-DRI (Stem et al., 1994). Firstly, both ligands were 
noted to have side chains inserted into the polymorphic pockets within this site. 
Secondly, and of particular interest in this chapter, the main -chain amide protons and 
carbonyl oxygen atoms of a 12 -13 residue stretch of each of the two peptides participated 
in nearly identical hydrogen -bonding schemes with the residues of the HLA -DR a, and 
ß, domains. More recently, X -ray crystallography has confirmed that these same two 
types of interactions also tether peptide ligands within the groove of mouse I -A 
heterodimers (Fremont et al., 1998h; Scott et al., 1998). Thus, in the context of the 
results presented herein and previously in Chapter 3, it may be interpreted that CLIP 
binds to the molecules, I -A ", I -Ak and I -Ai, principally through the formation of an 
elaborate hydrogen bond network within the peptide -binding groove. 
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4.4.2 The promiscuous binding of CLIP to I -A class II MHC variants is 
supported by a sequence- independent network of hydrogen bonds 
The dominant contribution of the hydrogen bond network to the association of CLIP with 
I -A molecules is likely to be a significant factor in the ability of this sequence to bind 
promiscuously to different class H MHC molecules. This is by virtue of the fact that the 
formation of such contacts is largely independent of both the sequence of the peptide 
ligand and the amino acid polymorphism within the groove (Brown et al., 1993). Indeed, 
of the 17 hydrogen bonds identified in the crystal structure of CLIP bound to HLA -DR3, 
11 involved residues that are conserved in most class II MHC molecules, of which 10 
took place to main chain atoms of the CLIP backbone (Ghosh et al., 1995). These 
conserved residues include aAsn 62, aAsn 69, otArg 76 and (3Asn 82, all of which are 
present in the known variants of the I -A allotype (Davis et al., 1989; Chapter], Figure 
1.4). 
The capacity of CLIP to form a sufficient number of main chain hydrogen bonds to 
sustain its interaction with different class II MHC molecules is facilitated by the 
conformation that it adopts within the peptide- binding groove. Specifically, an analysis 
of the CLIP sequence complexed with HLA -DR3 reveals that the main chain of the 
peptide is bound in a straight, extended conformation with a pronounced left- handed 
twist, such that successive side chains project from the backbone approximately every 
128° -130° (Ghosh et al., 1995). This finding is consistent with a prediction from the 
homology models of Lee & McConnell (1995) that the conformation of this ligand would 
be the same as that adopted by antigenic peptides binding within this site. In this respect, 
such an arrangement has been found in all peptide -class II MHC complexes analysed by 
X -ray crystallography to date (Stem et al., 1994; Ghosh et al., 1995; Fremont et al., 
1996, 1998b; Dessen et al., 1997; Scott et al., 1998) and is deemed to be similar to a type 
11 polyproline helix, which characteristically shows an angle of projection of -120° per 
residue (Stern et al., 1994). 
The ideal conformation for a ligand to adopt for binding to a class II MHC molecule 
would be one that provides the constituent amino acid atoms at suitable positions for 
interacting with the groove residues, while synchronously minimising steric repulsion. 
That adopted by CLIP and the other peptide ligands would appear to do just this. Taking 
the first residue in the conformation as that involved in the N- terminal -most hydrogen 
bond (typically the residue at relative position, P -2; Chapter 1, Figure 1.4a), then the 
periodic rotation of the amino acid side chains of a peptide in the type II polyproline helix 
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would result in every second or third residue projecting away from the binding site into 
the solvent (residues P -1, P2, P5, P8, P10; Stern et al., 1994). Meanwhile every third or 
fourth side chain would be oriented across or downwards into the groove to interact with 
the polymorphic residues of the MHC pockets (Pl, P3/P4, P6, P7, P9). For a bound 
peptide, this conformation minimises the risk of steric repulsion that may occur if no 
suitably- accommodating binding pocket is available for the individual side chains by 
limiting the number of contacts made through the amino acid side -chains. At the same 
time, the twisting arrangement of peptide backbone causes the outward projection of 
backbone amide protons and carbonyl oxygen atoms to maximise the opportunity of these 
atoms to participate in intermolecular hydrogen bonds with the residues of the groove. 
Consistent with CLIP adopting this conformation, the side chain substitution experiments 
performed in Chapter 3 which examine the binding of CLIP to I -A yielded the most 
notable effects at intervals of every third and/or fourth residue (Figures 3.2, 3.3 & 3.6). 
A similar result was obtained in equivalent experiments with HLA -DR variants (Geluk et 
al., 1995; Malcherek et aL, 1995). It may be envisaged that an alternative conformation 
would be less efficient at achieving these aims. For example, an extended 13- strand would 
only permit alternate side chains to project from the groove. Also unfavourable, an a- 
helix would not enable the peptide backbone to make any bonding interactions with the 
MEC groove due to the orientation of the main chain atoms along the axis of the helix to 
form an internal hydrogen bond network (Pauling et aL, 1951). 
The universal mode in which different ligands appear to bind to class II MHC molecules 
implies that they all may adopt the common type II polyproline conformation irrespective 
of the secondary structure of the determinant within the native progenitor protein (Stern et 
al., 1994; Fremont et al., 1996, 1998b; Dessen et al., 1997; Scott et al., 1998). 
Regarding the CLIP sequence, nuclear magnetic resonance (NMR) of a soluble 
recombinant form of the invariant chain protein has shown that the N- terminal third of the 
lumenal region (residues 58 -118) is largely unstructured in solution (Jasanoff et al., 
1995, 1999). This is consistent with the finding that this domain is highly susceptibility 
to proteolytic digestion and potential cleavage sites have been identified for the protease, 
papain, approximately every ten residues along its length, including a site within CLIP 
immediately N- terminal to Ala 94 (Park et al., 1995). However, when an interaction is 
formed with an a(3 dimer, the Ii domain encompassing residues, 72 -110, becomes 
ordered rapidly ( Jasanoff et al., 1999) and the susceptibility of both free CLIP and Ii to 
cleavage at this site is lost (Avva & Cresswell, 1994; Park et al., 1995). Resistance to 
proteolysis has also been reported to be acquired by other peptides when they bind within 
the class II MHC groove (Donermeyer & Allen, 1989). 
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The protection of the CLIP Ala 94 papain cleavage site within intact li is also seen when Ii 
trimers are complexed either singly or in trimeric form with HLA -DR3 molecules (Avva 
& Cresswell, 1994). Together with the overall flexibility of the Ii domain encompassing 
CLIP (Jasanoff et al., 1995, 1999), this would suggest that the CLIP sequence may bind 
within the MHC groove very early in the antigen presentation pathway. Indeed, the 
accessibility of the peptide -binding groove to the CLIP sequence within Ii has been 
demonstrated by the efficient presentation of antigenic peptides engineered into this 
protein in place of CLIP (Stumptner & Benaroch, 1997; van Bergen et al., 1997; Barton 
& Rudensky, 1998; Fujii et al., 1998; Malcherek et al., 1998; ten Bosch et al., 1999). 
Such modifications may also lead to the formation of aßli trimers that exhibit stability in 
the presence of SDS detergent (Stumptner & Benaroch, 1997; Barton & Rudensky, 
1998). Nevertheless, experiments performed with a CLIP- specific monoclonal antibody 
and T cell hybridomas show that, when bound to class II MHC molecules, the CLIP 
sequence in intact Ii does not assume an identical conformation as the isolated peptide 
(Morkowski et al., 1995; Eastman et al., 1996). Rather, the cross -reaction of these 
CLIP- specific reagents with some large Ii -class II MHC proteolytic intermediates such as 
LIP (Blum & Cresswell, 1988) would indicate that this conformation appears only later in 
the pathway, once the li protein has undergone some degree of proteolytic cleavage. This 
may be a consequence of the N- terminal residues of the CLIP sequence imposing physical 
constraints upon the adjacent element within the groove (Stumptner & Benaroch, 1997; 
see below, §4.4.4). 
4.4.3 Secondary structure predictions for Ii show a high degree of 
accuracy 
In this chapter, computational algorithms have been used to provide an estimate of the 
conformational tendencies of the CLIP sequence (Figure 4.1). From an input file 
containing the protein primary sequence, such algorithms are able to predict aspects of 
secondary structure by assessing the given sequence for a range of features. Typically, 
these take into account such parameters as the fraction of residues of any particular 
physicochemical type (individual amino acids have different propensities for certain 
secondary structure states), the position of each residue within the polypeptide chain 
(residues at the end of chains have greater flexibility due to fewer structural constraints), 
secondary -structure feedback effects (individual regions of defined secondary structure 
may influence each other during protein folding) and, also, by comparing the sequence 
with homologous segments from proteins of known three -dimensional structure. The use 
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of evolutionary information present in multiple sequence alignments also increases 
substantially the accuracy levels of the prediction, for example, by providing details of 
aligned deletions and insertions - these are known to occur more often in loop regions 
than in internal parts of a- helices and (3- strands (Salamov & Solovyev, 1995). 
Many automated systems are now available to perform secondary structure prediction 
algorithms for a protein of choice. The PHDSec method of Rost & Sander (1993, 1994) 
uses a system of neural networks together with a multiple alignment of the input sequence 
file from the SWISSPROT sequence database. The NNSSP program similarly employs 
profiles of multiple sequence alignments, but uses the simpler nearest- neighbour 
algorithm to score the local structural environment (Salamov & Solovyev, 1995). Both 
these methods yield similar overall three -state accuracies of prediction (a- helix, I3-strand 
and coil) of Q3 >72 %. 
The PliDsec and NNSSP methods both predict an equivalent conformational structure for 
the CLIP sequence whether it is an isolated peptide or encompassed within the intact Ii 
protein (Figure 4.1). This would suggest that other stretches of significant secondary 
structure within the intact Ii do not interfere with the ability of the CLIP region to assume 
this conformation. Although the type H polyproline helix actually adopted by CLIP 
(Ghosh et al., 1995) is beyond the prediction capabilities of such algorithms - these 
methods are restricted to giving estimates of regular a- helical or I3-sheet domains - this 
technique nevertheless predicted correctly that this sequence was favoured to assume 
some form of periodic structure. In this way, secondary structure prediction algorithms 
provide a useful guideline of conformational tendencies. 
As a further indication of the value of these predictions, other aspects of the PHDsec and 
NNSSP conformational estimates of Ii show good correlation with existing experimental 
data. For example, protein transmembrane domains typically fold into a- helical segments 
(Engelman et al., 1986; Singer, 1990) and, indeed, such a conformation is predicted for 
this region of the Ii protein, residues 32 -56 (Figure 4.1). Similarly, the helical stretch 
that was predicted within the N- terminus of Ii corresponds to the cytoplasmic tail, which 
contains the two targeting signals that mediate the localisation of this protein in the 
endocytic compartments, residues Asp 3 Ile 8 and Glu 12 Leu 17 (Chapter 1, Figure 
1.5; Pieters et al., 1993; Bremnes et al., 1994; Odorizzi et al., 1994; Pond et al., 1995). 
In agreement with the structural predictions shown in Figure 4.1, the Leu 7 Ile 8 motif 
has been identified by NMR to lie within a nascent helix, while the membrane proximal 
motif is part of a turn (Motta et al., 1995). AdditionaIIy, it has been reported that a 27- 
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amino acid peptide corresponding to this region trimerises into an a- helical bundle (Motta 
et al., 1997). 
Both the PHDsec and NNSSP methods also predict a high degree of a- helical content C- 
terminal to the CLIP sequence (Figure 4.1). The largest stretch of this corresponds well 
to the exon 6 residues, 163 -183, that are involved in the formation of Ii homotrimers 
(Biljmakers et al., 1994a). Indeed, a- helical content has been detected previously in this 
region by CD spectroscopy (Park et al., 1995) and NMR (Jasanoff et al., 1998). 
Moreover, the C- terminal stretch of the lumenal domain, Ii118 -193, encompassing the 
trimerisation signal has been found to be resistant to protease activity, consistent with a 
compact and well- ordered conformation (Jasanoff et al., 1995; 1999). An earlier analysis 
of the periodic hydrophobicity in the li protein has also revealed the likely presence of an 
amphipathic helix between residues, 146 -164 (Elliott et al., 1987a), later also detected by 
CD spectroscopy (Lu et al., 1990) and NMR (Jasanoff et al., 1998). This is compatible 
with the smaller stretch of helicity predicted by both PHDsec and NNSSP between residues, 
147 -155/156. Similarly, the helical character predicted in Figure 4.1 spanning residues 
Ii121 -132 has been reported previously using NMR techniques (Jasanoff et al., 1998). 
4.4.4 A self -release mechanism for CLIP binding to I -A molecules? 
In this study, the truncation of the N- terminal residues, Lys 86 and Pro 87, from the 
mouse CLIP86 -104 sequence has been shown to modulate the binding affinity of this 
ligand for I -A class II MHC molecules (Tables 4.2 -4.4 & Figure 4.7). In particular, 
binding to the allotype, I -Ak, was enhanced when such residues were removed. A similar 
but less -pronounced effect was also observed for I -A° molecules but not for I -A°. By 
comparison, the removal of the last two C- terminal native residues did not affect the 
ability of the CLIP sequence to bind to the different I -A class II MHC variants 
consistently. Further investigations into the role of these residues using single N- 
terminally- substituted CLIP81 -104 analogues confirmed that the Lys 86 and Pro 87 
residues did have an influence on the binding of CLIP to I -Ak, this time together with Lys 
83 (Figures 4.10 & 4.11). Specifically, the substitution of either Lys 83 and Pro 87 by a 
single L- alanine residue led to an enhancement in the ability of the CLIP sequence to bind, 
while a similar substitution of the Lys 86 residue decreased binding. By contrast, for I- 
A° and I -Au molecules, the effect of aII these substitutions, if any, was to decrease the 
ability of these peptides to bind (Figures 4.8- 4.12). 
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The increase in the binding of the CLIP sequence to mouse I -Ak molecules observed 
when certain native N- terminal residues were deleted (Tables 4.2 -4.4 & Figure 4.7) is 
consistent with the findings of a number of other investigations. For example, Chicz et 
al. (1992) have reported that an equivalently- modified human CLIP ligand, 90 -103, 
binds with higher affinity to HLA -DR1 than the longer, CLIP81 -103. Similarly, N- 
terminally- truncated CLIP ligands have been shown to exhibit better competitive ability 
for binding to HLA -DRI and DR7 (Geluk et al., 1995) and to the mouse allotypes, I -Ak, 
I -Ad and I -A" (Naujokas et al., 1998) than longer variants. Urban et al. (1994) have also 
reported that human CLIP ligands that exhibit intact N- terminal residues, 81 -89, are 
released preferentially from purified HLA -DR1 at low pH, while those cleaved between 
Ser 89 and Lys 90 remained bound, e.g. 90 -103. Lastly, Kropshofer et al. (1995a, 
1995b) have shown using a cell -free system that the presence of the N- terminal residues 
in human CLIP increases significantly the dissociation rate of this ligand from an FILA- 
DR a(3 dimer. For example, the time of half -maximal dissociation, t,,, from soluble, 
recombinant HLA -DR3 at pH 5.8 was 1.5 hours for the full -length CLIP8I -105 ligand, 
compared with nearly 6 hours for the N- terminally -truncated variant, CLIP90 -105 
(Kropshofer et al., 1995b). 
Of particular interest, the N- terminal CLIP residues reported herein to modulate the 
binding affinity of mouse CLIP for I -A molecules are the same as those found to enhance 
the dissociation of human CLIP from HLA -DR, all three being conserved in the Ii 
sequences of mouse, rat and human (Chapter 1, Figure 1.5). Kropshofer et al. (1995b) 
have shown that the introduction of a single L- alanine residue into the human CLIP 
sequence in place of any of the three residues, Lys 83, Pro 87 or, to a lesser extent, Lys 
86, led to an increase in the stability of the CLIP -HLA -DR3 complex similar to that 
observed with the CLIP90 -105 ligand. These authors have proposed that such residues 
in the human CLIP sequence have a specific role to ensure the efficient release of this 
ligand independently of the actions of HLA -DM when HLA a(3 dimers encounter antigen - 
derived ligands in the acidic endosomal compartments. In support of this notion, only 
50-70% of the peptides eluted from HLA -DR3 molecules expressed in HLA -DM° cell 
lines are CLIP variants (Kropshofer et al., 1995h). This would be expected to be nearer 
to 100% if these heterodimers were entirely reliant upon FILA -DM for facilitating the 
dissociation of CLIP (Kropshofer et al., 1995a, 1995b). 
The results presented in this study (Tables 4.2 -4.4 & Figures 4.7 -4.11) suggest that a 
similar mechanism of CLIP self- release may operate when this ligand binds to the mouse 
class II MHC allotype I -Ak but not in the interaction with T -Ad nor I -An. Although 
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additional experimentation is still needed to substantiate these findings, the possibility that 
such a mechanism does occur is appealing, particularly when the differences seen in the 
binding data with the L- alanine N- terminal substitutions between I -A° and I -A" are put 
into context with their different requirements for H -2M or its human equivalent, HLA- 
DM. The preliminary results on this matter were unclear (Stebbins et al., 1995), however 
it has been shown more recently that I -Ai molecules expressed in HLA -DM° cell Lines 
exhibit the same phenotype of defective antigen presentation as that described previously 
for HLA -DR molecules with the same cellular background (Stebbins et al., 1996; 
Weenink et al., 1997). Specifically, these molecules displayed an inability to form SDS- 
stable a(3 dimers, a failure to present peptides derived from intact antigens, a loss of 
expression of certain mAb epitopes and were occupied predominantly with CLIP (Mellins 
et al., 1990, 1991, 1994; Riberdy et al., 1992; Sette et al., 1992a). By contrast, I -Ak 
molecules expressed in the same HLA -DM° APC showed a much less severe defect in 
antigen presentation. For example, I -Ak all dimers did form SDS- stable dimers, did 
present at least some determinants derived from protein antigens and were largely free of 
CLIP (Brooks et al., 1994; Stebbins et al., 1996). Collectively, these findings would 
suggest that I -Ak molecules differ from those of the I -Ad allotype in that HLA -DM (or H- 
2M) is not an obligatory requirement for efficient presentation of antigen. In this respect, 
it is tempting to speculate that the relative allele- specific contributions of the two 
mechanisms, HLA -DM and CLIP self -release, may be determined by the overall affinity 
of this ligand for a particular class II MHC heterodimer. For example, the self -release of 
CLIP may be quite sufficient for class II MHC variants with a low affinity for this ligand, 
e.g. I -Ak, HLA -DR5 (Bangia & Watts, 1995; Liang et al., 1995; Sette et al., 1995; 
Ramachandra et al., 1996). However, those allotypes to which CLIP binds with higher 
affinity may still exhibiting some degree of the self -release mechanism but would be more 
reliant upon HLA -DM to facilitate its dissociation. This would include such molecules as 
I -Ad, IT,A -DR3, DR2 and DR1 (Bangia & Watts, 1995; Kropshofer et al., 1995a, 
1995b; Liang et al., 1995; Sette et al., 1995). 
Lastly, the substitution of any of the outermost two to three native N- terminal CLIP 
residues with D- alanine also was shown to increase the ability of CLIP86 -104 to compete 
for antigen presentation (Figures 4.3 & 4.5a) and, to a lesser extent, cell -surface binding 
(Figures 4.4 & 4.5b). While it is possible that this may again reflect the ability of these 
native N- terminal residues in CLIP to the reduce the binding affinity of this ligand for 
mouse I -A molecules this would seem unlikely, since the greatest effect of these 
substitutions was seen not with I -Ak where this mechanism is predicted to be most 
efficient, but with the I -A° and I -Ad allotypes. Most likely, the apparent increase in 
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binding observed for the D- alanine N- terminal- substituted peptides is merely an artefact of 
the increased resistance to proteolytic degradation that these residues provide. This theory 
is supported by the finding that this effect is reduced in the immunoassays conducted with 
purified MEC proteins where peptidases are less abundant (Figure 4.6). The strategy of 
introducing D -amino acids into peptide termini to protect them from proteolysis has been 
used to great effect in creating ligands that exhibit increased stability in serum -containing 
medium (Lamont et al., 1990; Powell et al., 1993; Alexander et al., 1994) and may 
indeed improve their inhibitory abilities. The role of the protective D- alanine species in 
these CLIP ligands in the experiments described here may be confirmed by conducting a 
binding analysis in the presence of protease inhibitors or using fixed APC in serum -free 
medium. 
4.5. Conclusions 
The experiments described in this chapter have elucidated a binding motif for the 
association of mouse CLIP with I -A class II MEC molecules, in particular, a critical role 
for the peptide backbone conformation has been established. Using a set of 
configurationally -substituted CLIP86 -104 analogues, together with different truncated 
variants, in a series of competitive binding assays it was apparent that CLIP interacts with 
the three molecules, I -Ad, I -Au and I -Ak, by a similar motif. Binding occurs through a 
continuous 13- residue sequence element encompassing the highly phylogenetically - 
conserved residues, 91 -99. Consistent with this, the X -ray crystallographic analysis of 
human CLIP complexed with the human class II MEC molecule, HLA -DR3, identifies 
this same stretch of residues as occupying the peptide- binding groove (Ghosh et al., 
1995). Extrapolating from this crystal structure, the sensitivity to configurational 
substitutions of these residues in mouse CLIP lies in the participation of their main -chain 
atoms in hydrogen bonds with conserved residues of the I -A binding groove, in an array 
which has an absolute requirement for a specific conformation. 
Additional to the interactions of CLIP within the groove, an examination of the binding of 
length -altered and/or side -chain -substituted analogues suggests that N- terminal CLIP 
residues that contact the c43 timer outside of this site may also modulate the affinity of 
this peptide. These early results appear to be consistent with the ability of CLIP to 
facilitate its own release from FILA -DR molecules (Kropshofer et al., 1995a; Kropshofer 
et al., 1995b) but more study is needed to confirm these findings for the variants of the I- 
A isotype. 
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The conserved main -chain hydrogen- bonding system, together with the lack of significant 
side -chain anchor interactions between CLIP and I -A c4 dimers (Chapter 3) enables this 
ligand to bind promiscuously to many different I -A allelic variants in a conformation that 
constitutes a universal binding determinant. It was therefore of interest to determine 
whether CLIP uses a similar mode of binding in its interaction with mouse class II N'IHC 
molecules of the I -E isotype. This possibility is examined in Chapter 5. 
CHAPTER 5. 
The binding of CLIP to mouse I -E class II MHC molecules 
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5.1. Introduction 
Sequence polymorphism in the a, and ß, domains of class II MHC molecules is 
significant in that it enables the different allelic variants expressed by an individual to 
present distinct subsets of antigen -derived peptides to the CD4' T lymphocyte population 
(Hurley & Steiner, 1995). However, mouse class H MHC molecules of the I -E isotype 
differ from their I -A counterparts in that their a -chain sequence is largely invariant 
(reviewed by Mengle -Gaw & McDevitt, 1985). Indeed, of the Ea alleles that have been 
sequenced, only Ea' shows any degree of variation within the first domain of the 
polypeptide, differing by just two amino acids (Ayane et al., 1986; for a description of the 
domain organisation of the class II MHC aß dimer, refer to Chapter 1, Figure 13). This 
would be expected to reduce considerably the extent of heterogeneity within the peptide - 
binding groove between different I -E allotypes. At the time of commencing this study, 
little was known of the structure of the I -E heterodimer or its mode of binding peptides. 
It was therefore of interest to determine whether I -E molecules bind CLIP in the same 
manner as that elucidated for allelic variants of the I -A isotype in Chapters 3 & 4. 
Previous experimental findings suggested that CLIP may not bind well to I -E class II 
MHC aß dimers. Firstly, the elution of naturally -processed peptides from these 
molecules fails to yield any peptides nested around the CLIP sequence, such as those 
found with HLA -DR, DQ and I -A (Rudensky et al., 1991; Chicz et al., 1992, 1993, 
1994; Hunt et al., 1992; Riberdy et al., 1992; Sette et al., 1992a; Vartdal et al., 1996). 
Secondly, synthetic CLIP ligands equivalent to those eluted from I -A variants display 
only a low affinity for purified I -E molecules but bind well to I -A under the same 
experimental conditions (Hunt et al., 1992), Lastly, it was noted in Chapters 3 & 4 of 
this study that there appeared to be very little, if any, evidence of CLIP binding to the cell - 
surface I -E molecules expressed by the I- A' /I -E' cell lines, C1127 (H -2k) and A20 (H -2°) 
in flow cytometry -based assays, whereas interactions with the I -A heterodimers were 
detected readily by this approach. The general incapacity of CLIP to associate with I -E 
MHC molecules under these experimental conditions is somewhat unexpected given the 
ability to co- immunoprecipitate the intact Ii protein with molecules of this isotype in the 
presence of 0.5% NP -40 detergent (Jones et al., 1978a). A thorough examination of the 
binding interaction of CLIP with I -E molecules was needed to explain these observations. 
It is interesting to note that a number of inbred mouse strains have been described that do 
not express cell -surface I -E class II MHC molecules, i.e. the E° or E -null phenotype 
(Jones et al., 1978b, 1981; Mathis et al., 1983). This defect is also estimated to affect up 
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to 20% of wild mouse populations (Klein & Figueroa, 1981) and has also been reported 
in other rodent species (Nizetic et al., 1987). It is most often related to mutations or 
deletions in the genetic locus that encodes the Ea polypeptide (Mathis et al., 1983; Klein, 
1986). The reverse situation has not been found, i.e. the natural occurrence of I -A° mice. 
In terms of how the lack of I -E expression may affect the adaptive immune response 
within these mice, Cosgrove et al. (1992) have reported that I -E and I -A a(3 dimers are 
mostly functionally equivalent, at least in terms of correcting the irregularities in the 
immune system of class H MHC- deficient mice. However, the expression of I -E 
transgenes in the E° non -obese diabetic (NOD) mouse has been shown to prevent the 
development of overt diabetes (Nishimoto et al., 1987). Similarly, other mouse strains 
that lack functional I -E molecules have been reported to be more prone to developing 
spontaneous autoreactivity (Li et al., 1993). Given the central role of Ii and CLIP in the 
class II MHC antigen presentation pathway, a detailed examination of the mode of CLIP 
binding to I -E molecules for comparison with that of I -A may help to illuminate how these 
molecules might differ both in their respective roles during antigen presentation and, 
potentially, in the development of autoimmunity. 
The experiments described in this chapter have sought to analyse the association of CLIP 
with allelic variants of mouse class II MHC isotype, I -E. The initial task of this 
investigation was to examine this interaction by three different experimental approaches in 
an effort to find an effective means of measuring the binding of CLIP to I -E molecules. 
Based on the findings of this analysis, the mode of interaction between CLIP and I -E has 
been defined using both substituted and/or truncated CLIP analogues in immunoassays 
with purified I -Ed proteins at pH 5.0. The details of this binding motif are compared with 
those obtained in Chapters 3 & 4 for the binding of CLIP to mouse I -A molecules. A 
possible reason for the inability to detect the binding of CLIP to I -E in previous assay 
methods is discussed. 
5.2. Materials and Methods 
All experimental procedures performed in this chapter are described in detail in Chapter 2. 
Briefly, the mouse B ceII Iínes A20 (H-2") and CH27 (H -2k) were used as APC in 
antigen -presentation assays, together with M12.A3 (I -Ed) in cell -surface peptide binding 
assays (Table 2.1). The T cell hybridomas, 13.26 (I -Ed- restricted, SWM132 -147- 
specific), X12 -26 (I-E"-restricted, Xrep12 -26- specific), 2B4 (I -Ek- restricted, mCytc88- 
103- specific), 4C1.6 (I- Ek- restricted, HEL105 -120- specific), 3D0 -54.8 (I- Ad- restricted, 
Ova323- 339 -specific) and 3A9 (I- Ak- restricted, HEL46 -61- specific) were used in the 
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antigen -presentation assays (Table 2.2), together with the IL -2- dependent T cell line, HT- 
2. Mouse I -Ed molecules were purified from detergent -solubilised membrane 
preparations from the BALB /c- derived B cell lymphoma, A20, by immunoaffinity 
chromatography on a 14.4.4S mAb column 02.6). I thank Mrs Y. M. Gautam 
(Laboratory technician) for purifying these proteins. 
The L- alanine and D- alanine- substituted CLIP86 -104 analogues have been Iisted 
previously in Chapter 3, Table 3.1 and Chapter 4, Table 4.1, respectively. The truncated 
and frameshifted CLIP analogues are listed in Tables 5.1 and 5.2, respectively, with 
additional substituted and/or length- altered CLIP ligands detailed in Table 5.3. CLIP81- 
104 analogues exhibiting single amino -terminal L- alanine substitutions are shown in 
Chapter 4, Table 4.5. Peptide concentrations used in the binding assays are stated in the 
figure legends. Briefly, competitor peptides were tested over the concentration range 6- 
400.tM in antigen- presentation assays ( §2.7.1) and between 25 -400 µM for cell -surface 
binding assays ( §2.7.2) and immunoassays with purified class II MI-IC molecules 
( §2.7.1). I wish to extend my thanks to Mrs Y. M. Gautam for performing the 
experiments shown in Figures 5.5 & 5.6, which illustrate the relative binding affinity of 
different peptides to purified I -Ed molecules as a function of pH. 
5.3. Results 
5.3.1 CLIP competes poorly for binding to I -E molecules in both antigen - 
presentation and cell- surface binding assays at pH 7.0 
Given the promiscuous nature of the binding of CLIP to different class II MHC 
molecules, it may be expected that this ligand would associate with all the different types 
of ot13 dimers present at the surface of cells in a flow cytometry -based peptide binding 
assay. Nevertheless, when biotinylated CLIP was incubated with A20 cells (I- Ad/I -Ed) in 
Chapters 3 ( §3.3.1) & 4 ( §4.3.1), the level of fluorescence that was generated suggested 
that this ligand was not binding to the I -E molecules, nor contributing to the pattern of 
competition by the L- or D- alanine- substituted CLIP analogues. To investigate these 
findings, CH27 and A20 cells were incubated with biotinylated CLIP86 -104 and one of a 
range of different I -E- or I -A- binding peptides (Figure 5.1). The ability of the I -A- 
binding peptides to inhibit the biotinylated CLIP signal versus those known to bind to I -E 
should reflect the relative contributions of CLIP associating with each of these isotypes. 
For the CH27 cell line (Figure 5.1a), the HEL46 -61 peptide (open triangles) effectively 
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Figure 5.1 Competition against biotinylated CLIP86 -104 for binding to 
cell -surface mouse class II MHC molecules at pH 7.0. 
The ability of CLIP86 -104 to inhibit the cell- surface binding of biotinylated CLIP86 -104 (50 pM) to (a) 
CH27 and (b) A20 cells was examined and compared with a panel of antigen -derived peptides, 
mCytc88 -103 (I -Ek), HEL105 -120 (Lou), Arep12 -26 (I -Ed -k, I -Ad), SWM132 -147 
Ova323 -339Y (I -Adak) and HEL46 -61 (I- Ad,k). Data shown represent the mean percentage inhibition f 
SD from two independent experiments. Cells were incubated with biotinylated peptide and competitor for 
18 hours at 37 °C before flow cytomteric analysis, as described in Chapter 2, §2.7 2. 
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suppressed the biotinylated CLIP signal, as did unbiotinylated CLIP86 -104 (open 
squares). The experiments with HEL46 -61 were conducted only at relatively low 
concentrations of competitor due to the cytotoxicity of this peptide at higher 
concentrations, related to its poor solubility in aqueous solutions. This peptide is known 
to bind well to I -Ak but poorly to I -Ek (Buus et al., 1987). By contrast, none of the 
known I- E- binding peptides (filled symbols) appeared able to inhibit the binding of the 
biotinylated CLIP86 -104. Together these results suggest that most, if not all, of the 
fluorescence signal generated when biotinylated CLIP is incubated with CH27 cells arises 
from associations with the I -Ak molecules and very little with I -Ek. 
In an equivalent experiment with the A20 cell line, an similar pattern of results was 
obtained (Figure 5.lb). The known I -E- binding peptides (filled symbols) were unable to 
inhibit the binding of the biotinylated CLIP86 -104 ligand, suggesting that the binding of 
CLIP occurred predominantly to the I -Ad molecules on the cell surface and not to I -Ed. 
The ability of the I -E- binding peptide from the bacteriophage lambda cI repressor protein, 
Xrepl2 -26 (filled circles) to show some competitive ability against the biotinylated CLIP 
lies in its capacity to form weak interactions with I -Ad molecules (Guillet et al., 1987). 
As with the CH27 cell line, the unbiotinylated CLIP86 -104 (open squares) was able to 
compete strongly against its biotinylated form. 
In order to examine further the binding of CLIP to cell -surface I -E class II MHC 
molecules, a reciprocal binding assay was conducted with the CH27 cell line, this time 
using biotinylated moth cytochrome c peptide, mCytc88 -103, to generate a signal of 
fluorescence. The mCytc88 -103 peptide binds to I -Ek molecules but not to I -Ak (Buus et 
al., 1987). As before, different I -A- and I -E- binding peptides were tested for their 
capacity to inhibit the fluorescence, so as to assess their relative affinities for I -Ek. 
Shown in Figure 5.2, the unbiotinylated, I -Ek- binding peptides, Xrep12 -26 (filled 
triangles) and mCytc88 -103 (filled squares) competed well with the biotinylated ligand. 
As expected, the I -A- binding peptides, HEL46 -61 (filled circles) and Ova323 -339Y 
(filled diamonds) did not inhibit significantly the biotinylated mCytc88 -103 signal. 
Unbiotinylated CLIP86 -104 (open squares) was also a relatively poor competitor for 
binding to I -Ek, yielding just 44 ± 7.5% inhibition at 400 AM compared with both the 
Arep12 -26 and mCytc88 -103 peptides which exhibited 50% inhibitory capacity of the 
biotin signal at approximately 75 µM and 140 µM, respectively. This result establishes 
that CLIP is capable of forming complexes with cell -surface I -E class II MHC molecules 
but that this interaction is of a low affinity. In this respect, the signal derived from the 
binding of CLIP to I -E molecules in Figure 5.1 is likely to have been overshadowed by 
that from the higher affinity interactions of this ligand with the I -A heterodimers. 
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Figure 5.2 Competition against biotinylated mCytc88-103 for binding to 
cell -surface I -Ek molecules at pH 7.0. 
The ability of CLIP86 -104 to inhibit the binding of biotinylated mCytc88 -103 (25 tM) to class II MHC 
molecules on the surface of CH27 cells was examined and compared in a competition assay with a panel 
of antigen- derived peptides, mCytc88 -103 (I -Ek), Axep12 -26 (I -Ek), HEL46 -61 (I -Ak) and Ova323- 
339Y (I -Ak). Data shown represent the mean percentage inhibition ± SD from two independent 
experiments. CH27 cells were incubated with biotinylated peptide and competitor for 18 hours at 37 °C 
before flow cytometric analysis, as described in Chapter 2, §2.7.2. 
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As an alternative means to investigate the binding of CLIP to cell -surface I -E molecules, 
CLIP86 -104 was used as a competitor in a series of antigen -presentation assays with I -E- 
restricted T cell hybridomas. Figure 5.3a shows the ability of CLIP86 -104 to compete 
for presentation to I -Ed- restricted T cell hybridomas relative to those restricted by I -Ad. 
Similar to the findings of the cell- surface binding assay with biotinylated mCytc88 -103 
(Figure 5.2), CLIP86 -104 was only able to inhibit a maximum approaching 50% of the I- 
E- restricted T cell stimulation, even at the highest competitor peptide concentration of 400 
µM. By contrast, the presence of CLIP86 -104 in an antigen- presentation assay with A20 
and the I -Ad- restricted T cell hybridoma, 3D0 -54.8, yielded nearly 100% inhibition of T 
cell stimulation at a concentration of just 10012M. A similar result was obtained with the 
CH27 cell line and the two I -Ek- restricted T cell hybridomas, 2B4 (mCytc88 -103- 
specific) and 4C1.7 (HEL105 -120- specific; Figure 5.3b). For example, CLIP86 -104 
competition at 400 sM yielded just 33 ± 7.6% inhibition of the I -Ek- restricted stimulation 
of the 2B4 hybridoma, compared with 94 ± 1.7% inhibition of the I -Ak- restricted T cell 
stimulation with the same concentration of CLIP. 
Finally, the binding of CLIP to I -E 41 dimers was examined using a recently- acquired 
cell line that expresses only class II MHC molecules of the I -E isotype at the cell surface. 
This cell line, M12.A3, is derived from the H -2d B cell lymphoma, M12.4.1, but exhibits 
a defect in the gene encoding the AX polypeptide (Glimcher et al., 1985). Accordingly, 
these cells stain positive with the I -E- specific mAb, 14.4.4S, and negative for the I -Ad- 
specific mAb, MK -D6 (Figure 5.4a). A cell -surface binding assay with M12.A3 ceIIs 
confirmed that biotinylated CLIP binds very poorly to the cell -surface I -Ed molecules 
under the conditions of this assay (Figure 5.4b). Data is shown in comparison to an 
equivalent experiment with the A20 cell line. 
5.3.2 CLIP binds well to purified I -Ed molecules at pH 5.0 
The findings of the antigen- presentation and cell -surface peptide binding assays suggested 
that CLIP had a low affinity for mouse I -E MHC molecules, at least under the conditions 
of these two experimental approaches (Figures 5.1 -5.4). In this respect, both assay 
methods examine peptide -MHC interactions in a cellular context within growth medium 
buffered at neutral pH (Chapter 3, §3.4.1). However, it has been observed frequently 
that the formation of peptide -class II MHC complexes may be enhanced markedly at low 
pH, equivalent to the conditions found within the endocytic compartments in which 
peptides are loaded in vivo (e.g. Jensen, 1990, 1991; Harding et al., 1991; Wettstein et 
al., 1991; Mouritsen et al., 1992; Sette et al., 1992b). It was therefore of interest to 
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Figure 5.3 Competition by CLIP86 -104 against the presentation of 
antigen to I- E- restricted T cell hybridomas at pH 7.0. 
CLIP86 -104 was tested as a competitor for presentation by the cell lines (a) A20 and (b) CH27, to the I- 
E- restricted T cell hybridomas, 1326 (I -Ed- restricted, SWM132 -147, 125 ag/mL), 12 -26a (I -Ed- 
restricted, Arep12 -26, 0.05 µM), 4C1.6 (I- Ek- restricted, HEL105 -120, 0.025 pM) and 2B4 (I -Ek- 
restricted, mCytc88 -103, 0.3 pM). The competitive ability of CLIP86 -104 against I- A- restricted antigen 
presentation is shown for each cell line for comparison (3D0 -54.8: I -Ad- restricted, Ova323 -339Y, 0.05 
pM; 3A9: I- Ak- restricted, HEL46 -61, I.5 pM). Data are presented as the mean percentage inhibition ± 
SD from two independent experiments. Cells were incubated with antigen - derived peptide and CLIP 
competitor for 18 hours at 37 °C before the supernatant was harvested and assayed for IL -2, as described 
in Chapter 2, §2.7.1. 
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Figure 5.4 The binding of biotinylated CLIP86 -104 to cell -surface I -Ed 
class II MHC molecules at pH 7.0. 
(a) Cells of the H -2d B lymphoblastoid line, M12.A3, express surface I -Ed molecules, as shown by 
staining with the I- E- specific mAb, 14.4.45. However, few I -Ad molecules are detected with the mAb, 
MK -D6, as a result of a defect in the gene encoding the 13 -chain of the I -A heterodimer (Glimcher et al., 
I985). By contrast, A20 cells express both I -Ed and I -Ad. (b) The binding of biotinylated CLIP86 -104 
was examined to the cell -surface class II MHC molecules of the M12.A3 and A20 cell lines. Shown is one 
of two independent experiments, both yielding equivalent results. Cells were incubated with biotinylated 
peptide for 18 hours at 37 °C before flow cytometric analysis, as described in Chapter 2, §2.7.2. 
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determine whether the binding of CLIP to I -E molecules would be facilitated under acidic 
conditions. 
The effect of pH upon the relative binding affinity of biotinylated CLIP for I -E molecules 
was assessed using purified I -Ed in an enzyme -linked immunoassay (Figure 5.5), The 
binding of biotinylated CLIP86 -104 to I -Ed was enhanced at pH 5.0 (closed circles), 
although some binding was still detectable at neutral pH (open circles). A similar effect of 
proton concentration was observed with the biotinylated antigen- derived peptide, 
mCytc88 -103 (Figure 5.6a). This effect is specific for I -Ed- binding peptides, since the 
biotinylated I- A- binding peptide, Ova322 -339, was unable to associate with these 
molecules at either pH (Figure 5.6b). It is important to note with this assay method that 
the exact values of optical density generated by the biotinylated peptides binding to the 
purified class H MEC molecules cannot be compared directly between I -A and I -E 
samples due to a number of experimental variables. These include the existing degree of 
peptide occupancy of the purified heterodimers and the specific affinity of the capturing 
mAb, M5 /114, for the different molecules. Similarly, optical density measurements 
cannot always be compared between different plates even bearing the same class lI MHC 
allotype, due to plate -to -plate variations in the extent of antibody coating. 
Overall, the binding of CLIP to I -E class II MHC molecules appeared to be highly 
sensitive to pH, seemingly more so than the interaction of this sequence with I -A aß 
dimers (Chapter 3, Figure 3.4). The relatively low affinity of CLIP for I -E molecules at 
neutral pH (Figure 5.5) provides an explanation for the inability to detect the formation of 
these complexes using either the antigen -presentation assay or cell- surface binding 
method, both of which are performed at neutral pH (Figures 5.1 -5.4). The immunoassay 
protocol conducted at pH 5.0 with purified I -Ed thus appeared to be the best means by 
which to examine subsequently the features of the CLIP sequence that are important for 
its interaction with I -E class II MHC heterodimers. 
5.3.3 A binding motif for the interaction of CLIP with I -Ed at pH 5.0 
In order to define the features of the CLIP sequence necessary for binding to mouse I -E 
MHC molecules, the same series of substituted and/or truncated CLIP analogues were 
used, as described previously with I -A variants in Chapters 3 & 4. Firstly, the D- alanine- 
substituted CLIP86 -104 analogues shown in Chapter 4, Table 4.1 were used to examine 
the conformation- dependent role of the peptide backbone in the interaction with purified I- 
Ed in an immunoassay at pH 5.0. Shown in Figure 5.7 are the results of one such assay, 
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Figure 5.5 The binding of CLIP86 -104 to purified I -Ed. 
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Biotinylated mouse CLIP86 -104 was incubated with mouse I -Ed class II MHC molecules at 37 °C for 48 
hours at pH 7.0 (open circles) or pH 5.0 (closed circles) in an ELISA -type assay, as described in Chapter 
2, §2.7.3. I -Ed molecules were affinity- purified from the BALB /c- derived B cell lymphoma, A20. Shown 
is one of two independent experiments with equivalent results. Binding is expressed in optical density 
(OD) units, read at 405 nm with a reference wavelength of 495 nm. The signal from non -specific 
associations was determined from the binding of hiotinylated peptide in the absence of MHC molecules 
and has been subtracted from data shown (pH 7.0, 0.073 OD units; pH 5.0, 0.066 OD units). 
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Figure 5.6 The binding of antigen- derived peptides to purified I -Ed. 
Biotinylated peptides (a) mCytc88 -103 and (b) Ova322 -339 were incubated with I -Ed class II MHC 
molecules at 37 °C for 48 hours at pH 7.0 (open circles) or pH 5.0 (closed circles) in an ELISA -type 
assay, as described in Chapter 2, §2.7.3. I -Ed proteins were affinity -purified from the BALB /c- derived B 
cell lymphoma, A20. Shown for each peptide is one of two independent experiments with equivalent 
results. Binding is expressed in optical density (OD) units, read at 405 nm with a reference wavelength of 
495 nm. The signal from non -specific associations was determined from the binding of biotinylated 
peptide in the absence of MHC molecules and has been subtracted from data shown (pH 7.0, 0.073 OD 
units; pH 5.0, 0.066 OD units). 
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Figure 5.7 Competition by D- alanine -substituted CLIP86 -104 for 
binding to purified I -Ed at pH 5.0. 
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Multiple doses of CLIP86 -104 analogues with single D- alanine substitutions were tested as competitors 
against biotinylated CLIP86 -104 (30 µM) for binding to [ -Ed molecules affinity -purified from the 
BALB /c- derived B cell lymphoma, A20 (Chapter 2, §2.6 & §2.7.3). A single competitor dose which 
yielded -50% inhibition of the biotinylated CLIP signal by wild -type CLIP86 -104 (cross -hatched fill 
pattern) is shown (150 µM). Solid bars represent competition by the substituted CLIP analogues and the 
maximum biotinylated CLIP signal with no competitor present is indicated by the empty bar. Assays 
were performed twice with consistent results. Binding levels are expressed as optical density (OD) units, 
read at 405 nm with a reference wavelength of 495 am. Non-specific signal was determined from the 
binding of biotinylated peptide in the absence of MHC molecules and has been subtracted from the data 
shown (I -Ed, 0.066 OD units). IC50 values are given for competitors above each bar. An asterisk 
represents an IC50 value >10001(M. 
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representative of the experimental findings. Mean ICso values, calculated from two 
independent experiments are given atop each bar to provide a quantitative representation 
of the overall trends observed. Here, the pattern of competition was consistent with that 
seen previously with the three I -A allotypes in Chapter 4 (Figures 4.3 -4.6). The ability 
of these configurationally -altered ligands to compete for binding to I -Ed molecules was 
eliminated when any of these single substitutions fell within the central region of the 
peptide, between residues Gln 90 and Met 99. 
Next, the contributions of the individual peptide side chains to the interaction between 
CLIP and I -Ed molecules were examined using the series of L- alanine- substituted 
CLIP86 -104 analogues listed previously in Chapter 3, Table 3.1. Figure 5.8 shows the 
results of one such assay. Again, mean ICS0 values of two independent experiments are 
provided atop each bar. Most notably, the substitution of several of the individual wild - 
type CLIP amino acid residues, Met 91, Thr 95, Leu 98 and Met 102 eliminated 
completely the ability of these particular analogues to compete for binding. The 
substitution of the Met 99 residue by L- alanine also led to a decrease in the capacity of the 
CLIP sequence to bind to the I -Ed molecules. By contrast, substitution of Pro 96 resulted 
in an improvement in binding. 
Lastly, the minimum length of the CLIP sequence required to sustain efficient binding to 
I -Ed molecules was assessed using the set of truncated peptides listed in Table 5.1. The 
data for the purified I -Ed at pH 5.0 are presented as mean ICS0 values ± standard deviation 
from two independent experiments and are shown in comparison to those obtained with 
purified I -Ad under the same conditions (discussed previously in Chapter 4, §4.3.2). As 
found for the I -Ad molecules, the CLIP sequence was unable to bind to I -Ed when it was 
truncated to 13 residues or below, i.e. peptides, CLIP89 -101, 90 -100 and 91 -99. 
However, further interpretation of these results is limited by the large experimental errors 
observed in these experiments. For example, it is not possible to determine the exact 
effects of removing the outermost residues of the CLIP sequence upon the binding to the 
I -Ed molecules, as done previously for variants of the I -A isotype in Chapter 4 ( §4.3.2). 
5.3.4 Conserved N- terminal residues modulate binding to I -Ed 
As discussed in Chapter 4 ( §4.4.4), Kropshofer et al. (1995a, 1995b) have proposed that 
the N- terminal residues of human CLIP may provide a self -release mechanism to enable 
this ligand to bring about its dissociation from HLA -DR class II MEC molecules 
independently of the actions of HLA -DM. Experiments in that chapter addressed the 
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Figure 5.8 Competition by L- alanine -substituted CLIP86 -104 for binding 
to purified I -Ed at pH 5.0. 
Multiple doses of CLIP86 -104 analogues with single L- alanine substitutions were tested for competition 
against biotinylated CLIP86 -104 (30 µM) for binding to I -Ed affinity -purified from the BALB /c- derived 
B cell lymphoma, A20 (Chapter 2, §2.6 & 2.7.3). A single competitor dose which yielded -50% 
inhibition of the biotinylated CLIP signal by wild -type CLIP86 -104 (cross -hatched fill pattern) is shown 
(300 }AM). Solid bars represent competition by the substituted CLIP analogues and the maximum 
biotinylated CLIP signal with no competitor present is indicated with the empty bar. Binding assays were 
performed twice with consistent results. Binding levels are expressed as optical density (OD) units, read 
at 405 nm with a reference wavelength of 495 nm. Non- specific signal was determined from the binding 
of biotinylated peptide in the absence of MHC molecules and has been subtracted from the data shown (I- 
Ed, 0.088 OD units). IC50 values are given for competitors above each bar. An asterisk represents an IC50 
value >1000 ptM. 
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Table 5.1 Competition by truncated CLIP for binding to affinity- 
purified mouse class II MHC molecules at pH 5.0. 
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CLIP ICso (µM) 
I-Ad I-Ed 
86-104 KPVSQMRMATPLLMRPMSM 91.19 ± 64.12 272.50 ± 67.15 
87-103 PVS QMRMAT PLLMRPMS 310.30 ± 369.90 248.50 ± 177.00 
88-102 VSQMRMATPLLMRPM 224.70 ± 150.15 212.90 ± 162.65 
89-101 SQMRMATPLLMRP > 1000 > 1000 
90-100 QMRMATPLLMR > 1000 > 1000 
91-99 MRMATPLLM > 1000 > 1000 
Residues were sequentially removed pairwise from each end of the CLIP86 -104 sequence. The 
truncated CLIP were then tested at multiple doses as competitors against biotinylated CLIP86 -104 
(30 JIM) for binding to the affinity- purified murine class [I MHC molecules, I -Ad and I -E ", in an 
immunoassay at pH 5.0. Binding was determined from optical density (OD) measurements at 405 
nm with a reference wavelength of 495 nm. Data are presented as mean ICw values (11M) ± SD from 
two independent experiments. The signal from non -specific associations was determined from the 
binding of biotinylated peptide in the absence of MHC molecules (I -A °, 0.191; I -E °, 0.091) and was 
subtracted from data before analysis. The maximum optical density recorded for each isotype was 
1.692 and 1.035 for I -A° and 1 -E ", respectively. 
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possibility of a similar role for the N- terminal residues of mouse CLIP to catalyse the 
release of this ligand from mouse I -A molecules. Here, it was of interest to examine these 
residues with respect to their interaction with mouse class II MHC molecules of the I -E 
isotype, this time at pH 5.0. 
The results from the immunoassay using truncated CLIP and I -Ed molecules (Table 5.1) 
did not provide any evidence of a contribution of binding energy, either positive or 
negative, by the native N- terminal residues of this peptide sequence. To investigate the 
role of N- terminal CLIP residues further, the binding of the set of frameshifted 15 -mer 
CLIP ligands was assessed in a competitive immunoassay (Table 5.2). Data are 
presented as mean IC values ± standard deviation from two independent experiments 
and are shown in comparison to those obtained with purified I -Ad under the same 
conditions (these latter results have been discussed previously in Chapter 4, §4.3.3). 
Overall, those CLIP ligands that contained ali or part of the original N- terminal sequence 
(CLIP86 -100, 87 -101 and CLIP88 102) were found consistently to compete better for 
binding to the I -Ed molecules than those that exhibited the corresponding C- terminal CLIP 
residues (CLIP89 -103, 90 -104). This is an equivalent result to that obtained for I -Ad 
under the same experimental conditions (Table 5.2) and for I -Ad, I -An and I -Ak 
previously, using the cell -surface peptide binding assay (Chapter 4, Table 4.3). 
Unfortunately, however, large experimental errors again made it difficult to assess the 
possibility that the individual N- terminal CLIP residues may mediate a self -release 
mechanism to free this ligand from its association with I -Ed molecules. 
Next, the contribution of the outermost CLIP residues to the interaction with the I -Ed 
molecules was explored by evaluating the binding abilities of another set of peptide 
analogues, this time exhibiting a number of different length variations and/or L- alanine 
substitutions (Table 5.3). As before, data are presented as mean ICS0 values ± standard 
deviation from two independent experiments and are shown in comparison to those 
obtained with purified I -Ad under the same conditions (discussed in Chapter 4, §4.3.3). 
Of particular interest, the truncation of the outermost residues of the CLIP86 -104 peptide 
appeared to improve slightly the capacity of this sequence to bind, e.g. CLIP87 -102 and 
88 -103. This result would be compatible with the native residues, Lys 86 and Pro 87, 
providing an inhibitory or weakening component to the binding interaction with I -Ed, as 
would be expected if these residues participated in a self -release mechanism like that 
proposed by Kropshofer et al. (1995a, 1995b) for HLA -DR molecules. However, large 
experimental error amongst the ICdo values for the different CLIP analogues again make it 
difficult to exclude the possibility that this improvement in binding may be the result of 
the truncation of the C- terminal residues, e.g. Ser 103 and Met 104. 
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Table 5.2 Competition by frameshifted CLIP 15 -mers for binding to 
affinity -purified mouse class II MHC molecules at pH 5.0. 
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CLIP IC50 (µm) 
I-Ad I-Ed 
86-100 KPVSQMRMATPLLMR 91.47 ± 71.07 179.60 ± 169.17 
87-101 PVSQMRMATPLLMRP 158.10 ± 85.98 126.60 ± 62.63 
88-102 VSQMRMATPLLMRPM 224.70 ± 150.15 212.90 ± 162.65 
89-103 SQMRMATPLLMRPMS > 1000 > 1000 
90-104 QMRMATPLLMRPMSM > 1000 > 1000 
Fifteen- residue CLIP variants were synthesised, each with a single amino acid frameshift. 
Analogues were tested at multiple doses as competitors against biotinylated CLIP86 -104 (30 15M) 
for binding to the affinity- purified mouse class II MHC molecules, I -Ad and I -Ed, in an 
immunoassay at pH 5.0. Binding was determined from optical density (OD) measurements at 405 
nm with a reference wavelength of 495 nm. Data are presented as mean IC50 values (15M) ± SD 
from two independent experiments. Background levels and maximum signals for each isotype are as 
in Table 5.1. 
Table 5.3 Competition by substituted and/or length- altered CLIP for binding to 
affinity-purified mouse class II MHC molecules at pH 5.0. 
CLIP IC50 (µM) 
I-Aa I-Ea 
86-104 KPVSQMRMATPLLMRPMSM 91.19 ± 64.12 272.50 ± 67.15 
81-104 LPKSAKPVSQMRMATPLLMRPMSM 336.80 ± 392.50 393.70 ± 198.65 
81-109 LPKSAKPVSQMRMATPLLMRPMSMDNMLL 441.70 ± 231.75 434.50 ± 348.55 
Ala-CLIP AAVSQMRMATPLLMRPMAA 325.40 ± 223.15 323.30 ± 127.60 
86-103 KPVSQMRMATPLLMRPMS 179.00 ± 136.17 240.80 ± 64.90 
86-103A KPVSQMRMATPLLMRPMA 219.00 ± 92.65 243.00 ± 160.85 
87-104 PVSQMRMATPLLMRPMSM 347.60 ± 58.75 302.40 ± 104.50 
87A-104 AVSQMRMATPLLMRPMSM 316.50 ± 352.10 381.10 ± 172.15 
87-102 PVSQMRMATPLLMRPM 397.50 ± 488.90 166.20 ± 60.15 
88-103 VSQMRMATPLLMRPMS 474.90 ± 1273.69 146.80 ± 82.64 
Substituted and /or length- altered CLIP analogues were tested at multiple doses as competitors against biotinylated CLIP86 -104 
(30 ttM) for binding to the affinity -purified murine class II MHC molecules, I -Ad and I -Ed, in an immunoassay at pH 5.0. 
Binding was determined from optical density (OD) measurements at 405 nm with a reference wavelength of 495 nm. Data are 
presented as mean IC55 values (µM) ± SD from two independent experiments. Background levels and maximum signals for each 
isotype are as in Table 5.L 
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Lastly, the role of these N- terminal CLIP residues in the binding to I -Ed molecules was 
examined using a series of CLIP81 -104 analogues incorporating single L- alanine 
substitutions of the residues, 81 -87 (Chapter 4, Table 4.4). A marked decrease in the 
binding capacity, compared to wild -type CLIP81 -104, was observed when either of the 
residues Lys 83 or Pro 87 were replaced by L- alanine (Figure 5.9a). These results 
closely resemble those seen for binding to I -Ad under the same conditions (Chapter 4, 
Figure 4.9b). Furthermore, when unbiotinylated variants were tested as competitors, 
these same substituted analogues, K83A and P87A, showed a corresponding decrease in 
the ability to inhibit the binding of the biotinylated wild -type peptide (Figure 5.9b). In 
this context, these particular native N- terminal residues appear to contribute positive 
binding energy to the interaction of CLIP with I -Ed MHC molecules, rather than 
destabilising it to facilitate peptide release. 
5.3.5 The induction of CLIP binding to cell -surface I -E molecules at 
neutral pH 
The results of both antigen- presentation and cell -surface binding assays in this chapter 
(Figures 5.1 -5.4) have indicated that the binding of CLIP to I -E class II MHC molecules 
is highly sensitive to proton concentration. Specifically, an interaction between these 
components may be detected substantially only under conditions of low pH (Figure 5.5). 
This would suggest that, at neutral pH, the CLIP ligand is unable to make sufficient 
favourable contacts with residues of the I -E peptide- binding groove to stabilise the 
complex. The amino acid side chains required in a peptide sequence to enable it to bind to 
I -E molecules have been determined by an examination of the natural ligands of these 
molecules. Typically, peptides that bind to I -E class II MHC molecules show a high 
frequency of polar residues. These occur most commonly within the ligand at the 
positions corresponding to the pockets, 6 and 9, with a specific preference for basic 
residues at P9 (Sette et al., 1989c; Marrack et al., 1993; Reay et al., 1994; Schild et al., 
1995). Most interestingly, both of these positions have been implicated previously in the 
pH- dependent binding of peptides to I -E aß dimers (Boniface et al., 1993; Fremont et 
al., 1996). 
To test the hypothesis that CLIP is unable to hind to I -E molecules at neutral pH due to a 
lack of electrostatically -suitable anchors, CLIP86 -104 analogues were synthesised with a 
single lysine residue introduced at either position, P6 (P96K), P9 (M99K) or both 
(P96K/M99K; Figure 5.10a). These peptides were then examined using a cell -surface 
binding assay for their ability to compete with the antigen- derived ligand, biotinylated 
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Figure 5.9 The binding of N- terminal L- alanine -substituted CLIP8I -104 
to purified I -Ed in an immunoadsorption assay at pH 5.0. 
(a) Biotinylated CLIP81 -104 analogues with single L- alanine substitutions in their N- terminus (dashed 
lines, open squares) were tested for binding to I -Ed molecules purified from the BALB /c- derived B cell 
lymphoma, A20. Shown in comparison with biotinylated wild -type CLIP81 -104 (solid line, filled 
sqaures), is one of three experiments, all with equivalent results. (b) Unbiotinylated variants of the same 
analogues were tested as competitors against biotinylated wild -type CLIP81 -104 (30 idM; solid line, 
filled squares). Shown is the mean percentage inhibition ± SD from two independent experiments. 
Peptides were incubated at pH 5.0 with immunopurified I -Ed for 48 hours at 37 °C before capture on a 
M5 /114 -coated microtitre plate, as described in Chapter 2, §2.7.3. The signal from non -specific 
associations was determined from the binding of biotinylated peptide in the absence of MHO molecules 
and has been subtracted from the data shown (a, 0.183 OD units; b, 0.098 OD units). 
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Figure 5.10 The binding of lysine -substituted CLIP analogues to cell - 
surface I -Ek molecules at pH 7.0. 
Substituted CLIP analogues were examined for their ability to compete with biotinylated mCytc88 -103 
(75.sM) for binding to the I -Ek molecules expressed on the surface of the cell line, CH27 (H -2k). Data are 
presented as the mean percentage inhibition ± SD from two independent experiments, CH27 cells were 
incubated with biotinylated peptide and competitor for 18 hours at 37 °C before flow cytometric analysis, 
as described in Chapter 2, §2.7.2. The signal from non- specific associations was determined in the 
absence of biotinylated peptide and has been subtracted from the results shown. 
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mCytc88 -103, for binding to I -Ek molecules expressed by CH27 cells (Figure 5.10b). 
Consistent with previous results (Figure 5.2), wild -type CLIP86 -104 (filled squares) 
was a poor competitor against the biotinylated antigenic peptide under these conditions. 
Indeed, in this assay, the ability of CLIP to compete was diminished even further than in 
Figure 5.2 due to a higher dose of biotinylated mCytc88 -103 used to generate the 
fluorescence signal, i.e. 75 µM in this instance, compared with 2511M in the previous 
assay. 
Strikingly, however, the introduction of a lysine residue into the P6 position of the 
CLIP86 -104 sequence (P96K, filled triangles) improved considerably its ability to 
compete with the biotinylated mCytc88 -103 for binding to the cell -surface I -Ek 
molecules. A similar substitution into the CLIP sequence at the P9 position (M99K, filled 
circles) enhanced further the binding potential, with the degree of inhibition approaching 
75% at 200 RM. The double lysine -substituted CLIP, P96K/M99K, also bound to the I- 
Ek molecules better than the wild -type CLIP86 -104 sequence but did not yield more 
inhibition of the biotinylated mCytc88 -103 signal than the M99K analogue alone. Taken 
together, these data support the hypothesis that CLIP is unable to associate with I -E 
molecules at neutral pH due to a lack of suitable residues to mediate the interactions which 
stabilise the binding of peptides at this pH. In this sense, the interaction of the peptide 
side chain within the P9 pocket appears to be more critical than that at the P6 site. 
5.4. Discussion 
5.4.1 CLIP binds within the I -E" peptide- binding groove through both 
main -chain and side -chain interactions 
The experiments described in this chapter have examined the interaction of CLIP with 
mouse class II MHC molecules of the I -E isotype. This was accomplished previously for 
I -A molecules by assessing the binding of different substituted and/or truncated CLIP 
analogues in both antigen -presentation and cell -surface peptide binding assays (Chapters 
3 & 4). However, unlike their I -A counterparts, I -E class II MHC molecules were found 
to bind CLIP ligands poorly using these same assay methods (Figures 5.1 -5.4). This 
was consistent with observations in Chapters 3 ( §3.3.1) & 4 ( §4.3.1) of an apparently 
negligible contribution from biotinylated CLIP binding to T-E heterodimers in cell -surface 
binding assays with the CH27 (H -2k) and A20 (H -2°) cell lines. 
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The formation of most peptide-class II MHC complexes has been noted to be augmented 
at low pH (e.g. Jensen, 1990, 1991; Harding et al., 1991; Wettstein et al., 1991; 
Mouritsen et al., 1992; Sette et al., 1992b). Thus, in an effort to find a better means with 
which to assess the association of CLIP with I -E molecules, the effect of proton 
concentration upon this interaction was examined in an immunoassay with purified I -Ed 
(Figure 5.5). At neutral pH, CLIP bound to the I -Ed molecules with low affinity. This 
result is consistent with the findings of the cell -surface and antigen- presentation assays 
(Figures 5.1 -5A) which were conducted with whole cells in media buffered by HEPES 
(pH 7.2 -8.2; Appendix B1). By contrast, the binding of CLIP to I -E molecules was 
enhanced at pH 5.0 to the extent that the presence of such complexes could now be 
measured experimentally (Figure 5.5). Based on these findings, a change in the 
methodology used to examine the CLIP -I -E interaction was implemented, such that all 
subsequent experiments were conducted using purified I -E molecules in an enzyme -linked 
immunoassay at pH 5.0. 
Using this approach to examine the binding of the truncated and/or substituted CLIP 
analogues to purified I -Ed, the features of CLIP that are important for interacting with 
these class II MHC molecules have been elucidated. Firstly, an assessment of the binding 
of D- alanine- substituted CLIP86 -104 analogues to I -Ed identified a critical role for the 
main -chain atoms of the central sequence element, CLIP90 -99, in providing positive 
binding energy to stabilise this interaction (Figure 5.7). Secondly, within this region of 
the CLIP sequence, the substitution by L- alanine of any of the side chains, Met 91, Thr 
95, Leu 98 or Met 102 eliminated the capacity of CLIP to bind to the I -Ed heterodimer. 
The L- alanine substitution of Met 99 also diminished the interaction, whilst the equivalent 
substitution of the Pro 96 residue led to an increase in binding capacity (Figure 5.8). 
Meanwhile, the assessment of the binding of truncated CLIP variants indicated that for 
efficient association of this sequence with the I -Ed molecules, these residues must be 
incorporated into a peptide of more than 13 residues in length (Table 5.1). The binding of 
CLIP81 -104 analogues exhibiting single L- alanine substitutions within the N- terminal 
sequence revealed that the conserved residues, Lys 83, Pro 87 and to a lesser extent, Lys 
86, also appeared to provide a favourable influence on the interaction of the CLIP ligand 
with I -Ed molecules (Figure 5.9). Lastly, strong binding of CLIP to I -Ek molecules at 
neutral pH was enabled by introducing lysine residues into either position, P6 (P96K) or 
P9 (M99K), within the peptide sequence (Figure 5.10). 
In order to interpret the experimental findings reported in this chapter regarding the mode 
of CLIP binding to I -Ed, it is necessary to have an understanding of how peptides 
associate typically with these molecules. Such details may now be extrapolated from the 
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X -ray crystal structures of the I -Ek aß dimer complexed with either the mouse 
haemoglobin peptide, mHb64 -76, or a determinant from the mouse heat shock protein 
70, mHsp236 -248 (Fremont et al., 1996). It may be assumed that I -Ed molecules are 
likely to share a high degree of structural homology with I -Ek given the slight divergence 
between their primary sequences, as characteristic of all class II MHC molecules of this 
isotype. For example, a comparison of the a -chain sequences of the I -Ed and I -Ek 
allotypes reveals just two amino acids differences over the entire protein, with these being 
restricted one each to the second domain and cytoplasmic tail (Ayane et al., 1986; for a 
description of the domain organisation of class II MHC molecules, see Chapter 1, Figure 
1.3). Additionally, the two molecules also exhibit 91% sequence identity between their 
respective E(3- chains (Mengle -Gaw & McDevitt, 1983). 
The X -ray crystallographic analysis of the I -Ek aß dimer (Fremont et al., 1996) revealed 
that peptides bind to these molecules in the same manner as ligands complexed with 
human FILA -DR (Brown et al., 1993; Stern et al., 1994; Ghosh et al., 1995) and mouse 
I -A molecules (Fremont et al., 1998b; Scott et al., 1998). Specifically, a nine -residue 
stretch of the peptide is encompassed within the peptide- binding groove, being tethered 
by both a comprehensive network of hydrogen bonds between the main -chain atoms of 
the peptide and the class II MEC residues, and interactions between the peptide side 
chains and the polymorphic class II MHC pockets. Furthermore, the I -Ek heterodimer 
exhibits the same location and spacing of the five major pockets observed in other crystal 
structures and predicted in homology models of HLA -DR and I -A molecules, 
corresponding to the relative positions within the bound peptide at Pl, P4, P6, P7 and 
P9, where Pl represents the first amino acid within the peptide N- terminus to be 
encompassed fully within the peptide- binding groove (Stern et al., 1994; Ghosh et al., 
1995; Lee & McConnell, 1995; Fremont et al., 1996, 1998b; Dessen et al., 1997; Lee et 
al., 1998; Scott et al., 1998; Weber et al., 1998). The arrangement of these pockets had 
been predicted previously for both I -Ek and I -Ed molecules based upon the results of 
substitution and truncation analyses of a range of different I- E- binding peptides, together 
with pool sequencing of natural ligands eluted from these molecules (Marrack et al., 
1993; Reay et al., 1994; Schild et al., 1995). 
Some details of the manner in which I -E class II MHC molecules bind CLIP may also be 
extrapolated from knowledge of how this sequence interacts with FILA -DR heterodimers 
since these molecules represent the human homologue of I -E, i.e. they too exhibit 
minimal variation in their a -chain sequence (e.g. Korman et al., 1982; Larhammar et al., 
1982; Lee et al., 1982; Das et al., 1983). The I -E and HLA -DR a- chains also display a 
high degree of amino acid sequence identity, as do the I -E and HLA -DR 0- chains, 
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excluding the hypervariable segments (Allison et al., 1978; Silver et al., 1979). For 
example, the Ea, domain shows 79% sequence homology at the protein level to its 
human counterpart, HLA -DRa, (McNicholas et al., 1982; for a complete alignment of the 
deduced amino acid sequences of mouse and human class II MHC molecules, see 
Figueroa & Klein, 1986 and Klein, 1986). By contrast, the a, and 13, domains of I -Ek 
and I-Ak molecules show just 55% and 62% sequence identity, respectively (Benoist et 
al., 1983b; Mengle -Gaw & McDevitt, 1983). 
In the context of details provided by the peptide -I -Ek crystal structures (Fremont et al., 
1996) and data from human CLIP crystallised in association with HLA -DR3 (Ghosh et 
al., 1995), the results presented herein regarding the binding of mouse CLIP to I -Ed class 
II MHC molecules indicate that positive binding energy is provided by both the formation 
of a hydrogen -bond network through the peptide backbone (Figure 5.7) and via several 
peptide side chains forming anchor interactions with the residues of the c43 dimer (Figure 
5.8). This latter feature is particularly noteworthy given that CLIP does not make 
significant anchor contacts through its side chains when binding to variants of the mouse 
I -A isotype, with the interaction instead being sustained predominantly by the main -chain 
hydrogen- bonding scheme (Chapter 3, §3.4.2 & Chapter 4, §4.4.1). 
5.4.2 An examination of specific CLIP side -chain interactions with 
pockets of the I -Ed peptide -binding groove 
Further insight into the molecular basis of the favourable interactions occurring at pH 5.0 
between the I -Ed molecules and the CLIP residues, Met 91, Thr 95, Leu 98, Met 99 and 
Met 102, may be gained from an examination of the particular sites upon the aß dimer at 
which these side chains interact. This may be accomplished by comparing known I -Ed- 
specific sequence polymorphism with details of the I -Ek crystal structures (Fremont et al., 
1996) and relating the points of allelic variation to the peptide -binding preferences of these 
two MIIC molecules. Despite the observation that I -E variants have a high degree of 
sequence conservation overall, such comparisons remain important because localised 
areas of polymorphism still exist within the f domains, affecting the character of the 
pockets within the peptide- binding groove. For example, the I -Ed and I -Ek allotypes 
exhibit just 78% protein sequence identity within this region (Mengle -Gaw & McDevitt, 
1983) Similar comparisons were performed in Chapter 3 ( §3.4.4) to elucidate how 
CLIP side -chains interact with I -A all dimers. For I -E molecules, additional information 
on this matter may also be provided from knowledge of how peptides interact with the 
homologous human molecules, HLA -DR. 
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A summary of the interactions made by CLIP side chains within the pockets of the I -Ed 
class II MHC peptide -binding groove is shown in Table 5.4, based upon the experimental 
results presented herein (Figure 5.8), together with data from X -ray crystallographic 
studies of I -Ek and other c43 dimers (Stern et al., 1994; Ghosh et al., 1995; Fremont et 
al., 1996, 1998b; Dessen et al., 1997; Scott et al., 1998), homology models (Bogen & 
Lambris, 1989; Sette et al., 1989a; Chu et al., 1994; Gregori et al., 1999), sequence 
comparisons (Benoist et al., 1983b; Mengle -Gaw & McDevitt, 1983; Ayane et al., 1986; 
Chu et al., 1994; Fremont et al., 1998b) and analyses of the peptide -binding motifs of 
different I -E allotypes (Guillet et al., 1987; Adoriní et al., 1988a; Bogen & Lambris, 
1989; Sette et al., 1989a, 1989b, 1989c; Evavold et al., 1992; Boniface et al., 1993; 
Marrack et al., 1993; Reay et al., 1994; Rammensee et aL, 1995; Schild et al., 1995; 
Gregori et al., 1999). Using the same approach, predictions are also given for how these 
CLIP residues might interact with I -Ek a0 dimers. 
The nature of the CLIP -1"-E interaction may be inferred by extrapolating from details of 
the X -ray crystallographic analysis of human CLIP complexed with HLA -DR3 (Ghosh et 
al., 1995). It may be anticipated that mouse CLIP would bind with the Met 91 anchor 
residue accommodated within the first major pocket, at relative position Pl. This binding 
register is confirmed by the findings reported herein, whereby the central sequence 
element of CLIP, residues 90-99, is critical for sustaining an interaction with the I -Ed 
molecule (Figure 5.7). The same alignment is also adopted when this ligand binds to 
different I -A allotypes (Chapter 3, §3.4.4; Lee & McConnell, 1995). 
In common with I-mA -DR molecules, the Pl pocket of I -E ct0 dimers is lined with a 
number of conserved, hydrophobic residues (Brown et al., 1993; Stern et al., 1994; 
Ghosh et al., 1995; Fremont et al., 1996; Dessen et al., 1997). The exact side -chain 
dimensions able to be accommodated within this pocket in both I-ILA -DR and I -E are 
dictated by the nature of the residue at the polymorphic position 86 in the 0 -chain of the 
heterodimer (Busch et al., 1991; Demotz et aL, 1993; Newton -Nash & Eckels, 1993; 
Verreck et al., 1993; Fremont et al., 1996). In I -Ed, the Pl pocket is large as a result of 
the 086 position being occupied by a small serine residue (Mengle -Gaw & McDevitt, 
1983). This situation is equivalent to presence of glycine at this position in HLA -DR1 
(discussed previously in Chapter 3, §3.4.5; Stern et al., 1994). Accordingly, pool 
sequencing of natural I -Ed peptide ligands has revealed a predominance of the bulky 
aromatic residues, tyrosine, tryptophan and phenylalanine at relative position, Pl (Schild 
et al., 1995). The requirement for the Met 91 CLIP side chain to act as an anchor for the 
binding interaction with I -Ed thus lies in the capacity of its side chain to make strongly 
favourable hydrophobic contacts within this pocket (Figure 5.8). It is interesting to note 
Table 5.4 The interaction of CLIP side chains with the pockets of the I -E peptide- binding groove. 
Shown are the amino acid residues whose atoms contribute to forming the major polymorphic pockets of the peptide- binding grooves of the class II MHC molecules, I -E5 
and I-Ek. Where data are available, these residues have been taken from the X -ray crystallographic analysis of the I -Ek ot43 dimer complexed with either of the antigen- derived 
peptides, murine heat shock protein 70, mHsp236 -248, or murine haemoglobin, mHb64 -76 (Fremont et al., 1996). Alternatively, residues have been assigned by 
equivalent analyses of allelic variants of the human homologue, FILA -DR, together with T-E homology models (Bogen & Lambris, 1989; Sette et al., 1989a; Chu et al., 
1994; Stern et al., 1994; Ghosh et al., 1995; Gregori et al., 1999). Within each pocket, these residues form either hydrogen bonds or van der Waals interactions with the 
atoms of the amino acid side chains of a bound peptide. Throughout this thesis, class II MHC residues are numbered according to the secondary structure -based sequence 
alignment of the al and ßi domains of the molecules, I -Ek, I -Ak and HLA -DR, reported by Fremont et al. (1998b). The primary amino acid sequences of the al and (3i 
domains of the different I -E molecules are taken from Benoist et al. (1983), Mengle -Gaw & McDevitt (1983), Ayane et al. (1986) and Chu et al. (1994). Polymorphic 
residues between the I -E molecules are italicised. Those underlined provide a specific physicochemical property to the pocket to govern its overall peptide side -chain 
preference. For each I -E allotype, the peptide residues commonly found at each of these positions have been taken from alignments of naturally- processed ligands (Guillet 
et al., 1987; Adorini et al., 1988a; Bogen & Lambris, 1989; Sette et al., 1989a, 1989b, 1989c; Evavold et al., 1992; Boniface et al., 1993; Marrack et al., 1993; Reay et 
al., 1994; Rammensee et al., 1995; Schild et al., 1995; Gregori et al., 1999). The individual side chains of the native CLIP sequence that bind at these positions are shown 
in italics beneath the respective pocket number. 
The nature of the interaction of the native CLIP side chains with I -E`' molecules is summarised from the results of the immunoassay at pH 5.0 presented in this chapter 
(Figure 5.8). 
bPredictions are also given for how these CLIP residues might interact with I -Ek ar3 dimers, based upon the data listed above. 
°(3Asp 57 is mutated to a serine residue in the I -Ag7 class II MHC molecule of the non -obese diabetic (NOD) mouse. The presence of a non -Asp residue at this position has 
been linked to the development of autoimmune diabetes in both these animals and in humans. The effects of this substitution on the peptide- binding properties of the I -A 7 
molecule are examined in Chapter 6 of this thesis. 
represents an anchor side chain within the CLIP sequence, such that binding to the I -E molecule is not sustained if this residue is substituted with L- alanine. 
represents the provision of positive binding energy by this CLIP side chain at the binding interface. 
Nrepresents the provision of negative binding energy by this CLIP side chain at the binding interface. 
represents no notable contribution of binding energy by the CLIP side chain to the interaction with I -E or, in the case of the wild -type CLIP residue at the P4 
position, Ala 94, where this side chain was not examined by substitution analysis. 
Allotype 
I-Ed 
Pl 
Met 91 
P4 
Ala 94 
P6 
Pro 96 
P7 
Leu 97 
P9 
Met 99 
alle 7, alle 31, aPhe 32, 
aVal 34, aTrp 43, ßí1e 85, 
ßSer 86, PPhe 89, PLeu 90 
Pocket character: large, hydrophobic 
Residues observed: e.g. Tyr, Trp, Phe 
"CLIP interaction: 
I-Ek alle 7, alle 31, aPhe 32, 
aVal 34, aTrp 43, Pile 85, 
ßPhe 86, PPhe 89, Pleu 90 
Pocket character: medium, hydrophobic 
Residues observed: e.g. Ile, Leu, Val 
CLIP interaction: 
aGln 9, PSer 13, ßAsp 70, 
ßAla 71, ßSer 74, ßTyr 78 
medium, acidic 
e.g. Lys, Arg 
aGln 9, PSer 13, ßGln 70, 
ßLys 71, ßGlu 74, Pal 78 
large, amphiphilic 
e.g. Ser, Val, Ile, Leu, Phe 
aGlu 11, aAsn 62, aVal 65, 
aAsp 66, ßVal 11 PSer 13 
medium, hydrophobic 
e.g. Ile, Val, Leu 
aGlu 11 aAsn 62, aVal 65, 
aAsp 66 ßCys 11 PSer 13 
medium, hydrophilic 
e.g. Gln, Asn, Asp, Glu 
aAsn 69 !Zia 28 ßTyr 47, 
PTrp 61, PPro 65, Pile 67, 
ßAsp 70 BAla 71 
shallow, solvent -exposed 
e.g. Lys, Arg 
aAsp 69, ßVal 28, ßPhe 47, 
PTrp 61, PPro 65, ßPhe 67, 
fGln 70, ßLys 71 
shallow, solvent -exposed 
degenerate 
aAsn 69, aVal 72, aMet 73, 
aArg 76, jiG1u 9 PAsp 57' 
narrow, hydrophobic 
e.g. Lys, Arg 
aAsn 69, aVal 72, aMet 73, 
aArg 76, ßGlu 9, PAsp 57' 
narrow, hydrophobic 
e.g. Lys, Arg 
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that the presence of an anchor residue at the PI position is not typically a stringent 
requirement for a peptide to be able to bind to molecules of the I -Ed allotype, presumably 
due to more important interactions taking place elsewhere within the groove (see below; 
Sette et al., 1989a). By contrast, this position represents a primary anchor site for natural 
ligands of I -Ek, such that the substitution of an amino acid here reduces binding 
dramatically (Leighton et al., 1991; Reay et al., 1994). In this respect, an anchor 
interaction may also be predicted between the Met 91 residue of the CLIP sequence and 
the hydrophobic P1 pocket of I -Ek molecules. Aliphatic residues are most common 
within natural ligands here as a result of the larger phenylalanine residue at 1186 (Mengle- 
Gaw & McDevitt, 1983; Marrack et al., 1993; Schild et al., 1995; Fremont et al., 1996). 
For example, the Pl pocket accommodates a valine or isoleucine side chain in the mHsp- 
I-Ek and mHI_I -Ek crystal structures, respectively (Fremont et al., 1996). This effect is 
similar to that seen when valine occupies the 086 position, as in HLA -DR3 (discussed 
previously in Chapter 3, §3.4.5; Ghosh et al., 1995; Dessen et al., 1997). 
The P4 pocket within the I -E peptide -binding groove is even larger than that 
accommodating the Pl side chain, as revealed in the X -ray crystallographic analysis of I- 
Ek complexed with the mHb64 -76 and mHsp236 -248 peptides (Fremont et al., 1996). 
The role of the native CLIP residue that corresponds to this site was not examined by 
substitution analysis in this study, being already L- alanine (Ala 94). However, such a 
small side chain is unlikely to contribute significant binding energy at this site, either 
positive or negative. Similar to HLA -DR molecules, the P4 pocket of I -E molecules is 
lined with a greater number of polymorphic residues than the Pl pocket which results in 
more marked allele -specific side -chain preferences at this position (Fremont et al., 1996; 
Stern et al., 1994; Ghosh et al., 1995; Rammensee et al., 1995; Chelvanayagam, 1997; 
Dessen et al., 1997; Gregori et al., 1999). Between the I -Ed and I -Ek cr11 dimers, the 
most important of these sequence variations involve the residues 1170, 071, 1174 and 078 
(Table 5.4; Mengle -Gaw & McDevitt, 1983). Consequently, the P4 pocket of I -Ek 
displays a preference for either aliphatic or polar side chains, with serine, valine and 
isoleucine residues being common in natural peptide ligands (Schild et al., 1995). Large 
aromatic residues may also be accommodated within this site, as indicated by the presence 
of phenylalanine in the P4 pocket of both peptide -I -Ek crystal structures (Fremont et al., 
1996). By contrast, this site within I -Ed class II MI-IC molecules is more electrostatically - 
negative in character due to the aspartic acid residue at position, 070 (Mengle -Gaw & 
McDevitt, 1983) and, consequently, basic residues are found frequently at this position in 
both I- Ed- binding peptides and natural ligands (Schild et al., 1995). 
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The P6 pocket of I -E and HLA -DR heterodimers also shows significant amino acid 
polymorphism between allotypes (Hammer et al., 1993; Rammensee et al., 1995; 
Chelvanayagam, 1997; Gregori et al., 1999). Two of the key residues involved in 
imparting chemical character to this site are located at positions 1311 and (313 (Ghosh et 
al., 1995; Dessen et al., 1997; Fremont et al., 1996). In the I -Ek molecule, these sites are 
occupied by the polar residues, cysteine and serine, respectively (Mengle -Gaw & 
McDevitt, 1983). Accordingly, this pocket accommodates the polar side chain of Glu 73 
in the mHb -I -Ek crystal structure and Ala 243 plus several water molecules in the mHsp- 
I-Ek complex (Fremont et al., 1996). From pool sequencing data and other analyses of I- 
Ek binding motifs, asparagine and glutamine residues are also commonly found at the P6 
position (Marrack et al., 1993; Reay et al., 1994; Schild et al., 1995). By contrast, this 
pocket within I -Ed molecules is more hydrophobic with a specific preference for aliphatic 
side chains (Schild et al., 1995), Nevertheless, the pyrrolidine ring of the CLIP Pro 96 
residue is inhibitory to binding at this site, presumably due to steric hindrance (Figure 
5.8). A similar situation would also be predicted for this residue interacting at the P6 
pocket of the I -Ek molecule. 
The P7 pocket of most class II MHC molecules is degenerate and able to accommodate a 
diverse range of different amino acid side chains, as described previously in Chapter 3 
( §3.4.4). This is likely to be a consequence of this site being shallow, with the incoming 
peptide side chain oriented towards the a- helical walls of the cleft rather than downwards 
towards the floor (Stern et al., 1994; Ghosh et al., 1995). The P7 pocket of I -Ek 
molecules would appear to be no exception and the side chain of the Glu 244 residue that 
interacts at this position in the mHsp -I -Ek crystal structure shows high solvent exposure 
(Fremont et al., 1996). Consistent with this arrangement, P7 side chains in peptide -I -Ek 
complexes form contacts with the aß dimer (Evavold et al., 1992; Driscoll et al., 1993) 
but may also interact with the TCR (Bhayani & Paterson, 1989; Leighton et al., 1991; 
Reay et al., 1994; Hsu et al., 1996). It might be expected that I -Ed molecules would 
show a similar lack of preference for the type of amino acid side chain that interacts within 
the P7 pocket since they share most of the MHC residues that line this site in I -Ek 
(Fremont et al., 1996), However, pool sequencing and the alignment of natural ligands 
eluted from I -Ed molecules have revealed that positively -charged residues are frequently 
accommodated at this position (Sette et al., 1989a; Schild et al., 1995). In this respect, it 
has been suggested that a basic side chain at P7 may form a salt -bridge with either 3Glu 
28 or the nearby 3Asp 70 of the I -Ed heterodimer (Bogen & Lambris, 1989; Sette et al., 
1989a; Leighton et al., 1991; positions 13114 and 13155, respectively, according to the 
HLA -A2 numbering used by these authors), this latter residue also having been proposed 
to contribute to the electrostatically -negative character of the P4 pocket (Schild et al., 
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1995). Both of these positions are occupied by uncharged amino acids in I -Ek (Mengle- 
Gaw & McDevitt, 1983). In this study, little difference was seen when the native CLIP 
residue, Leu 97, was substituted with L- alanine but neither side chain provides an 
assessment of charge discrimination (Figure 5.8). 
Lastly, the P9 pockets of all I -E class II MHC allotypes examined to date exhibit an 
identical preference for a positively- charged side chain (Marrack et aL, 1993; Reay et aL, 
1994; Schild et al., 1995; Gregori et al., 1999). This specificity arises from the ability of 
such a residue to provide considerable positive binding energy to the interaction by 
forming a salt bridge with the I- E- conserved amino acid, JGlu 9. In both peptide -I -Ek 
crystal structures, this residue lies at the base of a deep cavity which is otherwise 
predominantly hydrophobic along its length. Thus, the native CLIP residue, Met 99, is 
more favoured for binding to I -Ed than L- alanine at this position due to the ability of its 
side chain to participate in some of these hydrophobic interactions (Figure 5.8). 
Nevertheless, the lack of a positive charge to stabilise this complex further leaves it 
extremely sensitive to proton concentration, such that CLIP is unable to associate with 
both I -Ed and I -Ek molecules at neutral pH (Figures 5.1 -5.4). Accordingly, when a 
lysine residue is introduced into the CLIP sequence (M99K), this ligand may now bind to 
I -Ek molecules on the surface of CH27 cells at pH 7.0 (Figure 5.10). The pH 
dependence of the binding of CLIP to I -E class II MHC molecules is discussed further in 
§5.4.4. 
By comparison with the crystal structures of peptide -I -Ek complexes and similar analyses 
of HLA -DR and I -A molecules, the remaining CLIP residues at relative positions, P2, 
P3, P5 and P8 are all predicted to be oriented across or away from the I -E peptide- binding 
groove (Stern et al., 1994; Ghosh et al., 1995; Fremont et al., 1996, 1998b; Dessen et 
al., 1997; Scott et al., 1998). Indeed, for both I -Ek and I -Ed molecules, the side chains at 
these positions in antigen- derived peptides typically represent important contact sites for T 
cell recognition (Leighton et al., 1991; Evavold et al., 1992; Hsu et al., 1996). 
Therefore, it was somewhat unusual to find that the CLIP residues Thr 95 (P5) and Leu 
98 (P8) were able to form anchor associations with the I -Ed aß dimer (Figure 5.8). 
Likewise, the Met 102 residue of CLIP (P12) appears to be an anchor in the interaction 
with I -Ed (Figure 5.8), yet X -ray crystaIIographic analysis would predict it to lie outside 
of the groove. The orientation of all these residues makes it very difficult to elucidate the 
molecular basis of these observations. Of particular interest, a similar situation was noted 
for these same CLIP residues in the binding of this sequence to mouse class II MHC 
molecules of the I -A isotype in Chapter 3 ( §3.4.4). In that case, it was suggested that 
these favourable interactions at unconventional sites were an adaptive strategy to uphold 
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the binding of this ligand to the a(3 dimer in the absence of suitable residues within the 
major pockets of the groove. Regarding the peptide- binding motif of I -Ed, CLIP is 
indeed again lacking in many of the preferred anchor residues. For example, a key 
feature of the ligands of these molecules is the presence of positively- charged residues at 
relative positions P4, P7 and P9 (Table 5.4; Bogen & Lambris, 1989; Sette et al., 1989a, 
1989b, 1989c; Schild et al., 1995). The CLIP sequence exhibits basic residues only at 
positions, P2 (Arg 92) and P10 (Arg 100), both unsuitable for alignment with the 
appropriate negatively -charged pockets. 
The ability of the Thr 95 CLIP residue to form an anchor interaction with the I -Ed a3 
dimer may be related to the presence of the insignificant side chain of Ala 94 at position 
P4. Rammensee et al. (1995) have reported that some class II MHC molecules may 
exhibit slightly different spacings of anchor residues and incorporate the second peptide 
anchor, or simply additional bonds, at the P3 or P5 positions when an unsuitable residue 
is present at P4. Such interactions were not specifically noted for molecules of the I -E 
isotype from the alignment of known peptide ligands (Rammensee et al., 1995) but nor 
did such an approach predict the capacity of the human CLIP residue, Met 93, to form an 
anchor interaction with HLA -DR3 molecules, as has now been shown (discussed 
previously in Chapter 3, §3.4.4 & §3.4.5). It is interesting to note that within the crystal 
structure of the mHb64 -76 peptide complexed with I -Ek, the side chain of the P5 residue, 
Asn 72, may project from the groove to become a TCR contact site but it also interacts on 
the surface of the protein with 3Gln 70, a residue of significance in the P4 and P7 pockets 
also (Fremont et al., 1996). This position in the I -Ed (3 -chain is occupied by aspartic acid 
(Mengle -Gaw & McDevitt, 1983). Further experimentation is needed to determine 
whether an electrostatic contact also exists between the CLIP P5 residue, Thr 95, and 
3Asp 70 in the I -Ed molecule. 
A similar mechanism may be proposed to account for the ability of the CLIP P8 residue, 
Leu 98, to form an interaction with I -Ed. For example, Schild et al. (1995) have observed 
that the peptide residue that interacts within the last major pocket of the I -Ed groove is not 
always located at relative peptide position, P9, but is sometimes at P8. This occurs 
typically when a positively -charged residue is located at P8. However, such an 
arrangement for CLIP binding to I -Ed is not compatible with the significant effects seen 
when the Met 99 residue was substituted by L- alanine (Figure 5.8). Meanwhile for I -Ek 
molecules, the amino acid side chain that interacts with the last pocket of the groove may 
sometimes be located at P10, instead of P9 (Schild et al., 1995). In this case, the mouse 
CLIP sequence does indeed exhibit a suitable basic residue at this position, Arg 100. 
Nevertheless, sufficient positive binding energy was still not present in the interaction 
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between CLIP and I -Ek molecules to facilitate the formation of such complexes at neutral 
pH and the substitution of Arg 100 by L- alanine had little effect upon binding at pH 5.0 
(Figure 5.8). In this respect, it is possible that the binding of a P10 lysine residue within 
the last pocket of the I -Ek groove may produce a weaker salt bridge than the conventional 
interaction through a side chain at P9. For example, the pigeon cytochrome c peptide, 
pCytc81 -104, exhibits an alanine insertion that shifts the groove -terminal (P9) Lys 103 
residue to the P10 position relative to the moth cytochrome c sequence. An examination 
of the binding kinetics of these peptides has revealed that the pigeon cytochrome c peptide 
dissociated faster from I -Ek at pH 7.5 (Witt & McConnell, 1991), similar to the result 
observed when the P9 lysine of the mCytc peptide was substituted with alanine (Boniface 
et al., 1993). The effect of pH upon the binding of peptides to I -E class II MHC 
molecules is discussed further in §5.4.4. 
5.4.3 CLIP binds differently to 1 -A and I -E class II MHC molecules 
The binding of CLIP to I -Ed and I -A molecules differs significantly in the role of side - 
chain anchors. Such contrasting modes of binding might be predictable given the 
presence of similar essential contacts between CLIP and FILA -DR variants but not 
between this ligand and aß dimers of the HLA -DQ isotype (these molecules represent the 
human homologues of I -E and I -A, respectively, as discussed previously in Chapter 3, 
§3.4.5; Geluk et al., 1995; Ghosh et al., 1995; Malcherek et al., 1995). The ability to 
detect these differences in the mechanism of peptide binding between I -A and I -E 
molecules serves to illustrate the utility of employing the CLIP sequence to probe the 
peptide -binding interactions of individual class II MHC variants. 
When the side chains of antigen- derived ligands form anchor contacts with class II MHC 
molecules, these typically take place within the pockets of the peptide- binding groove 
where the local environment is subject to allelic hypervariability. Thus, the formation of 
productive anchor contacts between CLIP side chains and the residues of I -Ed makes it 
interesting to consider how this ligand is able to bind promiscuously to molecules of this 
isotype. Consolidating the details provided in §5.4.2, this would appear to be facilitated 
by the fact that only one of these interactions actually takes place by conventional means 
within a pocket of the groove, i.e. Met 91 at PI. Of further significance, this pocket is 
atypical in having a high degree of sequence conservation between I -E allotypes (Fremont 
et al., 1996). Meanwhile, the remaining anchor residues, Thr 95, Leu 98 and Met 102, 
would appear to interact with I -Ed elsewhere on the 4. dimer where the amino acid 
sequence is less polymorphic. For example, extrapolating from HLA -DR molecules, the 
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immediate environment of the P8 side chain, Leu 98, is predicted to be relatively 
conserved between allelic I -E variants (Chelvanayagam, 1997). In other words, none of 
the interactions detected in the association of CLIP with I -Ed are limited to this allotype 
but, rather, have the potential to form when this ligand binds to any I -E variant. 
A significant feature in the degenerate binding of CLIP to I -E molecules is the presence of 
the non -polymorphic a -chain (Ayane et al., 1986; Mengle -Gaw & McDevitt, 1985), as 
with HLA -DR molecules (Chapter 3, §3.4.5). Since the antigen- binding site is composed 
equally of residues from both the a- and 0-chains, the sequence conservation with the a, 
domain reduces the degree of variation between the individual allelic variants of this 
isotype considerably. By contrast, I -A molecules exhibit greater amino acid 
polymorphism in and around the binding groove (reviewed by MengIe -Gaw & McDevitt, 
1985) and conserved anchor contacts are less able to form (Chapter 3; Gautam et al., 
1995). The non -polymorphic a -chain within HLA -DR and I -E molecules also 
contributes to the degenerate binding of antigen -derived ligands, as illustrated by the 
frequency with which allelic variants within these isotypes share the same peptide side - 
chain preferences, e.g. the common preference for a hydrophobic side chain at P1 (Table 
5.4; Hammer et al., 1993; Rammensee et al., 1995; Schild et al., 1995; Gregori et al., 
1999). Such effects are again less prevalent in the peptide- binding motifs of different I -A 
class II MHC molecules (Chapter 3, Table 3.2; Reizis et al., 1998). The presence of 
conserved peptide anchor preferences between different FILA -DR molecules has been 
exploited to engineer a set of ligands which exhibit high -affinity binding to a broad range 
of FILA -DR molecules and are potent immunogens (Alexander et al., 1994). These 
authors have proposed that such ligands may be used to generate T cell help in a variety of 
vaccine applications. 
Nevertheless, the additional contacts made with the I -E peptide- binding groove through 
the CLIP side chains do not appear to add significantly to the binding energy of this 
interaction. For example, similar dissociation constants have been determined for CLIP - 
bound I -A and I -E class II MHC molecules at pH 5.5 (discussed further in §5.4.4; 
Bangia & Watts, 1995). Moreover, this ligand also forms side -chain interactions with 
HLA -DR3 aß dimers (Ghosh et al., 1995) yet these complexes remain unable to 
withstand dissociation of their subunits induced in the presence of SDS detergent (e.g. 
Riberdy et al., 1992; Sette et al., 1992a; Hitzel & Koch, 1996). Presumably a greater 
fulfilment of the specific pocket preferences of the I -Ed a(3 dimer than that provided by 
CLIP is still needed to provide sufficient binding energy to undergo the conformational 
change into the compact state. In this respect, it may be worthwhile to examine whether 
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greater stability in SDS detergent may be observed for I -E complexes with the CLIP 
analogue, M99K. 
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Lastly, it is interesting to consider how the high degree of sequence conservation within 
the a- chains of I -E and HLA -DR may affect antigen presentation by these class II MHC 
molecules. Such a feature is not functionally neutral, as shown by the significant effects 
upon the ability of I -E molecules to bind peptides and stimulate T cells when amino acid 
substitutions were introduced into the a -chain at positions equivalent to polymorphic sites 
in the I -A a -chain (Chu et al., 1994). The possible roles that have been proposed for this 
lack of polymorphism include shaping a unique T cell repertoire and enabling a particular 
array of ligands to be bound and presented. However, both of these theories appear to 
have more experimental evidence against them than support (appraised by Chu et al., 
1994). Certainly, the presence of a non -polymorphic a -chain within molecules of the I -E 
and HLA -DR isotypes does have positive effects on the ability of peptides to bind 
degenerately (reviewed by Rothbard & Gefter, 1991). With regards to the interaction 
with CLIP, this may be important in controlling the site and timing within the endosomal 
compartments at which these molecules associate with antigen- derived peptides. 
5.4.4 The pH dependence of CLIP binding to I -E 
In this study, a significant effect of proton concentration upon the binding of the CLIP 
sequence to I -E class II MHC proteins has been identified. Specifically, CLIP was found 
to be unable to associate with the I -E molecules expressed by the B lymphoma cell lines, 
A20 (H -2°), CH27 (H -2k) or M12.A3 (I -Ed) in both cell -surface and antigen- presentation 
assays conducted at neutral pH (Figures 5.1 -5.4). This ligand also bound with low 
affinity to purified I -Ed in an enzyme -linked immunoassay at pH 7.0 (Figure 5.5), By 
contrast, significant binding was observed when the I -Ed molecules and CLIP were 
incubated together at pH 5,0. These results are consistent with data published in a similar 
investigation at this time (Bangia & Watts, 1995). These researchers found that 
biotinylated mCLIP86 -102 bound to both purified I -Ed and I -Ek with similar affinity at 
pH 5.5 (dissociation constants, KÇ = 2.3 and 1.1 p,M, respectively) but binding was not 
detectable at pH 7.0. 
The effect of pH upon the binding of CLIP to I -E molecules is compatible with earlier 
reports that high proton concentrations may accelerate the association rates of antigen - 
derived peptides with class II MHC proteins (e.g. Jensen, 1990, 1991; Harding et al., 
1991; Wettstein etal., 1991; Mouritsen et aL, 1992; Sette et al., 19926). Indeed, Bangia 
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& Watts (1995) have determined that CLIP binds optimally to both I -Ed and I -Ek at pH 
5.0 which is within the range reported previously for antigenic determinants (pH 4.5 -5.5; 
e.g. Jensen, 1990, 1991; Wettstein et al., 1991; Mouritsen et al., 1992; Reay et al., 1992; 
Sette et al., 1992b). Also of note, these values correspond well to the conditions found 
within the endosomal environment, where peptide loading occurs in vivo. 
It has been proposed that acidic conditions promote the protonation of weakly acidic side 
chains within the class II MHC molecule, which may then provide a favourable 
environment for the formation of stable complexes (Harding et al., 1991; Jensen, 1991). 
Recently, this mechanism has been confirmed from the X -ray crystallographic structure of 
I -Ek complexed with two different antigen- derived peptides (Fremont et al., 1996). At the 
base of the pocket that accommodates the P6 peptide side chain within the I -Ek peptide - 
binding groove are situated two acidic residues, aGlu 11 and aAsp 66. Within the local 
geometry of this pocket, these carboxylic acids face each other and participate in an array 
of hydrogen bonds with a water molecule and the tightly co- ordinated, neighbouring 
amino acids, aGln 9, aAsn 62 and aAsn 69. Together with additional hydrogen bonds 
formed via other conserved polar residues, e.g. [3His 81, i3Asn 82, (3Trp 61 and aArg 
76, this network contributes positively to peptide binding by making critical contacts with 
main -chain atoms of the bound peptide to tether it within the I -E groove. Thus, the ability 
of low pH to facilitate stable peptide binding lies in the capacity of such conditions to 
protonate both of the acidic residues within the P6 pocket and, thereby, promote the 
formation of the anchoring hydrogen bond scheme. When a polar amino acid is present 
within the bound peptide at the P6 position, its side chain may also be involved, as 
illustrated in the mHb -I -Ek crystal structure, where the P6 residue is glutamic acid 
(Fremont et al., 1996). 
The pH- dependent hydrogen bond network identified in I -Ek involving the aGlu 11 and 
aAsp 66 residues is likely to be a feature of all I -E variants given the conserved nature of 
the a -chain sequence (Mengle -Gaw & McDevitt, 1985; Ayane et al., 1986). The 
involvement of the P6 side chain may also be exhibited by the molecules, I -E', I -E" and I- 
Eg7 which share with this allotype the preference for a polar side chain at this position 
(Schild et al., 1995; Gregori et al., 1999). A similar hydrogen bonding scheme to that in 
I -E" may also be predicted for HLA -DR allotypes. These molecules too exhibit conserved 
acidic residues at positions, al and a66. Nevertheless, one report has suggested that 
the interactions of HLA -DR heterodimers with peptide may still be less sensitive to 
hydrogen ion concentration than those of I -E (Sette et al., 1992b). Moreover, no such 
interactions additional to the usual array of main -chain hydrogen bonds have been noted 
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specifically in any of the HLA -DR X -ray crystallographic analyses to date (Stern et al., 
1994; Ghosh et al., 1995; Dessen et al., 1997). 
Peptide complexes with I -A class H MHC molecules, in common with those of both 
HLA -DR and I -E isotypes, also exhibit an elaborate network of hydrogen bonds between 
conserved polar side chains of the aß dimer and the main -chain atoms of the peptide 
backbone, including interactions via the MHC residues, aAsn 62 and aAsn 69 
(discussed previously in Chapter 4, §4.4.2; Fremont et al., 1996, 1998b; Scott et al., 
1998). However, I -Ad is the only allelic variant of the I -A isotype to exhibit aGlu 66 (a 
glycine in I -Ak) while none display an acidic residue at all. This latter position is 
occupied by a threonine residue in both I -Ad and I -Ak (Davis et al., 1989). Since the pH- 
dependent hydrogen bond network has been predicted to require the protonation of two 
carboxylate groups within the P6 pocket of I -E (Fremont et al., 1996) it is therefore 
unlikely that an equivalent system is present in I -A molecules. Accordingly, the optimum 
pH at which I -Ad binds antigen- derived ligands is higher than that for 1 -E molecules, 
typically between pH 5.5 -6.5 (Jensen, 1991; Sette et al., 1992b). Similarly, the binding 
of CLIP to I -Ad was not found to be altered dramatically between pH 5.5 and pH 7.0, 
yielding dissociation constants, Kd, of 2.7 µM and 4.3 ltM, respectively (Bangia & 
Watts, 1995). This finding is consistent with the ability to examine the binding of 
different CLIP analogues to I -Ad molecules in both antigen presentation and cell -surface 
binding assays at neutral pH in Chapters 3 & 4 of this study. Nevertheless, pH- 
dependent hydrogen bonds may form to some extent between I -Ak aß dimers and their 
peptide ligands. For example, these molecules have been reported to make such 
interactions optimally at more acidic conditions than I -Ad, even so low as pH 4.5 for the 
HEL46 -61 peptide (Harding et al., 1991; Jensen, 1992; Sette et al., 1992b; Mouritsen et 
al., 1992). Moreover, some features of the P6 pocket in the I -Ak crystal structure are 
reminiscent of the hydrogen- bonding network at the equivalent site in I -Ek, including a 
strong preference for a glutamic acid or glutamine at the corresponding position within 
bound peptide ligands (Fremont et al., 1996, 1998ó). 
The ability of high proton concentration to enhance the binding of peptides to some class 
II MHC molecules initially led some researchers to propose that the heterodimer may gain 
greater conformational flexibility under these conditions, possibly even opening up the 
structure of the binding groove (Jensen, 1992; Lee et al., 1992). In consideration of the 
molecular mechanism now believed responsible for these effects (Fremont et al., 1996; 
Wilson, 1996), it is more likely that any conformational changes within the aß dimer 
induced by low pH are very subtle. Consistent with this notion, two -dimensional nuclear 
magnetic resonance spectra (2D -NMR) of peptide -bound I -Ek molecules have not revealed 
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any changes in the conformation of the bound peptide as a function of proton 
concentration, from which it may be inferred that architecture of the binding cleft also 
does not change (Driscoll et al., 1993). Similarly, far -UV CD measurements have 
indicated that low pH does not cause any gross alterations with respect to neutral pH in 
the secondary structure of the class II MHC molecule (Boniface et al., 1996). Instead, by 
probing the structure of mouse aß dimers at low pH with the fluorescent dye, ANS (8- 
anilino-1- naphthalene -sulphonic acid), it has been revealed that these molecules assume a 
molten globule state associated with increased exposure of internal hydrophobic regions 
within the pH range where peptide binding is enhanced (Boniface et al., 1996; Runnels et 
al., 1996). Furthermore, near -UV CD spectra show that protonation appears to perturb 
the tertiary and/or quaternary interdomain contacts within these molecules to lead to 
localised unfolding (Boniface et al., 1996). The occurrence of such changes distal to the 
peptide- binding groove would explain the inability of these effects to be detected in the 
earlier NMR analysis by Driscoll et al. (1993), since that investigation focussed 
predominantly upon the a- carbon atoms of the bound peptide that are effectively some 
distance away. Lastly, it is interesting to note from the binding pattern of the ANS dye 
that these pH- induced structural changes occur in I -Ed, I -Ek and I -Ak at lower pH than for 
I -Ad (Runnels et al., 1996), consistent with the hypothesis that peptide binding to I -Ak 
may also be facilitated at low pH. 
The actual manner in which the pH- induced structural transitions contribute to enhanced 
peptide binding in different class H MHC molecules is not clear. Significantly, these 
changes take place regardless of whether the binding groove is occupied by a high- affinity 
peptide ligand or not (Boniface et aL, 1996; Runnels et al., 1996). Runnels et al. (1996) 
have proposed that some of the hydrogen bonds between peptide main -chain atoms and 
the residues of the MHC groove may be disrupted at high proton concentration so that 
only peptides with an adequate source of positive binding energy through side -chain 
contacts may remain bound. This would serve to increase the pool of class H MHC 
molecules available for binding peptides. Low pH has indeed been shown to enhance the 
dissociation of sub -optimally bound peptides (Reay et al., 1992; Sette et al., 1992b). In 
addition, HLA -DM and HLA -DR molecules show a similar unfolding of hydrophobic 
domains at low pH which would appear to enhance their intermolecular interactions 
( Ullrich et al., 1997). Under these conditions, the interaction with HLA -DM is proposed 
to facilitate peptide loading by stabilising this conformation of HLA -DR. It would be 
envisaged that a similar situation exists between H -2M and mouse I -E molecules. 
The hydrogen bonding interactions in and around the P6 pocket of the I -E peptide- binding 
groove may serve to explain the general observation that low pH enhances the binding of 
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peptides to these molecules, however some questions still remain to be answered 
regarding the binding of CLIP to these molecules. For example, these interactions do not 
account fully for the inability to detect CLIP I -E associations at neutral pH- Antigen - 
derived peptides with similar pH binding optima to that of CLIP still associate with I -E 
molecules at neutral pH, just less efficiently (Wettstein et al., 1991; Reay et al., 1992; 
Sette et al., 1992b). Secondly, the pH- dependent hydrogen bond scheme does not 
provide adequate explanation for the inability to detect naturally- processed CLIP ligands 
bound to purified I-E heterodimers (discussed previously, §5.1; Rudensky et al., 1991). 
This phenomenon presumably reflects the dissociation of CLIP from these molecules 
during isolation of the class II MHC proteins, a procedure which typically involves 
solubilising the membranes from cell lysates at pH 7.0, followed by affinity 
chromatography and elution at pH 11.5 (For a description of the methodology used to 
purify class II MHC molecules, see Chapter 2, §2.6). In this sense, it is interesting to 
consider why mouse CLIP is neither capable of forming nor sustaining a complex with I- 
E at neutral pH, when human CLIP would appear able to do both with HLA -DR 
molecules, despite the possible presence of an analogous pH- dependent hydrogen - 
bonding scheme (Chicz et al., 1992, 1993; Riberdy et al., 1992; Sette et al., 1992a, 1995; 
Fremont et al., 1996). 
The inability of I -E molecules complexed with CLIP to withstand the conditions of neutral 
pH is particularly unusual given that the P6 hydrogen bond array in the I -E aß dimer is 
usually protected well from forces that may disrupt it. For example, it may be envisaged 
that this network would be threatened by the deprotonation of the all and a66 carboxylic 
acids within this pocket or the entry of solvent into this site to provide alternative 
hydrogen bonding atoms, however neither of these effects appear to occur. In a general 
sense, Jensen (1992) has proposed previously that most peptide class H MHC complexes 
may remain stable at neutral pH on the cell surface as a result of alterations in the pK, 
values of the protonated groups or if the accessibility of these groups to solvent is 
reduced. Indeed, within the P6 pocket of I -E class II MHC molecules, both of these 
mechanisms would appear to operate (Fremont et al., 1996). Firstly, the P6 side chain of 
antigen -derived peptides that bind within the acidic environment of the endosomes in vivo 
is likely to shield the protonated carboxylate groups from the solvent. Secondly, the 
surrounding protein environment and specific interactions with neighbouring residues 
would appear to increase the pK values of the aGlu 11 and aAsp 66 carboxylate side 
chains relative to the model value of these groups when free in solution (typically 4.07 
and 3.90 at 25 °C, respectively; Dawson et al., 1986). 
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In seeking an explanation for the inability of CLIP to sustain an association with I -E 
molecules at neutral pH, one may speculate that the rigid form of the Pro 96 residue at P6 
in this sequence may not be effective in preventing solvent entry into this pocket when 
this complex reaches the cell surface. However, it must be noted that CLIP does not 
dissociate from HLA -DR molecules at the cell surface where Pro 96 is oriented just as 
unfavourably in this pocket (Ghosh et al., 1995). Indeed, homology modelling of the 
CLIP- HLA -DR3 interaction has revealed that a hydrogen bond normally found between 
the amide group of the P6 peptide residue and the conserved csAsn 62 cannot form when 
proline is accommodated within this site (Lee & McConnell, 1995). In this respect, it is 
possible that these differences between CLIP binding to I -E and HLA -DR variants may 
reflect that other side -chain interactions with these latter molecules provide more positive 
binding energy. In support of this, the replacement of the Pro 96 residue in the CLIP 
sequence with a polar side chain in the form of lysine (P96K) in this study did lead to 
stabilisation of CLIP -I -Ek complex at neutral pH in a cell -surface binding assay (Figure 
5.10). It is likely that the incorporation of this electropositive component into the P6 
pocket would fulfil favourable electrostatic contacts at pH 7.0 when the acidic residues 
aGlu 11 and aAsp 66 are negatively charged (Table 5.4). 
The effect of replacing the P9 residue Met 99 with lysine has also been examined in this 
study. This substitution created a CLIP ligand that was able to bind to I -Ek molecules 
under the conditions of a cell -surface binding assay, in fact even more so than P96K 
CLIP (Figure 5.10). This is presumably due to this residue also fulfilling the particular 
side -chain preferences of the I -Ek molecules, this time for a basic side chain at the P9 
position (Table 5.4; Sette et al., 1989a, 1989c; Marrack et al., 1993; Schild et al., 1995). 
In this respect, it is interesting to note that Boniface et al. (1993) have noted previously 
the importance of positively -charged residues in natural ligands of I -E molecules and 
identified a crucial need for such a residue to maintain peptide binding at neutral pH. For 
example, substitution by L- alanine of the P9 residue of the moth cytochrome c peptide, 
mCytc88 -103, Lys 103, increased its dissociation rate at pH 7.0 at least 30 fold. 
Nevertheless, the substitution of both native residues, Pro 96 and Met 99, by lysine in 
CLIP did not lead to an additive improvement of binding. It is possible that co- 
substitution introduces conformational constraints into the peptide such that it is unable to 
fulfil both molecular bonding requirements at the one time. 
In summary, the ability of a given peptide to bind to I -E class II MHC molecules at 
neutral pH or, similarly, to sustain complex formation under these conditions appears to 
hinge upon the maintenance of a pH- dependent hydrogen bond network additional to the 
usual array of these bonds within a peptide -class II MHC complex and/or upon the 
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presence of suitable anchor residues which provide additional stabilising interactions. At 
the P6 position, this means either the presence of a polar residue to contribute further to 
the hydrogen bonding scheme or fulfil electrostatic contacts or, alternatively, a residue of 
suitable fit to obstruct the entry of solvent into this pocket (Fremont et al., 1996). In 
consideration of CLIP binding to I -E molecules, the Pro 96 residue is inadequate in all 
these respects. The maintenance of the I -E complex with a P6- deficient peptide then 
depends upon there being a sufficient amount of positive binding energy provided 
through other contact points, such as the critical P9 anchor position ( Boniface et al., 
1993). Again, the CLIP sequence does not fulfil the preference for a basic residue at this 
position. Moreover, the CLIP sequence exhibits only one conventional anchor at the P1 
position and, instead, appears to stabilise the interaction through anchor residues at the 
atypical positions, P5, P8 and P12. Collectively, these deficiencies in the CLIP sequence 
with regards to the I -E peptide -binding motif contribute to the incapacity of this ligand to 
maintain an effective interaction with these molecules at neutral pH. By comparison, 
CLIP binds to FILA -DR molecules using a sufficient number of strong anchor side chain 
contacts via some or all of the residues, Met 91, Met 93 and Met 99 (Geluk et al., 1995; 
Ghosh et al., 1995; Malcherek et al., 1995), such that these complexes are able to persist 
at neutral pH, even if the hydrogen bonding scheme is weakened by the loss of the 
carboxylic acid protons. 
5.4.5 A self -release mechanism for CLIP binding to I -E molecules? 
As discussed in Chapter 4, Kropshofer et al. (1995a, 1995b) have proposed that the 
human CLIP sequence possesses features that enable it to facilitate its own release from 
HLA -DR molecules at low pH independently of the actions of HLA -DM. In this study, 
the binding of truncated CLIP ligands and CLIP81 -104 analogues with single L- alanine 
substitutions within residues, 81 -87, to purified I -Ed molecules has been assessed in 
competitive immunoassays at pH 5.0 in an effort to determine whether this activity may 
also be a feature of this ligand binding to I -E aß dimers (Tables 5.1, 5.2 & 5.3, Figure 
5.9). Although experiments with truncated ligands were not informative, those 
experiments with the L- alanine- substituted CLIP showed consistently that the replacement 
of either of the phylogenetically -conserved N- terminal residues, Lys 83 and Pro 87, 
caused a decrease in the ability of these peptides to bind at pH 5.0. The presence of these 
residues within the CLIP sequence would thus appears to provide a favourable 
contribution to the binding interaction with I -E° under these conditions, whereas the 
substitution of other residues within the N- terminal region of CLIP had little or no effect 
on the ability of this ligand to bind to I -E°. 
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In a general context, the findings presented herein with the K83A and P87A peptides and 
I -Ed (Figure 5.9) conflict with the observations of Kropshofer et al. (1995a, 1995b) who 
found that these same N- terminal residues within the wild -type human CLIP sequence 
contribute to the enhanced dissociation of this ligand from HLA -DR2 and DR3 molecules. 
However, as with the corresponding experiments with I -A molecules described in 
Chapter 4 ( 0.4.4), the experiments performed here with I -Ed are difficult to interpret 
with regard to the CLIP self -release mechanism proposed by Kropshofer et al. (1995a, 
1995b). For example, the results presented in this study reflect the thermodynamic 
stability of the complex, whereas those of Kropshofer et al. (1995a, 1995b) indicate the 
kinetic properties of the interaction. 
Despite the ambiguous results obtained in this study (Figure 5.9), some intriguing results 
reported elsewhere do support the notion that certain residues within the N- terminus of 
CLIP may promote the release of itself or other ligands from I -E heterodimers. Firstly, 
Brooks et al. (1994) have shown that T -Ek heterodimers transfected into the deletion 
mutant human cell line, T2, are able to form SDS- stable dimers, i.e. consistent with 
human CLIP being able to dissociate from I -E heterodimers independently of the catalytic 
actions of HLA -DM. Secondly, Adams & Humphreys (1995) have shown that the 
presence of mouse CLIP77 -92 in antigen -presentation assays (termed 'Ii -4' by these 
investigators) is able to enhance the T cell response to I -Ed- and I -Ek -bound peptides by 
promoting the exchange of peptides at the cell surface. 
5.5. Conclusions 
The experiments described in this chapter sought to examine the binding of CLIP to 
mouse class II MHC molecules of the I -E isotype. In many respects, this interaction has 
been found to be similar to the manner in which CLIP forms an association with I -A 
molecules, as determined in Chapters 3 & 4. For example, the binding of CLIP to the I -E 
ct3 dimer occurs through a sequence element of greater than 13- residues in length and 
which encompasses the phylogenetically- conserved residues, 91 -99. Furthermore, 
binding is supported by a network of hydrogen bonds that forms between the main -chain 
atoms of the CLIP backbone and conserved residues of the I -E peptide- binding groove. 
Unlike the binding of CLIP to I -A molecules, however, the interaction of this ligand with 
I -Ed has also been shown to involve the formation of a number of strong side -chain 
anchor contacts, e.g. Met 91, Thr 95, Leu 98 and Met 102. The substitution of any of 
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these residues by L- alanine eliminated the ability of the CLIP sequence to bind. 
Nevertheless, the presence of anchor contacts is unlikely to preclude degenerate binding 
of the CLIP ligand to different I -E allelic variants since only one of these interactions is 
expected to take place within a pocket of the polymorphic peptide -binding groove, that of 
Met 91 at PI, and residues lining this pocket are relatively conserved. The remaining 
anchoring side chains are predicted to contact the I -E a(3 dimer elsewhere on the molecule 
where the sequence is also highly conserved. In this respect, promiscuous binding to 
molecules of the I -E isotype is likely to be facilitated by virtue of the minimal 
polymorphism in the I- Ea- chain. 
A further difference between the interaction of CLIP with I -E molecules and those of the 
I -A isotype is that this ligand was found to be unable to bind to I -Ek and I -Ed at neutral pH 
but binding did occur at pH 5.0. Antigen- derived ligands have been reported to show a 
higher affinity for I -E molecules at lower pH as a result of such conditions facilitating the 
formation of a number of pH- dependent hydrogen bonds in the environment surrounding 
the P6 pocket within the groove (Fremont et al., 1996). A stable association between the 
CLIP ligand and I -Ek was able to be induced at pH 7.0 however, through the provision of 
an alternative source of positive binding energy in the form of an electrostatically - 
favourable residue at the P6 and/or P9 position of the peptide sequence. 
Thus, in Chapters 3 -5, the manner in which CLIP interacts with different mouse I -A and 
I -E class II MHC molecules has been elucidated successfully through an assessment of 
the binding of a range of different substituted and/or length- altered analogues. Moreover, 
it has been demonstrated in this chapter that it is possible to modify the CLIP sequence to 
produce a predictable result using both information on the sequence features of natural 
ligands, together with details of the spatial arrangement of atoms within the class II MHC 
peptide -binding groove. Together, these findings serve to illustrate the ability to employ 
the promiscuous CLIP ligand to probe the peptide -binding properties of a number of 
different class II MEC variants. In Chapter 6, this utility is applied to examine peptide 
interactions with the atypical class II MEC molecule, I -As', from non -obese diabetic 
(NOD) mice. 
CHAPTER 6. 
The interaction of CLIP with I -Ag7, an atypical class II MHC 
molecule from non -obese diabetic (NOD) mice 
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6.1. Introduction 
6.1. L Insulin- dependent diabetes mellitus (IDDM) - an organ- specific 
autoimmune disease 
T cell -mediated immune responses represent a critical component of the vertebrate 
adaptive immune system and serve to protect the host from potentially life -threatening 
infections. However, if a T lymphocyte with the propensity to recognise determinants 
derived from self -proteins escapes the mechanisms that instil immunological tolerance, 
this process may result in a disease state itself in which the host tissues become the target 
of immune attack. 
One such autoimmune disease in humans is type I or 'insulin-dependent' diabetes mellitus 
(IDDM). The development of this condition is preceded by a massive infiltration of 
lymphocytes into the pancreatic islets of Langerhans, a clinically- silent state referred to as 
insulitis. The actual metabolic disorder that is IDDM arises as the end -stage result of 
these immune cells mediating the selective destruction of the insulin -producing 13 cells 
within the islets. This causes endogenous insulin levels to fall until they are insufficient 
to maintain glucose homeostasis and affected individuals develop acute hyperglycaemia, a 
predicament characterised by the accumulation of excessive levels of glucose in the blood 
stream while the surrounding tissues are starved of an energy source (For a review of 
IDDM, see Castaño & Eisenbarth, 1990). 
As with many other autoimmune diseases, a primary risk factor for susceptibility to 
IDDM is the inheritance of certain MIIC alleles (for reviews on this subject, see Nepom & 
Erlich, 1991; Campbell & Milner, 1993; Thorsby, 1995; Pugliese & Eisenbarth, 1996). 
Early investigations revealed a strong risk association between IDDM and the 
serologically -defined HLA -DR3 and DR4 molecules. Among Caucasian individuals 
affected by IDDM, 95% express either HLA -DR3 and/or DR4, compared with an 
occurrence of just 40 -50% in unaffected subjects (Wolf et al., 1983). More recently, the 
development of molecular biology techniques has permitted more precise identification of 
HLA genetic variants on the short arm of chromosome 6 and has provided an appreciation 
of those alleles likely to be inherited together through linkage disequilibrium. From these 
studies, investigators have now refined the primary genetic association of IDDM in 
Caucasian populations to be at the HLA -DQ locus, which is closely linked to the HLA- 
DR3 and DR4 haplotypes. The alleles associated with the highest risk are DQB1 *0302 
and DQB1 *0201, expressed in the form of the class 11 MHC heterodimers, HLA -DQ8 
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(also known as HLA- DQ3.2; DQA1 *0301/DQB 1 *0302) and HLA -DQ2 
(DQA1 *0501/DQB1 *0201), respectively (Thorsby & Ronningen, 1993). For example, 
the probability of acquiring IDDM before 15 years of age in Norway is 0.3% (Joner & 
SOvik, 1989). Of Norwegian IDDM- affected individuals, 81% express HLA -DQ8 
molecules, while these are present in only 23% of control subjects (Thorsby, 1995). 
However the combination of both molecules appears to confer the highest risk: 4% of 
Norwegian individuals are born DQ2/DQ8 heterozygous, 12% of which will sooner or 
later develop IDDM (Rt nningen, 1997). The closely -linked loci that encode the 
polypeptide chains of the HLA -DR heterodimer are not without influence and several 
alleles of the DRBI *04 type have been identified that accentuate the primary risk of 
developing IDDM when expressed in association with HLA -DQ8, e.g. DRB1 *0405 
(Nepom, 1990; Cucca et al., 1995; Undlien et al., 1997). 
The disproportionate over -representation of HLA -DQ8 and DQ2 among IDDM patients, 
as opposed to control subjects, serves to illustrate the importance of these molecules in 
acquiring this condition. However, given the incomplete penetrance of this condition, 
even in individuals expressing both of these particular HLA variants, there are clearly 
more factors involved. Firstly, there would appear to be a contribution to the disease 
susceptibility from genetic factors outside of the MHC. This is illustrated by a higher 
concordance of IDDM development in monozygotic twins (35 -50 %) than HLA- identical 
siblings (15 -25 %; Thorsby & Rtónningen, 1993). Indeed, alleles within the HLA 
complex had been estimated previously to provide only 60 -70% of the genetic 
susceptibility to this condition (Rotter & Landaw, 1984). Another candidate genetic locus 
that has been examined extensively for its affect on diabetes susceptibility is that encoding 
the insulin precursor polypeptide, preproinsulin (e.g. Bell et al., 1984; Julicr et al., 1991; 
Lucassen et al., 1993; van der Auwera et al., 1993). Secondly, given that the 
concordance estimates for IDDM in monozygotic twins are not 100 %, there must be a 
strong influence of non -genetic factors in the development of this condition, such as 
environmental antigenic challenge or geographical location (e.g. Ginsberg -Fellner et al., 
1984; Bodansky et al., 1986; Helmke et al., 1986). It is interesting to note that factors 
also exist that protect an individual against IDDM. For example, individuals that express 
HLA -DQ6 (DQA1 *0102/DQB1 *0602) develop IDDM rarely, even in the presence of 
DQ8 or DQ2 (Thorsby & Ronningen, 1993). Similarly, the expression of either of the 
alleles, DRBI *0406 or DRB1 *0403, reduces the risk conferred by the DQ8 molecule 
(Cotta et al., 1995; Undlien et al., 1997). 
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6.1.2 The non -obese diabetic (NOD) mouse - an animal model of IDDM 
At present, many of the determinants, both inherited and non -genetic, that contribute to 
susceptibility or resistance to IDDM remain unknown. This makes it extremely difficult 
to design strategies to treat or, better, to prevent this multifactorial disease. In order to 
unravel further the aetiology of IDDM, researchers have made extensive use of a number 
of animal models. These provide a means by which genetic and environmental 
backgrounds may be manipulated to examine their effect upon the development and 
progression of autoimmune diabetes. 
The most widely studied of the animal models of IDDM is the non -obese diabetic (NOD) 
mouse. This strain originates from a female mouse that exhibited polyuria (the passage of 
excessive amounts of urine) and severe glycosuria (the presence of glucose in the urine) 
accompanied by rapid weight loss, which arose spontaneously during selective inbreeding 
of outbred Imperial Cancer Research (ICR) mice to derive a cataract -prone strain (CTS; 
Makino et al., 1980). What makes the NOD mouse such an excellent tool with which to 
study autoimmune diabetes is the significant number of features of the diabetic disease 
state that these animals share with human IDDM -affected individuals. Firstly, these two 
diabetic conditions appear to have a very similar pathology in that, like susceptible 
humans, NOD mice become diabetic spontaneously following pancreatic autoimmunity, 
specifically the destruction of the insulin -producing [3 cells in the islets of Langerhans 
(Fujita et al., 1982). 
Secondly, experiments with MHC congenie mouse strains have shown that the NOD 
MHC region is critical to the development of diabetes in these animals (Prochazka et al., 
1989; Wicker et al., 1992). Indeed, this appears to represent the strongest genetic 
association for disease susceptibility in these mice (discussed subsequently, §6.1.4). 
However, on their own, the genes encoded within the complete NOD MHC are still not 
sufficient to cause diabetes (Hattori et al., 1986; Wicker et al., 1989). Instead, like the 
human autoimmune diabetic condition, the development of this disease in the NOD mouse 
is under complex polygenic control (reviewed by Kikutani & Makino, 1992; Baxter & 
Cooke, 1995; Wicker et al., 1995). Work is currently under way to identify the gene 
products of a number of the candidate loci which have been localised by linkage analysis 
with an apparent influence on diabetes penetrance (reviewed by Baxter & Cooke, 1995; 
Wicker et al., 1995). 
Also in common with the human IDDM condition, the incidence of disease in NOD mice 
appears to be modulated by environmental factors. To date, evidence exists from colonies 
CLIP binding to I -A87 172 
of these animals around the world to indicate that both diet and exposure to 
microorganisms alter the endogenous immunoregulation functions within these mice that 
affect disease development (Elliott et al., 1988; . Oldstone, 1988; Coleman et al., 1990; 
Leiter et al., 1990; Wilberz et al., 1991). For example, compared with the incidence of 
disease in clean, pathogen -free NOD colonies, the number of animals contracting this 
disease is much lower in colonies maintained under conditions where the animals are at 
risk of microbial contamination (Pozzilli et al., 1993). 
It is also of interest to note that, although all NOD mice develop insulitis, the penetrance 
of the actual diabetic disease state is quite different between female and male mice: a 
cumulative incidence by 30 weeks of 70 -90% in females and 20-40% in males ( Makino 
et al., 1980). Given that castrated males show a higher incidence of diabetes than normal 
males, while ovariectomised females show a disease incidence more aligned with normal 
males (Makin et al., 1981), sex -related endocrine factors clearly have an influence upon 
the development of this disease in NOD mice. In this respect, an examination of the 
epidemiological figures of human IDDM incidence does not show a similar gender bias, 
however a higher incidence of disease or greater severity of symptoms in female 
individuals is observed commonly with other human autoimmune diseases, e.g. multiple 
sclerosis (MS), myasthenia gravis and systemic lupus erythematosus (SLE; Beeson, 
1994). 
6. 1.3 The mechanisms underlying the development of diabetes in NOD 
mice 
An overwhelming amount of experimental data exists regarding the development of 
autoimmunity and the diabetic condition in NOD mice (e.g. see the collection of reviews 
compiled by Eisenbarth & Lafferty, 1996 and Bach & Mathis, 1997). As with human 
IDDM, lymphocytic infiltration into the pancreatic islets of NOD mice occurs some time 
before the observation of overt diabetes. Peri- insulitis in NOD (the presence of 
lymphocyte infiltrate around the islet in the region containing the pancreatic ducts and 
blood vessels) may be observed histologically around the time of weaning at 4-5 weeks 
of age (Fujita et al., 1982). At 6 -8 weeks, the islet tissue itself begins to be invaded, 
leading to the specific destruction of the 13 cells. Hyperglycaemia is eventually detected in 
these mice 12 -15 weeks after birth and, ultimately, by 30 weeks of age 70-90% of 
female mice and 20-40% of males exhibit the symptoms of overt diabetes (Makino et al., 
1980). An examination of these facts has led some researchers to propose that the disease 
progression in NOD mice is regulated at two distinct "checkpoints ": the first at 3 -5 
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weeks, which involves the initial non -destructive infiltration of lymphocytes into the 
islets; the second is the later acute change whereupon the ß cells are targeted specifically 
for destruction, culminating in the diabetic disease state (André et al., 1996). The two 
phases apparent during the course of this disease have also been described as benign and 
malignant islet- associated autoimmunity, respectively (Gazda et al., 1997; Dilts & 
Lafferty, 1999). 
The elucidation of the factors involved in initiating pancreatic autoimmunity in NOD mice 
(the initiator phase) and those responsible for the actual destruction of the ß cells (the 
effector phase) has been very difficult. Complicating the situation is the number of 
different types of inflammatory cells found in the lesions within the pancreatic islets of the 
diabetic animals, including T cells of both CD4` and CD8' lineages, macrophages, 
dendritic cells and B cells (Kanazawa et al., 1984; Miyazaki et al., 1985; Signore et al., 
1989; Jansen et al., 1994). 
Regarding firstly the B cells, autoantibodies against islet -cell components are indeed 
found in the sera of both human individuals predisposed to IDDM and pre- diabetic NOD 
mice (Reddy et al., 1988; Zimmet et al., 1994; Gianani & Eisenbarth, 1996) - another 
feature shared between the human and mouse diabetic condition. Analysis of these 
antibody responses reveals that they are directed frequently against insulin (Palmer et al., 
1983; Michel et al., 1989) and the two isoforms of glutamic acid decarboxylase (GAD65 
and GAD67), an enzyme which catalyses the synthesis of the inhibitory neurotransmitter 
y- aminobutyric acid in neurons and islets cells (GABA; Baekkeskov et al., 1990). 
However, although at least the GAD- specific humoral reactivity is reported to coincide 
with the onset of insulitis in NOD mice (Tisch et al., 1993), neither the initiation of anti - 
islet autoimmunity nor 13-cell destruction appear to be antibody- mediated. Indeed, there is 
little evidence to show that these antibodies themselves are pathogenic (Gianani & 
Eisenbarth, 1996). Furthermore, NOD mice lacking B cells which still develop both 
insulitis and diabetes have been reported (Yang et al., 1997), although this is not always 
the case ( Serreze et al., 1996; Akashi et al., 1997; Noorchashm et al., 1997; Wong et al., 
1998). Instead, the significance of the B cells within the islet lesions may be as a source 
of antigen -presenting cells (APC) during the disease process ( Noorchashm et al., 1997, 
1999; Falcone et al., 1998; King et al., 1998; Serreze et al., 1998; Wong et al., 1998), 
with the true initiator and effector cells of autoimmune diabetes being T lymphocytes. 
This has been demonstrated by the ability to induce disease in neonatal or sublethally- 
irradiated NOD mice by the transfer of splenic T cells from diabetic animals (Wicker et 
al., 1986; Bendelac et al., 1987). Moreover, neonatal thymectomy reduces the incidence 
of insulitis and diabetes in NOD mice significantly (Ogawa et al., 1985; Makino et al., 
CLIP binding to I -A87 174 
1986). Further experimental work has revealed that CD4' and CD8' T lymphocyte 
subsets are both important to the diabetes disease process but to different extents at 
distinct stages in its progression (reviewed by Kikutani & Makino, 1992; Wegmann, 
1996; Kay et al., 1997; Verdaguer et al., 1997, Wong & Janeway, 1997). 
The following is a simple summary of the current thoughts on how the diabetic disease 
state is believed to arise and the ways in which participant cell types could be involved. 
Macrophages and dendritic cells (DC) are the earliest cell types to infiltrate the islets at the 
initiation of the autoimmune process (Jansen et al., 1994). Within this site, these cells 
have been shown to produce the pro -inflammatory cytokine, tumour necrosis factor -a 
(TNF -a; Dahlén et al., 1998). Next, the f3 cells appear to suffer damage, such that an 
abundance of soluble islet -cell autoantigens is released into the surrounding environment. 
This may occur directly through the actions of TNF -a, in combination with other 
cytokines, such as interleukin -1 (IL -1; Baquerizo & Rabinovitch, 1990; Rabinovitch et 
al., 1990; Delaney et al., 1997). Alternatively, T Iymphocyte populations may be 
recruited to the islets and CD8' T lymphocytes may inflict acute cytotoxic damage upon 
the 13 cells, for example, via 13 -cell class I MHC molecules (Jarpe et al., 1990; Calcinaro 
et al., 1996; Zechel et al., 1997). Self- antigens released from the damaged 13 cells are 
then taken up by APC and presented on their cell surface in association with class II MHC 
molecules Limited presentation of these peptides by intraislet APC may also occur 
without the need for acute lymphocyte-mediated (3-cell injury (Shimizu et al., 1995). The 
APC responsible for presenting (3-cell antigens are most likely macrophages, dendritic 
cells and/or B lymphocytes, since the 13 cells themselves do not express class II MHC 
molecules, although they may be induced to do so by particular cytokines (Wright et al., 
1986; Pujol- Borrell et al., 1987). Presentation of these antigens is also expected to occur 
in the draining lymph nodes by migrating APC. In the next critical step, CD4' T cells 
with anti-13 cell antigen specificities which have escaped the immunological mechanisms 
for maintaining peripheral tolerance recognise the self -peptides presented by the APC and 
become activated. The pathogenic CD4' T lymphocytes are specifically of the T helper 1 
(Thl) subset (Rabinovitch, 1994; Katz et al., 1995; Liblau et al., 1995; Pilström et al., 
1995), which means that upon their activation, they release further pro -inflammatory 
cytokines, e.g. interferon -y (IFN -y). Cytokines of this type are able to provide help to 
cytotoxic CD8' T cells to induce clonal expansion and to facilitate macrophage activation, 
thereby bringing about a considerable expansion of the inflammatory processes. 
Moreover, the ensuing attack upon the ß ceIIs leads to a further increase in the local 
availability of soluble self -proteins to increase the extent of antigen presentation and T cell 
recognition. Together, these events have the ultimate result that somewhere amongst this 
immunological frenzy, the pancreatic 13 cells are destroyed. 
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From studies with NOD mice, it has therefore become apparent that the destruction of the 
13 cells occurs as the end result of an inappropriately- directed inflammatory response. 
Intriguingly, while Th1 cytokines appear to be involved in the progression of the 
autoimmune process, the administration or induction of cytokines of the opposing Th2 
profile (e.g. interleukin 4 (IL -4), IL -5, IL -6, IL -10 and IL -13) appears to diminish the 
intensity of the disease (Rabinovitch, 1994; Liblau et al., 1995; Cohen, 1997b; Elias et 
al., 1997). This is consistent with Th2 cytokines being important anti -inflammatory 
agents, with their primary activities lying instead in the promotion of antibody secretion 
by B cells (for reviews on the Thl/ Th2 paradigm of CD4' T lymphocyte cytokine 
production, see Paul & Seder, 1994; Abbas et al., 1996; Romagnani, 1997). 
Consequently, in very simple terms, it seems likely that the pathogenesis of autoimmune 
diabetes may be determined ultimately by the overall balance between the response of the 
Thl /Th2 subsets of CD4' T lymphocytes. 
The exact effector mechanism(s) by which the 13 cells are destroyed is still unknown, as is 
the manner by which the other islet cells, such as the glucagon- producing a cells, escape 
destruction. However, for both of these interrelated events there is no shortage of 
potential mediators (reviewed by Benoist & Mathis, 1997). For example, CD8' T cells 
have been shown to be capable of lysing 13 cells directly in vitro by a perforin- dependent 
mechanism (Kagi et al., 1996; Utsugi et al., 1996), but it remains unclear as to the exact 
extent to which this occurs in vivo. Macrophages in the islets are also candidates for 
being the final effectors of I3-cell killing (Schwizer et al., 1984), as are both CD8' and/or 
CD4' T lymphocytes by inducing apoptosis through Fas/ Fas ligand interactions (Kurrer 
et al., 1997). Indeed, Th1 CD4' cells typically express higher levels of Fas ligand (FasL) 
than those of the Th2 type (Ramsdell et al., 1994) and inflammatory mediators of the kind 
present during insulitis have been shown to induce the expression of Fas on (3 cells 
(Chervonsky et al., 1997; Stassi et al., 1997). Furthermore, the pancreatic a cells also 
constitutively express Fas ligand and could contribute themselves to the death of the 
neighbouring 13 cells (Signore et al., 1997; for a further discussion of the potential role of 
Fas -FasL interactions in the destruction of islet ß cells, see De Maria & Testi, 1998). 
Meanwhile, as mentioned above, various soluble factors, such as cytokines and free 
radical species, have also been shown to induce [3-cell death in a non -specific manner 
(Bendtzen et al., 1986; Nerup et al., 1988; Pukel et al., 1988; Baquerizo & Rabinovitch, 
1990; Mandrup -Poulsen et al., 1990; Rabinovitch et al., 1990; Delaney et al., 1997). In 
this respect, (3 cells have been reported to be particularly sensitive to damage by oxygen 
free radicals as a result of their high metabolic rate and the relatively low activity of certain 
scavenging enzymatic systems within these cells, e.g, mitochondria) manganese 
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superoxide dismutase (MnSOD) and glutathione peroxidase (Malaisse et al., 1982; 
Asayama et al., 1986). 
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Also unknown is the identity of the critical diabetogenic determinant towards which T cell 
tolerance is broken which results in the onset of pancreatic autoimmunity. The discovery 
of such a molecule would provide an important target for preventive therapies of IDDM, 
however significant efforts to uncover it have been complicated by the diversity of T cell 
autoreactivities found within the islet infiltrates of mouse and human diabetic subjects 
(reviewed by Roep, 1996). In both NOD mice and human 1DDM patients, for example, 
spontaneous T cell responses may be detected against insulin (Naquet et al., 1988; 
Wegmann et al., 1994) and the 65 kDa GAD isoform, GAD65 (Atkinson et al., 1992; 
Kaufman et al., 1993; Tisch et al., 1993). T cell reactivity is also observed in NOD mice 
against both the mouse and human 60 kDa heat shock protein (hsp60) and the derivative 
peptide, p277 (residues 437 -460), antigens which also cross -react with a 65 kDa 
mycobacterial heat shock protein (Elias et al., 1990, 1991). T cell clones reactive to all of 
these autoantigens have been derived from the islets of diabetic mice and were shown to 
secrete Th 1 cytokines (IFN -y and/or TNF -a) and be pathogenic in healthy mouse 
recipients (Elias et al., 1991; Daniel et al., 1995; Wegmann, 1996; Zekzer et al., 1998). 
For some time, such variety in the autoreactive T cell responses in the islets of diabetic 
individuals has cast doubt on there being a single primary autoantigen responsible for 
triggering autoimmunity. However further experimentation has revealed that 
diversification of the immune response may arise simply as the disease progresses; a 
process known as "determinant spreading" (Steinman, 1995). For example, at 3-4 
weeks in NOD mice, concurrent with the onset of insulitis, spontaneous Thl responses 
have been found only to GAD of the panel of known autoantigens tested (Kaufman et al., 
1993; Tisch et al., 1993). In particular, these responses were directed at a limited region 
of the GAD protein, although some discrepancy exists over the exact peptide epitope 
(Kaufman et al., 1993; Zechel et al., 1997, 1998; Chao & McDevitt, 1997). At later time 
points, the specificity of this T cell autoreactivity was observed to expand intramolecularly 
to incorporate other determinants within the GAD protein (Kaufman et al., 1993) and, 
subsequently, the autoreactive T cell repertoire broadened even further, with responses 
being detected to epitopes on other 13 -cell antigens, including hsp65 and insulin (Kaufman 
et al., 1993; Tisch et al., 1993). In this respect, it is interesting to note that the Th 1 
cytokines that predominate at the site of autoimmune activity may themselves be 
responsible for inducing the diversification of the epitopes available for presentation - 
exogenous IFN -y has been shown to upregulate the expression of cathepsins B, H and L 
in mouse macrophages, the lysosomal cysteine proteinases critically involved in the 
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liberation of peptide determinants (Lafuse et al., 1995; Lah et al., 1995). This has been 
proposed to enhance the stringency of antigen processing to allow the release of 
previously cryptic epitopes and thereby promote the activation of further autoaggressive T 
cells of additional specificities (Zechel et al., 1998). 
Recently, support for GAD being the primary autoantigen to trigger the onset of 
pancreatic autoimmunity has been strengthened by the finding that NOD mice may be 
protected from diabetes by the expression of an antisense GAD gene in the islets, i.e. a 
nucleotide sequence that, when transcribed, complements the mRNA encoding this 
protein to prevent its translation (Yoon et al., 1999). Analysis of the immunological 
status of these animals has shown that they exhibit no anti -GAD T cell response, a 
marked reduction in spontaneous T cell responses to other autoantigens, such as hsp60 
and insulin, and T cells from these animals are unable to transfer disease to T cell - 
deficient NOD recipients. These results are compatible with earlier reports that neonatal 
or young NOD mice that receive an intrathymic injection of purified recombinant GAD65 
or a suspension of islet cells do not develop insulitis or diabetes, presumably through 
such treatments restoring T cell tolerance to 0-cell autoantigens (Tisch et al., 1993; 
GerIing et al., 1992; Charlton et al., 1994). Nevertheless, some aspects of antisense- 
GAD NOD mice remain to be assessed, for example, the effect of transplanting normal 
islets into these animals. Indeed, given that the exact role of GAD in the islets remains 
unknown, it may be that the downregulation of its expression within this site could 
simply interfere with the priming of T cells. Thus, the acceptance of GAD as the essential 
initiating autoantigen must await further experimentation. In this respect, it is interesting 
to note that the administration of several other known autoantigens, besides GAD, by a 
number of different routes has also been shown to modulate the severity of the disease 
symptoms in NOD mice (e.g. Zhang et al., 1991; Tisch et al., 1993; 1994; Elliott et al., 
1994; Petersen et al., 1994; Elias & Cohen, 1995; Birk et al., 1996; Tian et al., 1996; 
Bockova et al., 1997; Elias et al., 1997). Several lines of evidence exist to suggest that 
these self- antigen immunisations protect from disease by inducing a switch from an 
inflammatory Th1 -type response to the production of protective Th2 -type cytokines (Tian 
et al., 1996; Bergerot et al., 1997; Bockova et al., 1997; Cohen, 1997b; Elias et al., 
1997; Zechel et al., 1997). It is therefore possible that any significant immunological 
challenge in these mice may have the potential to halt the progression of the autoimmune 
cascade. This is compatible with the reduced incidence of diabetes observed in pathogen - 
exposed NOD colonies (Pozzilli et al., 1993). 
Further information on the autoantigens responsible for triggering 0-cell autoimmunity 
might be gained from an analysis of the particular TCR expressed by T lymphocytes 
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infiltrating the islets of NOD mice. For example, in the rodent model of multiple 
sclerosis, experimental autoimmune encephalomyelitis (EAE), very limited heterogeneity 
in TCR Va and V(3 gene usage is observed in the autoreactive T cells, consistent with this 
disease being triggered by the administration of a single antigen, myelin basic protein 
(MBP; Acha -Orbea et al., 1988; Zamvil et al., 1988). However, a similar analysis of 
TCR usage of islet -infiltrating T lymphocytes in 4-5 week old NOD mice reveals a 
heterogeneous array of TCR gene products (Candéias et al., 1991; Maeda et al., 1991; 
Nakano et al., 1991). Instead, researchers have had to examine the TCR expression of 
islet -infiltrating T cells of much younger mice to uncover signs of a monoclonal initiating 
event in the onset of autoimmune diabetes, i.e. T lymphocytes in the islets of 2 -week old 
NOD mice predominantly express a single V138 TCR gene product (Yang et al., 1996). 
This feature is obscured quickly following the induction of the immune response cascade, 
consistent with the determinant spreading observed over time in the spontaneous T cell 
responses to different autoantigens (Kaufman et al., 1993; Tisch et al., 1993). 
Unfortunately, however, any information regarding the target antigen recognised by these 
T lymphocytes still awaits the identification of the TCR a- chain(s) expressed by these 
cells. 
Despite considerable advances over the last fifteen years in our understanding of how 
autoimmune diabetes arises, it is clear that some important pieces of the puzzle are still 
missing. Further to those mentioned above, given that T cells with anti -self specificities 
are frequently found in disease -free individuals but show no pathogenic activity towards 
their target tissues (Schild et al., 1990; Agrawal et al., 1991; Oldstone et al., 1991; 
Guerder et al., 1994), the mechanism underlying the initial breakdown of peripheral 
tolerance is unknown. Moreover, it is not understood what triggers the transition from a 
benign lymphocytic lesion into an aggressive autoimmune assault on the ß cells. One 
theory put forward to explain these issues is that of molecular mimicry (reviewed by 
Baum et al., 1993). This concept proposes that anergised, self- reactive T ceIIs circulating 
in the periphery become re- activated following recognition of a high affinity, foreign 
peptide determinant which, by coincidence, shares sequence or structural homology with 
the autoantigen. With regards to IDDM, sequence homology does indeed exist between a 
GAD65 peptide, residues 255 -269, and a determinant from the P2 -C protein of the 
Coxsackie B4 virus (residues 32-47; Kaufman et al., 1992), an agent linked previously 
to the development of autoimmune diabetes (Yoon etal., 1979; D'Alessio, 1992). 
Furthermore, this same GAD peptide has been shown to elicit T cell responses in 
approximately 25% of newly- diagnosed IDDM patients tested and similar responses are 
also generated to the homologous viral determinant (Atkinson et al., 1994). 
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Nevertheless, more recent studies on the induction of IDDM by the Coxsackie virus now 
appear to support an alternative theory - that of the so- called bystander activation' of 
autoimmunity (Horwitz et al., 1998). This theory also includes a role for viruses in the 
development of autoimmune disease but an indirect one, whereby the localised 
inflammation brought about by a viral infection or superantigen activity creates a 
disruption of the normal immune processes leading to a breakdown in self tolerance 
(Benoist & Mathis, 1998; Schiffenbauer et al., 1998). Not mutually exclusive to this, a 
further theory proposes that a defect may occur in a critical immunoregulatory 
mechanism, such as the untimely death or anergy of a certain population of CD4' T cells 
vital to suppressing autoreactive effector T cells, or a change in their cytokine profile from 
Th2 to Thl (e.g. Zipris et al., 1991a; Kikutani & Makino, 1992; Shimada et al., 1996; 
Atkinson, 1997; Bergerot et al., 1997; Lafferty, 1997; Cameron et al., 1998; Salojin et 
al., 1998). Indeed, the existence of such a population of T cells that counterbalances 
autoreactive cells is suggested from experimental findings (Boitard et al., 1989; 
Hutchings & Cooke, 1990; Chosich & Harrison, 1993; Rashba et al., 1993; Singer et al., 
1993; Sempe et al., 1994). Alternatively, aberrant selection processes may occur within 
the thymus during thymocyte development to result in these immunoregulatory T cells 
existing in insufficient numbers or with inadequate specificities (Thomas -Vaslin et al., 
1997). 
6.1.4 Do class II MHC molecules play a central role in the development 
of autoimmune diabetes? 
An alternative way to examine the mechanisms by which T cell- mediated immunity 
triggers the onset of autoimmune diabetes is to investigate specifically how peptides are 
presented by the particular MHC molecules found within diabetes -stricken individuals, 
both human and mouse. This seems especially relevant given, firstly, the critical 
importance of MHC loci in providing susceptibility to this condition as discussed above, 
secondly, that MHC molecules play a critical role in the development of the T cell 
repertoire and, thirdly, that immune responses induced by T lymphocytes are ultimately 
the downstream result of the recognition of peptide fragments presented by MHC 
molecules. 
NOD mice express a unique MHC haplotype, H -2g' (formerly H- 2nod). The class I MHC 
molecules encoded within this set of alleles are serologically- identical to H -21(d and H- 
2Db (Ikegami et al., 1988). In other words, the class I MHC alleles in these mice are no 
different from those expressed by other inbred mouse strains, such as BALB /c (H -2d) and 
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C57BL /6 (H -2b) mice, i.e. mouse strains which do not develop autoimmune diabetes. 
However, this is not the case with the class II MHC molecules. APC derived from NOD 
mice exhibit no cell -surface class II MHC heterodimers of the I -E isotype, as a result of a 
deletion mutation in the promoter region of the gene encoding the Ea -chain (Lund et al., 
1990h). This mutation prevents the transcription of this gene, although mRNA is 
produced for the E(3 -chain (Hattori et al., 1986). Accordingly, I -E cell -surface 
expression in NOD mice may be restored by backcrossing them with mice transgeníc for a 
functional copy of the I -Ead or I -Eak gene (Nishimoto et al., 1987; Böhme et al., 1990) 
or by the direct introduction of an I -Ead transgene into fertilised NOD eggs by 
microinjection (Uehira et al., 1989; Lund et al., 1990a). 
Another significant feature of the NOD MHC haplotype is the particular form of H -2A 
class H MHC molecule expressed in these animals, I -Ag7. Sequence analysis of cDNA 
clones encoding this molecule reveals that the a -chain of the heterodimer is identical to I- 
Aad (Acha -Orbea & McDevitt, 1987). Similarly, the 3' half of the NOD (3 -chain gene, 
incorporating the sequence encoding the second external ((3,) domain, the transmembrane 
and cytoplasmic domains and the 3' untranslated region, is identical to that of the I -Aßd 
gene (for a description of the domain organisation of class II MHC molecules, refer to 
Chapter 1, Figure 1.3). The rest of the NOD I -A13g7 gene, however, including the 
sequence encoding the leader peptide, the 5' untranslated region and, most importantly, 
the sequence of the first external (0f) domain contains a number of nucleotide differences. 
On the whole, these differences are not remarkable. In fact, most of the specific 
nucleotide changes by which the I -Ag7 ß -chain differs from that of I -Ad, are observed in 
other mouse class II MHC allotypes (Figueroa & Klein, 1986; Acha -Orbea & McDevitt, 
1987). Moreover, the estimated 10.8% of nucleotides differing in the ß1 domains 
between I -Ag7 and I -Ad conforms with the general level of polymorphism observed in this 
domain between other A13 -chain alleles and I -Aßd (Acha -Orbea & McDevitt, 1987). 
However, one region of polymorphism is unique to I -Ag7 among mouse I -A class II 
MHC molecules and, indeed, among I -E and human HLA -DR molecules. This is a 
particular stretch of five consecutive nucleic acid changes between nucleotides, 248 and 
252. These substitutions create two codon changes and, in doing so, introduce two 
radical amino -acid substitutions into the I -M713-chain within a region of the polypeptide 
that is highly conserved within other human and mouse class II MHC molecules: position 
[356 (Pro -4 His) and position 1357 (Asp -* Ser). 
The most intriguing aspect of the mutations found in the NOD I -Ag7 class II MHC 
molecule is that sequencing of the (3 -chain of HLA -DQ8 (allele DQBI *0302), one of the 
critical HLA susceptibility molecules of human IDDM patients, reveals a similar loss of 
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the charged aspartic acid residue at position 57, this time replaced by an alanine (Todd et 
al., 1987). Furthermore, other class II MHC (3-chain alleles that are associated positively 
with susceptibility to IDDM also lack an aspartic acid residue at this position, having 
instead neutral residues in the form of serine, alanine or valine, e.g. DQB1 *0201 of 
HLA -DQ2 exhibits an alanine at position 1357 (Santamaria et al., 1991) and DRB1*0405 
expresses jSer 57 (Undlien et al., 1997). By contrast, aspartic acid is found at position 
57 in many DQ(3 allotypes which are neutral or associated negatively with the disease, 
e.g. DQBI *0301 of DQ3.1, DQBI *0602 of DQ6 (Santamaria et al., 1991) and 
DRB 1 *0406 (Undlien et al., 1997). A family study examining the identity of the 357 
residue as an IDDM protection/susceptibility marker has revealed that, in Caucasian 
populations, aspartic acid is by far the most common residue found at this position in 
non -diabetic individuals but it is significantly less frequent in patients with IDDM (Morel 
et al., 1988). Together, these findings suggest that the amino acid at position 57 in the 13- 
chain of class II MHC molecules is a significant determinant in influencing susceptibility 
to autoimmune diabetes. 
The importance of residue 57 in the class II MHC (3 -chain in predisposing individuals to 
autoimmune diabetes has been confirmed by the finding that the incidence of spontaneous 
diabetes is reduced in transgenic NOD mice that exhibit heterozygous expression of other 
I -A class II MHC molecules that exhibit J3Asp 57 (Miyazaki et al., 1990; Slattery et al., 
1990; Singer et al., 1993), or express the AV' polypeptide where residue Ser 57 has 
been altered by site -directed mutagenesis to Asp (Quartey -Papafio et al., 1995). 
Nevertheless, in most cases, these transgenic NOD mice still feature some degree of 
insulitis (Slattery et al., 1990; Singer et al., 1993; Quartey -Papafio et al., 1995). 
Moreover, NOD mice expressing ActkAßk in which position ß57 has been mutated from 
aspartic acid to serine are also protected against developing overt diabetes (Miyazaki et al., 
1990). Thus, despite the importance of this residue in contributing to diabetes 
development, residue 1357 alone is not sufficient to induce (3 -cell autoimmunity, a finding 
consistent with the known multifactorial nature of IDDM. Indeed, in some instances the 
so- called " codon 57" model of diabetes susceptibility does not appear to be applicable at 
all. For example, Caucasian individuals that are homozygous at the DQB1 locus for Asp 
57- positive alleles may still develop IDDM, while individuals expressing other DQBI 
genotypes that lack aspartic acid at this position never become diabetic (Rßnningen et al., 
1989; Baisch et al., 1990). Furthermore, the DQB1 alleles found with increased 
frequency in Japanese IDDM patients do exhibit an aspartic acid residue encoded at 
position f357 (Awata et al., 1990; Ikegami et al., 1990a). In the Bio- Breeding (BB) rat 
model of autoimmune diabetes, these rats, Iike NOD mice, express an class II MHC 
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molecule that lacks aspartic acid at position 57 (RT1.B °), however so too does the Lewis 
rat which is not susceptible to this condition (RTI.B'; Chao et al., 1989). 
It is of interest to note that the expression in NOD mice of a transgene encoding a 
modified A(3g7 chain exhibiting a His - Pro mutation at position (356, i.e. a reversion to 
the conserved mouse wild -type residue, also protects these animals from diabetes but, 
moreover, reduces the severity of insulitis as well (Lund et al., 1990a). Similarly, double 
transgenic NOD mice expressing the I -Ag' (3 -chain gene in which the codons for both 
(3His 56 and 13Ser 57 have been mutated to encode a proline and aspartic acid respectively 
- the so- called NOD.PD mice - develop neither substantial insulitis nor overt diabetes 
(Singer et al., 1998). Thus, both 13 -chain residues, 56 and 57, of the I -Ag' NOD class II 
MHC molecule exhibit the potential to influence profoundly the diabetogenic nature of the 
entire aß dimer, albeit to different extents. The mutation at 1356 appears unlikely, 
however, to be a contributing factor in human IDDM since a proline residue at the 1356 
position is conserved throughout HLA -DQ molecules (Todd et al., 1987). Also 
noteworthy, the effect of these I -Aa (3 -chain residues, 56 and 57, upon susceptibility to 
autoimmune diabetes in NOD mice appears to be secondary to the presence of a functional 
I -E class II MHC molecule - the expression of ant-Ea transgene in these animals 
prevents overt autoimmune diabetes and reduces insulitis (Nishimoto et al., 1987; Uehira 
et al., 1989; Böhme et al., 1990; Lund et al., 1990a). 
6.1.5 The mutations at positions 056 and (357 in I -Ag' may affect the 
binding of peptides 
How then do the 1356 and 057 residues of I -Ag' exert their influence upon the 
development of 13 -cell autoimmunity in NOD mice? Examination of X -ray 
crystallographic images of different human and mouse class II MHC aß dimers (Brown 
et al., 1993; Stern et al., 1994; Ghosh et al., 1995; Fremont et al., 1996, 1998b; Scott et 
al., 1998), together with an homology model of I -Ag' (Reizis et al., 1997b), locates the 
residues 56 and 57 within the 13 -chain HI a -helix that forms part of one of the walls of 
the peptide -binding groove, i.e. in close proximity to the C- terminal region of the bound 
peptide ligand (for a description of the structure of the class II MHC peptide -binding 
groove, refer to Chapter 1, Figure 1.4). In particular, the aspartic acid residue typically 
found at position 57 of the wild -type class II MHC 13 -chain is critically involved in 
stabilising this distal region of the peptide- binding groove. This is by consequence of the 
aspartyl carboxylate group participating in a salt bridge with the guanidino group of an 
arginine residue at position 76 in the a -chain directly beneath the exiting peptide, thereby 
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providing a vital link between the a, and (3, helical domains (Brown et al., 1993; Stem et 
al., 1994; as stated previously, class II MHC residues are numbered throughout this 
thesis according to the secondary structure -based sequence alignment of the a, and (3, 
domains of the molecules, I -Ak, I -Ek and HLA -DR, reported by Fremont et al., 1998b). 
The inability of this electrostatic interaction to form in I -Ag7 due to the Asp Ser 
mutation at the (357 position may therefore result in these molecules being inherently 
unstable. This could contribute to the development of autoimmunity in NOD mice by 
altering the capacity of these molecules to present peptides efficiently to CD4' T 
lymphocytes for both thymic selection and/or for subsequent peripheral immune 
responses. 
Also influencing the ability of class II MHC molecules to present peptides effectively, 
both the ßAsp 57 and aArg 76 residues that are involved in the class II MHC salt -bridge 
have the potential to form hydrogen bonds, either directly or indirectly via water 
molecules, with amide hydrogens atoms and carbonyl oxygen atoms of the peptide 
backbone (Stern et al., 1994; Ghosh et al., 1995; Fremont et al., 1996, 1998b; Weber et 
al., 1998). This situation is equivalent to that seen in class I MHC molecules where the 
side chains of the conserved residues, Tyr 84 (a, domain) and Thr 143 (a2 domain), 
occupy the positions analogous to aArg 76 and ßAsp 57, respectively (for a description 
of the domain organisation of class I MHC molecules, refer to Chapter 1, Figure 1.3; 
Brown et al., 1988; Madden et al., 1991; Fremont et al., 1992; Madden et al., 1992; 
Silver et al., 1992). Together, the Thr 143 and Tyr 84 in the class I MHC three - 
dimensional structure are positioned to hydrogen bond with the oxygen atoms of the 
peptide C- terminus carboxylate group, thereby tethering this end of the peptide in place. 
In the class II MFIC heterodimer, electrostatic restraint of this region of the bound peptide 
is less important, given the continuation of the peptide beyond this site, the absence of a 
C- terminal carboxylate and the number of other hydrogen bonds occurring elsewhere 
along the length of the peptide. Nevertheless, a hydrogen bond formed between the (3Asp 
57 residue and peptide main -chain atoms could provide a vital contribution to the overall 
stability of a peptide -class II MHC complex in terms of whether it is sufficiently long - 
lived to be recognised by CD4' T lymphocytes at the cell surface. In this way, the 
possibility that the serine residue at position 057 does not form such a bond in peptide - 
bound I -Ag7 class H MI-IC complexes, or that it is of lesser strength, may well influence 
the efficacy of the deletion of self -reactive T cell clones in the thymus and/or their 
subsequent activation in the periphery. 
Another possible contribution of the 1357 mutation in I -Ag7 to the development of 
autoimmunity may result from an alteration in the peptide repertoire presented by these 
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class II MHC molecules. The location of residue f357 at the base of the peptide -binding 
groove coincides with the pocket that accommodates the side chain of the P9 residue of 
the bound peptide. Thus, the f3Asp57Ser mutation in I -Ag' may influence the side -chain 
specificity of this particular binding site. For instance, in other mouse class II MHC 
molecules of the I -A isotype in which the (357 -a76 salt bridge is intact, the P9 pocket is 
small but relatively degenerate between allotypes, tolerating a range of peptide side chains 
of both aliphatic and polar characteristics (discussed in Chapter 3, §3.4.4 & Table 3.2). 
However, the inability to form the salt bridge at this site in I -Ag7 leaves the otArg 76 
amino acid unpaired. This drives a preference for I -Ag' to bind peptides that are able to 
make a compensatory interaction with the aArg 76 positive charge, the fulfilment of 
which should provide considerable positive binding energy to the interaction. 
Accordingly, sequencing of naturally -processed peptide ligands bound to I -Ag' has 
revealed that these peptides frequently exhibit negatively- charged amino acid residues at 
the P9 position in their C- terminus (Reich et al., 1994). 
Regarding the capacity of the Pro -> His mutation at position (356 to affect the 
development of diabetes, X -ray crystallographic structures of mouse and human class II 
MHC molecules reveal that this residue is chiefly oriented away from the peptide -binding 
groove (e.g. Brown et al., 1993; Stern et al., 1994; Fremont et al., 1998b; Scott et al., 
1998). However, it is likely that the f3Pro56His mutation may too affect antigen 
presentation by the I -Ag' molecule via effects on both the stability and specificity of 
peptide binding. For example, the substitution of the rigid cyclic proline residue for the 
more flexible histidine in I -Ag' will undoubtedly introduce changes into the conformation 
of the Hl a -helix of the 13-chain at this site (Chapter 1, Figure 1.4) which then may 
impact significantly upon the stability of the a(3 complex and/or its ability to form the 
typical hydrogen -bond network and side -chain interactions with peptide ligands. 
Moreover, this mutation introduces a positive charge into this position which may 
influence further the preference for negatively -charged residues at the C- terminus of I- 
Ag'- binding peptides, as described above for the J3Asp 57 mutation. 
Thus, the location of both the f356 and f357 residues within the environment of the class II 
MHC peptide- binding groove makes it is possible to envisage that amino acid changes at 
these positions within the I -M' heterodimer may impose significant changes upon the 
ability to bind peptides and the specific sequence features of the peptides that they do 
bind. Such effects would indeed have ramifications on the presentation of antigen to 
CD4' T lymphocytes during both thymic selection and later in the periphery, which may 
well be of such significance as to trigger autoimmunity. To examine this hypothesis, an 
analysis of how peptides bind to the wild -type I -Ag' molecule and the manner by which 
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the NOD -specific 13 -chain mutations in the peptide- binding groove influence ligand 
binding is clearly needed. 
185 
Presently, the I -Ag' class H MHC aß dimer is believed to be intrinsically unable to form 
strong interactions with peptide ligands. However, these conclusions have been drawn 
predominantly from the behaviour of these molecules when subjected to SDS -PAGE. 
Specifically, it has been reported that only a small percentage of these molecules is able to 
withstand dissociation of the a(3 subunits in the presence of SDS detergent (Carrasco- 
Marin et al., 1996; Harrison et al., 1997; Reizis et al., 1997b; Nabavieh et al., 1998). As 
discussed in Chapter 3 ( §3.4.6), this is a rather arbitrary approach for determining the 
overall complex stability and, thereby, assessing the efficiency of peptide binding. 
Firstly, the molecular basis of SDS- stability is only now becoming understood (e.g. 
Nelson et al., 1996; Natarajan et al., 1999b) while the functional consequences of this 
feature in vivo, if any, are still unknown. In this respect, even the majority of I -Ad class 
R MHC molecules are found to be unstable in the presence of SDS (Carrasco -Mann et 
al., 1996). Secondly, peptides different from the range of natural ligands accessible in 
vivo could possibly be acquired during cell lysis and protein purification, or simply as a 
result of using different growth medium preparations. These may yield a false 
representation of the stability state of the aß dimer under examination. Indeed, even 
within the different SDS -PAGE analyses of the I -Ag7 molecule, significant variation in the 
degree of susceptibility to dissociation has been found. For example, Harrison et al. 
(1997) reported that greater than 95% of I -Ag' molecules affinity -purified from detergent 
lysates of a B cell hybridoma dissociate into the component monomers when subjected to 
SDS -PAGE. Similarly, Carrasco -Mann et al. (1996) have reported that just 1% of 
radiolabelled I -Ag' molecules that are immunoprecipitated from NOD mouse splenic cells 
migrate as stable a(3 dimers when subjected to SDS -PAGE in sample buffer containing 
2% SDS. This is in contrast to the 12% of compact I -Ad molecules, 39% of I -Ak and 
78% of I -Ab detected in the same study. Similar results were also obtained when the class 
II MI-IC molecules were detected by Western blotting using an antibody against the 
cytoplasmic portion of the a- chain. However, Reizis et al. (1997b) have found that up to 
25% of metabolically - labelled and cell -surface -labelled I -Ag7 immunoprecipitated from 
NOD mouse splenocytes were in a compact conformation and resistant to SDS- induced 
dissociation. 
A more reliable approach is therefore required to determine fully the biochemical 
characteristics of peptide ligand interactions with I -Ag'. In this respect, the extensive 
array of different substituted and/or length -altered analogues of the promiscuous class II 
MHC- binding Ii peptide, CLIP, available in this laboratory provides an excellent resource 
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with which the ability of a single given peptide to bind to I -Ag7 may be investigated in 
some detail. The information produced in this manner on the specific molecular contacts 
formed between ligand and class II MHC molecule may provide a good indication as to 
the extent to which the binding of the peptide yields energy to stabilise the complex. The 
success of such analyses has been proven previously in Chapters 3 -5 through the 
elucidation of the molecular basis by which the CLIP ligand interacts with mouse class H 
MHC molecules of both I -A and I -E isotypes. 
The investigation into the effects of the mutations at positions 056 and (357 in the I -A47 
class H MHC molecule on CLIP binding may be extended further by comparing the 
results obtained with wild -type I -Ag7 with those of single amino acid revertants. In this 
respect, Quartey -Papafio et al. (1995) have generated previously three transfectant B cell 
lines, M12.NOD, M12.PRO and M12.ASP, from the I -A° cell line, M12.A3 (Glimcher et 
al., 1985), all of which have been provided to this laboratory as part of a collaborative 
study. The M12.NOD cell line expresses wild -type I -Ag7 molecules, while the M12.PRO 
and M12.ASP cell lines express variants of the I -Ag7, each with a single amino acid 
mutation, 0His56Pro and 0Ser57Asp, respectively. In other words, these latter two cell 
lines express at the respective 1356 and 057 positions the residue conserved in other 
mouse class II MHC molecules. 
In this study, the ability of a broad array of substituted and/or length -altered CLIP 
analogues to bind to wild -type I -Ag7 and the single amino acid -substituted variants I- 
Ag7Pro56 and I- Ag7Asp57 has been assessed in ceII- surface peptide binding assays. This has 
been achieved using the transfected mouse B lymphoblastoid cell lines, M12.NOD, 
M12.PRO and M12.ASP, respectively, as constructed by Quartey- Papafio et al. (1995). 
Data yielded on the stability and peptide- binding behaviour of the wild -type NOD class H 
MHC aß dimer, I -Aa, have been compared and consolidated with previous biochemical 
analyses of this molecule and the particular effects on peptide binding of the 0His56Pro 
and 0Ser57Asp mutations within the I -Ag7 molecule have been evaluated. Comparisons 
of these findings have also been made with results obtained from other mouse class H 
MEC molecules, such as those examined previously in Chapters 3 -5. Given the critical 
role of antigen presentation by class II MEC molecules in shaping the CD4{ T cell 
repertoire (Chapter 1, § 1.7.2) and in mediating cellular immune responses (Chapter 1, 
§1.7.1), possible mechanisms by which I -Ag7 may contribute to the development of 
autoimmune diabetes in NOD mice are discussed. 
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6.2. Materials and Methods 
All experimental procedures performed in this chapter are detailed in Chapter 2. Briefly, 
the mouse B cell lines, M12.A3 (I -Ed), M12.NOD (I -Ed, I -Ag7), M12.PRO (I -Ed, I - 
Ag7bP o 56) and Ml 2.ASP (I -Ed, I- Ag7SAsP S7) were provided generously by Dr A. Cooke, 
University of Cambridge, UK, as part of a collaborative study into the effects on ligand 
interactions of the (3Hís 56 and 13Ser 57 residues within the peptide- binding groove of the 
I -Ag' class II MHC molecule. The I -A° parental cell line, M12.A3, was derived from the 
H -2d B cell lymphoma, M12.4.1, by y- irradiation mutagenesis followed by negative 
selection with anti -I -Ad mAb (Glimcher et al., 1985). The transfected cell lines, 
M12.NOD, M12.PRO and M12.ASP were generated by Quartey -Papafio et al. (1995) by 
the transfection of A13 DNA constructs into M12.A3 cells. The mouse B cell lines, A20 
(H-2"), CH27 (H-2"), M12.D (I -Ad) and 1 -5.4 (I -Au), were also used as APC in cell - 
surface binding assays. All of these cell Iines are detailed in Chapter 2, Table 2.1. 
The L- alanine- and D- alanine- substituted CLIP86 -1 04 analogues used in the competitive 
binding assays have been listed previously in Chapter 3, Table 3.1 and Chapter 4, Table 
4.1, respectively. Truncated and frameshifted CLIP analogues are listed within §6.3.4 in 
Tables 6.1 and 6.2, respectively, with further substituted and/or length- altered CLIP 
ligands described in Table 6.3. The set of CLIP86 -104 analogues exhibiting amino acid 
substitutions at positions 99 and/or 100 are shown in Table 6.4 within §6.4.5. 
Sequences of the I -Ag'- binding antigen- derived peptides, MSA560 -574 and p12(166- 
185), are given in Figure 6.7a and b, respectively. Sequences of the antigen- derived 
peptides, rMOG8 -22 and HEL10 -23, are given in Figure 6.8a and b, respectively. 
Peptide concentrations used in binding assays are stated in the figure legends. In all 
competitive cell -surface binding assays (Chapter 2, §2.7.2), competitor peptides were 
tested over the concentration range, 16-2504M. 
I -Ag' molecules were purified from a detergent lysate of the transfected cell line, 
M12.NOD, by affinity chromatography on a 10 -3.6.2 mAb column using the standard 
protocol outlined in Chapter 2, §2.6. Other affinity- purified mouse class II MHC 
molecules shown in Figure 6.1 were prepared similarly on mAb columns as follows: I- 
A"; 10- 3.6.2, I -Ad; MK -D6, I -Ed & T -E"; 14.4.4S. Tris- tricine SDS -PAGE and Western 
blotting of purified class II MHC molecules were performed as described in Chapter 2, 
§2.5.2 and §2.5.4, respectively, with one amendment: I -Ag7 and I -Ak molecules were 
detected by immunoblotting with the unconjugated primary mAb, 10 -2.16, followed by 
horseradish peroxidase -conjugated goat anti -mouse IgG (GaM -HRP). I -Ad and I -Ed.k 
CLIP binding to I -A87 
were detected with biotinylated MK -D6 and 14.4.4S, respectively, followed by 
horseradish peroxidase -conjugated streptavidin (S -HRP). 
6.3. Results 
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6.3.1 SDS -PAGE is not a reliable technique with which to determine the 
peptide- binding capacity of class II MHC molecules 
I -Ag7 class II MHC molecules have been reported to be largely unstable in the presence of 
the ionic detergent, SDS and have therefore been deemed to bind peptides poorly 
( Carrasco .Mann et al., 1996, 1997; Harrison et al., 1997; Reizis et al., 1997b; Nabavieh 
et al., 1998). However, SDS -PAGE experiments are frequently subject to considerable 
variation. To illustrate this point, shown in Figure 6.1 is an example of one such 
experiment performed in this laboratory with affinity- purified I -Ag7. SOS -PAGE was 
conducted on a 1.2 -15% Tris- tricine gradient gel followed by immunoblotting and 
detection with the anti- I- Al3ku'g' mAb, 10 -2.16 (Oi et al., 1978). The strong band at 
approximately 60 kDa indicates that most of these molecules are in a compact 
conformation and thereby resistant to SDS- induced dissociation of their constituent 
subunits. Little monomeric 3 -chain is visible at approximately 30 kDa. Some 
degradation of the 10 -3.6.2 antibody in the affinity column used for the I -Ag' purification 
seems to have occurred, as apparent from the detection of immunoglobulin heavy and 
light chains (approximately 53 kDa and 23 kDa, respectively) in the I -Ar sample blotted 
with both 10 -2.16 and horseradish peroxidase -conjugated goat anti -mouse IgG (GaM- 
HRP; lane 1) and the background control sample of I -Ag7 blotted with GaM -HRP only 
(lane 2). Such degradation of the purifying mAb was not observed in the I -Ak preparation 
purified from a CH27 (H -2k) detergent lysate on a similar 10 -3.6.2 column when blotted 
with these same reagents (lane 3). This and other mouse class II MHC molecules 
affinity- purified in this laboratory are shown alongside the I -Ag7 samples for comparison 
of the degree of stability observed typically with each of these molecules in SDS: I -A' 
(lane 4), I -Ed (lane 5) and I -Ek (lane 6). 
In other words, affinity- purification of I -Ag' in this laboratory appeared to yield a high 
proportion of a(3 dimers resistant to SDS- induced dissociation, even in the presence of 
SDS at a final concentration of 4%. (Such assays are most frequently performed in 
sample buffer with a final concentration of 0.2 -2% SDS. For example, see the original 
SDS stability protocols of Billing et al., 1976; Springer et al., 1977; Pious et al., 1985). 
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4 
-C 
F- ß 
Mouse class II MHC proteins were purified from detergent lysates of B cell lines by immunoaffinity 
chromatography, as described in Chapter 2 (82.6): I -Ag7, M12.NOD, I -Ak & 1 -Ek, CH27; [ -Ad & I -Ed, 
A20. Pooled fractions containing purified class II MHC proteins were separated by SDS -PAGE on either 
a 10-20% tris- tricine gradient gel (I -Ag7, I -Ak, I -Ad) or a 12% tris- glycine gel (I -Ed, I -Ek) and transferred 
to nitrocellulose membranes for immunodetection (Chapter 2, §2.5): I -At7 & I -Ak, 10 -2.16 f GaM- 
HRP; I -Ad, biotinylated MK -D6; I -Ed & I -Ek, bìotinylated 14.4.4S. Compact class II MHC a(3 dimers are 
indicated by arrow C. Monomeric [3 -chain is indicated by arrow 3. 
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6.3.2 The 131-lis 56 and 3Ser 57 mutations in I -Ag' influence the binding of 
CLIP 
To examine more reliably the capacity of peptides to bind to the NOD class H MHC 
molecule, I -Ag', flow cytometry -based cell -surface binding assays were conducted with 
the promiscuous Ii- derived peptide, CLIP, using the transfectant B cell lines, M12.NOD, 
M12.PRO and M12.ASP, generated by Quartey -Papafio et al. (1995) and the I -A° 
parental cell line, M12.A3, as a control (Glimcher et al., 1985). 
Firstly, the levels of class II MHC molecules expressed at the cell surface of each of these 
four cell lines were assessed (Figure 6.2). The three transfected cell lines, M12.NOD, 
M12.PRO and M12.ASP, exhibited repeatedly equivalent levels of I -Ag' or its respective 
mutated forms on their surfaces, as determined by staining the cell -surface class II MHC 
molecules with the fluoresceinated anti -I -Ag7 mAb, OX6 -FITC (Figure 6.2a). As 
expected, the parental cell Iine, M12.A3, showed negligible surface- staining with this 
mAb nor, as shown previously, significant staining with the anti -I -Aßd mAb MK -D6- 
FITC (Chapter 5, Figure 5.4a), consistent with its I -A' phenotype. 
Staining with the fluoresceinated anti- I -Ectd mAb, 14.4.45 -FITC, revealed that all four 
cell lines also expréss similar levels of I -Ed, the only functional class II MHC molecule 
formed in the parental cell line, M12.A3 (Figure 6.2b; Glimcher et al., 1985). However, 
the presence of this molecule on the surface of these cells was not expected to interfere 
with subsequent CLIP binding assays given the poor ability of this peptide to bind to 
molecules of the I -E isotype under such conditions, as discussed in Chapter 5 ( §5.4.4). 
Subsequently, this assumption was proven to be correct (see below). 
Next, the direct binding of biotinylated CLIP86 -104 to the four cell lines, M12.A3, 
M12.NOD, M12.PRO and MI2.ASP, was assessed. As shown in Figure 6.3, 
concentration- dependent binding of this peptide to surface class II MHC molecules was 
readily detectable by flow cytometry for the three cell lines expressing forms of the I -Ag7 
aß dimer (filled symbols). By contrast, very little binding of the CLIP ligand was 
observed to the M12.A3 cell line which expresses only I -Ed at the cell surface (open 
squares). Consistent with the data presented previously (Chapter 5, Figure 5.4), it may 
thus be assumed that the fluorescence signal generated with the cell lines M12.NOD, 
M12.PRO and M12.ASP is the result of the biotinylated CLIP86 -104 peptide binding 
only to the particular forms of cell -surface I -Ag' molecules expressed by these cells. 
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Figure 6.2 Expression of I -Ag7 and I -Ed class II MHC molecules on the 
surface of transfected mouse B lymphoblastoid cell lines. 
The three transfected cell lines, M12.NOD (I -Ag7, I -Ed), M12.PRO (I- Ag7PO56, I -Ed) and M12.ASP (I- 
Ag7A8p57, I -Ed), together with the parental cell line, M12.A3 (I -Ed), were stained with the 
fluoresceinated mAb (a) OX -6 (recognising I- Af,k.rs,u,g7) or (b) 14.4.4S (recognising I- Ed,k,p,r,u) to 
determine their relative levels of expression of class II MHC molecules. A control sample of 
M12.NOD cells was stained with avidin -FITC to depict zero fluorescence. Flow -cytometric analysis 
was conducted as described in Chapter 2, §2.7.2. 
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Figure 6.3 The binding of CLIP86 -104 to mutated I -Ag7 class II MHC 
molecules. 
Biotinylated mouse CLIP86 -104 was examined for its ability to bind to the mutated forms of the I -Ao7 
class II MHC molecule expressed by the M12.A3- derived cell lines, M12.PRO (I- Ag7Pro56) and 
M12.ASP (I- Ag7Asp57) Binding was compared to that obtained with M12.NOD cells, which express 
wild -type I -At7 and, with the parental cell line, M12.A3. Data shown are representative of seven 
independent assays, all yielding equivalent results. Binding is expressed as median fluorescence intensity 
(MFI) from which background signals, measured in the absence of biotinylated peptide, have been 
subtracted (M12.A3, 3.40; M12.NOD, 2.69; M12.PRO, 3.05; M12.ASP, 2.64). MFI measurements have 
also been normalised for any minor differences in the levels of class II MHC expression between these 
cell lines, as determined by staining with OX6 -FITC. Cells were incubated with biotinylated CLIP for 18 
hours at 37 °C before flow cytometric analysis, as described in Chapter 2, §2.7.2. 
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The location of the mutations, (3His 56 and f3Ser 57, at the C- terminal end of the peptide - 
binding groove of I -Ar has led to the hypothesis that this molecule may bind peptides 
differently from other mouse class II MHC variants. Consistent with this, Figure 6.3 
shows that the mutation of residue (356 from a histidine in I -A 7 (M12.NOD cell line; 
filled squares) to the conserved proline (M12.PRO cell line; filled triangles) led to an 
increase in the ability of this peptide to bind to these cell -surface class II MHC molecules. 
This result was observed each of the seven times that this experiment was performed. 
However, a similar increase in binding capacity was not recorded for the similar reversion 
mutation at position 57, i.e. Ser -+ Asp between the I -Ag' molecules expressed by the cell 
lines, M12.NOD (filled squares) and M12.ASP (filled circles), respectively. Most often, 
similar levels of cell -surface binding of biotinylated CLIP86 -104 were observed between 
these two cell lines, as shown in the representative plot in Figure 6.3. It is important to 
note that, for complete accuracy, the median fluorescence intensities (MN) shown in this 
figure have been adjusted for even slight differences in the levels of I -Ag7 expression 
observed with OX6 -FITC staining between these cell lines on the day of experiment. 
This normalisation has been performed throughout this chapter where peptide binding 
levels between the different cell lines have been compared directly. 
Another way in which to investigate the ability of a peptide to bind to cell -surface class II 
MHC molecules is to establish competition between the given labelled peptide and its 
equivalent unlabelled form. This provides very specific information regarding peptide - 
binding capacity at only those sites where labelled and unlabelled ligand are in direct 
competition. To examine further the effects of the 1356 and 057 mutations on peptide 
binding to I -Av, competitive cell -surface binding assays were conducted, measuring the 
binding of biotinylated CLIP86 -104 in the presence of unlabelled analogue (Figure 6.4). 
From the results of the previous direct titration of biotinylated CLIP in Figure 6.3, a 
concentration of 50 µM of this peptide was chosen for these assays with each of the cell 
lines, M12.NOD, M12.PRO and M12.ASP. 
Unbiotinylated CLIP86 -104 inhibited the signal generated by the binding of the 
biotinylated CLIP86 -104 to the M12.NOD, M12.PRO, and M12.ASP cells in a 
concentration -dependent manner, consistent with these two peptides competing for the 
same single class of binding site (Figure 6.4). Interestingly, unlabelled CLIP86 -104 
(filled squares) did not compete as well with the biotinylated form for binding to the wild - 
type I -Ag7 molecules expressed on the M12.NOD cell surface (Figure 6.4a) as it did to the 
(3His56Pro mutated form of I -Ag7 expressed by the M12.PRO cells (I -At7 05`; Figure 
6.4b). For example, the concentration of unbiotinylated CLIP86 -104 required to inhibit 
50% of the biotinylated CLIP signal with M12.NOD cells (IC) was 215.55 ± 6.29 .LM, 
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Figure 6.4 Competition by CLIP ligands for cell- surface binding to 
mutated I -A87 class II MHC molecules. 
The 19 -mer, CLIP86 -104, and its two extended variants, CL]P81 -104 (24 -mer) and CLIP81 -104 (29- 
mer) were examined for their ability to inhibit the binding of biotinylated CLIP86 -104 (50 µM) to the 
M12.A3- derived cell lines, (a) M12.NOD (wild -type I -A57), (b) M12.PRO (I- Ag7Pro56) and (e) M12.ASP 
(I- Ag7AsP57). Data shown represent the mean percentage inhibition ± SD from six independent 
experiments. Before calculating % inhibition, median fluorescence intensity (MFI) measurements were 
normalised for any minor differences in the levels of class II MHC expression between these cell lines, as 
determined by staining with 0X6 -FITC. Cells were incubated with biotinylated peptide and competitor 
for 18 hours at 37 °C before flow cytometric analysis, as described in Chapter 2, §2.7.2. 
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a 4 -fold excess, compared with an IC50 of 141.15 ± 4.03 µM for M12.PRO cells (Table 
6.1). Unbiotinylated CLIP86 -104 was able to compete better still for binding to the I -Ac 
molecules expressed by the M12.ASP cell line that exhibited the f3Ser57Asp mutation (I- 
Ag7AsPS7; Figure 6.4c), to yield an ICSO value of just 88.56 ± 1.95 µM (Table 6.1). 
Thus, wild -type I -A57 molecules showed a greater preference for binding the biotinylated 
CLIP86 -104 over its unbiotinylated form (Figure 6.4a) than that exhibited by M12.ASP 
cells (Figure 6.4c). This is likely to reflect an increase in affinity conferred to the wild - 
type I -Ag7 aß dimer by the presence of the N- terminal biotin moiety on the labelled 
peptide - an interaction that does not add further positive binding energy to the 
association of CLIP with I- Ag7Asp57 molecules. However, this binding preference of I -Ag 
and, to a certain extent, the I- Ag'P`O56 form as well, was able to be modulated by extending 
the length of the unbiotinylated CLIP competitor peptide. For example, the longer 
CLIP81 -104 (filled triangles) and CLIP81 -109 ligands (filled circles) competed more 
favourably with the biotinylated CLIP86 -104 (5011M) for binding to the class II MHC 
molecules expressed by the cell lines, M12.NOD (Figure 6.4a; Table 6.1) and M12.PRO 
(Figure 6.4b; Table 6.1). By contrast, competition was not enhanced to the same extent 
with the longer CLIP ligands and the M12.ASP cells. Instead, all three unbiotinylated 
CLIP forms yielded a similar degree of inhibition of the biotinylated CLIP86 -104 binding 
to the I -A07A' 57 molecules (Figure 6.4c; Table 6.1). This latter result is similar to that 
seen in Chapter 3 (Figure 3.1) with these same extended CLIP variants binding to cell - 
surface I -Ak and I -A° molecules. Collectively, the I -Ag7 and I- Ag7Pro56 molecules thus 
appear to bind those peptides that offer the most contacts to stabilise the interaction 
preferentially. 
6.3.3 C- terminal residues of the CLIP86 -104 ligand are critical for 
binding to I -Ag7 
To investigate further the capacity of the I -Ag7 13 -chain mutations at positions 56 and 57 to 
affect the binding of peptides to this class II MHC variant, the specific features of the 
CLIP sequence necessary for interacting with this molecule were evaluated and compared 
with those of the single amino acid revertant forms, I- Ai'R°56 and I- Ag'¢sp57. Specifically, 
the same series of substituted and/or length -altered CLIP analogues as used successfully 
in Chapters 3 -5 to define CLIP binding motifs for mouse I -A and I -E class II MHC 
molecules, were assessed for their abilities to compete against biotinylated CLIP86 -104 
(5011M) for binding to the surface I -A molecules of the M12.NOD, M12.PRO and 
M12.ASP cell lines. 
Table 6.1 Competition by extended CLIP ligands for binding to mutated I -Ag7 class II MHC molecules. 
CLIP ICSO (µM) 
M12.NOD M12.PRO M12.ASP 
86-104 KPVSQMRMATPLLMRPMSM 215.55 ± 6.29 141.15 ± 4.03 88.56 ± 1.95 
81-104 LPKSAKPVSQMRMATPLLMRPMSM 131.75 ± 14.78 96.19 ± 6.38 68.84 ± 4.53 
81-109 LPKSAKPVSQMRMATPLLMRPMSMDNMLL 115.50 ± 0.42 86.42 ± 5.23 66.03 ± 5.40 
Longer CLIP ligands were tested at multiple doses as competitors against biotinylated CLIP86 -104 (50 isM) for binding to the cell -surface I -A class II 
MHC molecules expressed by the M12.A3- derived cell lines, M12.NOD (wild -type I -A0), M12.PRO (I -Ag' 6) and M12.ASP (I- Ag7ASp5'). Data are 
presented as mean IC50 values (pM) from two independent experiments. Between experiments, mean background MFI (median fluorescence intensity) of 
3.72, 3.00 and 3.01 relative units were recorded for each cell line, respectively, with mean maximum MFI measurements in the absence of competitor of 
21.78, 22.06 and 26.84 relative units, respectively. 
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Firstly, the extent to which atoms of the CLIP backbone participate in bonds with the 
residues of I -Ag' and its different forms, I- Ag7Pro56 and I- Ag7AsgS7, was examined by 
determining the binding ability of D- alanine- substituted CLIP86 -104 analogues listed 
previously in Chapter 4, Table 4.1. The results of one such assay, representative of the 
experimental findings, are shown in Figure 6.5. Mean IC50 values, calculated from two 
independent experiments are given atop each bar to provide a quantitative representation 
of the overall trends observed, i.e. the concentration of competitor peptide required to 
inhibit 50% of the biotinylated CLIP86 -104 signal. 
In common with the findings for mouse class II MEW molecules of both I -A and I -E 
isotypes in Chapter 4 (Figures 4.5 -4.6) and Chapter 5 (Figure 5.7), respectively, the 
ability of these configurationally - altered ligands to bind to the three different I -Ag7 variants 
was compromised severely when any of these substitutions fell in the central region of the 
peptide between residues Met 91 and Arg 100. However, unique to these I -Ag7- 
expressing cells, binding was also impaired considerably by the presence of a single D- 
alanine residue within the CLIP sequence C- terminal to this region. For example, D- 
alanine substitutions between Pro 101 -Met 102 abrogated completely the binding to the 
wild -type I -Ar and I- Ag7Pro56 molecules, while the binding of the D- alanine- substituted 
Ser 103 analogue was reduced also (Figure 6.5a, b). By contrast, the ability of these C- 
terminal configurational inversions to disrupt binding appeared less severe with the I- 
Ag7ASP5' class II MHC variant (Figure 6.5c). In particular, some degree of competition 
with the biotinylated CLIP was still observed with the configurationally -substituted Pro 
101 and Met 102 analogues for binding to I -A° AsP57 Together, these results indicate that 
the typical conformation -dependent contacts between the backbone atoms of the central 
CLIP residues, 91 -100, and the I -Ag' a3 dimer are critically important for maintaining 
this interaction. However, additional contacts between I -Ag7 and the C- terminus of this 
peptide (residues 101 -103) are also needed to stabilise the binding, the requirement for 
which appears to be influenced to some extent by the replacement of an aspartic acid at 
position 57 in the 3 -chain of the I -Ag' heterodimer with serine (Figure 6.5c). A similar 
effect was not observed when the histidine at position 356 in wild -type I -Ag' was 
substituted by proline (Figure 6.5b). 
[Next, peptide side -chain contributions to the interaction between CLIP and the I -Ag7 
heterodimer and its mutated forms, I- Ag'Pross and I- Ag7ASp57, were assessed using the 
series of L- alanine- substituted CLIP86 -104 analogues listed previously in Chapter 3, 
Table 3.1. Figure 6.6 shows the results of one such assay, representative of the 
experimental findings. Again, mean IC50 values, calculated from two independent 
experiments, are given atop each bar to provide a quantitative representation of the overall 
CLIP binding to I -Ag7 
20 
10 
0 
30 
20 
10 
0 
a. 
i 
220 374193 207 198 
200 
73 
* 
* 
M12.NOD 
** 
565 
209 
b. 
i 
48 153 
107 117 115 
0 
E 
38 
* 
M12.PRO 
* 
* 
382 
140 
c M12.ASP 
86 92 60 69 80 75 
.,! 
230 
* 
791 747 753 
274 
141 
63 
& 
N m 
â 
á 
m" 3 
D- alanine- substituted competitor peptide 
198 
Figure 6.5 Competition by D- alanine -substituted CLIP for cell- surface 
binding to mutated I -Ag7 class II MHC molecules. 
Multiple doses of CLIP86 -104 analogues with single D- alanine substitutions were tested as competitors 
against biotinylated CLIP86 -104 (50 µM) for binding to cell -surface I -A molecules of the cell lines (a) 
M12.NOD, (b) M12.PRO and (c) M12.ASP. A single competitor dose which yielded -50% inhibition of 
the biotinylated CLIP signal by wild -type CLIP86 -104 (cross- hatched fill pattern) is shown (M12.NOD, 
250 ttM, M12.PRO & M12.ASP, 125 µM). All assays were performed twice with consistent results. Solid 
bars represent competition by the substituted CLIP and empty bars indicate the maximal biotinylated 
CLIP signal when no competitor is present. Binding is expressed as median fluorescence intensity (MFI), 
from which background counts measured in the absence of biotinylated peptide have been subtracted 
(M12.NOD, 2.87; M12.PRO, 3.22; M12.ASP, 2.69). 
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Figure 6.6 Competition by L- alanine -substituted CLIP86 -104 for cell - 
surface binding to mutated I- Ag7class II MHC molecules. 
Multiple doses of CLIP86 -104 analogues with single L- alanine substitutions were tested as competitors 
against biotinylated CLIP86 -104 (50 µM) for binding to the cell- surface I -A molecules of the cell lines 
(a) M12.NOD, (b) M12.PRO and (c) M12.ASP. A single competitor dose which yielded -50% inhibition 
of the biotinylated CLIP signal by wild -type CLIP86 -104 (shaded fill pattern) is shown (M12.NOD, 250 
µM; M12.PRO & M12.ASP, 125 µM). All assays were performed twice with equivalent results. Solid 
bars represent competition by the substituted CLIP and empty bars indicate the maximal biotinylated 
CLIP signal with no competitor peptide. Binding is expressed as median fluorescence intensity (MFI), 
from which background counts, measured in the absence of biotinylated peptide, have been subtracted 
(M12.NOD, 2.92 ; M12.PRO, 3.16; M12.ASP, 2.94). 
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trends observed. For the wild -type I -Ag7 molecule, binding of the CLIP sequence was 
abrogated completely when any of the individual wild -type residues, Leu 97, Arg 100 and 
Met 102 were substituted by L- alanine (Figure 6.6a). Furthermore, the single 
substitution of the other C- terminal residues, Leu 98 and Pro 101, led to a significant 
reduction in the ability of these particular analogues to compete for binding. Meanwhile, 
the replacement of the methionine residue at position 99 in the CLIP86 -104 sequence by 
L- alanine led to a marked increase in the ability of this analogue to compete with the 
biotinylated CLIP86 -104. A smaller increase in binding was observed when Pro 96 was 
substituted similarly by L- alanine. 
For the I- Ag7 ' °56 class II MHC molecules expressed by the cell line, M12.PRO, the L- 
alanine substitution of single CLIP86 -104 residues yielded an almost identical pattern of 
results to those obtained with the wild -type I -Ag7 molecule (Figure 6.6b). For example, 
anchor contributions provided by the residues Leu 97 and Met 102 were identified, such 
that binding to the I- Ag7Pro56 molecules was not sustained when these residues were 
substituted. Similarly, the L- alanine substitution of Leu 98, Arg 100 and Pro 101 also 
reduced binding, while Pro 96 and Met 99 were somewhat inhibitory to the interaction. 
Notably, however, these effects were not observed to the same extent when the L- alanine- 
substituted CLIP analogues were examined for their ability to bind to the I- Ag7ASp'7 
molecules of the M12.ASP cell line (Figure 6.6c). For this variant of I -Ag7, only Leu 97 
appeared to provide major favourable interactions with the aß dimer, with some positive 
binding energy also being provided by Arg 100 and Met 102. Again, the Met 99 and Pro 
96 wild -type CLIP residues were both inhibitory to the binding of this sequence to the I- 
Ag7ASp57 molecule. Together, these results confirm the findings obtained with the 
backbone- disrupted analogues (Figure 6.5), that the binding of CLIP to I -Ag7 is critically 
stabilised by interactions of the C- terminal residues of the CLIP ligand. Furthermore, the 
finding that the majority of the side chains of the CLIP C- terminal residues may be 
substituted without significant effect on binding to the I- Ag7Asp$7 molecules adds 
conviction to the idea that the need for such additional interactions arises from the absence 
of an aspartic acid residue at position 57 in the I -Ag7 ß -chain (Figure 6.5c). By contrast, 
the lack of proline at position (356 did not show such an effect (Figure 6.5b). 
To investigate further the importance of the C- terminal CLIP residues in stabilising the 
interaction of this ligand with I -Ag', the binding of a series of frameshifted 15 -mer CLIP 
analogues to this class II MEC molecule was assessed in a competitive cell -surface assay 
(Table 6.2). These ligands have been used previously to determine the importance of 
specific N- terminal CLIP residues for binding to I -A and I -E molecules (Chapter 4, Table 
4.3 & Chapter 5, Table 5.2). Data presented in Table 6.2 depict the mean concentration 
Table 6.2 Competition by frameshifted CLIP 15 -mers for binding to mutated I -Ag7 
class II MHC molecules. 
CLIP ICso (1LM) 
M12.NOD M12.PRO M12.ASP 
86-100 KPVSQMRMATPLLMR > 1000 > 1000 246.40 ± 5.94 
87-101 PVSQMRMATPLLMRP > 1000 > 1000 265.65 ± 22.42 
88-102 VSQMRMATPLLMRPM 468.45 ± 2.19 478.30 ± 135.91 166.40 ± 7.50 
89-103 SQMRMATPLLMRPMS 260.75 ± 40.09 200.30 ± 1.41 126.40 ± 1.27 
90-104 QMRMATPLLMRPMSM 300.00 ± 7.64 215.25 ± 39.67 148.60 ± 5.94 
Fifteen -residue CLIP variants were synthesised, each with a single amino -acid frameshift. Analogues were tested at 
multiple doses as competitors against biotinylated CLIP86 -104 (50 pM) for binding to the cell -surface I -A class II MHC 
molecules expressed by the M12.A3- derived cell lines, M12.NOD (wild -type I -M7), M12.PRO (I- A87ß°56) and M12.ASP 
(I- A87Mp57). Data are presented as mean IC50 values (µM) from two independent experiments. Mean background MFI 
measurements and maximum signals recorded in the absence of competitors are as in Table 6.1. 
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of these frameshifted CLIP required to yield 50% inhibition (IC%f) of the biotinylated 
CLIP86 -104 signal (50 µM) for each of the cell lines, M12.NOD, M12.PRO and 
M12.ASP, calculated from two independent experiments. From these results, it is 
apparent that CLIP binding to I -Ag7 is extremely sensitive to any frameshifts which result 
in the loss of the C- terminal CLIP residues, Pro 101 & Met 102. For example, the 
peptides, CLIP86 -100 and 87 -101, are unable to compete for binding to I -Ag7 while 
CLIP88 -102, binds poorly. This further confirms the importance of the C- terminal 
region of the CLIP ligand for binding to I -M7 noted earlier in the backbone (Figure 6.5) 
and side -chain substitution assays (Figure 6.6). By contrast, truncations at the N- 
terminus that leave these C- terminal residues intact (CLIP89 -103 and 90 -104) have very 
little effect upon the binding affinity. In this respect, it is interesting to note that this 
pattern of results is in distinct contrast to the findings obtained in Chapter 4 (Table 4.3), 
with these same peptides binding to other I -A allotypes, I -A°, I -Ak and I -A °. There, those 
CLIP ligands that contained all or part of the original N- terminal sequence were found to 
bind better than those that exhibited the corresponding C- terminal residues. 
As with the previous side -chain and backbone substitution assays, an identical pattern of 
results is obtained between wild -type I -Ag' and I- Ag7P1O56 molecules for the binding of the 
frameshifted CLIP analogues (Table 6.2). Also as seen before, the pattern of binding 
indicating the importance of the CLIP C- terminal residues is not as marked with the I- 
Ag7Asp37 molecules expressed by the M12.ASP cells. For example, CLIP86 -100 still 
competes well with biotinylated CLIP for binding to I- M'ASp57 This supports further the 
notion that the loss of the aspartic acid residue at position 57 in the (3 -chain of the wild - 
type I -Ag' is a contributory factor in the need for additional interactions to form with the 
C- terminal CLIP residues in order to stabilise binding. Nevertheless, the pattern of these 
frameshifted peptides binding to I- Ag7Asp57 is still overall the same as that observed for I- 
Ag' and I- Ag7Pro5s in that CLIP9Q -104 binds better to I- Ag7Asp57 than CLIP86 -100 
(compare with Chapter 4, Table 4.3). This indicates that the lack of aspartic acid at 
position 57 in the G3 -chain of the I -Ag' molecule is not the sole feature which is 
responsible for the cluster of residues at the C- terminus of the CLIP ligand providing the 
unusual anchor contributions. 
Next, the minimum length of the CLIP ligand required for binding to the I -Ag' aß dimer 
and each of its variant forms, I- Ag7Pro56 and I- Ag7Asp57, was determined using a set of 
peptides truncated by a single residue at each end from the wild -type CLIP86 -104 
sequence, as shown in Table 6.3. As with the frameshifted peptides examined above 
(Table 6.2), data are presented as the mean concentration of truncated peptide required to 
yield 50% inhibition (ICSO) of the biotinylated CLIP86 -104 signal (50 µM) for each of the 
Table 6.3 Competition by truncated CLIP86 -104 for binding to mutated 1 -A97 class II 
MHC molecules. 
CLIP 
M12.NOD 
ICeo (µM) 
M12.PRO M12.ASP 
86-104 KPVS QMRMAT P LLMRPMSM 215.55 ± 6.29 141.15 ± 4.03 88.56 ± 1.95 
87-103 PVSQMRMATPLLMRPMS 184.05 ± 31.89 141.15 ± 32.88 86.62 ± 0.31 
88-102 VSQMRMATPLLMRPM 468.45 ± 2.19 478.30 ± 135.91 166.40 ± 7,50 
89-101 SQMRMATPLLMRP > 1000 > 1000 474.45 ± 21.57 
90-100 QMRMATPLLMR > 1000 > 1000 > 1000 
91-99 MRMATPLLM > 1000 > 1000 > 1000 
Residues were removed pairwise, sequentially from each end of the CLIP86 -104 sequence. The truncated CLIP were tested at 
multiple doses as competitors against biotinylated CLIP86 -104 (50 µM) for binding to the cell -surface I -A class II MHC 
molecules of the M12- A3- derived cell lines, M12.NOD (wild -type I -A7), M12.PRO (I- Ag7'°56) and M12.ASP (I -107A 57). 
Data are presented as mean IC50 values (p.M) from two independent experiments. Mean background MFI measurements and 
maximum signals recorded in the absence of competitors are as in Table 6.1. 
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cell lines, M12.NOD, M12.PRO and M12.ASP, calculated from two independent 
experiments. For the wild -type I -Ag7 molecule, the effect of truncating the CLIP ligand 
below 15 residues was severe, with no binding recorded whatsoever for the peptides 
CLIP89 -101, 90 -100 or 91 -99. Similarly for I- As7ProS6 any competition against the 
biotinylated CLIP86 -104 peptide by these shorter CLIP was unable to be measured. For 
I- Ag7Asp57 however, these progressive pairwise truncations caused a more gradual 
deterioration in the CLIP binding capacity, such that some inhibition of the biotinylated 
CLIP86 -104 signal was still able to be detected with the I3 -mer CLIP89 -101 peptide. 
This latter result is reminiscent of those obtained with other allotypes of the I -A class II 
MEC molecule, I -A°, I -Ak and I -Ad, using this same experimental approach (Chapter 4, 
Table 4.2). 
Lastly in this series of experiments, the contribution of the particular amino acid residues 
that flank the central sequence element, CLIP91 -99, to the interaction with the molecules, 
I -Ag7 I- As7ProS6 and I- Ag7Asp57, was explored further by evaluating the binding abilities of 
another set of CLIP86 -104 analogues, this time exhibiting a number of different 
truncations and/or L-alanine substitutions. Shown in Table 6.4 are the results of these 
peptides competing against biotinylated CLIP86 -104 for binding to the cell -surface I -A 
molecules of the cell lines, M12.NOD, M12.PRO and M12.ASP. Again, data are 
presented as mean ICSÓ values ± standard deviation from two independent experiments. 
Significant effects upon binding where not observed by sequence modifications at the N- 
terminus of the CLIP ligand, e.g. CLIP87 -104, 87A -104, consistent with these side 
chains not participating in favourable interactions with the three I -Ag7 variants (Figure 
6.6). However, of particular interest, the binding of CLIP to I -Ag7 and I- Ag7Pro56 
molecules was impaired significantly when the residues Ser 103 & Met 104 were deleted 
(i.e. CLIP87 -102). This is consistent with the side chain of Met 102 forming critical 
anchor contacts with these class II MHC molecules (Figure 6.6). In this context, it is 
envisaged that this anchor interaction might be weakened when this residue is not flanked 
by at least one other amino acid. By comparison, the binding of the CLIP ligand to I- 
Ag7Asp57 molecules was not affected as much by such modifications, consistent with the 
lesser contribution of the Met 102 residue to stabilising this interaction. It would also 
appear that the Ser 103 residue may provide some negative binding energy to the 
association of CLIP with the I -Ag7 ocf3 dimer, as indicated by the increase in binding 
observed when this residue was substituted by L- alanine (e.g. Ala -CLIP, 86- 103A). 
Alternatively, this may be the result of effects transmitted upon the neighbouring anchor 
residue, Met 102. Consistent with this, L- alanine substitution of the Ser 103 residue in 
the wild -type CLIP86 -104 sequence did not exhibit any effect upon binding affinity 
(Figure 6.6). 
Table 6.4 Competition by substituted and/or truncated CLIP86 -104 for binding to mutated I -A87 class II 
MHC molecules. 
CLIP ICso (µM) 
M12.NOD M12.PRO M12.ASP 
86-104 K PVS QMRMAT PLLMRPMSM 215.55 ± 6.29 141.15 ± 4.03 88.56 ± 1.95 
Ala-CLIP AAVS QMRMAT PLLMRPMAA 160.25 ± 9.69 115.60 ± 15.41 68.47 ± 5.13 
86-103 KPVSQMRMATPLLMRPMS 224.45 ± 10.96 150.25 ± 24.25 95.83 ± 1.20 
86-103A KPVSQMRMATPLLMRPMA 132.70 ± 12.87 86.03 ± 6.16 56.64 ± 0.04 
87-104 PVSQMRMATPLLMRPMSM 213.15 ± 7.57 180.10 ± 26.59 100.25 ± 4.46 
87A-104 AVSQMRMATPLLMRPMSM 227.00 ± 6.65 159.10 ± 12.45 108.10 ± 2.97 
87-102 PVSQMRMATPLLMRPM 476.75 ± 63.57 542.95 ± 123.67 134.05 ± 10.39 
88-103 VSQMRMATPLLMRPMS 189.65 ± 2.19 148.40 ± 9.62 92.81 ± 4.52 
Substituted and /or truncated CLIP86 -104 analogues were tested at multiple doses as competitors against biotinylated CLIP86 -104 (50 µM) for binding 
to the cell - surface I -A class II MHC molecules expressed by the M12.A3- derived cell lines, M12.NOD (wild -type I -Ac), M12.PRO (I- A8'R°ss) and 
M12.ASP (I -0 '1 '). Data are presented as mean IC50 values (µM) from two independent experiments. Mean background MFI measurements and 
maximum signals recorded in the absence of competitors are as in Table 6.1. 
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6.3.4 Serine at position 1357 in the I -Ag' MHC molecule bestows a 
preference for peptide ligands that exhibit an acidic residue at P9 
The 5 -chain mutations, f3Pro56His and (3Asp57Ser, in I -Ag' both have the potential to 
introduce preferences for negatively -charged side chains within the C- terminus of I -Ag'- 
binding peptides (discussed previously in §6.1.5). For example, the 5Asp57Ser 
mutation in I -Agl is predicted to confer a preference for an acidic residue at relative 
position P9 by consequence of the nearby unpaired positive charge of aArg 76 (Brown et 
al., 1993; Reich et al., 1994; Stern et al., 1994). An acidic residue which might interact 
with the 5His 56 residue of I -Ag', however, would be expected to be C- terminal to this 
position, perhaps at P10 or Pl l given the location of the 556 residue at the very edge of 
the binding cleft (Brown et al., 1993; Stern et al., 1994; Ghosh et al., 1995; Fremont et 
al., 1996, 1998b; Scott et al., 1998). To examine further the possible interactions of 
acidic residues with the 556 and 557 residues of the I -Ag' peptide -binding groove, a 
number of known ligands of this a5 dimer were examined for their ability to bind to the 
cell - surface molecules expressed by the four cell lines, M12.A3, M12.NOD, M12.PRO 
and M12.ASP. 
The sequences of the mouse serum albumin peptide, MSA560 -574, and the determinant, 
p12(166 -185), from the mouse heat shock protein 60 (HSP60), are shown in Figure 6.7a 
and 6.7h, respectively. Boxed amino acids indicate the 9- residue binding frame 
corresponding to the stretch of peptide likely to be accommodated within the 1 -M7 binding 
groove, as defined by the studies of Reich et al. (1994) and Reizis et al. (1997b), 
respectively. Notably, both of these I -Ag7- binding peptides exhibit an acidic residue in 
the form of glutamic acid at the P9 position (shown in bold), with a second C- terminal 
glutamic acid at position P10 (MSA) or Pll (p12). 
Representative experiments of the binding of biotinylated MSA560 -574 and p12(166- 
185) to the cell -surface class II MHC molecules of the cell lines, M12.A3, M12.NOD, 
M12.PRO and M12.ASP, are shown in Figures 6.7c and 6.7d, respectively. As 
performed previously with the binding of biotinylated CLIP ligands to these cell lines in 
Figure 6.3, adjustments have been made in the levels of median fluorescence intensity 
(MR) for any variations in the expression of the I -Ag7 class II MHC molecules. Both 
MSA and p12 peptides bound well to the wild -type I -M7 expressed at the surface of the 
M12.NOD cells (filled squares). This binding is specific for these class H MHC 
molecules on this cell line, as shown by the negligible associations recorded with the 
parental line, M12.A3, which expresses only I -E° (open squares). 
CLIP binding to I -Ag7 
a. MSA560-574 
b. p12(166-185) 
C. 
40 
CI) 
a.) 
30 
bio. MSA560 -574 
10 
C) 
ó 0 0 o o 
KPKATIAEQLKTVMDID 
EEIAQVATISANGDfKDIGNI 
d. 
25 
15 
10 
5 
0 
207 
bio. p12(166-185) 
ó 
Peptide concentration (tM) 
-0- M12.A3 
M12.NOD 
O M12.PRO 
-0- M12.ASP 
Figure 6.7 The binding of antigen- derived peptides to mutated I -M7 
class II MHC molecules. 
Biotinylated peptides (a) MSA560 -574, from mouse serum albumin, and (b) p12(166 -185), from mouse 
heat shock protein 60, were examined for their ability to bind to the mutated I -At7 class II MHC 
molecules expressed on the surface of the M12.A3- derived cell lines, M12.PRO (I- Ag7fto56) and 
M12.ASP (I- Ag7Asp57). Binding was compared to that shown with the M12.NOD cell line, also derived 
from M12.A3 but which expresses wild -type I -At7. In (e) and (d) are shown one of three independent 
experiments for each peptide. The level of non -specific binding of these peptides is indicated by the 
M12.A3 parental cell line. Binding is expressed as median fluorescence intensity (MFI) from which 
background signals, measured in the absence of biotinylated peptide, have been subtracted (M12.A3, 
3.40; M12.NOD, 2.69; M12.PRO, 3.05; M12.ASP, 2.64). MFI measurements have also been normalised 
for any minor differences in the levels of class II MHC expression between these cell lines, as determined 
by staining with OX6 -FITC. Cells were incubated with biotinylated peptide for 18 hours at 37 °C before 
flow cytometric analysis, as described in Chapter 2, §2.7.2. 
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Of particular note, there would not appear to be any electrostatic interactions formed 
between the MSA and p12 peptides and the wild -type I -Ag7 molecule via the 13His 56 
residue. This is indicated by the finding that the reintroduction of a proline residue at 
position (356 in I -Ag7 (I- Ag7Pro56 of the M12.PRO cells; filled triangles) did not impair 
binding. Indeed, such a modification led to an increase in the level of cell -surface binding 
of the MSA and p12 peptides, akin to that observed previously in the interaction of 
biotinylated CLIP86 -104 with M12.PRO cells (Figure 6.3). By contrast, there does 
appear to exist a relationship between the presence of an acidic residue in the C- terminal 
region of these peptides and the identity of the I -Ag7 residue at position (357 for productive 
binding. For example, the binding of both the MSA and p12 peptides to the I- Ag7Asp57 
molecules of the M12.ASP cells was extremely poor (filled circles). A negatively- 
charged side -chain at P9 would thus appear to be unfavourable when an aspartic acid 
residue is reintroduced at position 1357 of the I -Ag7 aß dimer. 
To examine further the influence of the 13Asp57Ser mutation in I -Ag7 on the preference for 
an acidic residue at the peptide position P9, two additional peptides were tested for their 
abilities to bind to this molecule and its single amino acid revertants. I- Ag7Pro56 and I- 
Ag7Asp57 the rat myelin oligodendrocyte glycoprotein determinant, rMOG8 -22 (Figure 
6.8a) and the hen egg lysozyme peptide, HEL10 -23 (Figure 6.8b). Like the MSA and 
p12 peptides, rMOG8 -22 exhibits an acidic residue at the P9 position in its binding frame 
(residue shown in bold within the boxed amino acids; Amor et al., 1996). Unexpectedly, 
however, unlabelled rMOG8 -22 peptide was found to compete equally well with the 
biotinylated CLIP86 -104 ligand for binding to the I -Aq7 expressed by the M12.NOD 
(Figure 6.8c; filled squares) as to the I- Ag7Asp57 molecules of the M12.ASP cells (filled 
circles). Also unexpected, this peptide showed reduced binding to the I- Ag7Pr°56 
molecules of the M12.PRO cell line (filled triangles). 
In comparison, the HEL10 -23 peptide does not exhibit an acidic residue at relative 
position P9 (residue shown in bold within the boxed amino acid binding frame; Harrison 
et al., 1997). A representative experiment of the binding of the biotinylated HEL peptide 
with the cell lines, M12.A3, M12.NOD, M12.PRO and M12.ASP, is shown in Figure 
6.8d, with MFI levels again adjusted for any variations in class II MHC expression 
between cell lines. As found for the MSA and p12 peptides previously (Figure 6.7), 
binding occurs specifically to the I -Ag7 molecules expressed by the M12.NOD cell line 
(filled squares) and not to I -E° also present on these cells, as indicated by the lack of 
fluorescence signal detected with the parental cell line, M12.A3 (open squares). 
Moreover, the binding of the BEL peptide to I -Ag7 indicates that the presence of an acidic 
residue at the peptide P9 position is not an absolute prerequisite for this interaction. The 
CLIP binding to I -Ag7 
a. rMOG8-22 
b. HEL10-23 
c. 
too 
PG YPIRALVGDIEQED 
AAIMKRHGLDNYIRGY 
rMOG8-22 
a 
75 
[ 50_ 
d. 
209 
bio. HEL10 -23 
Peptide concentration (µM) 
--o- M12.A3 
-6- M12.NOD + M12.PRO + M12.ASP 
Figure 6.8 The binding of antigen- derived peptides to mutated I -Ag7 
class II MHC molecules. 
The peptides (a) rMOG8 -22, from rat myelin oligodendrocyte glycoprotein, and (b) HEL10 -23, from 
hen egg lysozyme, were assessed for their ability to bind to the mutated I -Ag7 class II MHC molecules 
expressed by the cell lines, M12.PRO (I- Ag7Pro56) and M12.PRO (I- Ag7Asp57), Briefly, (c) rMOG8 -22 
was tested as a competitor against biotinylated CLIP86 -104 (50 11M) for cell -surface binding to 
M12.NOD, M12.PRO and M12.ASP cells. Data presented represent the mean percentage inhibition ± SD 
from two independent experiments. (d) Biotinylated HEL10 -23 was assessed for its ability to bind 
directly to the M12.PRO and M12.ASP cells. Binding was compared to that obtained with M12.NOD, 
also derived from M12.A3 but which expresses wild -type 1 -A57. Shown is one of three independent 
experiments, all yielding equivalent results. For the HEL peptide, binding is expressed as median 
fluorescence intensity (MFI) and non -specific associations are indicated by the M12.A3 parental cell line. 
For both (c) and (d), background signal, as determined in the absence of biotinylated peptide, has been 
subtracted from data (M12.A3, 3.40; M12.NOD, 2.69; M12.PRO, 3.05; M12.ASP, 2.64). MFI 
measurements have also been normalised for any minor differences in the levels of class II MHC 
expression between these cell lines, as determined by OX -6 -FITC staining. Cells were incubated with 
biotinylated peptide (± competitor) for 18 hours at 37 °C before flow cytometric analysis, as described in 
Chapter 2, §2.7.2. 
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absence of a proline residue at position 056 in I -Ag7 did not significantly affect the ability 
of HEL10 -23 to bind. Indeed, only a slight increase in the binding of this peptide was 
observed to the M12.PRO (filled triangles) when compared with the M12.NOD cells. 
Most importantly, however, in contrast to the results with the MSA and p12 peptides 
(Figure 6.7), the binding ability of the biotinylated HEL peptide was completely 
unaffected by the reintroduction of an aspartic acid residue into the 1357 position of the I- 
A° class II MHC molecule, i.e. this peptide bound equally weII to both the I -Ag' forms 
expressed by the M12.NOD and M12.ASP cell lines. 
6.3.5 I -Ag7- preferred peptides which exhibit an acidic P9 residue do not 
bind to mouse class II MHC molecules that express l3Asp 57 
The CLIP86 -104 peptide lacks any acidic residues in its C- terminus to fulfil either the 
desired charge interaction at the P9 pocket of the I -Ag' peptide -binding groove or to 
interact with the (3His 56 residue. In the context of the results presented in Figures 6.7 & 
6.8, it was therefore of interest to examine how the binding to I -Ag7 and its single amino 
acid revertant forms I- Ag'P`°ss and I -Ag7 S7 would be affected by the introduction of an 
acidic residue within this region of the CLIP sequence. 
Previous analyses of CLIP binding to other class II MHC molecules have indicated that 
residue Met 99 interacts typically within the P9 pocket of the peptide- binding groove (as 
described in Chapter 3, §3.4.4 & Chapter 5, §5.4.2). Accordingly, CLIP86 -104 
analogues were synthesised in which an acidic residue in the form of glutamic acid was 
introduced at this position (M99E; Table 6.5). The effect of such a residue was also 
tested at position 100 (R100E) within the CLIP86 -104 sequence, both as a single amino - 
acid substitution (R100E) and together with the replacement of the Met 99 side chain for 
an alanine residue (M99A/R100E). This latter peptide was synthesised in the event that 
the presence of methionine at position 99 in the single -substituted peptide was inhibitory 
to such an extent (as shown in Figure 6.6), that it masked any positive interactions made 
with an acidic residue at position 100. These three peptides were then tested alongside 
wild -type CLIP86 -104 and the singly -substituted M99A peptide for their abilities to 
compete against biotinylated wild -type CLIP86 -104 for binding to the forms of the I -M7 
molecule expressed by the cell lines, M12.NOD, M12.PRO and M12.ASP (Figure 6.9). 
Data are presented as mean percentage inhibition of the biotinylated CLIP signal from two 
independent experiments. 
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Table 6.5 Met 99 and/or Arg 100 -substituted CLIP86 -104 
analogues 
211 
wild-type K P V S Q M R M A T P L L M R P M S M 
M99A A 
M99E E 
R 100E 
M99A/R100E A E - - - - 
M99Q Q 
Amino acid sequences of CLIP86 -104 analogues bearing amino acid substitutions of residue 99 
and/or 100. Native amino acid residues are represented with a dash. 
As found previously in the L- alanine scan of the CLIP86 -104 sequence in Figure 6.6, the 
M99A peptide (filled diamonds) again competed considerably better than the wild -type 
CLIP sequence (open squares) for binding to I -Ag7 (Figure 6.9a), I- Ag7Pro56 (Figure 6.9b) 
and I- Ag7Asp57 (Figure 6.9c). The M99E peptide (filled circles) also competed extremely 
well for binding to I -Ag7 and I- Ag7Pr °56 however showed a remarkably poor ability to bind 
to I- Ag7Asp7 reminiscent of the binding of the MSA560 -574 and p12(166 -185) peptides 
to this same class II MI-IC variant (Figure 6.7). This result thus confirms that the residue 
equivalent to Ii- position 99 within the CLIP sequence is indeed the residue that interacts at 
the P9 pocket of the peptide- binding groove of the I -Ag7 aß dimer. 
Consistent with the alignment of Met 99 with the P9 pocket of the I -Ag7 groove, 
substitution of residue Arg 100 of the wild -type CLIP sequence for glutamic acid (R100E; 
filled triangles) did not create an analogue which bound well to I -Ag7. Indeed, the R100E 
peptide bound very poorly to both I -A57 and I- Ag7ProS6 (Figure 6.9). The L- alanine scans 
of the CLIP sequence shown in Figure 6.6 had not been completed at the time of 
designing this peptide or it would have been known that, in fact, the wild -type Arg 100 
residue is an important C- terminal anchor for the binding of CLIP to I -Ag7 molecules, and 
to a lesser extent, to I- Ag7Pr °56 However, binding of the R100E peptide was slightly 
better to I- Ag7AspS7 (Figure 6.9c). This is consistent with the wild -type Arg 100 residue 
providing less critical positive binding energy to stabilise the interaction between CLIP 
and this class 11 MHC variant (Figure 6.6c). Of particular interest, the removal of the 
favourable interaction between Arg 100 and the I -Ag7 and I- Ag7Pr °56 heterodimers by the 
R100E substitution was able to be compensated for by the replacement of the inhibitory 
methionine residue at position 99 with the smaller alanine in the peptide, M99A/R100E 
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Figure 6.9 Competition by substituted CLIP analogues for cell -surface 
binding to mutated I -Ag7 class II MHC molecules. 
Substituted CLIP86 -104 analogues were examined for their ability to inhibit the cell- surface binding of 
biotinylated CLIPS6 -104 (50 p.M) to the M12.A3- derived cell lines, M12.PRO (I- Ag7w °56) and 
M12.ASP (I- Ag7Asp57) which express mutated forms of the I -Ag7 class II MHC molecule. Binding was 
compared to that obtained with M12.NOD cells, also derived from M12.A3 but which express wild -type 
I -Ag7. Data shown represent the mean percentage inhibition ± SD from six independent experiments. 
Before calulating % inhibition, median fluorescence intensity (MFI) measurements were normalised for 
any minor differences in the levels of class II MHC expression between these cell lines, as determined by 
OX6 -FITC staining. Cells were incubated with biotinylated peptide and competitor for 18 hours at 37 °C 
before flow cytometric analysis, as described in Chapter 2, §2.72. 
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(filled squares). This peptide shows good binding to both I -Ag7 (Figure 6.9a), I- Ag7Pro56 
(Figure 6.9b), as well as to I- Ag7ASp57 (Figure 6.9c). 
In summary, both peptides, M99A and M99E, bound very weII to the I -Ag7 a1 dimer, 
but only M99A also binds to I- Ag7ASp57. To confirm that this was related to the presence 
of the negative charge at position P9 in the M99E peptide, another CLIP86 -104 analogue 
was synthesised, M99Q. The glutamine at position 99 in this peptide has the same 
molecular dimensions and similar polarity as the glutamic acid residue in M99E but lacks 
the negative charge (Table 6.5). The ability of the M99Q peptide (filled triangles) to 
compete against biotinylated CLIP86 -104 for binding to the MHC molecules, I -Ag7, I- 
Ag7ProS6 and I- Ag7ASp57 is shown in Figure 6.10, alongside wild -type CLIP86 -104 (open 
squares) and its substituted analogues, M99A (filled diamonds) and M99E (filled circles), 
for comparison. 
The introduction of a glutamine residue at position 99 of the CLIP sequence created 
unfavourable contacts between this peptide and all three forms of the I -Ag7 molecule 
expressed by the M12.NOD, M12.PRO and M12.ASP cell lines, as shown by its poor 
competitive abilities. In fact, the M99Q CLIP analogue competed as poorly for binding to 
I- Ag7Asp57 as the M99E analogue. Thus it maybe concluded that M99E binds well to I -Ag7 
and I- Ag7Pr °56 through the provision of a negative charge at position P9. Indeed, it would 
appear that this ligand was able to bind to these molecules despite the molecular 
dimensions of the glutamic acid residue at position 99 within the CLIP sequence being 
generally unfavourable for interacting at the P9 pocket of the I -Ag7 molecule. 
Lastly, given that the lAsp 57 residue is conserved in all other mouse class II MHC 
molecules (Mengle -Gaw & McDevitt, 1983; Davis et al., 1989), it was of interest to 
determine whether the presence of a negatively- charged residue at position 99 within the 
CLIP sequence would destroy the binding of this ligand to these variants, as found for the 
3Ser57Asp I -Ag7 revertant, I- Ag7ASp57 in Figures 6.7, 6.9 and 6.10. Shown in Figure 
6.11, the peptides M99A, M99E and M99Q were examined alongside wild -type CLIP86 - 
104 (open squares) for their ability to compete against biotinylated CLIP86 -104 for 
binding to the ceII- surface mouse class H MHC molecules, I -Ad (Figure 6.11a, b), I -A° 
(Figure 6.11c) and I -A5 (Figure 6.11d). Data are presented as mean percentage inhibition 
± standard deviation from two independent experiments. Compatible with the L- alanine 
scan reported in Chapter 3 (Figure 3.6) and by Gautam et al., 1995), the replacement of 
Met 99 by the smaller L- alanine residue (filled diamonds) led to an improvement of 
binding of this ligand to all three I -A variants examined. By contrast, the presence of a 
glutamine residue at this position was much less favourable to binding than both the 
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Figure 6.10 Competition by substituted CLIP analogues for cell -surface 
binding to mutated I- Ag7class II MHC molecules. 
CLIP86 -104 analogues substituted at position 99 were examined for their ability to inhibit the cell - 
surface binding of biotinylated CLIP86 -104 (50 µM) to the M12.A3- derived cell lines, M12.PRO (I- 
Ag7Pro56) and M12.ASP (I- Ag7AsP57) which express mutated forms of the I -Ag7 class II MHC molecule. 
Binding was compared to that obtained with M12.NOD cells, also derived from M12.A3 but which 
express wild -type I -Ag7. Data shown represent the mean percentage inhibition ± SD from six independent 
experiments. Before calculating % inhibition, median fluorescence intensity (MFI) measurements were 
normalised for any minor differences in the levels of class II MHC expression between these cell lines, as 
determined by OX6 -FITC staining. Cells were incubated with biotinylated peptide and competitor for 18 
hours at 37 °C before flow cytometric analysis, as described in Chapter 2, §2.7.2. 
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Figure 6.11 Competition by substituted CLIP analogues for cell -surface 
binding to diabetes - resistant I -A class II MHC molecules. 
Analogues of CLIP86 -104 exhibiting amino acid substitutions at position 99 were examined for their 
ability to inhibit the cell -surface binding of biotinylated CLIP86 -104 to the cell lines, A20 (H -2d), 
M12.D (I -Ad), 1 -5.4 (I -A °) and CH27 (H -2k). Data shown represent the mean percentage inhibition ± SD 
from two independent experiments. Cells were incubated with biotinylated CLIP (50 µM for A20, M12.0 
& CH27; 75 µM for 1 -5.4) and competitor peptide for I8 hours at 37 °C before flow cytometric analysis, 
as described in Chapter 2, §2.7.2. 
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smaller alanine residue and the wild -type methionine residue (filled triangles). This latter 
result is consistent with those shown in Figure 6.9 of the binding of this peptide to the 
MHC molecules, I -Ag', I- Ag7ProS6 and I- Ag7A'F'7. Most significantly, however, the M99E 
CLIP analogue (filled circles) did not bind to these three 'normal` mouse I -A molecules. 
(The greater experimental errors recorded for the CH27 cell line reflect the low affinity of 
the CLIP -I -Ak interaction, such that the binding of biotinylated CLIP86 -104 to CH27 
cells produces a lower signal of median fluorescence intensity; discussed in Chapter 3, 
§3.4.6). Thus the presence of an aspartic acid residue at position 1357 conserved in all 
other class II MHC molecules is likely to preclude the binding of peptides that exhibit an 
acidic residue at the P9 position. 
6.4. Discussion 
6.4.1 CLIP makes unique side -chain anchor interactions with residues 
of the wild -type I -Ag7 class II MHC molecule 
Experiments in this chapter have sought to explore biochemical characteristics of the NOD 
class H MHC molecule, I -Ag7, in particular, to determine the molecular details of how 
peptide ligands interact with this unusual a(3 heterodimer Similar information was 
obtained successfully for other mouse class II MHC molecules in Chapters 3 -5 by 
examining the binding of a broad array of substituted and/or length -altered variants of the 
promiscuously- binding invariant chain peptide, CLIP. Here in this chapter, analogues of 
this peptide have been used once again, this time to determine the features of the CLIP 
sequence that are critical for its interaction with I -Ag'. 
Using this approach, it has been revealed that CLIP86 -104 binds to wild -type I -Ag' by 
forming contacts through the backbone atoms of residues, 91 -100 (Figure 6.5). Similar 
interactions were found previously between this ligand and the other mouse I -A variants, 
I -Ad, I -Au and I -Ak (Chapter 4, §4.4.1). However, unique to I -As', the binding of CLIP 
is also critically reliant upon the formation of additional bonds via particular C- terminal 
residues of the peptide sequence (Figures 6.5 & 6.6, Tables 6.2 -6.4). Specifically, the 
side chains of Leu 97, Arg 100 and Met 102 appeared to form critical anchor interactions 
with the I -Ag7 a(3 dimer, without which binding was not sustained (Figure 6.6a). 
Additional positive binding energy was provided through side -chain interactions the 
residues, Leu 98 and Pro ICI, while the native CLIP residues, Pro 96 and Met 99, were 
inhibitory to binding. The binding to I -Ag' of additional longer CLIP ligands (Figure 6.4; 
Table 6.1), frameshifted 15 -mers (Table 6.2), truncated CLIP (Table 6.3) or analogues 
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that exhibited a combination of L- alanine substitutions and/or truncations (Table 6.4) also 
differed from that observed previously between these ligands and other mouse class II 
MHC molecules of both I -A and I -E isotypes (Chapter 3, Figure 3.1; Chapter 4, Figure 
4.2, Tables 4.2 -4.4 & Chapter 5, Tables 5.1 -5.3). For example, while the affinity of 
CLIP for I -Ad, I -Ak, I -A° and I -Ed molecules was influenced by changes at the N- 
terminus, the interaction of this ligand with I -Ag' was critically dependent upon the 
presence of the C- terminal residues, Pro 101 and Met 102. Lastly, a CLIP analogue that 
exhibited a glutamic acid residue at position 99 instead of the native methionine residue 
was found to bind with high affinity to the wild -type I -Ag7 molecule (Figures 6.9 & 
6.10). This result is consistent with reports that this aß dimer favours ligands that have 
an acidic residue at relative position, P9 (Reich et al., 1994; Amor et al., 1996; Harrison 
et al., 1997; Reizis et al., 19976; Zechel et al., 1997). 
In order to interpret the experimental findings reported herein with I -A °, it is necessary to 
have an understanding of how peptides typically bind to this class II MHC molecule. To 
date, a number of research groups have explored the interaction of I -Ag7 with different 
antigen- derived peptides and have proposed generalised motifs of the features preferred 
for binding to this atypical class II MHC variant. Moreover, although an X -ray 
crystallographic structure of I -Ag' has yet to be published, an approximation of the overall 
three -dimensional molecular arrangement of the atoms comprising its peptide -binding 
groove may be obtained from the X -ray crystallographic structures of the closely -related 
mouse class II MHC molecules, I -Ad (Scott et al., 1998) and I -Ak (Fremont et al., 
1998b). Indeed, the primary sequences of the a, domains of I -Ad and I -Ag' are identical 
(Acha -Orbea & McDevitt, 1987) while there are just 12 amino acid differences between 
the a, domains of I-A'7 and I -Ak, (Benoist et al., 1983a). Similarly, the (3, domain of I- 
Ag7 differs from that of I -Ak also by 12 residues and from I -Ad by 17 residues (Acha- 
Orbea & McDevitt, 1987). 
From an examination of such data, it would appear that interactions between antigen - 
derived peptide ligands and I -Ag' are not significantly different from those with other 
class II MHC molecules. For example, substitution and truncation analyses of a range of 
synthetic ligands (Reich et al., 1994; Amor et al., 1996; Harrison et al., 1997; Reizis et 
al., 1997b), together with sequence data of naturally -processed peptides eluted from 
affinity- purified I -Ag' (Reich et al., 1994), have revealed that important contacts are made 
with I -Ag' via the amino -acid side chains at the relative positions, Pl, P4, P6, P7 and P9 
of the bound peptide (Reizis et al., 1997b). By extrapolation from the I -Ad and I -Ak 
crystal structures (Fremont et al., 1998b; Scott et al., 1998), the positioning of these 
interactions corresponds, as expected, with the major specificity -determining pockets 
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within the peptide -binding groove. This has also been borne out in computer -generated 
homology models of the I -Ar protein structure (Amor et al., 1996; Reizis et al., 1997b) 
based upon the X -ray crystallographic coordinates of HLA -DR1 complexed with the 
influenza haemagglutinin peptide, HA306 -318 (Stern et al., 1994). Moreover, a ligand 
bound within the groove of the I -Ag' molecule may be predicted to exhibit a similar 
conformation to that seen in other peptide -class II MHC complexes, since the asparagine 
residues that are important for forming the main -chain hydrogen -bond network with the 
ligand in these molecules are also conserved in the I -Ag7 aß dimer (positions a62, a69 
and 082; Chapter 4, §4.4.2; Acha -Orbea & McDevitt, 1987; Liu et al., 1993). Thus, 
CLIP may be envisaged to bind to wild -type I -Ao with its backbone tethered by an 
elaborate system of hydrogen bonds, while its downward- oriented side chains are 
accommodated within the pockets of the peptide -binding groove. 
6.4.2 Most of the favourable interactions between CLIP side chains and 
wild -type I -Ag7 do not take place at conventional anchor pockets 
The participation of both backbone and side -chain atoms in the positive binding 
interactions of CLIP with the wild -type I -Ag7 a(3 dimer is unusual for a molecule of the I- 
A isotype (Figure 6.6a). Analysis of CLIP binding to I -A °, I -Au and I -Ak identified few, 
if any, favourable side -chain contacts (Chapter 3, Figures 3.2, 3.3 & 3.6). In order to 
understand specifically how the C- terminal CLIP residues, Leu 97, Leu 98 and Arg 100 - 
Met 102 might make favourable contacts with I -Ar, it is necessary to consider the 
probable spatial arrangement of the atoms of this a13 dimer in the vicinity of the predicted 
interaction sites. Such information is collated in Table 6.6 for the peptide- binding groove 
of I -Ag' and is based upon data from homology models of this molecule (Amor et al., 
1996; Reizis et al., 1997b), X -ray crystallographic studies of other class II MHC variants 
(Stern et al., 1994; Ghosh et al., 1995; Fremont et al., 1998b; Scott et al., 1998), 
sequence comparisons (Acha -Orbea & McDevitt, 1987; Davis et al., 1989; Liu et al., 
1993) and analyses of a subset of peptide ligands that bind to I -Ag' (Reich et al., 1994; 
Amor et al., 1996; Harrison et al., 1997; Reizis et al., 1997b, 1998). For comparison, 
data is also shown in Table 6.6 for the corresponding interactions of CLIP side chains 
with the pockets of the closely- related I -A° and I -Ak class II MHC molecules, as detailed 
previously in Chapter 3, Table 3.2. 
Firstly, it is significant to note that the unusual anchor interactions between CLIP and I 
Ag7 do not appear to arise from a change in the frame of binding. Indeed, the 
demonstration that the side chain at position Ii99 of the CLIP sequence interacts with the 
Table 6.6 The interaction of CLIP side chains with the pockets of the I -A87 peptide -binding groove. 
Shown are the amino acid residues whose atoms contribute to the major polymorphic pockets of the peptide -binding groove of I -A7. This information is presented in 
comparison to that of the closely -related class II MHC molecules, I -Ad and I -Ak, shown previously in Chapter 3, Table 3.2. For I -Ag7, residues have been taken from 
homology models of this a(3 dimer, where possible (Amor et al., 1996; Reizis et al., 1997). Alternatively, residues have been extrapolated from equivalent analyses and X- 
ray crystallographic studies of 1-Al' and I -A5 (Lee & McConnell, 1995; Tate et al., 1995; Liang et al., 1996; Nelson et al., 1996; Bartnes et al., 1997; Fremont et al., 
19986; Nydam et al., 1998; Scott et al., 1998; Weber et al., 1998). Within each pocket, these residues form either hydrogen bonds or van der Waals interactions with the 
atoms of the amino acid side chains of a bound peptide. Throughout this thesis, class II MHC residues are numbered according to the secondary structure -based sequence 
alignment of the et, and Í3i domains of the molecules, I -Ak, I -Ek and HLA -DR, reported by Fremont et al. (1998b). The primary amino acid sequences of the cr and ßi 
domains of the different I -A molecules are taken from Acha -Orbea & McDevitt (1987), Davis et al. (1989) and Liu et al. (1993). Polymorphic residues between the I -A 
molecules are italicised. Those underlined confer a specific physicochemical property to the pocket to govern its overall peptide side -chain preference. For I -As', the peptide 
side chains commonly found at each position have been taken from alignments of naturally -processed ligands of this molecule (Reich et al., 1994; Amor et al., 1996; 
Harrison et al., 1997; Reizis et al., 1997, 1998). The individual side chains of the native CLIP sequence that bind at these positions are shown in italics beneath the 
respective pocket number. 
'The nature of the interaction of the native CLIP side chains is summarised from the cell- surface binding assay (pH 7.0; Figure 6.6) presented in this chapter. 
"I3Asp 57 is mutated to a serine residue in the I -As7 class II MHC molecule from the non -obese diabetic (NOD) mouse. The presence of a non -Asp residue at this position 
has been linked to the development of autoimmune diabetes in both these animals and in humans. 
represents an anchor side chain within the CLIP sequence, such that binding to the I -A molecule is not sustained if this residue is substituted with L- alanine. 
represents the provision of positive binding energy by this CLIP side chain at the binding interface. / represents the provision of negative binding energy by this CLIP side chain at the binding interface. 
represents no notable contribution of binding energy by the CLIP side chain to the interaction with I -A or, in the case of the wild -type CLIP residue at the P4 
position, Ala 94, where this side chain was not examined by substitution analysis. 
Allotype 
I-Ag' 
Pl 
Met 91 
P4 
Ala 94 
P6 
Pro 96 
P7 
Leu 97 
P9 
Met 99 
("His 24, aPhe 54, ßAsn 82, aAsn 62, ßPhe 11, ßThr 71, aThr 11, aAsn 62, aGlu 66 aAsn 69, Tyr 30, ßTyr 47, 
ßThr 85 ßGlu 74 ßHis 9, ßPhe 11 ßTyr 61 
Pocket character: large, unrestricted 
Residues observed: e.g. Leu, Tyr, Glu, Gln 
°CLIP interaction: 
I-Ad aHis 24, aLeu 31, aPhe 32, 
aTrp 43, alle 52, aLeu 53, 
aPhe 54, Asn 82, ßPro 85 
Pocket character: large, unrestricted 
Residues observed: e.g. Tyr, Thr, Glu, Ser 
°CLIP interaction: 
I-A'` aPhe 24, aLeu 31, aPhe 32, 
aTrp 43, aArg 52 aArg 53, 
aPhe 54, ßAsp 82, ßThr 85 
Pocket character: medium, amphiphilic 
Residues observed: e.g. Asp, Glu, Thr, Cys 
°CLIP interaction: 
medium, amphiphilic 
e.g. Leu, Ile, Val 
aTyr 9, aGly 9a, aAsn 62, 
ßPhe 11, ßGly 13, ßThr 28, 
ßGlu 74, ßAla 78 
medium, hydrophobic 
e.g. Val, Ile, Leu, Ala 
aTyr 9, aGly 9a, aAsn 62, 
ßPhe 11, ßPro 13, ßLeu 26, 
ßlle 28, ßGlu 74 ßVal 78 
large, hydrophobic 
e.g. Ile, Val, Leu, Asn 
small, polar large, amphiphilic 
e.g. Ala, Thr, Ser, Val e.g. Leu, Arg, Tyr, Asn 
N 
aAsn 69, alle 72, aLeu 73, 
aArg 76 ßSer 57", ßTyr 60, 
ßTyr 61 
medium, basic 
e.g. Glu, Asp 
N 
aAsn 62, aAla 65 aGlu 66, aAsn 69, ßThr 28, ßTyr 30, aHis 68, aAsn 69, alle 72, 
ßVal 9, ßPhe 11, Tyr 30 ßTrp 61, 811e 67, G3Thr 71 aArg 76, ßVal 38, ßAsp 57k, 
ßTyr 60, ßTrp 61 
shallow, amphiphilic 
e.g. Ala, Val, Ser 
fi 
aThr 11, aAsn 62, aThr 65, 
aGly 66, aAsn 69, ßHis 9, 
ßPhe 11, ßTyr 30 
medium, polar 
e.g. Glu, Gln 
N 
shallow, hydrophobic medium 
e.g. Ala, Leu, Gly, Val e.g. Ala, Ser, Val 
aThr 65, aAsn 69, ßlle 28, 
ßTyr 30, ßTyr 47, ßTrp 61, 
(3Gln 64, ßTyr 67, ßArg 70 
shallow, hydrophobic 
no basic residues 
aHis 68, aAsn 69, alle 72, 
aLeu 73, aArg 76, ßTyr 37, 
ßAsp 57°, ßTrp 61 
medium, amphiphilic 
e.g. Ser, Thr, Ala, Gly 
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P9 pocket of I -Ag' (Figure 6.9) indicates that this ligand binds within the groove of this 
heterodimer in the same alignment as determined previously for the binding of CLIP to 
HLA -DR (Ghosh et al., 1995), I -A (Chapter 3, §3.4.4; Lee & McConnell, 1995) and I -E 
molecules (Chapter 5, §5.4.2). Thus, the first pocket in the I -Ag' peptide -binding 
groove, Pl, accommodates the CLIP side chain, Met 91. The lack of effect observed 
when this residue was substituted for the smaller alanine in Figure 6.6a is consistent with 
a previous consensus motif reported for peptides binding to I -Ag' suggesting that this 
pocket is particularly degenerate (Reizis et al., 1997b). Indeed, these authors tested a 
number of amino acids at Pl in a synthetic polyalanine nonamer that was anchored only at 
relative positions, P7 and P8, and found that representatives of all the major classes of 
amino acid side chains were accommodated efficiently. A similar lack of a specific side 
chain preference has been reported for the P1 pocket of I -Ad (Bartnes et al., 1997; For a 
full description of the Pl pocket of I -Ad, see Chapter 3, §3.4.4). Amor et al. (1996) have 
shown from their homology model of I -Ag' complexed with the peptide, PLP56 -70, from 
mouse proteolipid protein, that the side chain of the Asn 62 residue that binds in the PI 
pocket may hydrogen bond with 13Thr 85. 
The role of the native CLIP residue that corresponds to the I -Ag7 P4 pocket was not 
examined by substitution analysis in this study, being already L- alanine (Ala 94). 
However, it is likely that this small residue is accommodated passively at this position. 
Previous peptide -substitution analyses have shown that this site in I- Ag'receives aliphatic 
residues most favourably but aromatic or small polar side chains may also be accepted 
(Reizis et al., 1997b). Amor et al. (1996) have also proposed that there might be a 
specific bias towards a basic residue at this position. Indeed, such a preference was 
apparent when these authors aligned the binding frames of the peptides, PLP56 -70 and 
rMOG8 -22. However, Reizis et al. (1997b) have found that the introduction of a 
positively -charged side chain at this position into their anchored polyalanine nonamer 
caused a decrease in binding. In this respect, it is interesting to note that the residue 
suggested by Amor et al. (1996) to confer the preference for a basic residue at P4, (3Glu 
74, is also conserved in I -Ad and I -Ak and neither of these molecules has been reported to 
bind positively- charged residues at this position (Liu et al., 1993). Similarly, I -Ek shows 
a preference for aliphatic or polar P4 side chains despite the presence of [3Glu 74, while 
the I -Ed heterodimer does show a clear bias for basic residues at this position yet the [374 
position in this molecule is occupied by a serine. Instead, the acidic character of the P4 
pocket of I -Ed is provided by (3Asp 70, a position occupied by an arginine residue in I -Ag7 
(For a full discussion of the peptide- binding motifs of I -Ed and I -Ek, see Chapter 5, 
§5.4.2). The crystal structures of I -Ad and I -Ak have shown that the lIGlu 74 residue 
does not confer an acidic character to this pocket but, rather, makes extensive van der 
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Waals contacts with aliphatic peptide side chain bound at this position (Fremont et al., 
1998b; Scott et al., 1998). It is possible that the basic residues observed by Amor et al. 
(1996) to be enriched within I- Ag'- hínding peptides are instead at the P5 position. Such 
residues have been noted here in natural ligands of this molecule (Reich et al., 1994). 
Moreover, the P5 side chain is predicted to be oriented out of the groove (Stern et al., 
1994; Ghosh et al., 1995; Dessen et al., 1997; Fremont et al., 1998b; Scott et al., 1998) 
and basic residues typically represent good TCR contact sites (Alexander et al., 1994). 
The next prominent pocket within the peptide -binding groove of I -Ag7 occurs at relative 
position, P6. Amino -acid substitution analysis of antigen- derived ligands of I -Ag7 has 
revealed that this pocket optimally accommodates small, polar residues (Reizis et al., 
1997b). Thus, the enhancement of binding found in this study when the native CLIP 
residue, Pro 96, was replaced with alanine (Figure 6.6a) is likely to be the result of an 
alleviation of steric compression at this site. The small molecular dimensions of the P6 
pocket are also common to [ -Ad and I -Ak (Fremont et al., 19986; Scott et al., 1998) by 
consequence of a large residue at position a66 for I -A" and, similarly, at position 139 for 
I -Ak. In the I -Ag7 molecule, both of these particular residues are present, most likely 
making this pocket even smaller. The side chains of aGlu 66 and 1His 9 also contribute 
to the polar character of this pocket in I -Ag7. 
The P7 pocket of I -A'' represents the first site at which an anchor interaction takes place 
via a residue of the CLIP sequence, Leu 97 (Figure 6.6a). Substitution analyses of 
antigen- derived peptides have shown that a broad variety of amino acids may be 
accommodated here, most likely owing to the large molecular dimensions of this pocket, 
as revealed by homology modelling of the I -Ag7 peptide -binding groove (Reizis et al., 
19976). Such degeneracy in the side -chain preferences of the P7 pocket is a feature 
common to most I -A, I -E and HLA -DR class H MHC molecules (Chapter 3, §3.4.4 & 
Chapter 5, §5.4.2). Nevertheless, the side chains that provide the most positive binding 
energy at this site within I -Ag' are large with a hydrophobic component. The Leu 97 
residue of the CLIP sequence fulfils both of these requirements. The loss of binding 
observed in this study when this residue was replaced by alanine (Figure 6.6a), is 
equivalent to that seen by Reizis et al. (1997b) upon a similar substitution within their 
anchored polyalanine nonamer. For example, the ability of the 9 -mer synthetic ligand to 
inhibit T cell stimulation by antigenic peptide, p12(166 -185), increased from just 25% 
with an alanine residue at P7 to 75% when a leucine residue was introduced. 
Lastly, the wild -type CLIP residue at the P9 position, Met 99, is inhibitory to binding 
(Figure 6.6a) with either an alanine or a glutamic acid residue being more favoured 
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(Figure 6.9). The unusual specificity of the P9 pocket in I -Ag' for an acidic residue and 
the relationship of this to the I -Ag'- specific mutation at position 1357 is discussed in detail 
below ( §6.4.3). 
Thus, only in the one instance do any of the side -chain anchor interactions shown in this 
study to be critical for the binding of CLIP to I -Ag' occur at conventional specificity - 
determining pockets within the peptide- binding groove, namely, the residue Leu 97 at P7. 
The favourable interactions of the side chains, Leu 98, Arg 100, Pro 101 and Met 102 
must therefore all take place via atypical means. For example, the P8 side chain of 
ligands bound to I -Ag7 is predicted to extend outwards from the groove to represent a 
possible TCR contact site (Amor et al., 1996), an arrangement typical at this position in 
most class II MHC molecules (Stern et al., 1994; Dessen et al., 1997; Fremont et al., 
1998b; Scott et al., 1998). Meanwhile, extrapolating from the crystal structure of CLIP 
complexed with HLA -DR3, the residues Arg 100 (P10) and Pro IOI (P11) would be 
expected to lie at the outermost edge of the I -Ag' peptide -binding groove, with Met 102 
(P12) extending beyond this site altogether (Ghosh et al., 1995). 
The formation of these unconventional anchor residues between CLIP and I -Ag' is 
reminiscent of the interaction of CLIP with I -Ed molecules reported in Chapter 5 (Figure 
5.8). There too, the residues, Leu 98 and Met 102, together with Thr 95, formed anchor 
contacts with the class II MHC molecule outside of the pockets of the peptide -binding 
groove. Similarly, Met 102 was found to provide positive binding energy to the 
interaction between CLIP and the three I -A alIotypes, I -Ad, I -Ak and I -A" in Chapter 3 
(Figures 3.2, 3.3 &3.6) and Leu 98 was favourable to the association with I -Ad (Figures 
3.2 & 3.6). As discussed previously, it is difficult to elucidate how these residues 
contribute positive binding energy, particularly without relevant X -ray crystallographic 
data. For example, equivalent interactions were not present in the crystal structures of I- 
Ad and I -Ak complexed with antigen- derived peptides (Fremont et al., 1998b; Scott et al., 
1998) and, therefore, little structural detail of these molecules is available beyond the 
immediate environment of the prominent specificity pockets. Moreover, the knowledge 
of how the atoms are arranged around the C- terminus of a peptide bound to I -Ad and I -Ak 
may be of limited use anyway with respect to the I -Ag' a3 dimer, given the 
conformational differences that may be present in this area as a result of the f3Pro56His 
and (3Asp57Ser mutations (discussed subsequently in §6.4.4 & §6.4.5, respectively). 
Unfortunately, the homology models of I -Ag' also fail to provide much information on the 
structural organisation at the atomic level of this region of the a(3 dimer (Amor et al., 
1996; Reizis et al., l 997b), as does the crystal structure of CLIP complexed with HLA- 
DR3 ( Ghosh et al., 1995) and homology models of this ligand associated with I -Ad, I -A" 
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and I -Ak (Lee & McConnell, 1995). It is interesting to note, however, that the mouse 
CLIP residues Arg 100, Pro 101 and Met 102 have been identified to be critical for the 
activation of an I -Ab- restricted T cell hybridoma generated in li° mice that recognises the 
peptide, mCLIP86 -102 (Naujokas et al., 1998). Similarly, activation of another I -Ab- 
restricted T cell hybridoma, this time recognising human CLIP89 -102, is dependent upon 
the hCLIP residues at positions 100 (Gin) and 101 (Ala) (Morkowski et al., 1995). The 
availability of these residues as important TCR contact sites when CLIP binds to I -Ab is 
consistent with their predicted exposure to the solvent. 
6.4.3 An acidic residue at the P9 position of an I -Ag7- binding peptide 
provides a surrogate charge interaction with aArg 76 
In this study, the introduction of a glutamic acid into the CLIP sequence at the P9 position 
was found to result in a marked increase in the affinity of this peptide for I -A° (M99E; 
Figures 6.9 & 6.10). This finding is consistent with previous reports of the P9 pocket of 
the I -Ag' a(3 dimer having a preference for acidic residues. For example, such residues 
are commonly found within the C- terminus of naturally -processed peptides eluted from 
these molecules (Reich et al., 1994) and are also noted frequently in this region when 
sequences of synthetic I -Ag7- binding peptides are aligned (Amor et al., 1996; Harrison et 
al., 1997; Zechel et al., 1997). Moreover, Reizis et al. (1997b) have found that a 
glutamic residue at the P9 position in their anchored polyalanine nonamer yielded nearly 
100% inhibition of I -Ag7- restricted T cell proliferation stimulated by their reference 
peptide, compared with less than 25% inhibition provided by most other physicochemical 
types of amino acid side chain tested at this position. Similarly, when the P9 acidic 
residue is truncated from the C- terminus of a natural I -Ag7 ligand, such as MSA560 -574, 
binding is impaired severely (Reich et al., 1994). 
The ability of an acidic residue to provide positive binding energy to the interaction with I- 
Ag7 is considered to be a consequence of the 3Asp57Ser mutation in this molecule. 
Specifically, the inability to form the 357 -a76 salt bridge at the base of the P9 pocket 
leaves the positively- charged aArg 76 residue unpaired and seeking to create a surrogate 
ion- pairing with a suitable side chain in the peptide. Consistent with this, molecular 
models of the I -Ar peptide -binding groove appear to show that the side chain of the aArg 
76 residue is oriented into the P9 pocket, contributing a basic character to this site and 
ideally placed to form an ionic interaction with the incoming side chain of the P9 residue 
of the bound peptide (Amor et al., 1996; Reizis et al., I997b). 
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In common with I -Ar, other class II MHC molecules that lack an aspartic acid residue at 
position (357 also exhibit a preference for negatively -charged side chains at the P9 
position of peptide ligands, dictated by the unpaired positive charge of the ctArg 76 
residue. For example, substitution and truncation analyses of synthetic peptides which 
bind to HLA -DQ8 (DQAI *0301/DQB1 *0302; 3Ala 57) have revealed that the presence of 
an acidic residue at P9 yields a ligand capable of binding with high affinity to this 
molecule (Kwok et al., 1996a, 1996b; Godkin et al., 1997; Oiso et al., 1997). 
Moreover, such a residue is featured in all predominant naturally -processed peptides 
eluted from DQ8 (Chicz et al., 1994) and the enrichment of these residues in the Edman 
degradation cycles 12 -14 by pool sequencing confirms their location to be at P9. (Godkin 
et al., 1997). Peptides exhibiting acidic residues at the P9 position are similarly favoured 
for binding to HLA -DR4Dw 15 (DRAIDRB 1 *0405; f Ser 57), as determined by 
sequencing individual (Kinouchi et al., 1994) and pooled natural Iigands (Friede et al., 
1996), together with a binding analysis of substituted peptides (Marshall et al., 1994). 
Likewise, the determination of peptide- binding motifs for the Lewis rat RTI.B' class IT 
MHC molecule (3Ser 57) reveals that this heterodimer preferentially binds peptides with 
negatively- charged residues at P9 (Reizis et al., 1996; Wauben et al., 1997). Moreover, 
Reizis et al. (1996) have substituted such a residue into mouse CLIP86 -102 and observed 
a 10 -fold improvement in the binding of this peptide to RT1.B', akin to the experimental 
findings in this study with I -Ag' (Figure 6.9 & 6.10). 
Although an acidic residue at P9 provides significant positive binding energy to the 
interaction of peptides with I -Ag' through charge pairing with aArg 76, peptides lacking 
such a residue may still bind to this molecule. This is demonstrated clearly in this study 
by the ability to measure the binding of both wild -type CLIP and the M99A analogue to I- 
M7 (e.g. Figures 6.9 & 6.10). Harrison et al. (1997) have determined similarly that a C- 
terminal acidic residue is not necessary for peptides to be able to bind to I -Ar. However, 
close scrutiny of the I -Ag7 binding motif proposed by these authors reveals a likely error 
in the alignment of the peptide residues relative to the pockets of the I -Ag' groove. For 
example, the side -chain preferences determined by Harrison et al. (1997) for what they 
term the "P6" and "P9" primary anchors - large, hydrophobic residues and aromatic, 
hydrophobic or basic residues, respectively - would appear to be better aligned with the 
P4 and P7 pockets, respectively (Table 6.6). Not only do these side chain preferences fit 
much better at these positions with other assessments of the binding motif of I -Ag' and the 
molecular model of the I -Ag7 binding groove constructed by Reizis et al. (1997b; 
described above, §6.4.2) but the interaction of a basic residue at the P9 pocket, as 
proposed by Harrison et al. (1997), is likely to be extremely unfavourable (see below). 
Instead, the decrease in binding that is observed when a basic residue is substituted into 
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position "Pl 1" of the HEL10 -22 peptide in the study of Harrison et al. (1997), suggests 
that this is the true P9 residue. Moreover, the increase in binding affinity observed when 
Asn 19 at "P8" was substituted with alanine is more compatible with this residue 
interacting with the small P6 pocket of I -Ag7 (Table 6.6). Indeed, the true P8 residue 
would be unlikely to show such an effect given that it is predicted be oriented 
predominantly out of the peptide- binding groove to be an important TCR contact site 
(Amor et al., 1996). The Arg 21 residue at position "Pl l" fits this role much better, not 
only because basic residues are frequently critical for TCR recognition (Alexander et al., 
1994) but also because the substitution of this residue repeatedly shows a greater 
disruption of T cell activation than actual binding to the I -Ag' molecule (Harrison et al., 
1997). Cohen (1997a) and Reizis et al. (1998) have suggested similarly that an error 
exists in the alignment of the peptide -binding motif of Harrison et al. (1997) and the 
alignment of the HEL10 -23 peptide shown in Figure 6.8a has been adjusted accordingly. 
Nevertheless, true to the conclusion of Harrison et al. (1997) that peptides lacking acidic 
P9 residues may still bind to I -Ag7, the new alignment of their peptide- binding motif 
places an uncharged residue, Gly 22, at the P9 position of the HEL10 -22 peptide. 
Furthermore, truncation and substitution analysis of the binding to I -Ag' of this peptide 
did not indicate much significance in the nature of the residue found at this position. 
Confirmation of the binding of HEL10 -23 to I -Ag7, despite its lack of an acidic P9 
residue, is shown in this study in Figure 6.8. It is worth noting, however, that the 
substitution of an acidic residue into P9 did create a HEL analogue that bound appreciably 
well to I -Ag' (Harrison et al., 1997). The ability of peptides to bind to this class II MHC 
molecule without fulfilment of the major anchor requirement at the P9 position is 
discussed subsequently in §6.4.4. 
Just as peptides lacking an acidic P9 residue may still bind to I -Ag', the absence of an 
aspartic acid residue at position 1357 is not an absolute indicator that peptides exhibiting a 
negatively- charged P9 residues will be the most preferred for binding. HLA -DQ2 
(DQA1 *0501/DQB 1 *0201), for example, exhibits an alanine amino acid at position 1357 
but examination of the peptide sequence features preferred for binding to this heterodimer 
indicates that there is no specific selection of peptides with negatively -charged residues at 
P9. Indeed, the predominant naturally- processed ligands to be eluted from this class II 
MHC molecule exhibit residues with bulky aromatic or hydrophobic aliphatic side chains 
at the P9 position (Vartdal et al., 1996; van de Wal et al., 1997). Moreover, the results of 
amino acid substitution analyses of DQ2- binding peptides have indicated that these 
residues are the most favoured at this position, more so than either glutamic acid or 
aspartic acid (Johansen et al., 1996; van de Wal et al., 1996; Quarsten et al., 1998). 
Homology modelling of the HLA -DQ2 aß dimer based upon the X -ray crystallographic 
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structure of the HA- HLA -DRI complex (Stem et al., 1994) has indicated that the 
substitution of the aspartic acid residue at position 057 by alanine in this molecule causes 
a change in the dimensions of the P9 pocket from a recessed shelf to a particularly broad 
and deep cleft (Vartdal et al., 1996; van de Wal et al., 1997; Quarsten et al., 1998). This 
serves to explain the ability of the HLA -DQ2 molecule to accommodate bulky residues 
over the small P9 side chains preferred by the mutant DQ2 heterodimer, Mut57 -DQ2 
((3Asp 57; Quarsten et al., 1998). This latter form has now been identified to be a 
naturally- occurring allelic variant, designatedDQA1 *0501/DQB1 *0203 (Olerup et al., 
1997). Meanwhile, the lack of any strong preference for an acidic P9 residue to interact at 
this site may be explained by the observation that the free basic moiety of the aArg 76 
residue is oriented away from the pocket in the HLA -DQ2 heterodimer and is more ideally 
located to make interactions with the peptide backbone carbonyl groups than the side 
chain at position P9 (Quarsten et al., 1998). 
The P9 pocket of the I -Ag7 molecule differs from that of HLA -DQ2, not just by the degree 
of basicity bestowed upon it by the unpaired aArg 76 residue, but also in terms of its 
molecular dimensions. Specifically, extrapolation from the crystal structures of the 
closely -related I -Ad (Scott et al., 1998) and I -Ak a0 dimers (Fremont et al., 1998b), 
together with homology modelling of the I -Ag7 peptide- binding groove (Amor et al., 
1996; Reizis et al., 1997b) predicts that this site is relatively small despite the replacement 
of the 0Asp 57 residue for the smaller side chain of serine (Table 6.6). Consequently, I- 
Ag7 would be expected to be unable to accommodate bulky side chains at this site. This is 
demonstrated in this study by the high affinity binding of the M99A peptide to I -Ag7 
compared with that of wild -type CLIP (Figures 6.6, 6.9 & 6.10). Indeed, an alanine 
residue at this position in the CLIP86 -104 sequence was even able to overcome the 
extremely unfavourable placement of a glutamic acid residue at position 100 
(M99A/R100E; Figure 6.9). The ability of the M99A peptide to bind with higher affinity 
than wild -type CLIP to the other I -A allotypes, I -Ad, I -Au and I -A" also confirms the 
similarly small dimensions of the P9 pocket between these different molecules and I -Ag7 
(Figure 6.11, Chapter 3, Figures 3.2 & 3.6; Gautam et al., 1995). Moreover, the 
resemblance of this outcome with the results obtained with the revertant 1- Ag7Pro56 and I- 
Ag7A5p$7 molecules indicates that the novel 0-chain mutations in wild -type I -Ag7 do not 
change significantly the dimensions of this site. As described above, however, they do 
change the physicochemical characteristics such that I -Ag7 may bind a peptide with a 
bulky residue at the P9 position if this residue also exhibits a negative charge to provide 
sufficient binding energy to compensate for the steric conflict. This is illustrated in this 
study by comparing the high -affinity binding of the M99E peptide versus that of M99Q 
(Figure 6.10). 
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As shown in Figures 6.7, 6.9 & 6.10, the reintroduction into I -Ag7 of an aspartic acid 
residue at position 1357 (I- Ag7Asp5) eliminated the ability of an acidic peptide side chain to 
interact favourably within the environment of the P9 pocket. This result is consistent with 
the preference for such a residue being related to the unpaired electrostatic charge of the 
aArg 76 residue since, in these altered I -Ag7 molecules, the (357 -a76 salt bridge is now 
assumed to form. However, the low affinity of the CLIP M99E, MSA560 -574 and 
p12(166 -195) peptides for binding to I- Ag7AspS7 (Figures 6.7, 6.9 & 6.10) indicates that 
an acidic residue at this position is now a source of considerable negative binding energy. 
Similarly, a random 15 -mer peptide exhibiting a negatively -charged residue at the P9 
position has been shown to bind poorly to the I -Ag7 double mutant form, I- Ag7Pro56AsP57 
(Oiso et al., 1998). Collectively, these findings suggest that a repulsive interaction may 
occur between the negative charge of this side chain and that of the restored 13Asp 57 
residue. Alternatively, this site may generally be too small or too hydrophobic to 
accommodate a negatively -charged side chain and the water molecules of its associated 
hydration shell. Indeed, both the restricted volume and hydrophobicity of the P9 pocket 
have been noted previously in the X -ray crystallographic analyses of HLA -DRI (Stern et 
al., 1994), HLA -DR4 (Dessen et al., 1997) and I -Ad (Scott et al., 1998). By contrast, 
the lack of an acidic residue at P9 in the HEL10 -23 peptide (Gly 22 at this site) allows 
this Iigand to hind unhindered to I- Ag7ASpS7. Interestingly, however, the rMOG8 -22 
peptide also binds freely to the I- Ag7Asp57 a13 dimer, despite exhibiting an acidic P9 
residue in the I -At7 binding frame of this peptide, as determined by Amor et al. (1996). 
In this respect, it is possible that this peptide may exhibit two separate epitopes in 
different registers. This is not unheard of, indeed, overlapping epitopes within a peptide 
have even been described for a single class II MHC molecule (Zamvil et al., 1986; 
Quaratino et al., 1995) and may even exhibit similar antigenic surfaces to be recognised 
by the same T cell clone (Quaratino et al., 1995). The binding frame of the rMOG peptide 
for interaction with the I- Ag7ASP57 molecules may be just one amino acid different from that 
proposed by Amor et al. (1996) whereby Gly 9 represents the P1 residue, likely to be 
amply accommodated in the corresponding unrestricted pocket (Table 6.6). This would 
then align Ile 12 with the P4 pocket, which indeed prefers aliphatic residues, Ala 14 with 
the small P6 pocket, Leu 15 with the large P7 pocket, again a highly favoured residue at 
this position and, lastly, the unobtrusive Gly 17 at the P9 pocket, thereby avoiding both 
steric and electrostatic conflicts at this critical position. 
The unfavourable nature of the interaction between a negatively -charged side chain and 
the P9 pocket of the I- Ag'AsP57 a(3 dimer suggests that this may be the case also for other 
class II MHC molecules in which the 1357 -a76 salt bridge is intact. Consistent with this 
CLIP binding to 228 
notion, the M99E CLIP analogue was found to be unable to compete for binding to such 
molecules on the surface of the cells, A20 (H -2a), 1 -5.4 (I -Au) and CH27 (H -2'`) in this 
study (Figure 6.11). Nevertheless, it was feasible that the inability of ligand to bind was 
related simply to steric strain provided by the bulky side chain of the Glu 99 residue 
within the small P9 pocket of these molecules (Chapter 3, Table 3.2). This possibility 
was excluded by the finding that a glutamine residue at P9 did support some binding of 
CLIP, i.e. an uncharged residue of similar shape and size (M99Q; Figure 6.11). Reizis et 
al. (1997b) have also observed a reduction in the binding of CLIP to I -A° by the 
introduction of glutamic acid into the P9 position. Moreover, a number of other reports 
exist in the literature noting the inability of different class II MHC molecules that exhibit 
13Asp 57 to accommodate a negatively- charged residue at the P9 position, as determined 
by testing amino acid -substituted peptides. For example, the 34ps peptide, derived from 
GAD 65 (residues 253 -263), has a glutamic acid residue at the P9 position (Glu 261) and 
binds with high affinity to HLA -DQ8 but not to HLA -DQ3.1 (DQA1 *0301/DQB1 *0301; 
Kwok et al., 1996a). These proteins differ by just 6 amino acids, including residue 1357 
(Ala in DQ8; Asp in DQ3.1). Furthermore, the 34ps peptide does not bind to BLA- 
DQ3.3 (DQA1 *0301/DQB 1 *0303) which is identical in sequence to HLA -DQ8 except at 
position 1357 (Asp in DQ3.3). Binding of 34ps to HLA -DQ3.3 may be induced however, 
by the substitution of Glu 261 for an alanine residue, although this peptide now no longer 
readily binds to DQ8. Further examples of the inability of negatively -charged residues to 
be accommodated at the P9 position of class II MEC molecules exhibiting 13Asp 57 have 
been detailed by Sette et al. (1993), Marshall et al. (1994), Kwok et al. (1996b) and Oiso 
et al. (1997). This phenomenon is also indicated by the extreme infrequency of finding 
acidic residues in the P9 position in the predominant natural ligands eluted from different 
human and mouse class II MHC molecules that express 3Asp 57, as apparent in peptide 
elution and sequencing studies of Falk et al. (1994), Friede et al. (1996) and Rammensee 
et al. (1995). 
It has also been noted that peptides that exhibit basic residues at the P9 position are 
incapable of binding to I -M' (Reich et al., 1994; Katoh et al., 1996; Reizis et al., 1997b). 
Similarly, peptides of this type are extremely disfavoured for binding to other class II 
MHC molecules that lack an aspartic acid at the 1357 position, e.g. HLA -DQ8 (Kwok et 
al., 1996a) and RTI.B' ( Reizis et al., 1996; Wauben et al., 1997). This observation has 
led to the proposal that the inability of these peptides to bind to these molecules is the 
result of a repulsive interaction with the unpaired positive charge of the aArg 76 residue. 
Consistent with this, site- directed mutagenesis of the 13Asp 57 residue to serine in the 
HLA -DR molecule, DR A/DRB 1 * 1301, caused a significant decrease in the ability of this 
molecule to bind the peptide, MBPI52 -170, which exhibits an arginine at position P9 
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(Hurley & Steiner, 1995). Furthermore, peptides with basic residues at the P9 position 
may bind to other class II MHC molecules in which the 1357 -8E76 salt bridge is intact, 
e.g. HLA -DQ7 (DQA1 *0301/DQB1 *0301; Godkin et al., 1997), DQ1 molecules with the 
gene product of the 13-chain allele, DQB1 *05032 (Wucherpfennig & Strominger, 1995), 
HLA -DR2a (DRA/DRB5 *0101; Marshall et al., 1994) and all molecules of the I -E 
isotype (Rammensee et al., 1995; Schild et al., 1995). Nevertheless, for these latter two 
cases at least, it is known that basic residues at this position are favoured for binding 
specifically due to acidic character bestowed upon the P9 pocket by the residues 13Asp 30/ 
3Asp 37 and (3Glu 9, respectively (For a full description of the physicochemical 
characteristics of the I -E P9 pocket, see Chapter 5, §5.4.2). Instead, it would appear that 
the inability to bind peptides exhibiting basic residues at the P9 position is not a feature 
unique to class II MEC molecules that lack an aspartic acid at position 1357. For example, 
it has been observed that such peptides will also not bind to I -Ad (Bartnes et al., 1997; 
Reizis et al., 1997b). Nor are they readily bound by HLA- DR4Dw4 (DRA/DRB 1 *0401; 
Sette et al., 1993), HLA -DQ3.1 and DQ3.3 (Kwok et al., 1996a) or even the double 
revertant, I- _Ag7no56Asp57 (Oiso et al., 1998), all of which exhibit an intact 1357 -a76 salt 
bridge. Moreover, peptides with basic P9 residues bind poorly to both HLA -DQ2 and its 
f3Asp 57 mutant form, Mut57 -DQ2 (Johansen et al., 1996; van de Wal et al., 1996, 1997; 
Quarsten et al., 1998) despite much of the potential basicity of the DQ2 P9 pocket having 
been deflected away from this site, as described above (Quarsten et al., 1998). As with 
the inability of acidic residues to be accommodated at the P9 pocket of most class II MEC 
molecules, side chains that exhibit positive charges may be simply disfavoured at this site 
due to the general size restrictions (e.g. Chapter 3, Table 3.2). 
6.4.4 The lack of the 1357 -a76 salt bridge in I -Ag7 reduces the stability of 
this class II MHC molecule 
The formation of favourable contacts between the I -Ag' a(3 dimer and the CLIP side 
chains, Leu 97, Leu 98 and Arg 100 -Met 102 is unusual (Figure 6.6). As reported in 
Chapter 3 ( §3.4.2) and by Gautam et al. (1995), L- alanine scanning experiments 
performed on CLIP binding to other mouse class II MHC molecules of the I -A isotype, I- 
A', I -Ak and I -A° have shown that in only rarely did any CLIP side chains provide 
significant positive binding energy to the interaction, e.g. Leu 98 with I -Ad at pH 5.0 
(Figure 3.6). Instead, the majority of residues within the CLIP sequence were either 
neutral or inhibitory to binding and the association was maintained predominantly by the 
formation of the hydrogen bond network between atoms of the peptide backbone and 
conserved residues of the binding groove. 
CLIP binding to I -Ag7 230 
Like the preference of I -Ag' molecules to bind peptides with acidic residues at the P9 
position ( §6.4.3), the anchor interactions between the C- terminal residues of CLIP and 
this molecule may also be attributed to the absence of an aspartic acid residue at position 
1357, since all but one of the major favourable interactions (that of Leu 97 in the P7 
pocket) were found to disappear when such a residue was reintroduced into I -Ag7 (Figure 
6.6c). As noted previously ( §6.1.5), the lack of the 13Asp 57 residue in I -Ag7 is predicted 
to cause destabilisation in the surrounding region of the heterodimer through the inability 
to form the 1357 -a76 salt bridge, a critical link between the a, and f11 domains (e.g. 
Nalefski et al., 1995; Scott et al., 1998; for a description of the domain organisation of 
class II MHC molecules, see Chapter 1, Figure 1.3). Indeed, the disruption of this 
electrostatic interaction in I -Ad using site- directed mutagenesis has been shown to result in 
a reduction in the numbers of class II MHC molecules that reach the cell surface (Nalefski 
et al., 1995). This suggests that the molecules tend to be folded incorrectly and, 
consequently, may be targeted for degradation or simply accumulate intracellularly unable 
to traffic to the plasma membrane. Even in those dimers that do transport efficiently, the 
residues of the groove that are normally involved in bonds with peptide ligand may no 
longer be held in the correct orientation for such interactions to occur. The favourable 
contacts formed between I -Ag' and the C- terminal CLIP side chains may therefore be a 
means to counteract the greater flexibility of this region of the heterodimer and to tether 
the C- terminal region of the peptide in place where the formation of conventional bonds 
may be impaired. 
In support of the notion that the binding of CLIP86 -104 to I -Ag7 is reliant upon the 
formation of stabilising contacts additional to, or stronger than, those observed in other 
CLIP -I -A interactions, longer CLIP ligands were observed to bind preferentially to this 
molecule (Figure 6.4a & Table 6.1). Such ligands offer greater potential for the 
formation of both hydrogen bonds and side -chain interactions. This feature should not be 
confused with the inability of the truncated CLIP ligands in Table 6.3 to bind to this 
molecule since this also reflects the disruption of the main -chain hydrogen -bond network 
conserved in all peptide -class II MHC complexes (e.g. see Chapter 4, Table 4.2 and 
Chapter 5, Table 5.1). However, in this respect, the I -Ag7 -CLIP interaction was again 
more sensitive to these truncations than other class II MHC molecules under the same 
conditions (pH 7.0), a further indication of the reduced affinity of this molecule with 
regard to binding peptides. The reduction in the effect of having extra residues on the 
CLIP86 -104 ligand observed with I- Ag''sp57 also substantiates the idea that the need for 
additional interactions arises from the absence of the (3Asp 57 residue in wild -type I -At7. 
Consistent with this, longer CLIP ligands have been shown to bind better than shorter 
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variants to HLA -0Q2 molecules, which similarly lack an aspartic acid at position 1357 
(van de Wal et al., 1996; Vartdal et al., 1996). 
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As discussed previously ( §6.4.3), the presence of an acidic residue at the P9 position of 
an I -Ar peptide ligand provides a significant measure of positive binding energy to the 
complex by providing a stabilising interaction to compensate for the loss of the f357-a76 
salt bridge. It is probable that the additional bonds formed between the I -Ag7 heterodimer 
and CLIP also serve in the same manner to uphold the complex and might represent an 
alternative to having an acidic residue in the P9 position of the peptide. Indeed, the 
truncated ligand, CLIP90 -100, lacks the potential to form several of the requisite C- 
terminal anchor interactions and, accordingly, this peptide is unable to bind to the I -Ar 
class II MHC molecules (Table 6.3; Reizis et al., 1997b). However, the binding of this 
same peptide may be restored simply by the introduction of a glutamic acid residue at the 
P9 position (Reizis et al., 1997b; sCLIP89 -99 in the mouse Ii numbering used by these 
authors). Thus, it may be envisaged that all ligands that bind to I -Ag7 but lack an acidic 
P9 residue similarly exhibit other means of stabilising their interaction. For example, 
Harrison et al. (1997) found that the identity of the residues at relative positions P4 and 
P7 in the HEL peptide (using the adjusted alignment described above, §6.4.3) were 
extremely critical for binding to I -Ar. It is possible that anchor interactions at these 
positions are necessary for stabilising the complex in the absence of an acidic P9 residue 
to perform this task. Indeed, these authors do offer the suggestion that an acidic residue 
in the C- terminal region of the peptide might be an alternative to a non -tolerated residue at 
one of these positions (Harrison et al., 1997). 
The results presented herein are particularly interesting in light of the recent debate 
regarding whether or not I -Ag7 class II MHC molecules exhibit a general defect in their 
ability to form stable complexes with peptide ligands. Providing most support to this 
claim are the experimental findings of Carrasco -Marin et al. (1996). Firstly, these authors 
have reported experiencing considerable difficulties in being able to demonstrate the 
association of peptides with affinity- purified I -Ag7 in vitro. I -M' molecules extracted 
from APC also showed only weak interactions with the radioactive peptides with which 
they had been cultured. Next, these authors examined kinetic features of peptide -bound, 
radiolabelled I -Ar and found that the half -life of these complexes was shorter than that of 
other peptide -bound I -A variants, e.g. 5.5 h for I -Ar, compared with 9.3 h for I -Ad and 
13.4 h for I -Ab. Moreover, they observed that I -M7- expressing APC pulsed with 
antigenic peptides rapidly lost the ability to stimulate T cell hybridomas when the cultures 
were washed free of peptide, a result indicative of short-lived peptide -MHC complexes. 
By contrast, the levels of IL -2 produced by stimulated I -A'- restricted T cells were 
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equivalent regardless of whether the APC were washed free of excess HEL46 -61 peptide 
or cultured continuously in its presence. The long -lived nature of HEL -I -Ak complexes 
has been demonstrated previously by Nelson et al. (1994). Lastly, Carrasco -Marin et al. 
(1996) noted a correlation between the half -lives of different class H MHC molecules at 
the cell surface and the ability of these molecules to withstand dissociation of the c 1 
subunits upon SDS -PAGE, e.g. the vast majority of I -Ag' heterodimers (99 %) 
dissociated into their constituent monomers while 78% of I -Ab molecules migrated as 
stable dimers. 
Regarding firstly the difficulties of Carrasco -Marin et al. (1996) to demonstrate peptide 
binding to I -Ag7 in vitro, it is interesting to note that no such problems were encountered 
in this study using the flow cytometry -based peptide binding assay to measure the binding 
of biotinylated CLIP86 -104. Indeed, it was easier to detect biotinylated CLIP binding to 
cell- surface I -Ar molecules than to I -Ak and I -An in Chapter 3 (e.g. compare MFI levels 
between Figure 3.2 and Figure 6.3) although this may simply reflect differences in the 
total numbers of class II MHC molecules expressed by the respective APC rather than 
overall affinity for CLIP. Nevertheless, this result was not restricted to the interaction of 
CLIP with I -Ag' but binding was also able to be demonstrated using this method with the 
antigen- derived peptides MSA560 -574 and p12(166 -185) (Figure 6.7) and rMOG8 -22 
and HEL10 -23 (Figure 6.8). Other investigators too have successfully measured peptide 
binding to I -Ag7 class II MHC molecules. For example, Harrison et al. (1997) conducted 
their examination of the binding of the peptide HEL10 -23 with affinity -purified I -Ag' in 
an ELISA -type assay, while Reizis et al. (1997b) used an antigen presentation assay to 
examine different peptide -I -Ag7 interactions. In this respect, it is possible that the 
contrasting findings are simply a consequence of the distinct experimental systems and 
reagents used by the different investigators. 
Secondly, in consideration of the reduced lifespan of peptide -I -Ag7 complexes claimed by 
Carrasco -Mann et al. (1996), Reizis et al. (1997b) have provided conflicting data that 
shows that metabolically -labelled I -Ag' molecules immunoprecípitated from NOD 
splenocytes exhibit a normal lifespan, comparable to that of I -A` molecules. These 
authors have also shown that the HSP60 peptide, p12(166 -185), binds to I -Ag' on the 
surface of glutaraldehyde -fixed macrophages to form a very stable complex, still able to 
trigger significant T cell activation 8 days after the washout of free peptide. Moreover, 
this is not simply the result of the peptide being cross -linked to the MHC a43 dimer, for 
example, through the side chain of the Lys 180 residue, because greater than 50% of the 
initial T cell response was still observed after 24 h of dissociation using unfixed splenic 
APC; parameters deemed similar to those observed with other peptide -bound class II 
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MHC molecules (Reizis et al., 1997b). However, in this respect, the p12(166 -185) 
peptide used in these experiments is perhaps not truly representative of the majority of I- 
M7- binding peptides since the binding of this peptide was also shown by these authors to 
confer the very rare feature of SDS- stability to I -Ag7 heterodimers (see below). 
The only finding of Carrasco -Marin et al. (1996) to be accepted widely to date is that 
concerning the inability of I -Ar class II MHC dimers to withstand denaturation in the 
presence of SDS detergent. The agreement on this matter comes in spite of the 
experimental variation observed between laboratories in the proportional estimates of 
compact dimers formed (Carrasco -Mann et al., 1996; Reizis et al., 1997b; discussed 
previously, §6.1.5). Incidentally, it is difficult to determine where the SDS -PAGE data 
presented in Figure 6.1 of this study fits in, given the absence of any quantitative 
measurements of the respective bands by laser densitometry. Regardless, the finding that 
a lower proportion of compact I -M7 a(3 heterodimers are formed upon SDS -PAGE than 
other class II M IC variants has perhaps only complicated our efforts to understand the 
role of these particular molecules in the development of autoimmune diabetes in NOD 
mice since the functional significance of this phenomenon, if any, remains unknown. For 
example, debate continues over whether the ability to withstand SDS- induced dissociation 
has any relevance on the overall lifespan of the peptide -class II MHC complex. Nelson et 
al. (1994) have reported that SDS -stable I -Ak complexes exhibit half -lives up to twice as 
long as unstable complexes of this same class II MHC variant. However, Reizis et at 
(1997b) have shown that both the SDS -stable and unstable forms of I -Ar exhibit similar 
lifespans within the APC. Likewise, SDS -stable and unstable forms of HLA -DQ8 persist 
in the cell for equivalent lengths of time (Reizis et al., 1997a). It has also been shown 
that the behaviour of a given peptide -class H MHC complex in SDS is unrelated to 
whether it may be recognised by CD4+ T lymphocytes (Wu et al., 1996). 
The HSP60 peptide, p12(166 -185), is unique amongst I -A 7- binding ligands in 
exhibiting the ability to stabilise this dimer in the presence of SDS detergent (Reizis et al., 
1997b). Substitution analysis has shown that this capacity is dependent largely upon the 
identity of the residue present at the relative peptide position, Pl (Reizis et al., 1997a). 
This finding is consistent with the currently -held belief that SDS -stability in class II MHC 
molecules relates to the fulfilment of side -chain anchor preferences at the pockets within 
the peptide -binding groove (discussed previously in Chapter 3, §3.4.3 & §3.4.6). The 
actual significance of these interactions has been proposed to lie in the resultant burial of 
hydrophobic residues within the class II MIIC dimer, these being the primary sites to 
which the SDS molecules bind (Natarajan et al., 1999b). In simplistic terms, it is 
envisaged that a class II MHC molecule with a peptide associated only tenuously is likely 
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to be more loosely folded such that more non -polar surface is exposed. The detergent 
molecules may then bind in a co- operative manner to these regions, bringing about the 
loss of the peptide and triggering the dissociation of the a and (3 subunits. 
Consistent with the proposed molecular basis for SDS stability described above, 
Carrasco -Marin et al. (1996) used the finding that I -Ag' dimers rarely withstood SDS - 
PAGE to uphold their argument that these molecules are intrinsically unable to form 
strong interactions with peptide ligands. However, the concept that peptides must only be 
associated weakly if they do not confer SDS -stability to the aß dimer is still disputed. 
For example, Nelson et al. (1996) have shown that the contacts required for the formation 
of SDS -stable HEL(46- 61) -I -Ak complexes represent only a subset of those needed to 
maintain peptide binding. This strongly supports the idea that class II MHC heterodimer 
stability in SDS detergent is quite a separate property from binding strength. In this 
respect, it is interesting to note that the p12 analogues that exhibited PI substitutions and 
were unable to trigger the formation of SDS -stable I -Ag7 molecules nevertheless showed 
equivalent binding capacities to those capable of conferring it, as measured in a 
competitive binding assay (Reizis et al., 1997a). 
Collectively, the data described above indicate that I -Ag7 molecules do form stable 
interactions with peptide ligands but only if they fulfil one of two criteria: either an acidic 
residue at P9 (e.g. as shown by the peptides, p12(166 -185), MSA560 -574, rMOG8 -22) 
or the means elsewhere within the peptide to form strong bonds with the aß heterodimer. 
These latter interactions may be in the form of unconventional side chain- dependent 
contacts, such as those seen in this study with the CLIP ligand or, alternatively, by 
fulfilling anchor preferences elsewhere in the I -Ar peptide -binding groove, as proposed 
above for the HEL1O -22 peptide (Harrison et al., 1997). Whatever the specific source, 
these bonds serve to compensate for the loss of the f357 -a76 salt bridge and provide 
much needed stability to the I -Ag' peptide- binding groove. In this respect, I -Ag7 may 
indeed be considered to exhibit a general defect in peptide binding since these 
requirements no doubt reduce considerably the subset of ligands that are able bind to this 
molecule. Indeed, a single 3Asp57Ser mutation in I -Ad has been shown to cause 
significant impairment in the ability of these molecules to present their typical ligands 
(Nalefski et al., 1995). This may also be extrapolated to other class II MHC molecules 
that similarly lack the 3Asp 57 residue. For example, Marshall et al. (1994) have shown 
that the substitution of an aspartic acid at position f357 for a serine in HLA -DR molecules 
leads to a dramatic decrease in the binding affinity of the class II MHC molecule for a 
simple polyalanine peptide anchored at relative positions, Pl and P5, e.g. DRB1 *0401 
(RAsp 57), IC50 = 13 nM compared with DRB 1 *0405 (i3Ser 57), IC50 = 14000 nM. 
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Furthermore, the difference in binding capacity observed between the best and poorest 
ligands of the HLA -DQ2 molecule was considerably greater than that observed for the 
Mut57 -DQ2 variant (Quarsten et al., 1998). The consequences in vivo of these effects on 
antigen presentation are discussed in §6.4.6. 
Meanwhile, the inability of I -Ar to form complexes that are stable under the conditions of 
SDS -PAGE should only be taken to mean that the binding of peptides does not induce the 
molecule to adopt the same structural form as when such ligands bind to other class II 
MHC all dimers- one should be wary of using this technique as a means to measure 
peptide affinity. In this respect, Nabavieh et al. (1998) have shown by expressing these 
molecules in different cellular backgrounds that SDS -instability is a feature intrinsic to I- 
M7, one unaffected by the specific antigen -processing and presentation machinery of the 
NOD environment. Similarly, Peterson & Sant (1998) have shown that this feature is not 
the result of an inability of I -Ag' to associate with Ii nor H -2M. Indeed, the H -2Ma and 
H -2Mb genes of NOD mice exhibit very close sequence identity with those of the d 
haplotype and are, therefore, unlikely to have a direct contribution to any of the unusual 
features of the I -Ag' molecule (Hermel et al., 1995). Instead, it has been proposed that 
the incapacity of I -Ag' to form significant numbers of SDS -stable dimers is yet again a 
consequence of the lack of an aspartic acid residue at position 057 (Nabavieh et al., 
1998). The structural disruption in the peptide -binding groove suggested to result from 
this mutation could potentially impair the ability of the I -Ag' heterodimer to shield its non - 
polar surfaces. Support for this proposal has come from the finding that the human class 
II MHC molecules HLA -DQ8 (OAla 57), DQ2 (OAla 57) and DQ1 (Pal 57) are also 
predominantly unstable in the presence of SDS detergent (Buckner et al., 1996; Reizis et 
al., 1997a). By contrast, the majority of HLA -DQ6 molecules (OAsp 57) formed SDS - 
resistant a(3 dimers. Furthermore, stability in SDS was also shown by HLA -DQ9 
(DQA1 *0301IDQB 1 *0303; also known as HLA- DQ3.3), which differs from DQ8 by just 
a single amino acid residue, Ala > Asp at position 057. Nevertheless, the reintroduction 
into I -Ag7 of an aspartic acid at position 057 (together with correction of the 0Pro56His 
mutation) did not enable these molecules to withstand SDS -induced dissociation 
(Carrasco -Mann et al., 1996). Moreover, FILA -DQ7 exhibiting an aspartic acid at 
position 057 has also been shown to be predominantly unstable in SDS (Reizis et al., 
1997a) and RT1.B rat class II MHC molecules appear to be SDS -stable regardless of 
whether they express an aspartic acid at this position (RT1.Ba) or a serine (RT1.B''; 
Reizis et al., 1997b). Thus, although a non -Asp residue at position 1357 would appear to 
predispose towards an inability to form SDS -stable dimers, there are clearly additional 
factors involved. 
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Lastly, in addition to upholding the global structure of the peptide -binding groove, the 
[Asp 57 residue may also make direct contact with the bound peptide by forming a 
hydrogen bond with a suitable donor group, typically a main -chain amide nitrogen. Such 
interactions are present in the complexes of HA HLA -DR1 (Stern et al., 1994), CLIP 
HLA-DR3 (Ghosh et al., 1995) and HEL I -Ak (Fremont et al., 1998b; Weber et al., 
1998). However, the exact importance of the 1357 hydrogen bond for stabilising peptide 
binding is unclear, given that such an interaction is not apparent in the crystal structures of 
I -A° complexed with the OVA323 -339 or HÁ126 -138 peptides (Scott et al., 1998), nor 
in the complex between the human collagen II peptide, CII261 -273, and FILA -DR4 
(Dessen et al., 1997). Nevertheless, it is possible that the loss of this hydrogen bonding 
potential in the I -Ag7 molecule may be compensated to some extent by the presence of the 
polar serine residue at this position. It may be envisaged that the hydroxyl group of this 
residue could form an alternative hydrogen bond if an acceptor group in the peptide 
backbone, such as a carbonyl oxygen atom, is orientated appropriately. 
6.4.5 The 13Pro56His mutation present in the I -Ag' class II MHC 
molecules reduces peptide exchange at the cell surface 
In contrast to the effects of the (3Asp57Ser mutation, the unusual presence of a histidine 
residue at position 56 in the I -Ag7 [3-chain did not impact directly upon the intermolecular 
interactions between this molecule and the CLIP ligand in this study. For example, 
correction of the (3Pro56Hís mutation did not alter the importance of the C- terminal CLIP 
side chains as anchors - the formation of favourable interactions through the residues 
Leu 97, Leu 98 and Arg 100 Met 102 was as important for the CL1P86-104 ligand to 
bind to I- Ag7Pro56 (Figure 6.6b) as it was for the interaction with wild -type I -M7 (Figure 
6.6a). Moreover, both the I -Ag7 and I- Ag7Pro56 molecules showed the highest affinity for 
the longer CLIP ligands, i.e. those capable of providing the greatest intermolecular 
contact, either through a biotin moiety or additional peptide residues (Figure 6.4 & Table 
6.1). This adds further support to the concept that the need for these stabilising 
interactions arises as a result of the loss of the (357 a76 salt bridge and is not due to the 
mutation of the [Pro 56 residue to histidine in the wild -type I -Ág7 molecule; a finding 
consistent with the orientation of the 1356 residue away from the groove (e.g. Brown et 
al., 1993; Stern et al., 1994; Fremont et al., 1998b; Scott et al., 1998). 
Nevertheless, although both I -Ag7 and its single amino acid revertant form, I- Ag7Pro56, are 
similar in their need for CLIP to provide anchor interactions through its C- terminal 
residues, these molecules do appear to differ in their capacity for peptide exchange at the 
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cell surface. For example, experiments examining the direct binding of biotinylated 
CLIP86 -104 to the cell -surface class II MHC molecules of M12.NOD, M12.PRO and 
M12.ASP revealed that a higher proportion of 1 -Ag7t °56 molecules were receptive for 
binding the biotinylated ligand than either of the other two forms, wild -type I -Ag7 and I- 
Ag7ASp57 (Figure 6.3). All three cell lines were determined to be expressing equivalent 
number of class II MHC molecules at the surface by OX6 -FITC staining (Figure 6.2a). 
Furthermore, the titration of other biotinylated peptides, this time derived from protein 
antigens, yielded a similar result (Figures 6.7 & 6.8), i.e. the M12.PRO cells consistently 
bound more biotinylated p12(166 -185), MSA560 -574 and HEL10 -23 peptide than the 
M12.NOD and M12.ASP cells, again despite all expressing similar levels of class II 
M IC molecules. The presence of histidine at position 56 in the ß -chain of wild -type I- 
Ag7 (and I- Ag7Asp57) thus appears to reduce the capacity of this molecule to bind peptides 
by exchange at the cell surface. 
The flow cytometry-based assay method used in this study evaluates specifically the 
association of a biotinylated peptide across the total pool of cell -surface class II MHC 
molecules in a sample (for a discussion of this assay method, see Chapter 3, §3.4.1). Of 
these, between 1 -15% have been estimated to be receptive for binding peptides, i.e. 
approximately 103 -104 class II MHC molecules per cell (Truce() et al., 1980; Watts & 
McConnell, 1986; Buus et al., 1988; Busch et al., 1990; Roche & Cresswell, 1990b; 
Ceppellini et al., 1989). One feature to influence significantly the level of fluorescence 
signal obtained in such experiments is the composition of peptide ligands already bound. 
Given that I -Ag7 appears to bind less exogenously -added peptide than its single amino 
acid revertant form, I- Ag7Pro56 it may therefore be envisaged that more of the wild -type 
heterodimers may have ligand already bound tightly within the groove. Alternatively, I- 
Ag7 may be generally unreceptive to binding peptides at the cell surface as a consequence 
of an inherent structural defect in the 43 complex. 
Conflicting evidence exists concerning the possibility that the majority of I -Ag7 class II 
MEC molecules may be loaded with peptides in stable complexes at the cell surface. On 
the one hand, Reich et al. (1994) have eluted successfully a range of different naturally - 
processed peptides from these molecules and shown subsequently their capacity to rebind 
as synthetic analogues. On the other hand, however, Reizis et al. (1997b) have reported 
that the overall yield of peptides isolated from purified I -Ag7 is very low compared with 
that from other class II MHC molecules. Indeed, these latter authors have put forward the 
suggestion that a large fraction of these molecules at the cell surface may in fact be empty; 
a scenario which would be expected to lead to higher levels of peptide binding at the cell 
surface. In direct conflict to the findings of the study presented herein, this claim was 
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supported by the report that the p12 peptide bound to I -Ag' at the surface of fixed APC at 
lower concentrations than required for other peptide -I -A combinations (Reizis et al., 
1997b). In this respect, it is possible that the findings of Reizis et al. (1997b) may be 
misleading as a result of these authors making comparisons between individual I -A 
allotypes binding different peptides. This problem has been avoided in this study by 
taking advantage of the promiscuous nature of the CLIP86 -104 ligand to examine the 
interaction of this single peptide with the different class II MHC variants. Furthermore, 
the interpretations presented herein regarding the extent of cell- surface peptide exchange 
have been restricted to closely -related class II MHC molecules, specifically, I -Ag' and its 
two revertant forms, I- Ag7P`o56 and I- Ag'""S', which differ from the wild -type heterodimer 
by just a single amino acid at position 1356 or 1357. 
Although seeming to conflict with the findings reported in this study, the suggestion by 
Reizis et al. (1997b) that many I -Ag' dimers may be devoid of peptide ligand at the cell 
surface is not without merit, since it would appear to be more in keeping with the very 
restricted range of peptides expected to have the capacity to form optimal interactions with 
these molecules, as described in §6.4.4. Indeed, it might be imagined that many of the 
peptides that associate initially with this particular class II MHC molecule are ultimately 
unable to form sufficient bonds to stabilise the association and thus eventually dissociate 
to leave the peptide- binding groove empty; a potential explanation for the reduced lifespan 
of some peptide -I -Ag7 complexes reported by Carrasco -Mann et al. (1996). In support of 
this, the majority of peptides eluted from I -Ag' were shown to exhibit the preferred acidic 
residue with the C- terminus, the major contributor to forming stable associations with this 
molecule (Reich et al., 1994). 
It is interesting to note that CLIP was not amongst the peptides eluted from I -Ag7, a 
finding reminiscent of peptide elution studies of I -E class II MHC molecules (Chapter 5, 
§5.4.4). Unlike the situation with I -E, however, it has been shown that CLIP binds to I- 
Ag' better at neutral pH than in acidic conditions, ostensibly as a consequence of a less 
pronounced preference for an acidic residue at P9 in this environment (Reizis et al., 
1997b). Similarly, Hausmann et al. (1999) have reported that CLIP -I -Ag' complexes that 
are formed at neutral pH dissociate rapidly at pH 5.0, but this particular result should be 
considered with some caution since the CLIP ligand used to show this, residues 87 -101, 
lacked the Met 102 residue identified in this study to provide critical anchoring contacts 
with the a13 dimer (Figure 6.6) and it remains unknown whether this truncated ligand is 
produced in viva. Indeed, the same peptide, CLIP87 -101, did not bind to the wild -type 
I -Ag' molecules at neutral pH in the cell -surface peptide binding assays presented herein 
(Table 6.3). Nevertheless, CLIP has been reported to bind optimally to HLA -DQ8 
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molecules ((3Ala 57) also at a less acidic pH than other peptides (Buckner et al., 1996). 
Thus, the lower overall degree of competitive CLIP86 -104 binding to the wild -type I -Ao 
molecules in this study (Figure 6.4) does not appear to arise as a result of the interactions 
being unfavourable in the neutral conditions under which these experiments were 
conducted. Consistent with this, the same effect was observed for the association of 
wild -type I -Ar with the antigenic peptides, p12(166 -185), MSA560 -574 and HEL10- 
23, the former two exhibiting the preferred acidic P9 residue (Figures 6.7 & 6.8d). 
Instead, the proposed inability of many peptides to form stable interactions with I -Ag' 
and, related to this, the reduced lifespan of some peptide -I -Ag7 complexes (both 
discussed in §6.4.4), both suggest a potential explanation for the reduced cell -surface 
peptide binding observed in this study for I -Ao. Class II MHC molecules devoid of 
peptide ligand have been reported to undergo a rapid conformational rearrangement into a 
form in which they are no longer "active" for binding peptide. To become receptive 
again, the all dimer must undergo a very slow conformational reversion. This 
phenomenon has been so far been observed in the molecules, I -Ek (Rabinowitz et al., 
1998) and HLA -DR (Natarajan et al., I999a), and some evidence also exists to suggest 
that it may take place in I -Ak and I -A" (Mason et al., 1995). If ligands tend to dissociate 
from I -Ag' more readily than from other class II MHC molecules, then it is possible that a 
high number of these expressed at the cell surface are also in an inactive form. This 
would indeed result in the total pool of I -Ag' molecules at the plasma membrane binding 
exogenously -added peptides to a lesser extent than other allotypes, as observed in this 
study (Figures 6.3, 6.7 & 6.8). Moreover, this theory reconciles the finding of a low 
yield of peptides eluted from these molecules (Reizis et al., 1997b) with the reduced 
amount of cell- surface binding of antigen- derived peptides, even those that exhibit an 
acidic residue at P9 (Figure 6.7 & 6.8). 
The inability to elute CLIP ligands from I -Ag' aß dimers raises the possibility that even 
this peptide may ultimately lack the ability to maintain a long -term association with these 
molecules at the cell surface, despite the additional stabilising interactions that take place 
through its C- terminal side chains. This would also have a significant impact on the 
extent of cell -surface peptide exchange via these molecules. Specifically, CLIP -class II 
MHC complexes arise as natural biosynthetic intermediates following the proteolytic 
degradation of the invariant chain protein and a small percentage of these appear to traffic 
to the cell surface (discussed previously in Chapter 5, §5.4.5). Whether this occurs by 
error or as a mechanism to broaden the spectrum of antigenic peptides to be presented to T 
cells, the cell- surface CLIP -a(3 complexes typically represent a major source of the 
molecules susceptible to peptide exchange (Riberdy et al., 1992; Griffin et al., 1997). If, 
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however, this ligand ultimately dissociates from I -Ag7 before more thermodynamically - 
favoured peptides are available, as implied by the inability to elute CLIP from these 
molecules, then the population of I -Ag' heterodimers at the cell surface to which 
exogenously -added peptide normally binds may be reduced considerably. An analysis of 
the relative amounts of CLIP present at the cell surface in association with I -Ag7 compared 
with other class II MHC I -A allotypes is currently under way in this laboratory, as part of 
the doctoral research of Ms A. Bhatnagar. 
One interesting finding of the study presented herein is that the reduced capacity of I -Ar 
molecules to bind exogenously -added peptides appears to be a consequence, not of the 
(3Asp57Ser mutation in these molecules, but of the (3Pro56His mutation. In this respect, 
it may be envisaged that, while the (357 mutation in I -Ao is responsible for the selectivity 
of this molecule in terms of what peptides may bind, it is ultimately the (356 mutation that 
makes the molecules unreceptive to binding peptides at the cell surface. In this sense, if a 
histidine residue at position 1356 somehow reduces cell- surface peptide binding then, by 
extension, the proline residue normally present in class II MHC aß dimers at this position 
must play a role in keeping these molecules receptive at the plasma membrane. As 
mentioned previously ( §6.1.5), this residue lies within the Hl a -helix of the (31 domain 
which contributes to the walls of the binding cleft (Brown et al., 1993; Stem et al., 1994; 
Fremont et al., 1998b; Scott et al., 1998). The restricted rotational angles of the proline 
amino acid are likely to confer a peculiar spatial arrangement of atoms at this site within 
the helix which appears to maintain this region of the peptide -binding groove both suitable 
for peptide binding and peptide exchange. It is probable that the replacement of the 3Pro 
56 residue by a histidine in the I -Ag' dimer would cause a very different ordering of the 
atoms in the three -dimensional space around this site and affect the coiling of the Hl a- 
helix. Indeed, a conservative amino acid substitution at another residue within this same 
helix, position (361, has been shown to change the configuration of this region of the 
peptide- binding groove such that the formation of at least one hydrogen bond with the 
peptide ligand is affected and T cell recognition of the complex is impaired (Tate et al., 
1995). The resulting change in the conformation of this region of the I -Ag7 peptide - 
binding groove due to the 13Pro56His mutation may make this molecule more susceptible 
to peptide dissociation or to undergoing rearrangement into the inactive form once the 
peptide has dissociated. This is contrary to a proposal by Reizis et al. (1997b) that I -Ar 
molecules may be unusually stable in the absence of bound peptide through the formation 
of a unique interaction between residues otGlu 66 and 3His 9. The consequences of these 
possibilities upon antigen presentation in the NOD mouse are discussed subsequently in 
§6.4.6. 
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The findings of this study regarding the extent of peptide binding to cell -surface class II 
MHC molecules rely upon the assumption that the OX6 monoclonal antibody used to 
measure the relative levels of these molecules recognises each of the three I -Ag7 forms 
with a similar efficiency. This is indeed likely to be the case, since this mAb is known to 
recognise a sequential epitope of the 0 -chain that is common to many class II MHC 
molecules, e.g. I -Ak° of (McMaster, 1981; Reske & Weitzel, 1985; Liu et al., 1993), 
some of which also exhibit the particular polymorphisms observed in I -Ag7 (Liu et al., 
1993). Moreover, OX6 binds to the RT1.B1 molecules of Lewis rats which exhibit a 
serine at position 057 (Reske & Weitzel, 1985) but also recognises I -Ak which exhibits 
the more typical aspartic acid at this site (Liu et al., 1993). In this respect, it is interesting 
to note that many of the mAb that react with I -A 7 also cross -react with I -Ak" "1 molecules 
(e.g 10 -2.16, 10- 3.6.2; Sher et al., 1984) but, surprisingly, I -Ag7 is rarely recognised by 
mAb raised to I -Ad, e.g. MK -D6 (Hattori et al., 1986; Liu et al., 1993), despite these two 
molecules exhibiting greater sequence homology (Acha -Orbea & McDevitt, 1987). The 
molecular basis of this property appears to be a two- residue insertion relative to I -Ag7 at 
positions 065 and 066 in the I -Ad heterodimer (Liu et al., 1993; numbered as according to 
the secondary structure -based sequence alignment of the a, and 0, domains of the 
molecules, I -Ak, I -Ek and HLA -DR, reported by Fremont et al., 1998b). In the X -ray 
crystallographic structure of I -A ", these two residues fall at the junction of the Hl and 
H2a helices of the 0- chain, their side chains extending upwards from the plane of the 
binding cleft to represent potential TCR contact sites (refer to Chapter 1, Figure 1.4; Scott 
et al., 1998). The projection of these residues from the main structure of the peptide - 
binding groove also makes them potential determinants for recognition by mAb. Indeed, 
the sequence spanning the residues, 063 -67, has been identified as critical to the binding 
of the I -Ad- reactive mAb, MK -D6 (Braunstein et al., 1990), hence providing an 
explanation for the inability of this mAb to cross -react with I -Ag'. 
The relative insertions in the I -Ad protein at positions 065 and 066 are also present in I -Ar 
and I -A4 and, accordingly, these molecules are also recognised by MK -D6 (Liu et al., 
1993). An examination of the aligned amino -acid sequences of the 0- chains of I -E and 
HLA -DR variants reveals that equivalent residues are present in these molecules too 
(Fremont et al., 1998b). By contrast, I -Ag7 is more similar to I- Ak. °`'`t all of which lack 
these residues (Liu et al., 1993). In correspondence with this, none of these molecules 
are detected by MK -D6 (Liu et al., 1993) although all are recognised by the mAb, 10- 
3.6.2 and 10 -2.16 (Sher et al., 1984). The specific residues bound by these latter two 
mAb still remain to be mapped but it is known that they exist in a single linear sequence 
upon the 0 -chain (Sher et al., 1984). In this respect, it is tempting to speculate that their 
shared epitope resides in the same stretch of polypeptide as that of the MK -D6 mAb, 
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thereby providing an explanation for the ability of these monoclonal antibodies to 
distinguish class H MHC molecules based upon the whether they exhibit the relative 
insertions at positions, 1365 and 1366. Indeed, these insertions do appear to cause a 
significant structural difference: when compared with the crystal structures of I -Ek 
(Fremont et al., 1996), HLA -DR1 (Stem et al., 1994), HLA -DR4 (Dessen et al., 1997) 
HLA -DR3 (Ghosh et al., 1995) and I -A5 (Scott et al., 1998), the crystal structure of I -Ak 
shows a region of significant structural divergence around the Hl helix of the (3 -chain and 
its junction with the adjoining H2a helix (Fremont et al., 1998b). Fremont et al. (1998b) 
have calculated that the change in this region in I -Ak translates to a 1.5 A shift in the C- 
terminal half of the Hl helix towards the H2a helix relative to the equivalent residues in I- 
Ek or FILA -DR. Related to this, it is interesting to note that the only difference perceived 
between the crystal structures of the SDS- unstable CLIP -DR3 complex and the SDS - 
stable HA -DR1 complex was a 1.5 A shift towards the peptide- binding groove of a small 
segment of the (3 -chain a -helix between the residues, 065 -074 (Ghosh et al., 1995). If 
the different three -dimensional arrangement of these residues has any relevance upon the 
behaviour of these complexes in the presence of SDS detergent, one must wonder how 
the relative deletions of the 1365 and 1366 residues in the molecules 1- Ag''k'"''s'f impact upon 
this. 
Lastly, there exists a possibility that the 0Pro56Hís mutation present within I -Ao may 
contribute a further preference for C- terminal acidic residues in peptide ligands through 
the introduction of a positively- charged side chain at this site (discussed previously in 
§6.1.5). In this study, the rMOG8 -22 peptide, which exhibits a cluster of acidic residues 
at the positions, P9, P10, P12 and P13 in its C- terminus (Figure 6.8a), bound less to the 
I- Ag'Pro56 mutant than to the wild -type I -Ag' molecule (Figure 6.8c). One could speculate 
that this ligand forms a stabilising interaction with the I -M' all dimer between one of its 
other C- terminal acidic residues and the OHis 56 residue. The reversion to the proline 
residue at 1356 in I -Ag', i.e. to form I- Ag7Pro56 thus removes this favourable charge 
interaction thereby negatively affecting the ability of this peptide to compete for binding. 
6.4.6 The unusual properties of I -An' may alter CD4' T cell activities both 
during thymic selection and within the periphery 
The amino acids unique to the I -Ag' heterodimer at positions 1356 and 1357 have been 
shown previously to influence the diabetogenic potential of this class II MHC molecule in 
the NOD mouse (Lund et al., 1990a; Quartey -Papafio et al., 1995; Singer et al., 1998). 
Accordingly, the findings of this study have a number of implications for the functioning 
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of CD4' T lymphocytes in vivo, the cellular population ultimately responsible for the 
development of autoimmune diabetes in these animals. 
Of major significance, the results of this investigation support the possibility that the I -Ag7 
heterodimer may direct the intrathymic selection of a unique CD4` T cell repertoire in 
NOD mice. Indeed, there exist a number of possibilities by which the biochemical 
peculiarities of the I -Ar molecule may modulate the outcome of any given MHC -TCR 
interaction within the thymus when viewed in the context of the differential avidity model 
of T cell selection. As described in Chapter 1 (§1.7.2), this model proposes that the fate 
of an immature thymocyte is decided by the product of the affinity of the TCR for the 
peptide -MHC complex, the affinity of the peptide for the MHC molecule, the 
concentration of the peptide -MHC complex on the APC and the number of TCR on the 
thymocyte (Ashton -Rickardt et al., 1994; Ashton -Rickardt & Tonegawa, 1994). 
Specifically, T cells undergo positive selection when the overall avidity of the interaction 
of their TCR with a peptide -MHC complex is above a certain threshold, but if this avidity 
is too high, the thymocyte is targeted for deletion during negative selection. 
Firstly, peptides exhibiting acidic P9 anchors (as discussed in §6.4.3 & §6.4.4) will be 
likely to predominate in the binding cleft of I -M7 molecules at the cell surface. As a 
result, such complexes will represent the most probable targets for high avidity TCR 
interactions thereby skewing negative selection towards the deletion of thymocytes 
recognising primarily these peptides. At the same time, the generally poor ability of a 
broad range of other peptides to form highly stable complexes with I -Ag7 (discussed in 
§6.4.4) will mean that many potentially self- reactive T cells that are normally deleted in 
other mouse strains may escape into peripheral circulation in the NOD mouse. An 
equivalent effect has been observed in H -2M knockout mice where the occupation of most 
class II MHC molecules by CLIP fragments prevents presentation of other self -antigens 
necessary for the induction of self -tolerance. Accordingly, CD4` T lymphocytes derived 
from H -2M° animals react strongly with syngeneic APC presenting a wild -type peptide 
repertoire (Surh et al., 1997; Tourne et al., 1997; Lee et al., 1999). A similar result was 
obtained with T cells from the so- called AbEap mice which have been engineered to 
express just a single peptide -class II MHC complex of residues 52 -86 of the I -Ea 
polypeptide covalently linked to the 0-chain of I -Ab (Ignatowicz et al., 1996). 
It is possible that NOD mice may exhibit an even more significant defect in the positive 
selection of T cell specificities. Indeed, this is supported by the demonstration that the 
NOD thymic epithelium alone is sufficient to select an autoimmune T cell repertoire when 
grafted into athymic mice of the non -autoimmune -prone strain, C57BL /6 (Thomas-Vaslin 
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et al., 1997). In this respect, the limited peptide- binding specificities of the I -At7 
heterodimer, as demonstrated in this study ( §6.4.3 & §6.4.4), may also have significant 
consequences upon the positive selection of immature thymocytes. To date, a number of 
investigators have shown a strong correlation between the extent of peptide diversity in 
the thymus and the breadth of the TCR repertoire (Ashton -Rickardt et al., 1994; Hogquist 
et al., 1994; Bevan, 1997; Grubin et al., 1997; Surh et al., 1997; Barton & Rudensky, 
1999; Janeway, 1999). Regarding NOD mice, the inability of many peptide ligands to 
fulfil the motif requirements of 1 -Ag7 may mean fewer thymocytes will fulfil the avidity 
threshold to undergo positive selection. As a result, the collection of CD4+ T 
lymphocytes present in these animals may exhibit a number of "holes ", possibly including 
TCR specificities involved in essential immunoregulatory functions. This feature may be 
exacerbated further by the impaired ability of I -Ag7 molecules at the cell surface to 
undergo ligand exchange (discussed in §6.4.5). Again, an equivalent effect has been 
observed in H -2M° and A"Eap mice whereby certain TCR specificities that are present in 
normal mouse strains are not selected to mature in these animals (Ignatowicz et al., 1996; 
Grubin et al., 1997; Surh et al., 1997; Tourne et al., 1997). 
In concert with the peptide- specificity effects, particular molecular aspects of the I -Ag' 
heterodimer may also influence which thymocytes will mature into immunocompetent 
CD4' T cells in the NOD thymus. For example, the loss of the 1357 -a76 salt bridge is 
predicted to cause localised destabilisation within the heterodimer (Nalefski et al., 1995) 
and may lead to peptide -I -Ag7 complexes which have unusually short half -lives 
(Carrasco -Mann et al., 1996, 1997; discussed previously in §6.4.4). Together, these 
events may be envisaged to reduce the capacity of a TCR to engage such a complex for 
sufficient duration to allow the necessary signals to be transduced within the thymocyte to 
direct an appropriate outcome. 
Another possible disturbance in the selection of the CD4+ T cell repertoire in NOD mice 
may arise from the conformational abnormalities predicted in I -Ag7 due to the unique 
sequence at the 1356 and 1357 positions. Given the proximity of these positions to the 
peptide- binding groove, any alterations in the spatial arrangement of the surrounding 
atoms may have effects on both the ability of a given peptide to bind to this heterodimer 
and on the recognition of this complex by different TCR. In this respect, Chervonsky et 
al. (1998) have shown recently that different T cells may discriminate even between very 
subtle conformational changes introduced into a single class II MHC molecule by the 
binding of different peptides. Moreover, Yassine -Diab et al. (1999) have reported that 
polymorphism in the peptide -binding groove may bias the selection of particular TCR 
variable domain gene segments even when peptide binding is unaffected by these amino 
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acid changes. Regarding NOD mice, T cell clones have been identified that recognise 
peptides complexed with I -Ag' but not the same peptides bound to either its double 
revertant form, I- Ag7P` °56Asp37 nor to I -Ad (Kanagawa et al., 1997). Similarly, T cell 
clones have been isolated from NOD.ASP mice restricted to I -Ag7 57 but which show no 
cross -reaction with wild -type I -Ag7 (Quartey- Papafio et al., 1995). CD4` T cell clones 
have also been reported with the ability to differentially recognise HLA -DQ allotypes 
based solely upon the identity of the residue present at position (357 (Lundin et al., 1988; 
Sterkers et al., 1988; Kwok et al., 1996b). Molecular modelling of a number of HLA- 
DQ variants has revealed interesting differences in the surface contours of the binding 
clefts of these molecules which appear to be aligned with their relative genetic associations 
with the development of IDDM (Hoover & Marta, 1997; Sanjeevi et al., 1997). These 
common features were not limited solely to the effects of polymorphism at position f357 
but may induce the selection of a novel repertoire of CD4` T cells in IDDM- susceptible 
individuals, possibly enriched in autoaggressive specificities or, alternatively, lacking 
those associated with the control of the thymocyte population in the periphery. 
The efficiency of T cell selection is likely to he impaired further if the cell -surface 
expression of I -Ag' is reduced, as suggested by the results of site- directed mutagenesis of 
I -Ad in which the formation of the (357 -a76 salt bridge was disrupted ( §6.4.4; Nalefski et 
al., 1995). As mentioned above, the number of peptide -I -Ag' complexes on the cell 
surface is a critical parameter in determining the fate of T cells during positive selection 
(Ashton -Rickardt et al., 1994; Ashton -Rickardt & Tonegawa, 1994). The outcome on T 
cell development of defective cell -surface expression of class II MHC molecules has been 
illustrated previously in mice that exhibit a deletion of the Ii gene. The lack of the Ii 
protein to co- ordinate the intracellular trafficking of the aß dimers means that such 
molecules only rarely reach the plasma membrane (Bikoff et al., 1993; Viville et al., 
1993; Elliott et al., 1994a; described in Chapter 1, §1.4.2). Moreover, of those that do 
achieve cell -surface expression in Ii° mice, the peptide repertoire that they present appears 
to be altered significantly and the complexes may exhibit atypical conformational states. 
Similar to the effects described above for the H -2M knockout and AbEap mice, CD4' T 
lymphocytes derived from animals lacking Ii have been shown to be diminished in 
numbers and lack a number of the TCR specificities found in normal mice (Bikoff et al., 
1993; Viville et al., 1993; Tourne et al., 1995). 
All of the potential effects of the I -Ag' heterodimer upon the intrathymic selection of TCR 
specificities within the NOD mouse are related outcomes from the presence of the amino 
acids, 13His 56 and 13Ser 57, of this atypical class II MHC molecule. There exists also the 
strong possibility that the unusual biochemical features of peptide -I -Ag' complexes may 
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render these molecules incapable of interacting effectively with immature thymocytes such 
that even those T cells with the highest avidity reactivities for self -antigen are not deleted 
efficiently in these animals, i.e. those CD4' T cells that exhibit specificities for peptides 
exhibiting acidic P9 anchors. This proposal is supported by reports of a high incidence of 
autoreactive T cells in NOD mice (Ridgway et al., 1996; Carrasco -Mann et al., 1997). 
However, T cells that recognise self- peptides have also been described in other mouse 
strains (Schild et al., 1990; Agrawal et al., 1991; Oldstone et al., 1991; Guerder et al., 
1994). What appears to be unusual in NOD mice is that a proliferative CD4` T cell 
response is able to be stimulated readily by immunising with a number of different self - 
antigens (Ridgway et al., 1996), an effect not generally observed in other mouse strains 
(Ridgway et al., 1996; Ridgway & Fathman, 1998). This may be indicative of an 
immune regulatory defect in NOD mice, a possible consequence of lacking a certain 
regulatory T cell subset, as discussed previously ( §6.1.3). 
Another interesting possibility is that the self -reactive T cells that escape into peripheral 
circulation in NOD mice may exhibit higher affinities for their self- antigen MHC targets 
than those present in other mouse strains. For example, it may be envisaged that to 
achieve the avidity threshold for positive selection in NOD mice, T cells are selected that 
exhibit higher than usual affinities for self -antigens in order to compensate for the 
generally diminished ability of 1-Ar molecules to form stable peptide complexes. This 
prospect has been reviewed by Ridgway & Fathman (1998). Similarly, only the very 
highest affinity T cells would exceed the avidity threshold above which negative selection 
is triggered. In this respect, it is interesting to note that the dominant T cell epitope of rat 
myelin basic protein (MBP), rAc1-11, which induces EAE in susceptible mice, exhibits a 
very low affinity for its restriction element, I -A°, thereby enabling encephalitogenic T 
cells to escape tolerance induction in the thymus (Fairchild et al., 1993). However, the 
intraperitoneal administration of substituted analogues of this peptide that form more 
stable complexes with the I -A" molecule induces the deletion of these specificities and the 
animals become less susceptible to disease (Liu et al., 1995; Liu & Wraith, 1995). 
Autoimmune disease in an individual is not triggered simply by the release of autoreactive 
T cells from the thymus into circulation. The destruction of host tissues occurs only after 
these cells become activated by recognising antigen presented by MHC molecules in the 
periphery. Like the selection of TCR specificities, the efficiency with which mature T 
cells are activated has also been proposed to operate by a differential avidity mechanism 
- interrelationships appear to exist between the numbers of TCR on the T cell, the 
peptide MHC concentration on the APC, the affinity of the TCR for this complex and the 
affinity of the MHC molecule for the peptide (Chapter 1 , §1.7.1; Kim et al., 1996; Alam 
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et al., 1999; Legge et al., 1999). An effector response is induced when the overall avidity 
of the interaction between a T cell and a particular peptide -MHC combination is 
sufficiently high to trigger and subsequently downregulate a certain number of TCR 
(Viola & Lanzavecchia, 1996; Lanzavecchia, 1997; Lanzavecchia et al., 1999). 
Regarding NOD mice, it is likely that the same features of the atypical I Ag' class II MHC 
molecule that influence the repertoire development of the CD4+ T lymphocyte population 
in the thymus will also impact significantly upon the functioning of these cells in 
circulation. For example, as in the thymus, I -Ag' molecules in the periphery would be 
expected to present a unique array of peptides by consequence of their unusual preference 
for a negatively- charged P9 anchor ( §6.4.3). This collection of ligands may include 
potential immunopathogenic determinants, unable to bind significantly to class II MHC 
allotypes of other mouse strains as a result of the contrasting binding motifs. In this 
respect, this suggestion is consistent with the determinant selection model of 
autoimmunity (Smilek et al., 1990). Indeed, I -Ag7 is the only one of ten different mouse 
class II MHC allotypes tested that exhibits the ability to present the GAD65 determinant, 
residues 255 -269, and the closely -related peptide, residues 32-47, of the Coxsackie B4 
viral protein, P2 -C, both of which exhibit an acidic residue within their C- terminal region 
and have been implicated in the development of this disease (Tian et al., 1994; described 
previously in §6.1.3). However, the propensity for autoimmunity to develop in NOD 
mice is likely to be increased further by the effects of the other biochemical peculiarities of 
the I -Ag7 heterodimer upon the functioning of the T cell repertoire, i.e. the likely 
difference in the conformational arrangement of atoms around the 1356 and 1357 residues, 
the potential reduction in numbers of peptide -I -Ag7 complexes expressed on APC 
(Naiefski et al., 1995) and the possibility that such complexes may exhibit short half -lives 
(Carrasco -Mann et al., 1996, 1997). Collectively, these properties of the I -Ao a(3 dimer 
may compromise the capacity of this molecule to elicit the appropriate response when 
interacting with peripheral T cells. 
6.5. Conclusions 
In this study, the possible molecular mechanisms that underlie the genetic association of 
the class II MHC molecule, I -Ag7, with autoimmune disease have been investigated. This 
has been achieved by assessing the ability of different substituted and/or length- altered 
CLIP analogues to compete against biotinylated CLIP86 -104 in cell- surface binding 
assays using the I -Ag7- expressing B lymphoma cell line, M12.NOD. The specific 
contributions of the two unusual I -Ag' polymorphisms, (3Pro56His and (3Asp57Ser, on 
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peptide interactions have also been dissected by examining the binding of the CLIP 
analogues to two further cell lines, M12.PRO and M12.ASP, each expressing a single 
amino -acid revertant form of the I -Ag7 class II MHC molecule, I- M7pr° 6 and 1- M7nsp57 
respectively (Quartey -Papafio et al., 1995), 
From the results of these experiments, it is apparent that the binding of CLIP to I -Ag' is 
supported by a network of hydrogen bonds between the peptide backbone and the 
residues of the class II MHC groove, in a fashion similar to that found in the association 
of this ligand with I -A °, I -Ak and I -Ad (Chapter 4). However, the interaction of CLIP 
with I -Ag7 exhibits some important differences. For example, binding to the I -Ao a(3 
dimer is dependent upon a number of critical anchor contacts made through the C- terminal 
residues of the CLIP sequence, Leu 97, Arg 100 and Met 102. Additional positive 
binding energy is provided through the side chains of Leu 98 and Pro 101. However, of 
these favourable side -chain interactions, only that via Leu 97 is predicted to take place by 
conventional means within a pocket of the I -Ag7 peptide- binding groove. 
The requirement for additional positive interactions to uphold the binding of CLIP to I -Ag7 
appears to be a consequence of the 13Asp57Ser mutation in the heterodimer, since the 
extent to which these contacts form may be modulated by the reintroduction of such a 
residue. This is consistent with the participation of (3Asp 57 in other class II MHC a(3 
dimers in a salt bridge with aArg 76 that stabilises the region of the binding groove in the 
vicinity of the peptide C- terminus. The absence of an aspartic acid residue at position (357 
also confers upon the I -Ag7 molecules a preference to bind peptides that exhibit a 
negatively -charged residue at the P9 position, in order to provide a compensatory 
electrostatic interaction with the unpaired aArg 76 side chain, e.g. the CLIP M99E 
analogue. However, such peptides are unable to bind to the I -M7 molecule when (3Asp 
57 is reintroduced, i.e. I- As7Asp57 and similarly, to other mouse I -A class II MHC 
molecules that exhibit the conserved (3Asp 57 residue. Meanwhile, the lack of a proline at 
position 56 in the I3-chain of I -Ar leads to inefficient peptide exchange at the cell surface, 
such that exogenously -supplied peptides do not bind to the same extent to the wild -type 
heterodimer as to I- Ag7ProS6 
Thus, the mutations at the 13-chain residues 56 and 57 in the I -Ao molecule of NOD mice 
both influence the binding of CLIP to this 41 dimer, compared with other class H MHC 
molecules of the I -A isotype. These findings provide reasonable evidence to suggest that, 
in NOD mice, the manner in which peptide antigen is presented by the I -Ag7 class II MHC 
molecules to the TCR of CD4' T lymphocytes is also unique. For example, only a 
restricted range of peptides are likely to exhibit the structural features suitable to be 
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accommodated stably within the peptide -binding groove of this molecule. These 
properties of I -As7 would be expected to have significant consequences upon CD4+ T 
lymphocyte activities, both in the thymus during the development of the T cell repertoire 
and, later, within the periphery. In this way, these mutations may well contribute to 
development of autoimmunity in these animals. 
CHAPTER 7. 
Final discussion 
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The major focus of this study was to elucidate the molecular mechanisms by which the 
phylogenetically -conserved, li- derived peptide, CLIP, is able to bind promiscuously to 
different mouse class II MHC molecules. Early in this investigation, the X -ray 
crystallographic analysis of a human CLIP ligand complexed with HLA -DR3 confirmed 
that this interaction takes place within the MEC peptide- binding groove, the same site at 
which fragments of protein antigens bind for cell -surface presentation to CD4+ T 
lymphocytes (Ghosh et al., 1995). The results of this study have shown that CLIP from 
mouse Ii is able to associate with different T -A and I -E class II MHC molecules, 
irrespective of their individual peptide- binding motifs, by consequence of a unique mode 
of interaction. Firstly, the predominant source of positive binding energy is an 
intermolecular hydrogen bond network, presumably similar to that observed in the CLIP - 
HLA -DR3 crystal structure (Chapter 4, §4.4.1 & Chapter 5, §5.4.1; Ghosh et al., 1995). 
This is able to form independently of the peptide amino acid sequence because it involves 
only the main -chain atoms. Secondly, allele- specific anchor contacts within the 
polymorphic pockets are avoided in favour of a small number of atypical favourable 
interactions between CLIP side chains and regions of the groove between the classical 
pockets that are conserved among allotypes (Chapter 3, §3.4.4 & Chapter S, §5.4.2). 
This is a novel finding. Additionally, contacts have been identified between CLIP and the 
a13 dimer outside the peptide -binding groove. These occur at both the N- and C- termini. 
In particular, the previously undescribed positive interaction deriving from the side chain 
of Met 102 plays an important role in stabilising the binding of mouse CLIP to class H 
MHC molecules. The side chain at this position in human CLIP is leucine and it remains 
to be determined whether Leu 102 is important in this system as well. 
This study has also identified a number of inhibitory contacts that may be present in the 
binding of CLIP to mouse class II MHC molecules. These are typically a consequence of 
steric conflict between the residues of the peptide- binding groove and the bulky side 
chains of the proline residue at position 96 and/or one of the three methionines within this 
peptide sequence (Chapter 3, §3.4.4 & Chapter 5, §5.4.2). Incorporating these 
unfavourable interactions into the general binding motif of CLIP proposed above, it may 
be envisaged that this ligand exhibits an intermediate affinity for the different a(3 dimers. 
This is of fundamental importance in the pathway of class H MHC antigen presentation. 
For example, it is critical that this affinity is not so high as to hinder the replacement of 
CLIP by suitable antigen- derived peptides with appropriate anchors in the presence of 
HLA- DM/H -2M (Gautam et al., 1997). However, the CLIP region represents the 
primary site of interaction between intact Ii and class II MHC molecules (Freisewinkel et 
al., 1993; Biljmakers et al., 1994a). Therefore, the affinity of this sequence also needs to 
be of sufficient strength to uphold this interaction to enable Ii to target the aß dimers from 
Final discussion 251 
the ER into the endocytic route and, similarly, for the isolated CLIP fragments to maintain 
the binding groove in a receptive state following the proteolytic degradation of Ii (Mason 
et al., 1995; Rabinowitz et al., 1998; Natarajan et al., 1999a). 
Some isotypic differences in the manner in which CLIP binds to I -A and I -E molecules 
have been observed in this study. For example, CLIP was found to be unable to sustain 
an association with I -E molecules at neutral pH although binding to I -A molecules was 
detected under the same conditions (e.g. Chapter 5, Figure 5.3). I -E molecules typically 
display a lower optimum pH for binding peptides than those of the I -A isotype as a result 
of high proton concentration facilitating the formation of a number of hydrogen bonds in 
these complexes additional to those in common with peptide -I -A complexes (Jensen, 
1990; Mouritsen et al., 1992; Reay et al., 1992; Sette et al., 1992b; Fremont et al., 1996; 
Wilson, 1996). This property may have functional significance in the nature of the 
antigen- derived ligands typically bound by the I -A and I -E mouse class II MHC 
heterodimers by influencing the site within the endocytic route at which these molecules 
form stable complexes with cognate peptides (Jensen, 1991; Sette et al., 1992b). Also of 
note, the few favourable contacts made by CLIP side chains with these molecules are 
considerably stronger for I -Ed a(3 dimers so as to represent anchor interactions (Chapter 
5, Figure 5.8). By comparison, an equivalent effect was observed only for one residue in 
the association of CLIP with the I -Ad allotype under the same experimental conditions at 
pH 5.0 (Chapter 3, Figure 3.6). The presence of several anchor contacts may be a 
general feature of the interaction of CLIP with molecules of the I -E isotype. The 
evolution of this binding mechanism may have been facilitated by the non -polymorphic I- 
Ea polypeptide (Ayane et al., 1986). 
The role of the N- terminal residues of CLIP in modulating the affinity of this peptide for 
different mouse class II MHC molecules requires further investigation. For example, the 
binding of CLIP to I -At was enhanced at pH 7.0 when either of the residues, Lys 83 and 
Pro 87, were substituted with L- alanine (Chapter 4, Figures 4.10 & 4.11). By 
comparison, these same modifications to the CLIP sequence resulted in a decrease in the 
binding to I -Ed molecules at pH 5.0 (Chapter 5, Figure 5.9). It may be misleading to 
attempt to interpret these findings in terms of either the ability of the Ii -4 peptide 
(CLIP77 -92) to promote peptide exchange from I -E molecules at the cell surface (Adams 
& Humphreys, 1995) or the self -release of human CLIP from FILA -DR molecules 
(Kropshofer et al., 1995b), since different experimental approaches were used in each 
case. In particular, there exist inconsistencies in the pH at which the experiments were 
performed and the data of Kropshofer et al. (1995b) have assessed specifically the kinetic 
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properties of this interaction whereas the results presented herein reflect thermodynamic 
stability. 
The capacity of particular N- terminal residues within the CLIP sequence to modulate the 
binding affinity of this ligand for different class II MHC molecules is certainly interesting 
given that these residues are not all accommodated within the peptide- binding groove. 
Indeed, only 15 of the 24 residues of the human CLIP81 -104 peptide that were 
crystallised in association with the HLA -DR3 molecule showed clear, interpretable 
electron density indicative of binding in an ordered manner within this site, namely 
residues Pro 87 -Ala 101 (Ghosh et al., 1995). The remaining outermost amino- and 
carboxyl -terminal residues protrude from the groove in a manner facilitated by its being 
open at both ends. In this sense, the ability of intermediate- length CLIP ligands to bind 
better to some class II MHC molecules than longer variants (Chicz et al., 1992; Urban et 
al., 1994; Geluk et al., 1995; Naujokas et aL, 1998) makes it interesting to speculate that, 
should such peptides occur in vivo through the actions of aminopeptidases, then the 
efficient displacement of CLIP in the endosomes may be hindered and antigen 
presentation impaired. Fortunately, however, an examination of the naturally -processed 
Ii peptides eluted from different aß dimers reveals that such N- terminally- truncated CLIP 
ligands are not generated frequently in vivo (Rudensky et al., 1991; Chicz et al., 1992, 
1993; Hunt et al., 1992; Rammensee et al., 1995). Although the sites of bond lysis 
within the protruding C- terminus are quite variable, the cleavages at the similarly- exposed 
N- terminus are very precise. This would appear to be a consequence of the number of 
proline residues within this sequence rendering it a poor substrate for aminopeptidases 
(Rötzschke & Falk, 1994). 
Within the mouse CLIP sequence, proline residues are located at positions 82 and 87 
(Chapter 1, Figure 1.5). The distance between these residues appears to be of a suitable 
length to permit endopeptidase cleavage between these two sites, most commonly 
between residues Ala 85 and Lys 86 (Rudensky et al., 1991). This results in the majority 
of CLIP ligands eluted from mouse allotypes exhibiting Lys 86 as their N- terminal 
residue. It was for this reason, that the CLIP86 -104 sequence was chosen to be the 
representative wild -type peptide in all the experiments described in this thesis. The 
protection of the N- terminus of the CLIP sequence from proteolysis results in these 
ligands being some of the longest seen binding to mouse class H MHC molecules a 
minimum of 15 residues in length within the typical range of 12 -19 amino acids 
(Rudensky et al., 1991; Hunt et al., 1992). Similarly, naturally -processed human CLIP 
ligands fall at the larger end of the range of peptides eluted from HLA molecules, in this 
case measuring at least 21 residues within a range of 10 -28 amino acids. The extended 
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length of such human CLIP ligands relative to their mouse counterparts arises from the 
presence of two additional proline residues within human CLIP at positions 84 and 85 
(Ser and Ala in the mouse sequence, respectively; Chapter 1, Figure 1.5). Thus, human 
CLIP does not display the same groove -proximal cleavage site as seen in mouse Ii, but is 
lysed typically N- terminal to Leu 81 or Lys 83 (Chicz et al., 1992, 1993, 1994; Riherdy 
et al., 1992; Sette et al., 1992a). Peptides exhibiting identical intact N- terminal sequence 
may also be generated in vitro by the proteolytic digestion of aOIi complexes (Ghosh et 
al., 1995). However, amino -terminal proline residues are not unique to CLIP but are also 
found in a number of other class II MEC ligands where they likewise appear to function 
as stop signals for N- terminal trimming by aminopeptidases once the peptide has bound 
within the groove (Kropshofer et al., 1993). Such a feature may be of use in predicting 
potential T -cell epitopes within a protein (Godkin et al., 1998). 
Mindful of the problems that exist in comparing different types of experimental data, a 
closer examination of the manner in which N- terminal CLIP residues are proposed to 
interact with distinct class II MHC molecules does nevertheless reveal a number of 
similarities. Firstly, Kropshofer et al. (1995b) have proposed that the N- terminal 
residues of human CLIP may contact an effector site on the HLA -DR a3 dimer, 
presumably very close to the peptide- binding groove. In support of this notion, the 
CLIP81 -89 fragment is able to mediate release of the core sequence, CLIP90 -105, from 
HLA -DR3 when provided in a trans arrangement. Moreover, a kinetic analysis of this 
interaction indicated that these two fragments were not competing for the same binding 
site (Kropshofer et al., 1995a). Similarly, the Ii -4 ligand does not compete directly with 
the antigenic peptides for the binding groove but is proposed to promote the exchange of 
peptides from cell -surface I -Ed and I -Ek molecules at allosteric effector site (Adams & 
Humphreys, 1995; Adams et al., 1997). The inability of Ii -4 to bind within the groove 
presumably arises as a result of it lacking the majority of CLIP residues identified in this 
study as being important for such an interaction, residues 90-99 (Chapter 5, §5.4.1). 
Accordingly, this ligand is not found associated naturally with class II MHC molecules 
(e.g. Rudensky et al., 1991; Hunt et al., 1992). 
Secondly, Kropshofer et al. (1995b) have suggested that the significance of the Lys 83 
and Lys 86 residues in the self -release of human CLIP from FILA -DR molecules may lie 
in the nature of their side chains. Positively- charged primary amines have also been 
shown to promote the dissociation of CLIP from HLA -DR aß dimers (Avva & 
CresswelI, 1994). Similarly, the Lys 83 residue of mouse CLIP was found to influence 
the binding affinity for I -Ak and I -Ed molecules in this study (Chapter 4, Figures 4.10 & 
4.11; Chapter 5, Figure 5.9) and mouse Ii -4 exhibits five positively- charged side chains, 
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one of which, Arg 82, is critical within the septameric minimal sequence, CLIP77 -83, for 
promoting peptide exchange from I -Ek and I -Ed (Adams et al., 1997). Other peptides that 
have multiple positive charges also exhibit a similar effect as Ii -4 upon I -E -bound 
determinants. For example, typical Iigands of I -Ed molecules themselves exhibit a 
number of basic residues (Chapter 5, Table 5.4) and the addition of a second such peptide 
to an I -Ed- restricted antigen -presentation assay has been shown to induce the exchange of 
the first peptide within the MHC groove (Adoriní et al., 1989). This interchange appears 
to take place irrespective of whether the competitor is added simultaneously with the 
original antigenic peptide or up to 24 h later, suggesting that the free ligand has an 
influence on the kinetics of dissociation of the bound peptide. Free I -Ed- binding peptides 
in general are able to accelerate the decline in presentation capacity of antigen -pulsed APC 
(Pedrazzini et al., 1991). The inclusion of peptides enriched in positively -charged side 
chains, such as the homopolymer, poly -L- lysine (14- 19 -mer) or the neuropeptide, 
dynorphin A (Dynl -13, a 13 -mer exhibiting 5 basic residues) in a binding assay with 
detergent- solubilised I -Ed and the antigenic hen egg lysozyme peptide, HEL107 -116, 
results in enhanced binding of the HEL peptide (de Kroon & McConnell, 1993, 1994). 
The stimulation of I -Ed- restricted T cells specific for the HEL107 -116 peptide is also 
increased in the presence of these non -stimulatory competitors, indicative of an expansion 
in the number of I -Ed molecules complexed with this ligand. 
In light of the possible role of positive charges in the interaction of N- terminal CLIP 
residues with different class II NE-IC molecules, the effector site on the aß dimers may 
contain a number of negatively- charged groups. For HLA -DR molecules, the location of 
this site has been proposed to be on the a, domain of the molecule following the 
observation that the binding of CLIP8I -105 and CLIP81 -98 to HLA -DR1, DR2 and 
DR3 molecules is inhibited in the presence of the superantigen Staphylococcus aureus 
enterotoxin B (SEB; Kropshofer et al., 1995a; Vogt et al., 1995), known to bind 
exclusively to this domain outside of the groove (Jardetzky et al., 1994). Similarly, 
inability of SEB to inhibit the association of CLIP92 -105 and other groove- residing 
peptides, together with the competitive nature of the kinetics of the SEB /CLIP81 -105 
inhibition, would suggest that SEB and the N- terminal CLIP residues, 81 -89, are 
competing for the same or overlapping binding sites on the HLA -DR molecules. 
Candidate negatively -charged residues on the HLA -DR a, domain are aAsp 17, aGlu 
21, and aAsp 35 (Kropshofer et al., 1995a), interestingly, all of which are conserved or 
conservatively -substituted in the equivalent domains of H -2A, H -2E, HLA -DP and -DQ 
molecules. Furthermore, just such a region of negative charge has been detected on the I- 
Ek a(3 dimer in proximity to the amino terminus of the bound peptide during fluorescence 
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energy transfer experiments to assess the charge -to- charge interactions with the moth 
cytochrome c peptide, mCytc88 -103 (Boniface et al., 1993). 
255 
Meanwhile, Kropshofer et al. (1995b) have proposed that the N- terminal Pro 87 residue 
of CLIP may also modulate the dissociation rate of this ligand from different HLA -DR 
molecules. Similarly, a proline residue at position 82 within mouse Ii -4 is deemed to be 
important for promoting peptide exchange from I -Ek and I -Ed (Adams et al., 1997) and 
the experiments presented herein also found Pro 87 to influence the binding affinity of the 
mouse CLIP Iigand for both I -Ak and I -E° molecules, albeit in different ways and at 
different pH (compare Chapter 4, Figures 4.10 & 4.11 and Chapter 5, Figure 5.9). The 
importance of such a residue may reflect that it has a critical role in stabilising a particular 
conformation. Molecular modelling of the proline -rich mouse Ii -4 peptide has shown that 
this sequence is likely to form a type II polyproline helix with the positively -charged side 
chains aligned on one face (Adams & Humphreys, 1995). Similarly, CD measurements 
of the quasi -palindromic human Ii peptide, Ii78 -92, have revealed a measure of order 
consistent with a significant contribution from multiple, stabilised 0-turns resulting from 
the four prolines and six positively -charged side chains within this sequence 
(LRMKLPKPPKPVSKMR; Lu et al., 1990). Moreover, the Pro 87 side chain was 
defined in the crystal structure of CLIP complexed with HLA -DR3 even though this 
residue extends well beyond the peptide -binding groove into the solvent and does not 
participate in any direct bonding interactions with the residues of the c43 dimer (Ghosh et 
al., 1995). In this sense, the visualisation of both the residues, Pro 87 and Val 88, at the 
relative positions P -4 and P -3, respectively, in the X -ray crystallographic analysis of 
CLIP -HLA -DR3 is unusual. In similar analyses of other peptide -class II MHC 
complexes, only as many as 13 residues of the bound ligand exhibit interpretable electron 
density, typically those corresponding to relative positions, P -2 -P11 (Stern et al., 1994; 
Fremont et al., 1996, 1998b; Dessen et al., 1997; Scott et al., 1998). 
A further key feature in the self -release of CLIP from different class II MHC molecules is 
proton concentration. Specifically, both Kropshofer et al. (1995a, 1995b) and Urban et 
al. (1994) have noted that this process takes place with HLA -DR variants nearly 
exclusively at low pH. Moreover, HLA -DR3 molecules expressed in HLA -DM° cell 
lines may be loaded with antigenic peptide in a weakly- acidic environment at 37 °C, 
indicative of the CLIP ligand dissociating from the peptide -binding groove under these 
conditions (Riberdy et al., 1992; Monji et al., 1994). In this respect, this process differs 
from the ability of polycationic peptides to facilitate the release of peptides from I -E 
molecules. All experiments reporting this latter phenomenon were conducted at neutral 
pH (Adorini et al., 1989; Pedrazzini et al., 1991; de Kroon & McConnell, 1993, 1994; 
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Adams & Humphreys, 1995; Adams et al., 1997). Complexes of the dynorphin peptide 
with I -Ea are less stable at pH 5.0 than at pH 7.0, such that the ability of this peptide to 
enhance the dissociation of HEL107 -116 from these molecules is reduced at acidic pH 
(de Kroon & McConnell, 1993, 1994). However, peptide exchange from I -E molecules 
is more pronounced in live APC compared with those fixed in glutaraldehyde, suggesting 
that internal cellular activities do influence these interactions (Adorini et al., 1989; 
Pedrazzini et al., 1991). It is possible that an intracellular environment is created within 
the endocytic compartments that is enriched in the competitor peptide and pre -loaded class 
II MHC complexes, so as to increase the likelihood of exchange taking place. 
Alternatively, the fixative process in glutaraldehyde may simply lead to the peptides 
becoming cross -linked to their aß dimers such that they are no longer able to dissociate. 
The different pH conditions under which the N- terminal residues of CLIP may modulate 
the binding of this peptide to HLA -DR and I -E molecules has led to several contrasting 
mechanisms being proposed to account for these processes. Firstly, Kropshofer et al. 
(1995b) at one time suggested that the self -release of CLIP from FILA -DR molecules may 
occur via a conformational change induced in the aß dimer when the N- terminal residues 
interact with the effector site. However, it is difficult to envisage how this process might 
be facilitated at low pH since the negatively- charged groups on the a, domain would be 
expected to be protonated under such conditions thereby abrogating the formation of any 
electrostatic contacts. Such a mechanism is more compatible with the ability of mouse Ii- 
4 to facilitate the dissociation of peptides from the I -E peptide- binding groove at neutral 
pH, as suggested by Adams & Humphreys (1995). Instead, Kropshofer et al. (1995a) 
have proposed that stabilising interactions form between the human N- terminal residues 
of CLIP and the HLA -DR aß dimer at neutral pH but become compromised under 
conditions of high proton concentration. Consistent with this, the sequence element, 
Ii71 -88, in the intact Ii protein has also been reported to contact class II MHC molecules 
at pH 7.4 and contribute to stabilising the aßIi trimer (Vogt et al., 1995; Stumptner & 
Benaroch, 1997). Such effects are believed to be particularly important for those class II 
MHC variants with a low affinity for CLIP. Nevertheless, the same N- terminal residues 
of the human CLIP sequence do still appear to impose physical constraints upon the 
adjacent sequence within the groove. For example, HLA -DRI molecules complexed with 
intact Ii do not exhibit stability in SDS detergent like those occupied only with the CLIP 
fragment unless the N- terminal residues, 82 -89, within the Ii protein are deleted 
(Stumptner & Benaroch, 1997). This is similar to the effect of replacing the groove - 
bound CLIP sequence within intact Ii with known antigen- derived ligands (Stumptner & 
Benaroch, 1997; Barton & Rudensky, 1998). 
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An additional mechanism has also been proposed by which the dissociation of ligands 
bound to I -E a(3 dimers may be accelerated by peptides enriched in basic residues. This 
involves specifically those polycationic competitors that are able to bind in the peptide - 
binding groove themselves, e.g. Dynl -13 but not Ii -4. In this process, the competitor 
peptide is suggested to bind stepwise in the individual pockets of the MHC binding 
groove as each is vacated by the existing ligand. Although seemingly unfavourable in 
terms of entropy, such a process would account for the faster off -rate of peptides by 
preventing the reassociation of the original peptide. This process is believed to involve 
predominantly I -Ed molecules as their groove exhibits a number of negatively -charged 
pockets (Chapter 5; Table 5.4). Further support for this mechanism is provided by 
experimental results with the antigenic HEL peptide and Dynl -13 that indicate that these 
ligands exhibit similar affinities and share the same binding site on the I -Ed heterodimer 
(de Kroon & McConnell, 1993). An examination of the kinetics of the peptide 
displacement reaction is compatible with an intermediate of two peptides bound to the 
same heterodimer (de Kroon & McConnell, 1994). However, given the close proximity 
of the a, effector site to the peptide- binding groove, it is also possible the Dyn peptide 
simply overlaps with the groove to yield the results seen by de Kroon & McConnell 
(1993, 1994). 
It is clear that further work is still needed to clarify the exact role of the N- terminal CLIP 
residues in modulating the binding affinity of this ligand for different class H MHC 
molecules. Unfortunately, the experiments performed in this study seeking evidence of 
this phenomenon in CLIP -bound mouse I -A and I -E molecules do not contribute much to 
resolving the confusion. For example, the binding of N- terminally- substituted CLIP to I- 
Ed was examined herein using only a truncated form of the Ii -4 ligand, missing one of the 
critical residues implicated in the mechanism, Arg 78 (Adams et al., 1997). Moreover, 
these experiments were conducted at acidic pH whereas this process is reported to take 
place for I -E molecules at neutral pH (Adams & Humphreys, 1995) and the optimum pH 
at which to investigate the possibility of a CLIP self -release mechanism from I -A 
molecules is unknown. In order to address all of these concerns, a thorough examination 
of the dissociation rates of N- terminally- substituted CLIP analogues from the individual 
mouse class II MHC molecules under different pH conditions should be undertaken. Of 
further significance, the enzyme -linked immunoassays conducted in this study to assess 
the binding affinity of N- terminally- substituted mouse CLIP for both I A and I -E 
molecules used an inappropriate detergent in the citrate -phosphate binding buffer 
(Appendix B5.3). This detergent, IGEPAL CA -630, is similar in structure and chemical 
properties to the more well -known non -ionic detergent, Nonidet P -40 (NP -40), which 
has been shown to reduce the rate of dissociation of CLIP from HLA -DR3 and thereby 
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obscure any indications of a CLIP self -release process (Kropshofer et al., 1995b). For 
example, in the presence of NP -40, the time of half- maximal dissociation, t12, of 
CLIP81 -104 from HLA -DR3 is nearly 6 hours at 37 °C, pH 5.8, compared with -30 
minutes in the presence of the detergent Zwittergent -12 (ZW -12) or -2 hours in a 
detergent -free system (Kropshofer et al., I995b). Similarly, Avva & Cresswell (1994) 
have shown that some detergents facilitate the dissociation of CLIP from HLA -DR 
molecules in vitro better than others. SDS, for example, not only induces CLIP 
dissociation but proceeds to denature the entire molecule. These researchers also found 
that detergents containing short (8 -10 carbon), unbranched hydrocarbon chains, such as 
octyl glucoside, were also effective in facilitating CLIP removal. By contrast, little or no 
dissociation of CLIP was detected from HLA -DR in the presence of those with longer 
hydrocarbon chains, even at pH 5.0 where CLIP dissociation from these molecules is 
usually enhanced. For this reason, it would be advisable to perform future experiments 
with purified class II MHC aß dimers in either ZW -12 or octyl glucoside or, 
alternatively, using a detergent -free system with water -soluble proteins similar to that 
employed by Urban et al. (1994). 
In the event that a self -release mechanism is confirmed to operate upon mouse CLIP -class 
II MHC complexes, it then remains to be determined the extent to which such a process is 
significant in vivo. Certainly, some sort of release mechanism additional to that mediated 
by HLA -DM would appear to be responsible for the ability of I -Ak molecules to bind 
antigenic peptides in FILA -DM° cell lines (Brooks et al., 1994; Stebbins et al., 1996). 
However, it would seem unnecessary that such a mechanism should also operate upon 
CLIP -bound I -E molecules. These complexes appear already to be remarkably unstable at 
neutral pH as a result of inadequate anchor residues and would therefore be expected to 
dissociate readily at the cell surface (Chapter 5, §5.4.4). Nevertheless, it may be 
envisaged that CLIP and similar polycationic peptides might play a role in vivo in 
facilitating the release of other peptides from I -E molecules. Given that cognate peptides 
typically bind irreversibly to class II MHC molecules (Buus et al., 1986; Roosnek et al., 
1988; Reay et al., 1992), this may be a distinct mechanism to broaden the spectrum of 
antigenic determinants that may be presented to T cells independently of the actions of 
I-ILA- DM/H -2M. However, the role of these latter proteins is not simply to facilitate the 
dissociation of class II MHC -bound peptides. HLA -DM and H -2M are also significant in 
maintaining the peptide -binding groove of empty aß dimers in a form receptive for 
binding new ligands (Chapter 1, §1.5.2). Is a two -peptide intermediate also able to 
perform this function? 
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It is interesting to note that several features of the proposed self -release mechanism of 
CLIP from HLA -DR molecules do show remarkable similarities to the manner in which 
the HLA -DM proteins are believed to facilitate the release of this Iigand from class II 
MHC aß dimers. Firstly, like HLA -DM (Kropshofer et al., 1996; van Ham et al., 1996; 
Weber et al., 1996), the N- terminal residues of CLIP have been shown to be capable of 
accelerating the release of not just this peptide, but also a range of others that lack optimal 
anchor residues ( Kropshofer et al., 1995b). Secondly, CLIP self -release is favoured 
under conditions of low pH and non -ionic detergent ( Kropshofer et al., 1995a, 1995b), 
similar to the actions of HLA -DM (Sanderson et al., 1996). For example, while no 
association between FILA-DR and HLA -DM is detected in NP -40, solubilisation of these 
molecules in the weaker, non -ionic detergent, digitonin, does permit their coprecipitation 
(Sanderson et al., 1996). This encourages speculation that both of these mechanisms of 
CLIP dissociation from the class 11 MHC peptide- binding groove may act operate by a 
similar means, possibly even via the same effector site. Indeed, the CerCLIP.1 
monoclonal antibody that is specific for the N- terminal residues of CLIP that protrude 
from the groove, has been shown to block HLA -DM- mediated release of CLIP from 
HLA -DR3 (Denzin & Cresswell, 1995). Nevertheless, these two mechanisms do not 
appear to act cooperatively since the N- terminal residues are not required for HLA -DM to 
facilitate CLIP removal, e.g. FILA -DM accelerates the dissociation rate of both CLIP81- 
104 and the N- terminally- truncated, CLIP89 -101, from HLA -DRI and DR3 molecules 
equally well (van Ham et aL, 1996; Weber et aL, 1996). 
The advantages and limitations of the three experimental methods used in this study to 
assess the binding of CLIP to different mouse class II MHC aß dimers have been 
discussed previously in Chapter 3 ( §3.4.1). A recurring issue throughout this thesis has 
been whether the behaviour of different class II MHC aß dimers in the presence of SDS 
detergent reflects accurately the capacity of these molecules to form stable associations 
with peptide ligands. It is of particular concern that this property should he interpreted in 
this manner by so many investigators when its molecular basis is still in the process of 
being elucidated (e.g. Nelson et al., 1996; Natarajan et al., 1999b). Moreover, an inexact 
correlation has been reported to exist between the stability of some peptide -class II IvIHC 
complexes in SDS and their half -lives in vivo (Reizis et al., 1997b) while the relevance of 
this property to the ability of such complexes to stimulate a T cell response remains 
unclear (Wu et al., 1996). A number of potential problems with this practice have also 
been perceived that may influence the experimental outcome. For example, the cellular 
background in which the class II MHC molecules are expressed may affect the availability 
of certain subsets of peptides, as may different growth medium preparations and the 
procedures used between individual laboratories to isolate the class II MHC proteins. 
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AIso of note, there would appear to be no standardised final concentration of the SDS 
detergent with which such experiments are conducted - available Iiterature cites a range 
anywhere between 0.2% and 4% (Billing et al., 1976; Springer et al., 1977; Pious et al., 
1985; Stumptner & Benaroch, 1997). 
The approach chosen in this study by which to dissect the interaction between CLIP and 
different mouse class II MHC molecules has been to assess the binding ability of an array 
of substituted and/or length- altered analogues of this peptide sequence. Such a procedure 
allows a given peptide to be analysed at the level of the individual constituent amino acids 
to determine which side chains are important for modulating the MHC binding affinity 
through contacts with the residues of the peptide -binding groove and which are oriented 
outwards from the molecule and thereby, in the case of antigen- derived ligands, are able 
to influence T -cell responses through interactions with the TCR. This approach is over - 
simplistic in the sense that it assumes that each individual residue contributes to the 
binding interaction independently of the others in the peptide sequence. However, this 
study has shown that, through the careful comparison of the results with data on the 
known peptide- binding preferences of the aß dimer of interest and the molecular structure 
of this protein from X -ray crystallographic studies and homology models, it is possible to 
achieve a remarkably accurate assessment of the manner in which a peptide may bind. 
Indeed, the utility of this technique is demonstrated by the capacity to predict correctly the 
binding affinity of a monosubstituted ligand for a given class II MHC molecule, e.g. the 
association of the P96K and M99K ligands with I -Ed (Chapter 5, Figure 5.10). 
Moreover, the CLIP sequence itself provides an excellent tool for this process by virtue of 
its ability to bind to so many different class II MHC variants. 
As a further illustration of how CLIP may be employed to probe the peptide -binding 
features of different class H MI-1C molecules, this ligand has been used in this study to 
provide important information on how the peculiar sequence at positions 1356 and 357 in 
I -Ag7 affects the ability of this a3 dimer to interact with peptides (Chapter 6). Together, 
these details suggest means by which the I -Ag7 class II MEC molecule may contribute to 
the development of autoimmune diabetes in NOD mice. The first step of this process is 
the escape of self -reactive CD4' T cells from tolerance induction in the thymus by the 
aforementioned mechanisms (Chapter 6, §6.4.6). Next, in the periphery, these T cells 
may recognise unique 3 -cell autoantigen epitopes presented by I -Ag' and their affinity for 
self -peptide MHC targets may be relatively high. In normal mouse strains, this would 
lead to these cells being tolerised. In NOD mice, however, the reduced stability, low cell - 
surface expression and altered conformational features of the I -Ag' heterodimer may 
jointly cause the overall avidity of the interaction to be reduced below the threshold of 
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immunotolerogenic functions, falling instead within the range in which effector responses 
are generated. Serial engagement of the peptide I -Ag7 complexes may then lead to the 
activation of these autoreactive T cells and they begin to proliferate and release cytokines 
of the Th l phenotype. It is possible that the bias towards the production of pro - 
inflammatory mediators may also be attributable to the atypical properties of the I -Ar 
molecule - the same factors that determine whether an effector response is to be mounted 
might also influence of what nature it will be, i.e. the affinity of a peptide for a given 
MHC molecule, the affinity of the TCR for this complex and the ligand concentration on 
the surface of the APC (Murray et al., 1993, 1994, 1998; Kumar et al., 1995; Pfeiffer et 
al., 1995). Similarly, the time period over which T cells differentiate may also be critical 
in determining whether Th1 or Th2 cells predominate (Rogers & Croft, 1999). In this 
respect, it is of interest to note that activated 13- cell -specific T cells in the diabetes- resistant 
NOD.PD trans genic mice typically release cytokines of the Th2 phenotype (Singer et al., 
1998). 
The many potential consequences of the llPro56His and 3Asp57Ser mutations within the 
I -Ag' molecule upon the functioning of the NOD immune system are in accordance with 
the H -2g7 MIIC representing the most important genetic loci affecting the susceptibility of 
these animals to diabetes (Prochazka et al., 1989; Wicker et al., 1989). However, the 
effects of the defective functioning of the I -Ag7 heterodimer are not limited only to (3-cell 
autoreactivity in these animals - in addition to insulitis and diabetes, NOD mice exhibit 
an abundance of other autoimmune manifestations (Table 7.1). For example, a Sjögren's 
syndrome -like pathology may be present in these animals, arising from inflammation of 
the lacrimal gland and the submandibular and parotid tissues of the salivary glands 
(Miyagawa et al., 1986; Goíllot et al., 1991; Humphreys -Beher et al., 1994; Robinson et 
al., 1998). Like autoimmune diabetes, this condition has been shown to be the outcome 
of an autoreactive Thl -type response, in this case targeting the 120 kDa cytoskeletal 
protein, a -fodrin (Yanagi et al., 1998) - the same autoantigen identified to be critical in 
this condition in humans (Haneji et al., 1997). Also, these animals may be induced to 
develop experimental autoimmune conditions, for example, systemic autoimmune 
rheumatic disease (ARD), a disorder resembling systemic lupus erythematosus (SLE) 
may be generated by immunisation with heat -killed Mycobacterium bovis , (bacillus 
Calmette -Guérin vaccine; BCG; Baxter et al., 1994a, 1994b). It would seem to be highly 
improbable that this widespread autoreactivity in NOD mice could result solely from the 
capacity of the I -Ag' molecule to bind a unique repertoire of autoepitopes, as proposed in 
the determinant selection model of autoimmunity. Instead, these findings are more likely 
indicative that these animals suffer a substantial defect in the immunoregulatory 
mechanisms that are responsible for maintaining tolerance to self -proteins. It may be 
Table 7.1 Autoimmune conditions affecting NOD mice 
Autoimmune manifestation Reference 
Spontaneous: insulitis/ diabetes 
thyroiditis 
parathyroiditis 
sialadenitìs 
inflammation of adrenal cortex/testes 
antibodies to multiple autoantigens 
anti -nuclear autoantibodies 
haemolytic anaemia in senescence 
Inducible: autoimmune rheumatic disease (ARD) 
experimental rheumatoid arthritis (ERA) 
experimental autoimmune encephalomyelitis (EAE) 
experimental autoimmune prostatitis (EAP) 
Makino et al., 1980 
Asamoto et al., 1984 
Krug et al., 1991 
Miyagawa et al., 1986 
Asamoto et al., 1984 
Reddy et al., 1988 
Humphreys -Beher et al., 1993 
Baxter & Mandel, 1991 
Baxter et al., 1994 
Kouskoff et al., 1996 
Bernard et al., 1997 
Rivero et al., 1998 
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speculated that this may also arise, at least in part, from the atypical properties of I -Ag', 
for example, through the failure of this class II MHC molecule to select appropriate 
suppressor specificities in the thymus and/or by its biochemical inadequacies hindering 
the effective activation of regulatory T cells. 
The absence of diabetes in transgenic NOD mice that express I -Ag' molecules modified at 
position 056 and/or 057, serves to illustrate the importance of these two particular 0- 
chain positions in vivo with regards to developing 0 -cell autoimmunity (Chapter 6, 
§6.1.4; Lund et al., 1990a; Quartey -Papafio et al., 1995; Singer et al., 1998). However, 
it is interesting to note that the degree of protection conferred upon these animals differs 
between the specific transgenes. For example, NOD.PD mice (I -A fluII O36Asp7) are 
protected from diabetes and develop only minimal peri- insulitis (Singer et al., 1998). 
Yet, these animals do still exhibit 0 -cell specific autoantibodies and lymphocytic 
infiltration of the submandibular salivary glands. The phenotype is similar in NOD mice 
expressing the I- A0g7Pro56 transgene, the NOD.PRO mice (Lund et al., 1990a). By 
contrast, NOD.ASP mice (I- A0g7AsP57) are not completely protected from diabetes (an 
incidence of 12% in female mice at 30 weeks compared with 60% in age- matched 
controls) and exhibit considerable islet infiltration in addition to sialadenitis and anti - 
insulin autoantibodies (Quartey -Papafio et al., 1995). 
In the context of the 2- checkpoint model of autoimmune diabetes progression (André et 
al., 1996; Chapter 6, §6.1.3) and the similar benign/malignant description of islet - 
associated autoimmunity (Ganda et al., 1997; Dilts & Lafferty, 1999), it is apparent that 
the expression of the modified I -Ag7 transgenes in all three cases is unable to prevent the 
release of autoaggressive thymocytes from the thymus in these animals (Checkpoint 1; 
benign autoimmunity). However, peripheral immunoregulatory mechanisms now appear 
to be in place to thwart the effector phase of autoreactivity which culminates in the 
destruction of the 0 cells (Checkpoint 2; malignant autoimmunity). The finding that these 
mechanisms appear to be more effective in the NOD.PD and NOD.PRO animals than 
those expressing the I- A0g7Asp7 transgene is interesting, given the results presented in this 
study which determine that the 0Ser57Asp mutation in I -Ag' has many more striking 
effects upon the binding of a representative peptide, CLIP, than that of 0His56Pro 
(Chapter 6, §6.4.3 -§6.4.5). It may be envisaged that the enhanced cell- surface peptide 
exchange by the I- Ag7Pr°56 molecule contributes to superior functioning of the extrathymic 
regulatory processes present in these animals. An alternative mechanism may be that the 
particular spatial arrangement of atoms within the peptide -binding groove that results from 
the presence of a proline residue at position 056 is better able to be recognised by 
regulatory T cells. The possibility that conformational features around the 056 and/or 
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357 residues may influence T cell interactions (Chapter 6, §6.4.6) is supported by the 
differences in cytokine profile produced between islet- reactive T cells from wild -type 
NOD and NOD.PD mice (Singer et al., 1998). In this respect, it would have been 
interesting to examine in this study the capacity of CLIP to bind to the double revertant 
molecule, I-Ag7Pro56Asp57 to see how this compared with the single substituted forms. 
Unfortunately, however, none of the cell lines in existence known to express this 
molecule were able to be obtained by this laboratory. Similarly, speculation regarding the 
ability of the specific residues present at the positions (356 and 357 to modulate T cell 
effector responses must remain tentative at this stage since appropriately- restricted T cell 
hybridomas were not available during the course of this study to examine this concept 
further. 
Other possible mechanisms of protection from diabetes afforded by the expression of the 
transgenes I- Ag7ProS6 I- Ag7Asp' and I- Ag'PrOS6ASPS' in NOD mice are suggested from studies 
involving the introduction of other non -NOD class II MHC molecules into these animals. 
In this respect, the inability of the modified I -Ag7 molecules to bring about the deletion of 
diabetogenic T cells does not appear to be unusual - these latter investigations have 
determined that intrathymic deletion or anergy of autoreactive specificities is a relatively 
uncommon means by which introduced molecules bestow protection from autoimmune 
diabetes - or perhaps just rarely complete (see reviews by Baxter & Cooke, 1995; 
Böhme et al., 1995; Slattery & Miller, 1996). For example, transgenic NOD mice 
expressing I -Ak (Miyazaki et al., 1990; Slattery et al., 1990), I -A° (Nishimoto et al., 
1987), I -Ad (Singer et al., 1993) or a functional I -E molecule (Lund et al., 1990a) are 
protected from diabetes but still exhibit to some extent a range of signs indicating the 
presence of an autoreactive T cell repertoire, e.g. sialadenítis, various degrees of insulitis, 
the capacity to provoke diabetes in these animals by treatment with the diahetogenic agent, 
cyclophosphamide (CYP) and/or the ability to transfer diabetes to lymphocyte- deficient 
NOD recipients. Hanson et al. (1996) have also shown that the prevention of 
diabetogenesis by the expression of an I -E transgene requires the continued presence of 
this molecule on peripheral APC, a finding incompatible with the clonal deletion theory of 
transgene protection which would only require thymic expression during T cell ontogeny. 
Moreover, Parish et al. (1993a) found no evidence of the deletion of specific Vß TCR 
elements in diabetes -resistant NOD mice expressing an I -E transgene and Reich et al. 
(1991) have retracted their earlier evidence for such a process (Reich et al., 1989). 
Nevertheless, the negative selection of diabetogenic CD4' thymocytes by introduced class 
II MI-IC molecules has been demonstrated in NOD mice that express a (3 -cell reactive, I- 
Ar- restricted, transgenic TCR (Schmidt et al., 1997, 1999). This deletion appears to 
take place following engagement of the TCR transgene- expressing thymocytes and the 
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non -NOD class II MHC heterodimers on thymic bone -marrow- derived APC and is 
complete in the presence of I -A°, H -2k and H -2 1, By comparison, mice that express 
only I -Ak or I -A4 attain only partial deletion of the diabetogenic T cell clones and exhibit a 
correlating degree of insulitis. 
The presence of insulitis but not overt diabetes in the majority of NOD mice that express 
transgenic class II MEG molecules is more consistent with peripheral mechanisms of 
protection. Such mechanisms include a.) immune deviation, whereby transgenic class II 
MHC molecules stimulate the production of regulatory Th2 -type cytokines, as discussed 
above for the NOD.ASP, NOD.PRO and NOD.PD mice, b.) determinant stealing, 
involving competition for a diabetogenic epitope between the transgenic heterodimer and 
I -Ag' which prevents the formation of the complex required for disease induction (Böhme 
et al., 1995), c.) a related theory known as determinant capture, whereby diabetogenic 
epitopes are unavailable for associating with I -Ag' because the transgenic molecule has 
bound to an adjacent epitope on the same peptide chain (Deng et al., 1993), d.) 
determinant displacement, where high affinity peptides derived from the transgenic class 
II MEC molecule itself out -compete diabetogenic ligands for binding to I -Ag' (Kikutani & 
Makino, 1992) or e.) the positive selection of immunoregulatory TCR specificities, a 
mechanism involving both thymic and peripheral activities (Lühder et al., 1998). From 
the results of the study presented herein, the mechanism of determinant stealing, in 
particular, would seem on first appearance unlikely given the number of differences in the 
peptide -binding motifs of different mouse class II MHC molecules versus I -Ag7, 
especially those of the I -E isotype with their preference for basic residues at the P9 
position (compare Chapter 5, Table 5.4 with Chapter 6, Table 6.6). Indeed, Gregori et 
al. (1999) have characterised recently the peptide- binding motif of the NOD I -Eg' 
molecule, i.e. the aß heterodimer that may be produced between the endogenous NOD I- 
Eßg7 polypeptide and that encoded by an I -Ea transgene, and have shown it be quite 
different from that of I -Ag7. It might be, however, that such differences are the key to the 
success of this mechanism if, as suggested previously, low affinity ligands of disease - 
associated class II MHC molecules are a significant part of the problem in the 
development of autoimmune disease, through their inability to trigger the deletion of 
autoreactive T cells (Chapter 6, §6.4.6). 
Further elucidation of the specific mechanism(s) that act to protect different class II MHC- 
transgenic NOD mice from diabetes must await refinement of the systems used to generate 
and study such animals since it is clear from the findings to date that some of the effects 
observed are complications arising from such factors as the tissue distribution of 
transgene expression (Böhme et al., 1990; Parish et al., 1993b; Podolin et al., 1993; 
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Pilström & Böhme, 1997), the manner in which the transgene is introduced into the NOD 
mouse (Nishimoto et al., 1987; Lund et al., 1990a) and the number of copies of this 
element present in these animals (Hanson et al., 1996; Singer et al., 1996). For example, 
high copy numbers of [ -A13- encoding transgenes cause abnormal development of B cells 
such that any resulting protection from diabetes in NOD may arise more from a deficiency 
in the numbers of APC present or in autoantibody production than from a specific 
function of the transgene itself (Gilfillan et al., 1990a, 1990b). The report that diabetes 
incidence may be reduced also by the introduction of the wild -type I -A57 transgene itself 
serves to highlight further some of the problems that exist in assessing MHC- transgene 
NOD mice (Wherrett et al., 1997). Nevertheless, such studies in general have provided 
explanation for the observation that the incidence of diabetes in NOD mice is highest 
when I -Ar is expressed in a homozygous state (Prochazka et al., 1989; Wicker et al., 
1989). 
Despite the potentially widespread immunological effects of the atypical amino acids at 
positions 1356 and 1357 within the I -Ag7 molecule upon the NOD mouse, it is still clear that 
the expression of this heterodimer alone is not sufficient for diabetes development. For 
example, the expression of even the entire NOD MHC in congenie mouse strains of the 
B 10 or B6 genetic background did not lead to the development of insulitis or diabetes in 
these animals (Chapter 6, §6.1.2; Wicker et al., 1995). Similarly, Biozzi AB/H mice 
express a novel MHC haplotype, H -2d4í, which includes I -Ag7 but these animals do not 
develop spontaneous autoimmune diabetes (Liu et al., 1993). Likewise, CTS mice share 
their class II MHC genes with NOD mice but do not become diabetic (Ikegami et al., 
1990b; Koide & Yoshida, 1990). Significantly, however, the expression of the CTS 
MHC on a NOD background is diabetogenic (Makino et al., 1991). These findings all 
serve to illustrate the contribution of other genetic aspects of NOD mice in the induction of 
autoimmune disease. For example, Piganelli et al. (1998) have described a defect in the 
ability of NOD macrophages to mature and proliferate in response to various growth 
factors. This appears to arise from a reduced capacity of these APC to process and 
present antigen, possibly resulting from a deficiency in the intracellular levels of the thiol 
coenzyme, glutathione (GSH), which is important for reducing disulphide bonds to 
enable unfolding of the tertiary structure of protein antigens. Together with the 
biochemical defects of the I -Ag7 molecule, the impaired ability of NOD macrophages to 
process and/or present autoantigens may be envisaged to reduce the ability to T cells to 
become sufficiently activated to induce peripheral tolerance and/or to activate 
immunoregulatory T cells. Furthermore, NOD T cells themselves may exhibit an intrinsic 
inability to attain the activation threshold required to induce peripheral tolerance or a 
regulatory Th2 response. For example, abnormalities have been noted in the ability of 
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NOD T cells to produce IL -2 and IL -4 upon TCR ligation, a defect leading to proliferative 
hyporesponsiveness (anergy) of regulatory Th2 cells (Zipris et al., 19911); Rapoport et 
al., 1993a; Jaramillo et al., 1994). In addition, the activation of regulatory T cells by 
APC in a syngeneic mixed lymphocyte reaction (SMLR) is deficient in NOD mice 
(Serreze & Leiter, 1988). From these results, it has been suggested that NOD T cells 
exhibit a defect in their TCR- mediated signal transduction along the PKC/Ras/MAPK 
pathway of activation (Rapoport et al., 19936). NOD mice also appear to have a 
deficiency in the number of NK T cells they possess, a cellular subset proposed to be a 
major source of the cytokine, IL -4, from which Th2 cells are induced to develop (Bach et 
al., 1997a). All of these possible effects may be woven into the model outlined above of 
the specific effects of the I -Ag' heterodimer to obtain a more comprehensive view of how 
autoimmune disease develops in these animals. 
The importance of the remainder of the NOD genetic background besides the H -2g' 
genotype upon the development of autoimmunity has been illustrated clearly in studies 
with congenic NOD mice that express alternative MHC genes. Despite the lack of I -Ar, 
these animals still display an assortment of autoimmune manifestations. For example, the 
congenic mouse, NOD.H -26, which derives its MHC from the C57BL /10 (B 10) strain, 
develops extensive lymphocytic infiltration of the pancreas and submandibular glands, as 
well as exhibiting autoantibodies (Wicker et al., 1992). Meanwhile, the I -Ak class H 
MHC molecule has been identified as permissive for the development of experimentally - 
induced thyroiditis (Vladutiu & Rose, 1971) and, accordingly, NOD.H -2k (or H -2h4) 
congenic mice exhibit spontaneous thyroiditis and anti -thyroglobulin autoantibodies with 
an incidence increased over that observed in wild -type NOD mice (19.6% versus 14.3% 
at one year, respectively; Wicker et al., 1995; Damotte et al., 1997). Interestingly, 
diabetes, if not insulitis, is for the most part not present in any of these NOD congenic 
strains, suggesting that I -Ag7 has an additional role in influencing the tissue to be targeted 
for autoimmune attack. Nevertheless, the incidence of these other manifestations of 
autoimmunity in these animals is still low compared with that of autoimmune diabetes in 
the wild -type NOD animals - 19.6% spontaneous thyroiditis in the H -2k congenic mice 
at one year ( Damotte et al., 1997) versus up to 100% insulitis in wild -type NOD mice at 
30 weeks with 70-90% of females exhibiting overt autoimmune diabetes (Makino et al., 
1980). This demonstrates without a doubt that the effects of background genes in the 
NOD mouse are still very much secondary to the effects of the I -Ag7 class II MHC 
molecule in predisposing these animals to autoimmune pathology. 
The results of this study have demonstrated clearly that the mutations at positions 1356 and 
1357 in the I -Ag' heterodimer have significant impact upon the presentation of peptides by 
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this particular class II M IC molecule. Moreover, from an examination of these effects, it 
has been possible to envisage how it may be that the identity of the amino acid residues at 
these two positions in the 13-chain of the I -A° molecule contributes to the development of 
autoimmunity in NOD mice. Although the 13Pro56His mutation is unique to the mouse I- 
As' molecule, the loss of an aspartic residue at position 1357 of class II MHC molecules is 
a polymorphism known to occur in other animals and there too it appears to predispose an 
individual to autoimmune disease. For example, 13Asp 57- negative class II MHC variants 
are common in other rodent strains used routinely to model human autoimmune 
conditions, both spontaneous and induced (Table 7.2). Most significantly, however, the 
lack of an aspartic acid residue at position 1357 is a major factor in determining the 
susceptibility of humans to IDDM (Chapter 6, §6.1.4; Todd et al., 1987). Furthermore, 
as with NOD mice, this particular polymorphism is also associated with the development 
of many other human autoimmune disorders {Table 7.3). The apparent evolutionary 
maintenance of amino acid polymorphism at position 1357 in these various mammalian 
species has been suggested to emphasise the functional significance of this residue in 
modulating immune responses (Olerup et al., 1997). 
Since its derivation (Makino et al., 1980), the NOD mouse has been studied extensively 
in the hope that elucidation of the factors that cause autoimmune diabetes in this animal 
may lead to a means of treating and/or preventing IDDM in humans. What then are the 
implications of the results presented herein regarding the development of IDDM in 
humans? For the most part, the results obtained concerning the effects of the 3Asp57Ser 
sequence motif in I -Ag7 on peptide binding may be applied also to human class II MHC 
molecules that lack an aspartic acid residue at this position. For example, it would be 
expected that 13Asp 57- negative class II HLA molecules would bind preferentially peptide 
ligands that exhibit acidic P9 residues, to provide compensatory positive binding energy 
for the loss of the stabilising 1357 -a76 salt bridge. Indeed, analysis of the peptide - 
binding motif of HLA -DQ8 would indicate this to be true (Kwok et al., 1996a, 1996b; 
Godkin et al., 1997; Oiso et al., 1997). However, to date, no extensive examinations of 
the binding of CLIP to such HLA molecules have been conducted. In this respect, the 
findings of this study would predict that, in order to sustain an association with (3Asp 57- 
negative human class II MHC molecules, the CLIP ligand would form a number of 
atypical interactions between the side chains of its C- terminal residues and those of the 
HLA peptide -binding groove. 
The likelihood that additional bonds are required to maintain the interaction between 
human CLIP and 13Asp 57- negative class II FILA molecules is consistent with reports that 
these molecules, like I -Ag', are less stable than those that exhibit an aspartic acid at this 
Table 7.2 Rodent models of autoimmune disease associated with ßAsp 57- negative class II MHC molecules. 
Animal Class II MHC 1357 Autoimmune condition Reference 
Biozzi mouse 
Bio- Breeding rat 
Lewis rat 
Buffalo rat 
I-Ag7 
RTI.B° 
RT 1.B' 
RT1.Bb 
serine chronic relapsing EAE 
rheumatoid arthritis 
serine IDDM 
spontaneous lymphocytic thyroiditis 
serine experimental autoimmune encephalomyelitis (EAE) 
collagen -induced arthritis (CIA) 
experimental autoimmune myasthenia gravis (EAMG) 
experimental autoimmune uveoretinitis (EAU) 
experimental autoimmune myocarditis 
experimental autoimmune neuritis (EAN) 
serine experimental autoimmune encephalomyelitis (EAE) 
experimental autoimmune thyroiditis (EAT) 
Baker et al., 1990 
Bouvet et al., 1990 
Nakhooda et al., 1977 
Sternthal et al., 1981 
Yamamura et al., 1986 
Griffiths et al., 1981 
Lindstrom, 1979 
Wacker & Kalsow, 1973 
Kodama et al., 1990 
Kadlubowski et al., 1980 
Jones et al., 1990 
Silverman & Rose, 1975 
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Table 7.3 The association of ßAsp 57- negative class II HLA alleles 
with human autoimmune disease. 
Allele ß57 Disease Reference 
DQB1 *0201 alanine IDDM 
coeliac disease 
systemic lupus erythematosus 
myasthenia gravis 
autoimmune thyroid disease 
dermatitis herpetiformis 
NAITP 
Addison's disease 
Stiff -man syndrome 
multiple sclerosis 
DQB1 *0302 alanine IDDM 
coeliac disease 
chronic idiopathic urticaria 
insulin autoimmune syndrome 
atrophic autoimmune thyroiditis 
rheumatoid arthritis 
Addison's disease 
multiple sclerosis 
DRB1 *0405 serine IDDM 
rheumatoid arthritis 
Vogt -Koyanagi -Harada disease 
Thorsby, 1995 
Sollid et aL, 1989 
Scofield et al., 1994 
Spurkland et al., 1991 
Santamaría et al., 1994 
Otley et al., 1991 
L'Abbe et al., 1992 
Partanen et al., 1994 
Pugliese et al., 1993 
Haegert et al., 1993 
Thorsby, 1995 
Mantovani et al., 1993 
O'Donnell et al., 1999 
Uchigata et al., 1992 
Cho et al., 1993 
Angelini et al., 1992 
Boehm et al., 1991 
Haegert et al., 1993 
Caillat-Zucman et al., 1992 
Tan et al., 1993 
Shindo et al., 1994 
neonatal autoimmune thrombocytopenic purpura 
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position (Buckner et al., 1996; Reizis et al., 1997a). Therefore, it may be envisaged that 
the same mechanisms proposed in Chapter 6 ( §6.4.6) for I -Ag7 might be applied to these 
human molecules to explain the frequency with which they are associated with the 
development of autoimmunity. Of particular interest in this regard is the recent 
publication of Nepom & Kwok (1998). These investigators have reviewed the current 
structural and functional knowledge of IDDM -associated HLA -DQ alleles and have 
outlined a number of immunological possibilities by which these molecules may 
contribute to the development of autoreactivity through inefficient molecular interactions 
and intercellular miscommunications. These suggestions are very much in accord with 
those proposed herein for I -As', i.e. the defective positive and negative selection of TCR 
specificities in the thymus leading to a potentially autoreactive T -cell repertoire circulating 
in the periphery, the presentation of a unique range of peptide ligands possibly including 
diabetogenic epitopes derived from (3 cell autoantigens, the inappropriate activation of T 
cells recognising such determinants and, lastly, the dysregulation of the ensuing 
autoimmune response culminating in the selective destruction of the (3-cell islet tissue. 
The situation in humans does differ from NOD mice however, in that gene products of 
several other class II HLA loci are expressed simultaneously with the (3Asp 57- negative 
variants in these individuals and that such molecules have the capacity to modify the risk 
of autoimmunity developing, e.g. the molecules, HLA -DR4 (DRA/DRB1 *0406) and 
HLA -DQ6 (DQA1 *0102/DQB 1 *0602), both confer protection from IDDM when 
expressed alongside HLA -DQ8 (Chapter 6, §6.1.1). The mechanisms proposed to 
account for this are the same as those outlined above to explain the ability of different 
class II MHC encoding transgenes expressed in NOD mice to protect these animals from 
diabetes and/or insulitis. Once again, thymic deletion of self -reactive TCR specificities in 
these individuals would appear to be the least likely possibility given that signs of immune 
activation to islet antigens are still evident in non- progressor HLA- DQ6/DQ8 
heterozygotes (i. e. those which do not develop diabetes) in the form of autoantibodies and 
subclinical 13-cell dysfunction (McCulloch et al., 1990; Pugliese et al., 1995; Gianani et 
aL, 1996). Instead, the mechanisms of determinant stealing or determinant capture appear 
to be favoured to account for the ability of HLA polymorphism to modulate the risk of 
diabetes development. For example, it has been proposed that a hierarchy of affinities for 
binding diabetes -associated epitopes exists for different HLA variants due to their varying 
peptide -binding motifs, such that these molecules compete for binding the same or 
overlapping determinants - an individual is susceptible to developing IDDM if the 
molecule present with the highest affinity for the diabetogenic ligand is one which lacks 
an aspartic acid at position 1357 (Nepom, 1990). This suggestion is supported by the 
finding that the protective molecule, HLA- DRA/DRB5 *0101, binds with high affinity an 
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epitope from the GAD autoantigen that overlaps the determinant presented by ITLA -DQ8 
with homology to the Coxsackie P2 -C protein (Bach et al., 1997b). Alternatively, it has 
been suggested that it is the differential capacity of these molecules to present tolerogenic 
peptides that is of significance (Sheehy, 1992; Undlien et al., 1997). Either way, these 
proposals presuppose that protective HLA molecules bind ligands with higher affinity 
than IDDM- susceptibility variants to form more stable complexes. The finding that the 
protective molecule, HLA- DQA1 *0102/DQB1 *0602, shows remarkable stability in SDS 
detergent (Reizis et al., 1997a; Ettinger et al., 1998), in marked contrast to HLA -DQ8 
(Buckner et al., 1996; Reizis et al., 1997a) has been interpreted to support this notion, yet 
half -Iife measurements of both complexes in vivo are very similar (Reizis et al., 1997a), 
illustrating again the point that the resistance of dimers to SDS- induced dissociation may 
be reflective more of conformational stability than of peptide- binding affinity. 
Nevertheless, it is possible that the particular conformation associated with this 
phenomenon is better able to induce T cell tolerance or stimulate a Th2 -type effector 
response to repress autoreactivity. 
The findings from transfection studies with NOD mice, as described above, demonstrate 
clearly that it is by no means inevitable that benign autoimmunity in these animals should 
progress to the so- called malignant state whereupon the (3 cells are destroyed. Similarly 
in humans, IDDM is characterised by a long, asymptomatic but autoantibody -positive 
stage from which only certain individuals advance to hyperglycaemia and clinical diabetes 
(e.g. Gorsuch et al., 1981; Palmer et al., 1983; Srikanta et al., 1985; Atkinson et al., 
1986; Bonifacio et al., 1990; Riley et al., 1990). This prodromal phase thus represents a 
significant opportunity in which to intervene in the autoimmune process with therapies. 
To date, a number of preventative strategies have been tested in NOD mice with relative 
success (Table 7.4; reviewed by Bowman et al., 1994), often owing to the ability of these 
agents to divert anti-islet immune reactivity away from the Thl -type response of the ß -cell 
destructive process towards that of an anti- inflammatory Th2 profile. A number of these 
strategies have also been trialed in human subjects at high risk of developing IDDM or in 
newly- diagnosed patients, e.g. BCG vaccination (Shehadeh et al., 1994), 
immunosuppression by cyclosporin A (Stiller et al., 1984; Dupre et al., 1988), 
subcutaneous injection of insulin (Keller et al., 1993) and oral administration of 
nicotinamide (Vague et al., 1987). However, the utility of these different therapeutic 
interventions for IDDM has been limited by the number of undesirable side effects which 
arise as a result of the generally non -specific manner in which these treatments act or 
through the use of preparations containing much 'immuno -irrelevant' material. 
By contrast, it is possible that the vaccination of susceptible individuals with distinct 
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Factor administered Reference 
Immunosuppressive agents: cyclosporin A Morì et al., 1986 
FK -506 Miyagawa et al., 1990 
Cytokines: TNF -a Satoh et al., 1989 
IL -la Jacob et al., 1990 
IL -2 Serreze et al., 1989 
Antibodies: anti -CD3 Chatenoud et al., 1994 
anti -CD4 Shizuru et al., 1988 
anti -CD8 Wang et al., 1996 
anti- IFN -y, anti -TNF -a Rabinovitch, 1994 
anti -IL -12 Rabinovitch, 1994 
anti -TCR Sempe et al., 1991 
anti -I -A Boitard et al., 1988 
anti -B7 Lenschow et aL, 1995 
anti- L- selectin Yang et al., 1993 
anti- VLA -4a Yang et al., 1993 
Immunopotentiators: BCG Harada et al., 1990 
CFAb Sadelain et al., 1990 
OK -432` Toyota et al., 1986 
microbial challenge Singh & Rabinovitch, 1993 
corticosteroids Rabinovitch et al., 1992 
antioxidants Rabinovitch et al., 1992 
Nicotinamide Yamada et aL, 1982 
Insulin: oral Zhang et al., 1991 
subcutaneous Atkinson et al., 1990 
Soluble TCR McKeever et al., 1996 
Peptide antigens see text 
'very late antigen adhesion molecule 4 
'complete Freunds adjuvant 
'preparation of a low virulence Streptococcus pyogenes strain 
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peptide antigens could be a more selective approach by which the development of the 
autoimmune pathology might be prevented. In this respect, studies such as this advance 
considerably our ability to identify appropriate immunogenic determinants within whole 
proteins by contributing to an understanding of the manner in which different MHC 
molecules bind unique subsets of peptides. Through an appreciation of such details, it 
may then be possible to develop synthetic protein analogues that will be able to minimise 
adverse reactions while still maintaining high affinity for the MHC molecule and 
maximum immunogenicity. Knowledge of the molecular basis of different MT-IC peptide - 
binding motifs may also be used to induce the specific type of immune response desired, 
simply by altering the composition of a vaccine, for example, with regard to Thl versus 
Th2- inducing determinants. 
Regarding IDDM, it may be envisaged that the occupation of the class II MHC binding 
site by a peptide competitor may serve to prevent the presentation of diabetogenic 
determinants to autoaggressive T lymphocytes or alternatively, in the case of 
immunodominant epitopes, may induce a response which regulates such cells (reviewed 
by Adorini & Nagy, 1990a, 1990b; Smilek et al., 1990; Fairchild et al., 1994). An 
equivalent strategy has been shown to be effective in preventing the development of EAE 
in susceptible mouse strains (Wraith et al., 1989; Gautam et al., 1992a). More recently, a 
number of investigators have indeed demonstrated the capacity to inhibit the development 
of diabetes in NOD mice by immunisation with any of the peptides, p12(166 -185) and 
p277(437 -460) from mouse HSP60 (Elias & Cohen, 1995; Bockova et al., 1997), 
residues 9 -23 of the insulin B -chain (Daniel & Wegmann, 1996), p14(202 -221) from 
GAD65 (Zechel et al., 1997), a synthetic 14 -mer (Hurtenbach et al., 1993), Xrep12 -26 
(Vaysburd et al., 1995) and a cyclic peptide derived from residues 056-77 of I -Ar itself 
(Dunsavage et al., 1999). The data provided in this study aids in this process by 
contributing further information regarding the peptide- binding motif of the I -Ag7 class II 
MHC molecule. In particular, this study has identified a CLIP analogue, M99E, which 
binds selectively and with high affinity to I -Ag7, but not to OAsp 57- positive mouse class 
II MHC molecules of the I -A isotype (compare Chapter 6, Figures 6.10 & 6.11). Given 
that OAsp 57- negative class II HLA molecules are also associated with susceptibility to 
IDDM in humans, it is possible that this information could be applied to peptide vaccine 
design for the prevention of human autoimmune diabetes as well. 
One final question concerning the development of autoimmunity both in NOD mice and in 
humans is whether there exists any relevance of CLIP or invariant chain in this process. 
Given the critical functions of each of these components in the operation of the class II 
MHC- mediated pathway of antigen presentation (Chapter 1, § 1.4.2 & § 1.8), any 
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deviations in the affinity or timing of their interactions with the aß dimer may be 
envisaged to have significant consequences upon the subsequent presentation of antigen 
to CD4' T lymphocytes, both in the thymus and the periphery. Indeed, the association of 
invariant chain and/or CLIP with class II MHC molecules to preclude the inappropriate 
binding of peptides from intracellular self -proteins may be an important mechanism 
towards suppressing autoimmune responses (e.g. Charron, 1992; Ansari, 1993). This 
notion is supported by the observation that susceptibility to collagen -induced arthritis is 
diminished in mice that exhibit impaired Ii degradation through a deficiency in the 
expression of the lysosomal cysteine proteinase, cathepsin S (Nakagawa et al., 1999). 
With regards to NOD mice, the likelihood that the levels of CLIP associated with I -Ag' at 
the plasma membrane may be different from other mouse class H AMC molecules has 
been discussed previously, including the possibility that the resultant reduction in cell - 
surface ligand exchange may affect the diversity of TCR specificities selected in the 
thymus (Chapter 6, §6.4.5 & §6.4.6). Consistent with this notion, 15% of autoreactive 
T cells from wild -type NOD mice also recognise the I -Ag' heterodimer in the context of 
the T2 cell line which lacks expression of H -2M, such that these T cells would appear to 
be interacting with class H MHC molecules either occupied with CLIP or devoid of 
peptides altogether (Kanagawa et al., 1998). Contrasting levels of CLIP or other Ii- 
derived peptides have also been found with particular class II HLA molecules that confer 
different degrees of risk of developing human autoimmune conditions, e.g. IDDM (Chicz 
et al., 1994), juvenile dermatomyositis (Reed et al., 1997), rheumatoid arthritis 
(Kirschmann et al., 1995; Friede et al., 1996). Moreover, the possible effects of variable 
interactions between Ii/CLIP and class II MHC molecules may not be limited to 
autoimmunity -T cell recognition of CLIP class II MHC complexes has been linked to 
other immunological disease states, including cyclosporin- induced syngeneic and 
autologous graft- versus -host (GVH) reactions (Hess et al., 1997a, 1997b, 1998; Chen et 
al., 1998) and house dust mite allergies, this latter condition involving the CLIP ligand 
acting as a weak agonist to stimulate T cells reactive to an allergen- derived peptide that 
shows some sequence homology (Kristensen et al., 1996). Molecular mimicry has also 
been proposed to take place between CLIP and a fragment of the retroviral p12 Gag 
polyprotein during mouse acquired immunodeficiency syndrome (MAIDS) which is 
caused by a defective mouse Ieukaemia virus (MuLV; Morse, 1996). Meanwhile, Hyoty 
et al. (1993) have identified an identical 7 -amino acid residue stretch shared between Ii 
(residues 56-62) and the mumps virus nucleocapsid protein which is capable of inducing 
some immunological cross -reactivity between these two proteins. The association of Ií 
with class II MHC molecules has also been shown to affect the binding ability of some 
superantigens (Ericson et al., 1994; Vogt et al., 1995) and, lastly, altered levels of 
expression of Ii have been reported in a number of malignant cell types, suggesting likely 
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consequences upon the anti- tumour immune response (e.g. Elliott et al., 1987b; Yao & 
Humphreys, 1988; Clements et al., 1992; Veenstra et al., 1993; Lu et al., 1994; Saito et 
al., 1997; Bosshart & Jarrett, 1998; Jiang et al., 1999). All of these findings serve to 
illustrate the need to achieve a thorough understanding of CLIP and invariant chain and 
their interactions with class II MHC molecules. 
In conclusion, investigations such as this into the basic mechanisms underlying the 
binding of peptides to different class II MEC molecules lead to a better understanding of 
the intricacies of antigen presentation and how amino acid sequence polymorphism in and 
around the peptide- binding groove may impact upon the generation of T cell- mediated 
immune responses. This information is invaluable in the development of effective 
immunotherapies, both for combating infectious microbial agents and in the management 
of autoimmune conditions where the barrier of self -non -self discrimination has been 
breached. With respect to the treatment or prevention of the autoimmune pathology, the 
ultimate goal is to have the ability to identify self -peptides that are involved in the disease 
process and to engineer synthetic antagonists for selective immunological intervention. 
Through its ability to bind promiscuously, the CLIP sequence of invariant chain 
represents a remarkable tool with which these aspects of class II WIC antigen 
presentation may be investigated, with the possibility also of using this ligand as the basic 
framework upon which selective antagonists may be constructed. 
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APPENDIX A: REAGENTS AND SUPPLIERS 
Reagent Supplier 
ABTS, 2, 2'- azino -bis(3- 
ethylbenzthiazoline-6-sulphonic acid) 
acetic acid, glacial 
acrylamide/ bisacrylamide 
antipain, hydrochloride 
aprotinin 
APS, ammonium persulphate 
benzalkonium chloride 
borax, sodium tetraborate 
boric acid 
brornophenol blue 
BSA, bovine serum albumin 
citric acid, monohydrate 
DMSO, dimethyl sulphoxide 
EDTA, ethylenediamine tetraacetic acid 
ethanol 
FBS, foetal bovine serum 
FITC, fluorescein isothiocyanate 
formaldehyde, formalin 
Geneticin, G -418 sulphate 
glutamine, L- 
glycerol 
glycine 
HEPES, N-2- hydroxyethylpiperazine - 
N' -2- ethanesulphonic acid 
hydrochloric acid 
hydrogen peroxide 
IGEPAL CA -630 
Sigma Chemical Co., MO, USA 
Ajax Chemicals, NSW, Australia 
National Diagnostics, GA, USA 
Sigma Chemical Co., MO, USA 
Sigma Chemical Co., MO, USA 
Ajax Chemicals, NSW, Australia 
Sigma Chemical Co., MO, USA 
Ajax Chemicals, NSW, Australia 
May & Baker, WC, Australia 
Sigma Chemical Co., MO, USA 
Armour Pharmaceuticals, Eastbourne, UK 
BDH Chemicals, VIC, Australia 
Sigma Chemical Co., MO, USA 
Ajax Chemicals, NSW, Australia 
Ajax Chemicals, NSW, Australia 
Trace Biosciences, NSW, Australia 
Pierce, IL, USA 
Sigma Chemical Co., MO, USA 
Gibco BRL, NY, USA 
Gibco BRL, NY, USA 
Merck , VIC, Australia 
Merck, WC, Australia 
Boehringer- Mannheim, Mannheim, Germany 
Ajax Chemicals, NSW, Australia 
BDH Chemicals, WC, Australia 
Sigma Chemical Co., MO, USA 
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leupeptin, trifluoroacetate salt 
2 -ME, 13- mercaptoethanol 
methanol 
milk powder, non -fat 
MRA, mycoplasma removal agent 
penicillin- streptomycin solution 
pepstatin A 
phenol red 
PI, propidium iodide 
PMSF 
potassium chloride 
RPMI 1640 medium 
SDS, sodium dodecyl sulphate 
silver nitrate 
sodium acetate 
sodium azide 
sodium bicarbonate 
sodium carbonate 
sodium chloride 
sodium citrate 
sodium hydroxide 
sodium phosphate, dibasic 
thymidine, [methyl -3H], 5 mCi 
trícine 
trimethylamine 
Tris 
trypan blue 
Tween -20 
Sigma Chemical Co., MO, USA 
BDH Chemicals, Dorset, UK 
Merck, VIC, Australia 
Bonlac Food Industries, VIC, Australia 
ICN Biomedicals, Tokyo, Japan 
Sigma Chemical Co., MO, USA 
Sigma Chemical Co., MO, USA 
Sigma Chemical Co., MO, USA 
Sigma Chemical Co., MO, USA 
Sigma Chemical Co., MO, USA 
Ajax Chemicals, NSW, Australia 
Commonwealth Serum Labs, VIC, Australia 
BDH Chemicals, Dorset, UK 
Sigma Chemical Co., MO, USA 
Ajax Chemicals, NSW, Australia 
BDH Chemicals, Dorset, UK 
Sigma Chemical Co., MO, USA 
Merck, VIC, Australia 
Merck, VIC, Australia 
BDH Chemicals, VIC, Australia 
BDH Chemicals, VIC, Australia 
MaIlinckrodt, VIC, Australia 
Amersham, NSW, Australia 
Sigma Chemical Co., MO, USA 
BDH Chemicals, Dorset, UK 
Gibco BRL, NY, USA 
Sigma Chemical Co., MO, USA 
Sigma Chemical Co., MO, USA 
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APPENDIX B: BUFFERS, SOLUTIONS AND MEDIA 
B 1. Cell culture 
RPMI 1640 culture medium 
208.8 g RPMI powdered medium 
40 g NaHCO3 
Dissolve in ddH2O and make up volume to 20 L. 
-+ Filter sterilise (0.2 gm) and store at 4 °C in the dark. 
-+ For complete growth medium, add to 500 mL RPMI 1640 solution: 
5 -10% (v /v) heat -inactivated FBS 25 -50 mL stock 
0.05 mM (3- mercaptoethanol 0.5 mL of 50 mM stock 
2 mM L- glutamine 10 mL of 100 mM stock 
10 mM HEPES 2.5 mL of 2 M stock 
antibiotics 1.25 mL Pen -Strep solution 
-4 Sterile filter (0.2 gm) into sterile Schott bottles and store at 4 °C in the dark. 
Heat -inactivated foetal bovine serum (FBS) 
Incubate FBS in a water bath at 56 °C for 2 hours. 
Gently agitate solution periodically to ensure uniform heating. 
Aliquot into sterile tubes and store at -20 °C. 
50 mM 13- mercaptoethanol stock solution 
3- mercaptoethanol (2 -ME) stock concentration = 14.3 M. 
Add 35 gL 2 -ME to 10 mL complete RPMI media in fume hood. 
Sterile filter (0.2 gm) and store at 4 °C up to 4 months. 
2 M HEPES 
Dissolve 47.7 g in 100 mL ddH2O. 
- Aliquot into 2.5 mL volumes and store at -20 °C. 
Mycoplasma Removal Agent 
Mycoplasma Removal Agent (MRA) stock concentration = 50 gg /mL. 
To treat cell culture for possible mycoplasma contamination, add MRA diluted to 
0.5 gg /mL with complete RPMI medium. 
Incubate for 1 week. 
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10 mg /mL G -418 sulphate stock solution 
Dissolve 5 g Geneticin in 500 mL sterile complete RPMI medium. 
Sterile filter (0.2 µm) and aliquot into 10 mL volumes. 
Store at -20 °C. 
-+ For 200 sg/mL solution: Add one 10 mL aliquot to 500 niL complete RPMI. 
For 1 mg /mL solution: Add one 10 mL aliquot to 90 mL complete RPMI. 
5% (w /v) Benzalkoníum chloride stock solution 
Dissolve 5 g of benzalkonium chloride in 100 mL ddI42O. 
-4 Stir thoroughly to dissolve. 
Humidity tray solution 
0.025% (w /v) benzalkonium chloride 
1% (w /v) SDS 
-4 Make up to 2 L with sterile ddH2O. 
10 mL of 5% (w /v) stock 
200 mL of 10% (w /v) stock 
Phosphate -buffered saline 
1.9 mM NaH2PO, (anhydrous) 0.23 g 
8.1 mM Na2HPO4 (anhydrous) 1.15 g 
154 mM NaCI 9.00 g 
-4 Dissolve in 900 mL ddH2O and adjust pH to 7.4 with 1 M HCI. 
Make up volume to 1 L and store at room temperature. 
B2. Antibodies 
B2.1 Protein A- Sepharose antibody purification 
1.O M Tris, pH 8.0 
-- 24.23 g dissolved in 200 mL ddH2O, adjust pH to 8.0 with concentrated HCI. 
100 mM Tris, pH 8.0 
- Take 20 mL 1.0 M Tris, pH 8.0 and make up volume to 200 mL with ddH2O. 
10 mM Tris, pH 8.0 
-+ Take 2 mL 1.0 M Tris, pH 8.0 and make up volume to 200 mL with ddH2O. 
100 mM glycine, pH 3.0 
1.50 g dissolved in 200 mL ddH2O, adjust pH to 3.0 with HC1. 
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B2.2 Biotinylation of monoclonal antibodies 
Biotin labelling buffer 
0.1 M NaHCO3 
0.1 MNaCi 
16.80 g 
11.69 g 
-4 Dissolve in ddH2O and adjust pH to 8.4 with concentrated HC1. 
-0 Make up volume to 2 L and store at room temperature. 
B2.3 FITC conjugation to monoclonal antibodies 
FITC labelling buffer 
0.05 M boric acid 
0.2 M NaCI 
6.18 g 
23.38 g 
-0 Dissolve in ddH2O and adjust pH from =6 to 9.2 with concentrated NaOH. 
-+ Make up volume to 2 L and store at 4 °C. 
-0 Prepare buffer <_2 weeks before use. 
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FITC dialysis buffer 
0.1 M Tris 24.23 g 
0.1% (w /v) NaN3 20 mL of 10% (w /v) stock 
0.2 M NaC_I 23.38 g 
-0 Dissolve in ddH2O and adjust pH from =11 to 7.4 with concentrated HCI. 
-0 Make up volume to 2 L and store at 4 °C. 
B3. Gel Electrophoresis 
B3. 1 SDS -polyacrylamide gel electrophoresis (SDS -PAGE) 
Resolving gel buffer, pH 8.8 
90.855 g Tris dissolved in ddH2O to 1.5 M 
-0 Adjust pH to 8.8 (from =12) with concentrated HCI. 
-0 Make up volume to 500 mL. 
Stacking gel buffer, pH 6.8 
24.228 g Tris dissolved in ddH2O to 1.0 M 
-4 Adjust pH to 6.8 (from =11) with concentrated HC1. 
-0 Make up volume to 200 mL. 
10% (w /v) Ammonium persulphate 
Dissolve 0.5 g in 5 mL ddH2O. 
- May be stored for several weeks at 4 °C. 
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SDS -PAGE Tris - Glycine sample buffer (4x) 
63 mM Tris, pH 6.8 2.5 mL 1 M stock 
10% glycerol 4 mL 
2% (w /v) SDS 0.8 g 
0.0025% (w /v) bromophenol blue 200 ¡AL of 0.5% (w /v)stock 
-+ Make up volume to 10 mL with ddH2O. 
-0 For reducing conditions, add 2 -ME to sample buffer to a final concentration of 
2 -5% (v /v) immediately before use. 
SDS -PAGE Tris -Glycine running buffer (10x) 
25 mM Tris 29 g 
192 mM glycine 144 g 
0.1% (w /v) SDS 10 g 
-0 Dissolve in ddH2O and make up volume to 1 L. 
-+ lx running buffer should be pH 8.3. Do not adjust with acid or base. 
SDS -PAGE Tris -Tricine sample buffer (4x) 
0.0625 M Tris, pH 6.8 2.5 mL of 2M stock 
12% (v /v) glycerol 4.8 mL 
2% (w /v) SDS 0.8 g 
0.00125% (w /v) phenol red 500µL of 0.01% (w /v) stock 
-0 Make up volume to 10 mL with ddH2O. 
-0 For reducing conditions, add 2 -ME to lx sample buffer to a final 
concentration of 2 -5% (v /v) immediately before use. 
SDS -PAGE Tris - Tricine anode buffer (10x) 
0.2 M Tris 
-0 Dissolve in ddH2O and adjust pH to 8.9. 
-9 Make up volume to 1 L. 
242.3 g 
SDS -PAGE Tris- Tricine cathode buffer (10x) 
0.1MTris 121g 
0.1 M tricine 179 g 
0.1% (w /v) SDS 10 g 
-a Dissolve in ddH2O and make up volume to 1 L. 
--0 lx running buffer should be pH 8.3. Do not adjust with acid or base. 
B3.2 Silver staining 
Gel fixing solution 
150 mL EtOH (analytical grade) 
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50 mL glacial acetic acid 
300 mL ddH2O 
30% (v/v) EtOH 
300 mL EtOH (analytical grade) 
700 mL ddH2O 
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20% (w /v) silver nitrate 
Dissolve I g silver nitrate in 5 mL ddH2O 
Store in a brown bottle wrapped in foil 
-+ For a 0.1% (w /v) solution: 250 µL+ 50 mL ddH2O immediately before use. 
2.5% (w /v) sodium carbonate /0.02% (w /w) formaldehyde 
Dissolve 1.25 g sodium carbonate in 50 mL ddH2O 
Add 26.3 ltL of a 38% (w /w) formalin solution (in fume hood) 
-{ Make fresh immediately before use. 
1% (v /v) acetic acid 
500111, glacial acetic acid 
50 mL ddH2O 
B3.3 Western blotting 
NOVEX Western transfer buffer (10x) 
12 mM Tris 29 g 
96 mM glycine 144 g 
-4 Dissolve in ddH2O and make up volume to 1.6 L. 
pH should be -8.3. Do not adjust with acid or base. 
Immediately before use dilute to lx and add McOH to 20% (v /v). 
Western blocking buffer (PBS -T/ milk) 
0.1% (v /v) Tween -20 
5% (w /v) non -fat milk powder 
-4 Dissolve in 500 mL cold PBS. 
Western wash buffer (PBS -T) 
0.1% (v /v) Tween -20 
-4 Dissolve in 500 mL cold PBS. 
500 µL 
25 g 
500 11L 
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B4. Purification of class II MHC proteins 
B4 .1 Preparation of antibody affinity columns 
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Coupling buffer 
0.1 M NaHCO3 16.8 g 
0.5 M NaCI 58.4 g 
0.02% (w /v) NaN3 4 mL of 10% (w /v) stock 
- Dissolve in 1.5 L ddH20 and adjust pH from =7.9 to 8.3 with NaOH. 
-0 Adjust volume to 2 L. 
1 mM HCl 
Add 43 µL concentrated HC1 to 500 mL ddH2O. 
Alternatively dilute 500 tL 1 MHC1 into 500 mL ddH2O. 
0.2 M Glycine buffer, pH 8.0 
Dissolve 3 g glycine in 150 mL ddH2O. 
Adjust pH to 8.0 with NaOH and make up volume to 200 mL. 
0.1 M Acetate buffer, pH 4.0 
0.1 M NaOAc 1.64 g 
0.5 M NaC1 5.844 g 
- Dissolve in 150 mL ddH2O and adjust pH to 4.0. 
- Make up volume to 200 mL. 
0.5% (v /v) IGEPAL/PBS 
To 2 L sterile PBS, add 5 mL IGEPAL 
Mix well and store at 4 °C. 
B4.2 Affinity purification of class II MHC molecules 
PBS lysis buffer 
Lyse cells at 10s per nL of 0.5% (v /v) IGEPAL/PBS 
Immediately before use add protease inhibitors at the following recommended 
working concentrations: 
2 mM EDTA 
1 mM PMSF 
2 µg/mL leupeptin 
2 µg/mL antipain 
2 l.tg/mL pepstatin A 
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2 µg/mL aprotinin 
Class 17 MHC elution buffer 
50 mM trimethylamine 
150 mM NaCI 
2.5 mM NaN, 
5 mM EDTA 
10% (v /v) glycerol 
0.5% (v /v) IGEPAL 
0.7 mL (in fume hood) 
6 mL 5 M NaC1 
0.2 mL 2.5 M NaN3 
2 mL 0.5 M EDTA 
20 mL glycerol 
1 mL IGEPAL 
-4 Dissolve in ddH2O, adjust pH to 11.5 and make up volume to 200 mL. 
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Citrate phosphate neutralising buffer, pH 5.0 
Stock solutions: 
A: 0.1 M citric acid (monohydrate) 5.25 g in 250 mL ddH2O 
B: 0.2 M Na2HPO, (anhydrous) 7.10 g in 250 mL ddH2O 
-4 For pH 5.0 buffer: 24.3 mL A + 25.7 mL B, dilute to 100 mL with ddH2O. 
-' Add IGEPAL to 0.5% (v /v) and NaN3 to 0.05% (w /v). 
For eluate neutralisation: Add 80 µL into tubes for each mL to be collected. 
Class II MHC dialysis buffer 
0.5% (v /v) IGEPAL 
0.025% (w /v) NaN3 
-, Add to 2 L cold PBS. 
I35. Peptide binding assays 
B5.1 Antigen presentation assay 
10mL 
10 mL of 10% (w /v) stock 
0.05 mCi /mL j3H]thymidine 
[3H]thymidine stock concentration = 5 mCi/mL 
Add 500 µL [3H]thymidine to 10 mL complete RPMI media. 
Sterile filter (0.2 µm) and store at 4 °C. 
-4 For pulsing cells: dispense 10111, per well (0.5 µCi). 
B 5.2 Cell- surface binding assay 
FACS medium 
1% (w /v) BSA 
0.05% (w /v) NaN3 
-+ Dissolve in 2 L cold PBS, stirring well. 
- Sterile filter (0.2 µm) and store at 4'C. 
20 g 
10 mL of 10% (w /v) stock 
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- Alternative: add 20 mL heat -inactivated FBS (to 1% v /v) instead of BSA. 
Note: The addition of sodium azide to the medium serves to slow cellular 
metabolism to minimise the modulation and internalisation of surface antigens due 
to antibody capping. 
10 mg /mL Propidium iodide stock solution 
Reconstitute 10 mg PI in 1 mL sterile PBS containing 0.1% (w /v) NaN3. 
Before use, titrate new stock against cell aliquots using serial dilutions in FACS 
medium from 100 -1 .sg/mL. 
B5.3 Purified class II MHC binding assay 
50 pg /mL goat anti -mouse IgG 
Goat anti -mouse IgG (H +L) stock concentration 2.4 mg/mL 
--+ For one ELISA plate (10 mL): 208 .tL IgG + 9792 µL PBS. 
- Note: Due to an excess of IgG, antibody solutions may be collected following 
incubation and reused for coating subsequent plates. 
Borate buffer, pH 8.0 
Stock solutions: 
A: 0.2 M boric acid 
B: 0.05 M borax 
3.09 g in 250 mL ddH2O 
4.77 g in 250 mL ddH2O 
- 4 For pH 8.0 buffer: 50 mL A + 4.9 mL B, dilute to 200 mL with ddI2O. 
Citrate phosphate binding buffer 
Stock solutions: 
A: 0.1 M citric acid (monohydrate) 5.25 g in 250 mL ddH2O 
B: 0.2 M Na2HPO, (anhydrous) 710 g in 250 mL ddH2O 
-+ For pH 5.0 buffer: 24.3 mL A + 25.7 mL B, dilute to 100 mL with ddH2O. 
-* For pH 7.0 buffer: 6.5 mL A + 43.6 mL B, dilute to 100 mL with ddH2O. 
--4 Add IGEPAL to 0.5% (v /v) and NaN3 to 0.01% (w /v). 
Milk Buffer 
0.1% (v /v) Tween -20 
5% (w /v) skim milk 
0.1% (w /v) BSA 
0.1% (w /v) NaN3 
-4 Dissolve in 98 mL PBS. 
-- Store at 4 °C. 
1001tL 
5g 
1 mL of 10% (w /v) stock 
1 mL of 10% (w /v) stock 
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MBN solution 
To 9800 µL of milk buffer, add 200 µL 25% (v /v) IGEPAL. 
Neutralising Buffer 
300 mM Tris, pH 7.5 
3.5% (w /v) skim milk 
0.7% (w /v) BSA 
0.07% (w /v) NaN, 
0.07% (v /v) Tween -20 
0.35% (v /v) IGEPAL 
ABTS developing solution 
ABTS 
citric acid 
sodium citrate 
- Dissolve in 100 mL ddH2O. 
pH should be 4.5 ± 0.2. Do not adjust. 
-{ Store at 4 °C in dark (wrap bottle in foiI). 
- Per plate: immediately before use add 10 µL E1202 to 10 mL ABTS solution. 
-- Test 1001.(L on 20 µL streptavidin -HRP solution before adding to plate. 
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9083µ.L 
0.35 g 
700 µL of 10% (w /v) stock 
70 µL of 10% (WM stock 
7iL 
140.tL of 25% (v /v) stock 
0.11 g 
0.55 g 
0.71 g 
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